Modified aminoacids, pharmaceuticals containing these compounds and method for their production

Abstract

The present invention relates to modified amino acids of general formula whereinA, Z, X, n, m, R, R2, R3, R4 and R11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Description

The present invention relates to modified amino acids of general formula

their tautomers, their diastereomers, their enantiomers, their mixtures and salts thereof, particularly physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them.

In the above general formula I

R denotes an unbranched C 1-7 -alkyl group which may be substituted in the ω-position

by a C 4-10 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or biphenylyl group,

by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-2H-2-oxoimidazopyridinyl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 1,3-dihydro-2H-2-oxoimidazol-1-yl or 3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, wherein the latter two groups may each be mono- or disubstituted in the 4- and/or 5-position or in the 5- and/or 6-position by lower straight chained or branched alkyl groups, by phenyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl-1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl groups and the substituents may be identical or different,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, contains an oxygen, sulphur or additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group,

or by a 6-membered heteroaromatic ring linked via a carbon atom, which contains one, two or three nitrogen atoms,

whilst a 1,4-butadienylene group may be attached both to the above-mentioned 5-membered heteroaromatic monocyclic rings and to the 6-membered heteroaromatic monocyclic rings, in each case via two adjacent carbon atoms, and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

an unbranched C 1-6 -alkylamino group optionally substituted at the nitrogen atom by a C 1-6 -alkyl group or by a phenylmethyl group, which may be substituted in the ω-position

by a C 4-10 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or biphenylyl group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or 1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl-group,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, contains an oxygen, sulphur or an additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group, or

by a 6-membered heteroaromatic ring linked via a carbon atom, containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene group may be attached both to the 5-membered and to the 6-membered heteroaromatic monocyclic rings, in each case via two adjacent carbon atoms, and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned above for the substitution of the alkyl and alkylamino groups in the ω-position and optionally also partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms or by alkyl groups, C 3-8 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, wherein the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino and benzoylmethylamino groups may in turn additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino or acetylamino group, or the group of formula

 wherein

p denotes the number 1 or 2,

o denotes the number 2 or 3 or, if Y 1 and Y 2 are not simultaneously nitrogen atoms, o may also denote 1.

Y 1 denotes the nitrogen atom if R 5 is a free pair of electrons, or the carbon atom,

Y 2 is the nitrogen atom or the group >CH—,

R 5 is a free pair of electrons if Y 1 denotes the nitrogen atom or, if Y 1 denotes the carbon atom, R 5 denotes a hydrogen atom, a C 1-3 -alkyl group, a hydroxy, cyano, aminocarbonyl, carboxy, alkoxycarbonyl, aminocarbonylamino, phenylmethyl or phenyl group,

R 6 denotes the hydrogen atom or, provided that Y 1 is not a nitrogen atom, R 6 together with R 5 may denote an additional bond,

R 7 denotes the hydrogen atom or, provided that Y 1 is not a nitrogen atom and R 5 and R 6 together constitute an additional bond, R 7 together with R N may also denote a 1,4-butadienylene group,

R N denotes a hydrogen atom or a C 1-6 -alkyl group which may be mono- or disubstituted in the ω-position

by a C 5-7 -cycloalkyl group, by a 1-naphthyl, 2-naphthyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, piperidinyl, morpholinyl, pyrrolidinyl, hexahydro-1H-1-azepinyl, aminocarbonyl, alkylaminocarbonyl, acetylamino, cyano, aminocarbonylamino or alkylaminocarbonylamino group or by phenyl, pyridinyl or diazinyl groups, whilst these substituents may be identical or different,

a C 5-7 -cycloalkyl group, a phenyl, pyridinyl, cyano, amino, benzoylamino, aminocarbonyl, alkylaminocarbonyl, alkoxycarbonyl, phenylalkoxycarbonyl, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, N-(aminocarbonyl)-N-alkylamino, N-(alkylaminocarbonyl)-N-alkylamino, N-(alkylaminocarbonyl)-N-phenylamino, phenylaminocarbonylamino, [phenyl(alkylamino)]carbonylamino, N-(phenylaminocarbonyl)-N-alkylamino, N-(phenylaminocarbonyl)-N-phenylamino, benzoylaminocarbonylamino, phenylalkylaminocarbonylamino, pyridinylaminocarbonylamino, N-(aminocarbonyl)-N-phenylamino, N-(alkylaminocarbonyl)-N-phenylamino, N-(aminocarbonylaminocarbonyl)-N-phenylamino, N-(pyridinyl)-N-(aminocarbonyl)amino, N-(pyridinyl)-N-(alkylaminocarbonyl)amino, phenylamino, pyridinylamino, 4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl or diazinylamino group,

a saturated, mono- or di-unsaturated 5- to 7-membered aza, diaza, triaza, oxaza, thiaza, thiadiaza- or S,S-dioxido-thiadiaza-heterocycle.

wherein the above-mentioned heterocycles may be linked via a carbon or nitrogen atom and

may contain one or two carbonyl groups adjacent to a nitrogen atom,

may be substituted at one of the nitrogen atoms by an alkyl, alkanoyl, aroyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, phenylalkoxycarbonylalkyl, phenylmethyl or phenyl group,

may be substituted at one or two carbon atoms by a branched or unbranched alkyl group or by a phenyl, phenylmethyl, naphthyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl, 1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl group, wherein the substituents may be the same or different,

and wherein a C 3-6 -alkylene group may additionally be attached to the above-mentioned heterocycles via two adjacent carbon atoms or an olefinic double bond of one of the above-mentioned unsaturated heterocycles may be fused with a benzene, pyridine, diazine, 1,3-oxazole, thiophene, furan, thiazole, pyrrole, N-methyl-pyrrole, quinoline, imidazole or N-methylimidazole ring,

or if Y 1 is not a nitrogen atom and R 5 and R 6 together denote an additional bond, R N together with R 7 may also denote the 1,4-butadienylene group,

or, if Y 1 is a carbon atom, R N together with R 5 , including Y 1 , also denotes a carbonyl group or a saturated or mono-unsaturated 5- or 6-membered 1,3-diaza-heterocycle which may optionally contain one or two carbonyl groups in the ring and, if it is unsaturated, may be benzofused at the double bond and may be substituted at one of the nitrogen atoms by a methyl, aminocarbonyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, phenylalkoxycarbonylalkyl, phenylmethyl or phenyl group,

whilst the phenyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl, 1-methylpyrazolyl, imidazolyl- or 1-methylimidazolyl groups contained in the residues mentioned under R 5 , R 7 and R N , as well as benzo, thieno, pyrido- and diazino-fused heterocycles in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 3-8 -cycloalkyl groups, nitro, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonylamino, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, hydroxyalkylaminocarbonyl, (4-morpholinyl)carbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1-azepinyl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, methylenedioxy, aminocarbonylamino, aminocarbonylaminoalkyl, alkylaminocarbonylamino, alkanoyl, cyano, trifluoromethoxy, trifluormethylthio, trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups, wherein the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino, benzoylaminocarbonylamino and benzoylmethylamino groups may in turn additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino- or acetylamino group

and unless otherwise specified the alkyl groups contained in the above-mentioned radicals may contain 1 to 5 carbon atoms,

X denotes an oxygen atom or 2 hydrogen atoms,

Z denotes a methylene group or the group —NR 1 , wherein

R 1 denotes a hydrogen atom or an alkyl or phenylalkyl group,

R 11 denotes a hydrogen atom, a C 1-3 -alkyl group, an alkoxycarbonyl group having a total of 2 to 4 carbon atoms or a phenylmethyl group,

n denotes the number 1 or 2 or, if m is 1, n may also be 0,

m denotes the number 0 or 1,

R 2 denotes a phenyl, 1-naphthyl, 2-naphthyl, 1,2,3,4-tetrahydro-1-naphthyl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl, 1-formyl-1H-indol-3-yl, 1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl, 4-imidazolyl, 1-methyl-4-imidazolyl, 2-thienyl, 3-thienyl, thiazolyl, 1H-indazol-3-yl, 1-methyl-1H-indazol-3-yl, benzo[b]fur-3-yl, benzo[b]thien-3-yl, pyridinyl, qui-nolinyl or isoquinolinyl group,

whilst the above-mentioned aromatic and heteroaromatic groups in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms or by branched or unbranched alkyl groups, C 3-8 -cycloalkyl groups, phenylalkyl groups, alkenyl, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonylalkyl, carboxyalkyl, alkoxycarbonyl, carboxy, dialkylaminoalkyl, dialkylaminoalkoxy, hydroxy, nitro, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, methylsulphonyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkanoyl, cyano, tetrazolyl, phenyl, pyridinyl, thiazolyl, furyl, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups, and the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino- and benzoylmethylamino groups may in turn additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom, or by an alkyl, trifluoromethyl, amino or acetylamino group,

A denotes a bond or the divalent group of formula

(which is linked to the NR 3 R 4 group via the —CX group)

 wherein

R 8 and R 9 together denote an n-propylene group or

R 8 denotes a hydrogen atom or an alkyl- or phenylalkyl group and

R 9 denotes a hydrogen atom or a branched or unbranched C 1-5 -alkyl group which, if it is unbranched, may be substituted in the ω-position by a hydroxy, mercapto, amino, alkylamino, dialkylamino, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl, hexahydro-1-azepinyl, methylthio, hydroxycarbonyl, aminocarbonyl, aminoiminomethylamino, aminocarbonylamino, phenyl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl, 1-formyl-1H-indol-3-yl, 4-imidazolyl, 1-methyl-4-imidazolyl, 1-naphthyl, 2-naphthyl- or pyridinyl group, whilst the above-mentioned heterocycles, phenyl and naphthyl groups may in turn be mono-, di- or trisubstituted in the carbon skeleton by fluorine, chlorine or bromine atoms or by methyl, alkoxy, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl, cyano, trifluoromethoxy, methylsulphonyloxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, wherein the substituents may be identical or different, and wherein the hydroxy, mercapto, amino, guanidino, indolyl and imidazolyl groups contained in the groups mentioned for R 9 may be substituted with the protecting groups commonly used in peptide chemistry, preferably with the acetyl, benzyloxycarbonyl or tert.butyloxycarbonyl group,

R 3 denotes a hydrogen atom,

a C 1-7 -alkyl group which may be substituted in the ω-position by a cyclohexyl, phenyl, pyridinyl, diazinyl, hydroxy, amino, alkylamino, dialkylamino, carboxy, aminocarbonyl, aminocarbonylamino, acetylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-(1-piperidinyl)-1-piperidinyl, 4-morpholinyl, hexahydro-1H-1-azepinyl, [bis-(2-hydroxyethyl)]amino, 4-alkyl-1-piperazinyl or 4-(ω-hydroxyalkyl)-1-piperazinyl group,

a phenyl or pyridinyl group,

wherein the above-mentioned heterocyclic groups and phenyl groups may additionally be mono-, di- or trisubstituted in the carbon skeleton by fluorine, chlorine or bromine atoms or by methyl, alkoxy, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl, cyano, methylsulphonyloxy, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups and the substituents may be identical or different,

R 4 denotes a hydrogen atom or a C 1-3 -alkyl group optionally substituted by a phenyl or pyridinyl group or

R 3 and R 4 together with the enclosed nitrogen atom denote a group of general formula

 wherein

Y 3 denotes a carbon atom or, if R 12 denotes a free pair of electrons, Y 3 may also be the nitrogen atom,

r denotes the number 0, 1 or 2,

q denotes the number 0, 1 or 2,

R 10 denotes a hydrogen atom or an amino, alkylamino, dialkylamino, alkyl, cycloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aminoiminomethyl, aminocarbonylamino, alkylaminocarbonylamino, cycloalkylaminocarbonylamino, phenylaminocarbonylamino, aminocarbonylalkyl, aminocarbonylaminoalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxyalkyl or carboxy group,

a phenyl, pyridinyl, diazinyl, 1-naphthyl, 2-naphthyl, pyridinylcarbonyl- or phenylcarbonyl-group which may be mono-, di- or trisubstituted in the carbon skeleton by fluorine, chlorine or bromine atoms, or by alkyl, alkoxy, methylsulphonyloxy, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl, aminocarbonylamino, aminocarbonylaminomethyl, cyano, carboxy, carbalkoxy, carboxyalkyl, carbalkoxyalkyl, alkanoyl, ω-(dialkylamino)alkanoyl, ω-(dialkylamino)alkyl, ω-(dialkylamino)hydroxyalkyl, ω-(carboxy)alkanoyl, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different,

a 1,3-dihydro-2-oxo-2H-imidazolyl, 2,4(1H,3H)-dioxopyrimidinyl or 3,4-dihydro-2(1H)-oxopyrimidinyl group bound via a nitrogen atom, which may be substituted by a phenyl group or fused at the double bond to a benzene, pyridine or diazine ring,

a 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl group,

a 4- to 10-membered azacycloalkyl group, a 5- to 10-membered oxaza, thiaza- or diazacycloalkyl group or a 6- to 10-membered azabicycloalkyl group,

wherein the above-mentioned mono- and bicyclic heterocycles may be bound via a nitrogen or carbon atom and

may be substituted by a C 1-7 -alkyl group, by an alkanoyl, dialkylamino, phenylcarbonyl, pyridinylcarbonyl, carboxyalkanoyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylsulphonyl, cycloalkyl- or cycloalkylalkyl group, by a cycloalkylcarbonyl, azacycloalkylcarbonyl, diazacycloalkylcarbonyl or oxazacycloalkylcarbonyl group optionally substituted in the ring,

whilst the alicyclic parts contained in these substituents may comprise 3 to 10 ring members and the heteroalicyclic parts may comprise 4 to 10 ring members and

the above-mentioned phenyl and pyridinyl groups may in turn be mono- , di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl, alkoxy, methylsulphonyloxy, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl, aminocarbonylamino, aminocarbonylaminomethyl, cyano, carboxy, carbalkoxy, carboxyalkyl, carbalkoxyalkyl, alkanoyl, ω-(dialkylamino)alkanoyl, ω-(carboxy)alkanoyl, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different, or

R 10 together with R 12 and Y 3 denotes a 4- to 7-membered cycloaliphatic ring in which a methylene group may be replaced by an —NH— or —N(alkyl)— group,

whilst a hydrogen atom bound to a nitrogen atom within the group R 10 may be replaced by a protecting group,

R 12 denotes a hydrogen atom,

a C 1-4 -alkyl group, wherein an unbranched alkyl group may be substituted in the co-position by a phenyl, pyridinyl, diazinyl, amino, alkylamino, dialkylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-methyl-1-piperazinyl, 4-morpholinyl- or hexahydro-1H-1-azepinyl group,

an alkoxycarbonyl, cyano or aminocarbonyl group or a free pair of electrons, if Y 3 denotes a nitrogen atom, and

R 13 and R 14 in each case denote a hydrogen atom or,

if Y 3 is a carbon atom, R 12 together with R 14 also denotes another carbon-carbon bond, wherein R 10 is as hereinbefore defined and R 13 denotes a hydrogen atom or

if Y 3 is a carbon atom, R 12 together with R 14 also denotes another carbon-carbon bond and R 10 together with R 13 and the enclosed double bond denotes a partially hydrogenated or aromatic 5- to 7-membered mono- or bicyclic carbocycle or heterocycle,

whilst all the above-mentioned alkyl and alkoxy groups and the alkyl groups present within the other groups mentioned may contain 1 to 7 carbon atoms, unless otherwise specified,

all the above-mentioned cycloalkyl groups and the cycloalkyl groups present within the other groups named may contain 5 to 10 carbon atoms, unless otherwise specified, and

the term “aroyl group” used above denotes, for example, the benzoyl or naphthoyl group.

The protecting groups mentioned in the foregoing definitions and hereinafter are the protecting groups which are commonly known from peptide chemistry, particularly

a phenylalkoxycarbonyl group having 1 to 3 carbon atoms in the alkoxy moiety, optionally substituted in the phenyl nucleus by a halogen atom, by a nitro or phenyl group or by one or two methoxy groups,

for example the benzyloxycarbonyl, 2-nitro-benzyloxycarbonyl, 4-nitro-benzyloxycarbonyl, 4-methoxy-benzyloxycarbonyl, 2-chloro-benzyloxycarbonyl, 3-chloro-benzyloxycarbonyl, 4-chloro-benzyloxycarbonyl, 4-Biphenylyl-α,α-dimethyl-benzyloxycarbonyl or 3,5-dimethoxy-α,α-dimethyl-benzyloxycarbonyl group,

an alkoxycarbonyl group having a total of 1 to 5 carbon atoms in the alkyl moiety,

for example the methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, 1-methylpropoxycarbonyl, 2-methylpropoxycarbonyl or tert.butyloxycarbonyl group,

the allyloxycarbonyl, 2,2,2-trichloro-(1,1-dimethylethoxy)carbonyl or 9-fluorenylmethoxycarbonyl group or

the formyl, acetyl or trifluoroacetyl group.

The present invention relates to racemates, where the compounds of general formula I have only one chiral element. However, the application also covers the individual diastereomeric pairs of antipodes or mixtures thereof which occur when there is more than one chiral element in the compounds of general formula (I).

Particularly preferred are compounds of general formula I wherein Z denotes NR 1 and m assumes the value 0 and which are in the D- or (R)-configuration with regard to the partial amino acid structure of the formula

and which are in the L- or (S)-configuration with regard to the partial amino acid structure of formula

which may be present in the group A. As for the other compounds covered by general formula I, the preferred isomers are those which are spatially constructed analogously to the (R)-configured partial structure of formula V with regard to the partial structure of formula VI

The compounds of general formula I have valuable pharmacological properties based on their selective CGRP-antagonistic properties. The invention further relates to medicaments containing these compounds, their use and the preparation thereof.

A subgroup of compounds of general formula I which deserves special mention comprises those wherein

A, R 2 , R 3 , R 4 , R 11 , X, Z and m and n are as hereinbefore defined and

R denotes an unbranched C 1-6 -alkylamino group optionally substituted at the nitrogen atom by a C 1-6 -alkyl group or by a phenylmethyl group, which may be substituted in the ω-position

by a C 4-10 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or biphenylyl group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or 1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl-group,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, contains an oxygen, sulphur or an additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group, or

by a 6-membered heteroaromatic ring linked via a carbon atom and containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene group may be attached both to the 5-membered and to the 6-membered heteroaromatic monocyclic rings via two adjacent carbon atoms in each case and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned above for the substitution of the alkylamino groups in the ω-position and optionally partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 3-8 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino- and benzoylmethylamino groups in turn may additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino or acetylamino group,

whilst all the above-mentioned alkyl and alkoxy groups and the alkyl groups present within the other groups mentioned may contain 1 to 4 carbon atoms, unless otherwise stated,

their tautomers, their diastereomers, their enantiomers, mixtures thereof and the salts thereof.

Another subgroup of compounds of general formula I deserving special mention comprises those wherein

R 2 , R 3 , R 4 , R 11 , X, Z and m and n are defined as for the first subgroup hereinbefore,

R denotes an unbranched C 1-7 -alkyl group which may be substituted in the ω-position

by a C 4-10 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl- or biphenylyl-group,

by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-2H-2-oxoimidazopyridinyl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 1,3-dihydro-2H-2-oxoimidazol-1-yl- or 3,4-dihydro-2(1H)-oxopyrimidin-3-yl-groups, whilst the latter two groups may each be mono- or disubstituted in the 4- and/or 5-position or in the 5- and/or 6-position by lower straight-chained or branched alkyl groups, by phenyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl-1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl groups, and the substituents may be identical or different,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or in addition to a nitrogen atom contains an oxygen, sulphur or an additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group,

or by a 6-membered heteroaromatic ring linked via a carbon atom, which contains one, two or three nitrogen atoms,

whilst a 1,4-butadienylene group may be attached both to the above-mentioned 5-membered and to the 6-membered heteroaromatic monocyclic rings, in each case via two adjacent carbon atoms, and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl- and biphenylyl-groups mentioned hereinbefore for the substitution of the alkyl groups in the ω-position and optionally partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 3 8 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino and benzoylmethylamino groups may in turn additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino or acetylamino group, and

A denotes a single bond,

whilst all the above-mentioned alkyl and alkoxy groups and the alkyl groups present within the other groups mentioned may contain 1 to 4 carbon atoms unless otherwise stated,

their tautomers, their diastereomers, their enantiomers and the salts thereof.

Preferred compounds of the above general formula I are those wherein

R denotes an unbranched C 1-5 -alkyl group which may be substituted in the ω-position

by a C 4-7 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or (4-biphenylyl) group,

by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-2H-2-oxoimidazopyridinyl, 1,3-dihydro-2(2H)-oxoimidazo[4,5c]quinolin-3-yl, 1,3-dihydro-2H-2-oxoimidazol-1-yl or 3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, whilst the latter two groups may each be mono- or disubstituted in the 4- and/or 5-position or in the 5- and/or 6-positions by lower straight-chained or branched alkyl groups, by phenyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl-1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl groups, and the substituents may be identical or different,

by a 5-membered heteroaromatic ring linked via a carbon atom and containing a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, an oxygen, sulphur or additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group,

or by a 6-membered heteroaromatic ring linked via a carbon atom and containing one or two nitrogen atoms,

whilst a 1,4-butadienylene group may be attached both to the 5-membered and to the 6-membered heteroaromatic monocyclic rings via two adjacent carbon atoms in each case and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

or an unbranched C 1-4 -alkylamino group optionally substituted at the nitrogen atom by a C 1-3 -alkyl group or by a phenylmethyl group, which may be substituted in the ω-position

by a C 4-7 -cycloalkyl group, by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or (4-biphenylyl) group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl or 1,3-dihydro-2H-2-oxo-imidazo[4,5-b]pyridin-3-yl group,

by a 5-membered heteroaromatic ring linked via a carbon atom and containing a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, an oxygen, sulphur or additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group,

or by a 6-membered heteroaromatic ring linked via a carbon atom and containing 1 or 2 nitrogen atoms, whilst a 1,4-butadienylene group may be attached to both the 5-membered and to the 6-membered heteroaromatic monocyclic rings via two adjacent carbon atoms in each case and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned above for the substitution of the alkyl and alkylamino groups in the ω-position and optionally also partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms or by alkyl groups, C 5-7 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, wherein the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino and benzoylmethylamino groups may in turn additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino or acetylamino group, or the group of formula

 wherein

p denotes the number 1 or 2,

o denotes the number 2 or, if Y 1 and Y 2 are not simultaneously nitrogen atoms, o may also denote 1.

Y 1 denotes the nitrogen atom if R 5 is a free pair of electrons, or the carbon atom,

Y 2 is the nitrogen atom or the group >CH—,

R 5 is a free pair of electrons if Y 1 denotes the nitrogen atom or, if Y 1 denotes the carbon atom, R 5 denotes a hydrogen atom, a C 1-3 -alkyl group, a hydroxy, cyano, aminocarbonyl, carboxy, alkoxycarbonyl, aminocarbonylamino, phenylmethyl or phenyl group,

R 6 denotes the hydrogen atom or, provided that Y 1 is not a nitrogen atom, R 6 together with R 5 may denote an additional bond,

R 7 denotes the hydrogen atom or, provided that Y 1 is not a nitrogen atom and R 5 and R 6 together constitute an additional bond, R 7 together with R N may also denote a 1,4-butadienylene group,

R N denotes the hydrogen atom or a C 1-3 -alkyl group, which may be monosubstituted in the ω-position

by a C 5-7 -cycloalkyl group or by a 1-naphthyl, 2-naphthyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, piperidinyl, morpholinyl, pyrrolidinyl, hexahydro-1H-1-azepinyl, aminocarbonyl, alkylaminocarbonyl, acetylamino, cyano, aminocarbonylamino or alkylaminocarbonylamino group, or may be mono- or disubstituted by phenyl, pyridinyl or diazinyl groups, whilst these substituents may be identical or different,

a cyclohexyl, phenyl, pyridinyl, cyano, amino, benzoylamino, aminocarbonyl, alkylaminocarbonyl, alkoxycarbonyl, phenylalkoxycarbonyl, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, N-(aminocarbonyl)-N-alkylamino, N-(alkylaminocarbonyl)-N-alkylamino, N-(alkylaminocarbonyl)-N-phenylamino, phenylaminocarbonylamino, [N-phenyl(alkylamino)]carbonylamino, N-(phenylaminocarbonyl)-N-alkylamino, N-(phenylaminocarbonyl)-N-phenylamino, benzoylaminocarbonylamino, phenylalkylaminocarbonylamino, pyridinylaminocarbonylamino, N-(aminocarbonyl)-N-phenylamino, N-(alkylaminocarbonyl)-N-phenylamino, N-(aminocarbonylaminocarbonyl)-N-phenylamino, N-(pyridinyl)-N-(aminocarbonyl)amino, N-(pyridinyl)-N-(alkylaminocarbonyl)amino, phenylamino, pyridinylamino, diazinylamino or 4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl group,

a saturated, mono- or diunsaturated 5- to 7-membered aza, diaza, triaza, oxaza, thiaza, thiadiaza- or S,S-dioxidothiadiaza heterocycle,

whilst the above-mentioned heterocycles may be linked via a carbon or nitrogen atom and

may contain one or two carbonyl groups adjacent to a nitrogen atom,

may be substituted at one of the nitrogen atoms by an alkyl, alkanoyl, aroyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, phenylalkoxycarbonylalkyl, phenylmethyl or phenyl group,

may be substituted at one or two carbon atoms by a branched or unbranched alkyl group, by a phenyl, phenylmethyl, naphthyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl, 1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl group, whilst the substituents may be identical or different,

and wherein a C 3-4 -alkylene group may additionally be attached to the above-mentioned heterocycles via two adjacent carbon atoms or an olefinic double bond of one of the above-mentioned unsaturated heterocycles may be fused with a benzene, pyridine, diazine, 1,3-oxazole, thiophene, furan, thiazole, pyrrole, N-methyl-pyrrole, quinoline, imidazole or N-methylimidazole ring,

or, provided that Y 1 is not a nitrogen atom and R 5 and R 6 together denote an additional bond, R N together with R 7 may also denote the 1,4-butadienylene group or,

if Y 1 denotes a carbon atom, R N together with R 5 , with the inclusion of Y 1 , may also denote a carbonyl group or a saturated or monounsaturated 5- or 6-membered 1,3-diazaheterocycle which may contain one or two carbonyl groups in the ring adjacent to a nitrogen atom and, if it is unsaturated, may also be benzo-fused at the double bond and substituted at one of the nitrogen atoms by a methyl, aminocarbonyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, phenylalkoxycarbonylalkyl, phenylmethyl or phenyl group,

whilst the phenyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl, 1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl groups contained in the residues mentioned under R 5 , R 7 and R N , as well as benzo-, thieno-, pyrido- and diazinofused heterocycles in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 4-7 -cycloalkyl groups, nitro, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulphonylamino, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, hydroxyalkylaminocarbonyl, (4-morpholinyl)carbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1-azepinyl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, methylenedioxy, aminocarbonylamino, aminocarbonylaminoalkyl, alkylaminocarbonylamino, alkanoyl, cyano, trifluoromethoxy, trifluormethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, wherein the substituents may be identical or different and the alkyl groups contained in the above-mentioned groups may contain 1 to 3 carbon atoms unless otherwise specified,

X denotes the oxygen atom or 2 hydrogen atoms,

Z denotes the methylene group or the group —NR 5 — wherein

R 1 denotes a hydrogen atom or a C 1-3 -alkyl group,

R 11 denotes a hydrogen atom, a C 1-3 -alkyl group or an alkoxycarbonyl group having 2 to 4 carbon atoms altogether,

n denotes the number 1 or 2 or, if m is 1, n may also be 0,

m denotes the number 0 or 1,

R 2 denotes a phenyl, 1-naphthyl, 2-naphthyl, 1,2,3,4-tetrahydro-1-naphthyl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl, 1-formyl-1H-indol-3-yl, 1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl, 4-imidazolyl, 1-methyl-4-imidazolyl, 2-thienyl, 3-thienyl, thiazolyl, 1H-indazol-3-yl, 1-methyl-1H-indazol-3-yl, benzo[b]fur-3-yl, benzo[b]thien-3-yl, pyridinyl, quinolinyl or isoquinolinyl group,

whilst the above-mentioned aromatic and heteroaromatic groups in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, or by branched or unbranched alkyl groups, C 4-7 -cycloalkyl groups, phenylalkyl groups, alkenyl, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonylalkyl, carboxyalkyl, alkoxycarbonyl, carboxy, dialkylaminoalkyl, dialkylaminoalkoxy, hydroxy, nitro, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, methylsulphonyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkanoyl, cyano, tetrazolyl, phenyl, pyridinyl, thiazolyl, furyl, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, and the substituents may be identical or different,

A denotes a bond or the divalent group of formula

(linked to the R 3 R 4 N— group of general formula (I) via the carbonyl group)

 wherein

R 8 and R 9 together denote an n-propylene group or

R 8 denotes a hydrogen atom or a C 1-3 -alkyl group and

R 9 denotes a hydrogen atom or a branched or unbranched C 1-4 -alkyl group which, if it is unbranched, may be substituted in the ω-position

by a hydroxy, mercapto, amino, alkylamino, dialkylamino, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl, hexahydro-1-azepinyl, methylthio, hydroxycarbonyl, aminocarbonyl, aminoiminomethylamino, aminocarbonylamino, phenyl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl, 1-formyl-1H-indol-3-yl, 4-imidazolyl, 1-methyl-4-imidazolyl, 1-naphthyl, 2-naphthyl- or pyridinyl group, whilst the above-mentioned heterocycles and phenyl groups may in turn be mono-, di- or trisubstituted in the carbon skeleton by fluorine, chlorine or bromine atoms, or by methyl, alkoxy, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl, cyano, trifluoromethoxy, methylsulphonyloxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different and any hydroxy, mercapto, amino, guanidino, indolyl and imidazolyl groups contained in the groups mentioned for R 9 may be substituted by a protecting group,

R 3 denotes a hydrogen atom,

a C 1-4 -alkyl group which may be substituted in the ω-position by a cyclohexyl, phenyl, pyridinyl, diazinyl, hydroxy, amino, alkylamino, dialkylamino, carboxy, aminocarbonyl, aminocarbonylamino, acetylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-(1-piperidinyl)-1-piperidinyl, 4-morpholinyl, hexahydro-1H-azepin-1-yl, [bis-(2-hydroxyethyl)]amino, 4-methyl-1-piperazinyl- or 4-(ω-hydroxyalkyl)-1-piperazinyl group,

a phenyl or pyridinyl group,

wherein the above-mentioned heterocyclic radicals and phenyl groups may additionally be mono-, di- or tri-substituted in the carbon skeleton by fluorine, chlorine or bromine atoms or by methyl, alkoxy, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl, cyano, methylsulphonyloxy, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups and the substituents may be identical or different,

R 4 denotes a hydrogen atom or a methyl or ethyl group optionally substituted by a phenyl or pyridinyl group

or R 3 and R 4 together with the enclosed nitrogen atom denote a group of general formula

 wherein

Y 3 denotes a carbon atom or, if R 12 denotes a free pair of electrons, Y 3 may also be the nitrogen atom,

r denotes the number 0, 1 or 2,

q denotes the number 0, 1 or 2,

R 10 denotes a hydrogen atom or an amino, alkylamino, dialkylamino, alkyl, cycloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aminoiminomethyl, aminocarbonylamino, alkylaminocarbonylamino, cycloalkylaminocarbonylamino, phenylaminocarbonylamino, aminocarbonylalkyl, aminocarbonylaminoalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxyalkyl or carboxy group,

a phenyl, pyridinyl, diazinyl, 1-naphthyl, 2-naphthyl, pyridinylcarbonyl or phenylcarbonyl group which may be mono-, di- or trisubstituted in the carbon skeleton by fluorine, chlorine or bromine atoms, or by alkyl, alkoxy, methylsulphonyloxy, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl, aminocarbonylamino, aminocarbonylaminomethyl, cyano, carboxy, carbalkoxy, carboxyalkyl, carbalkoxyalkyl, alkanoyl, ω-(dialkylamino)alkanoyl, ω-(dialkylamino)alkyl, ω-(dialkylamino)hydroxyalkyl, ω-(carboxy)alkanoyl, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl-oder trifluoromethylsulphonyl groups, whilst the substituents may be identical or different,

a 1,3-dihydro-2-oxo-2H-imidazolyl, 2,4(1H,3H)-dioxopyrimidinyl or 3,4-dihydro-2(1H)-oxopyrimidinyl group bound via a nitrogen atom, which may be substituted by a phenyl group or fused at the double bond to a benzene, pyridine or diazine ring,

a 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl group,

a 4- to 10-membered azacycloalkyl group, a 5- to 10-membered oxaza, thiaza or diazacycloalkyl group or a 6- to 10-membered azabicycloalkyl group,

wherein the above-mentioned mono- and bicyclic heterocycles may be bound via a nitrogen or carbon atom and

may be substituted by a C 1-7 -alkyl group, by an alkanoyl, dialkylamino, phenylcarbonyl, pyridinylcarbonyl, carboxyalkanoyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylsulphonyl, cycloalkyl or cycloalkylalkyl group, by a cycloalkylcarbonyl, azacycloalkylcarbonyl, diazacycloalkylcarbonyl or oxazacycloalkylcarbonyl group optionally alkyl substituted in the ring,

whilst the alicyclic parts contained in these substituents may comprise 3 to 10 ring members and the heteroalicyclic parts may comprise 4 to 10 ring members and

the above-mentioned phenyl and pyridinyl groups may in turn be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl, alkoxy, methylsulphonyloxy, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl, aminocarbonylamino, aminocarbonylaminomethyl, cyano, carboxy, carbalkoxy, carboxyalkyl, carbalkoxyalkyl, alkanoyl, ω-(dialkylamino)alkanoyl, ω-(carboxy)alkanoyl, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different, or

R 10 together with R 12 and Y 3 denotes a 4- to 7-membered cycloaliphatic ring in which a methylene group may be replaced by an —NH— or —N(alkyl)-group,

whilst a hydrogen atom bound to a nitrogen atom within the group R 10 may be replaced by a protecting group,

R 12 denotes a hydrogen atom, a C 1-2 -alkyl group which may be substituted in the ω-position by a phenyl, pyridinyl, diazinyl, amino, alkylamino, dialkylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-methyl-1-piperazinyl, 4-morpholinyl or hexahydro-1H-azepin-1-yl-group,

an alkoxycarbonyl, cyano- or aminocarbonyl group or a free pair of electrons, if Y 3 denotes a nitrogen atom, and

R 13 and R 14 in each case denote a hydrogen atom or,

if Y 3 is a carbon atom, R 12 together with R 14 also denotes another carbon-carbon bond, wherein R 10 is as hereinbefore defined and R 13 denotes a hydrogen atom or

if Y 1 is a carbon atom, R 12 together with R 14 also denotes another carbon-carbon bond and R 10 together with R 13 and the enclosed double bond denotes a partially hydrogenated or aromatic 5- to 7-membered mono- or bicyclic carbocycle or heterocycle,

whilst all the above-mentioned alkyl and alkoxy groups and the alkyl groups present within the other groups mentioned may contain 1 to 4 carbon atoms, unless otherwise specified,

all the above-mentioned cycloalkyl groups and the cycloalkyl groups present within the other groups named may contain 5 to 7 carbon atoms, unless otherwise specified, and

the term “aroyl group” used above denotes, for example, the benzoyl or naphthoyl group,

their tautomers, their diastereomers, their enantiomers and their salts.

One subgroup of preferred compounds of general formula I deserving special mention comprises those wherein

A, R 2 , R 3 , R 4 , R 11 , X, Z and m and n are defined as given hereinbefore defined for the preferred compounds of general formula I,

R denotes an unbranched C 1-4 -alkylamino group optionally substituted at the nitrogen atom by a C 1-3 -alkyl group or by a phenylmethyl group, which may be substituted in the ω-position

by a C 4-7 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or (4-biphenylyl) group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl or 1,3-dihydro-2H-2-oxo-imidazo[4,5-b]pyridin-3-yl group,

by a 5-membered heteroaromatic ring linked via a carbon atom, and containing a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, an oxygen, sulphur or additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group,

or by a 6-membered heteroaromatic ring linked via a carbon atom and containing 1 or 2 nitrogen atoms, whilst a 1,4-butadienylene group may be attached both to the 5-membered and to the 6-membered heteroaromatic monocyclic rings via two adjacent carbon atoms in each case and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned above for the substitution of the alkylamino groups in the ω-position and optionally partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 5-7 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino- and benzoylmethylamino groups in turn may additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino or acetylamino group,

whilst all the above-mentioned alkyl and alkoxy groups and the alkyl groups present within the other groups mentioned may contain 1 to 4 carbon atoms, unless otherwise stated,

their tautomers, their diastereomers, their enantiomers, mixtures thereof and the salts thereof.

Another subgroup of compounds of general formula I deserving special mention comprises those wherein

R 2 , R 3 , R 4 , R 11 , X, Z and m and n are defined as for the first preferred subgroup hereinbefore,

R denotes an unbranched C 1-5 -alkyl group which may be substituted in the ω-position

by a C 4-7 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or (4-biphenylyl) group,

by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-2H-2-oxoimidazopyridinyl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 1,3-dihydro-2H-2-oxoimidazol-1-yl or 3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, whilst the latter two groups may each be mono- or disubstituted in the 4- and/or 5-position or in the 5- and/or 6-position by lower straight-chained or branched alkyl groups, by phenyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl-1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl groups, and the substituents may be identical or different,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or in addition to a nitrogen atom contains an oxygen, sulphur or an additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group,

or by a 6-membered heteroaromatic ring linked via a carbon atom, which contains one or two nitrogen atoms,

whilst a 1,4-butadienylene group may be attached both to the 5-membered and to the 6-membered heteroaromatic monocyclic rings, in each case via two adjacent carbon atoms, and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned hereinbefore for the substitution of the alkyl groups in the ω-position and optionally partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 5-7 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino and benzoylmethylamino groups may in turn additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino or acetylamino group, and

A denotes a single bond,

whilst all the above-mentioned alkyl and alkoxy groups and the alkyl groups present within the other groups mentioned may contain 1 to 4 carbon atoms unless otherwise stated,

their tautomers, their diastereomers, their enantiomers, mixtures thereof and the salts thereof.

Preferred compounds of the above general formula I are those wherein

R denotes an unbranched C 1-3 -alkyl group which may be substituted in the ω-position

by a C 5-7 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or (4-biphenylyl) group,

by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 1,3-dihydro-2H-2-oxoimidazol-1-yl or 3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, whilst the latter two groups may be substituted in the carbon skeleton by a phenyl, pyridinyl or diazinyl group,

by a 5-membered heteroaromatic ring linked via a carbon atom and containing a nitrogen, oxygen or sulphur atom or two nitrogen atoms, wherein a nitrogen of an imino group may be substituted by an alkyl group,

or may be substituted by a pyridinyl group,

whilst a 1,4-butadienylene group may be attached both to the 5-membered heteroaromatic monocyclic rings and to the pyridinyl group, in each case via two adjacent carbon atoms, and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

or an unbranched C 1-4 -alkylamino group optionally substituted at the nitrogen atom by a methyl or ethyl group, which may be substituted in the ω-position

by a C 5-7 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or (4-biphenylyl) group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2(1H)-oxoquinolin-3-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl or 1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl group,

by a 5-membered heteroaromatic ring linked via a carbon atom and containing a nitrogen, oxygen or sulphur atom or two nitrogen atoms, whilst a nitrogen atom of an imino group may be substituted by an alkyl group,

or by a pyridinyl group,

whilst a 1,4-butadienylene group may be attached both to the 5-membered heteroaromatic monocyclic rings and to the pyridinyl group, in each case via two adjacent carbon atoms, and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned hereinbefore for the substitution of the alkyl and alkylamino groups in the ω-position as well as optionally partially hydrogenated mono- and bicyclic heteroaromatic rings may additionally be mono- or disubstituted in the carbon skeleton by fluorine, chlorine or bromine atoms or by alkyl, nitro, alkoxy, trifluoromethyl, hydroxy, amino, acetylamino, propionylamino, alkanoyl, cyano or trifluoromethoxy groups, whilst the substituents may be the same or different,

or the group of formula

 wherein

p denotes the number 1 or 2,

o denotes the number 2 or, if Y 1 and Y 2 are not simultaneously nitrogen atoms, it may also denote the number 1,

Y 1 denotes the nitrogen atom if R 5 denotes a free pair of electrons, or the carbon atom,

Y 2 denotes the nitrogen atom or the group >CH—,

R 5 denotes a free pair of electrons if Y 1 denotes the nitrogen atom or, if Y 1 denotes the carbon atom, R 5 denotes a hydrogen atom, a C 1-3 -alkyl group, a hydroxy, cyano, aminocarbonyl, carboxy, alkoxycarbonyl or aminocarbonylamino group or a phenylmethyl or phenyl group optionally substituted at the aromatic moiety by a fluorine, chlorine or bromine atom or by a methyl, methoxy, ethoxy, trifluoromethyl, hydroxy, amino or acetylamino group,

R 6 denotes the hydrogen atom or, if Y 1 is not a nitrogen atom, R 6 together with R 5 may also denote an additional bond,

R 7 denotes the hydrogen atom or, provided that Y 1 is not a nitrogen atom and R 5 and R 6 together denote an additional bond, R 7 together with R N may also denote the 1,4-butadienylene group,

R N denotes the hydrogen atom or a C 1-3 -alkyl group, which may be monosubstituted in the ω-position

by a C 5-7 -cycloalkyl group or by a 1-naphthyl, 2-naphthyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, piperidinyl, morpholinyl, pyrrolidinyl, hexahydro-1H-1-azepinyl, aminocarbonyl, methylaminocarbonyl, acetylamino, cyano, aminocarbonylamino or alkylaminocarbonylamino group, or may be mono- or disubstituted by phenyl, pyridinyl or diazinyl groups, whilst these substituents may be identical or different,

a cyclohexyl, phenyl, pyridinyl, cyano, amino, benzoylamino, aminocarbonyl, alkylaminocarbonyl, alkoxycarbonyl, phenylalkoxycarbonyl, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, N-(aminocarbonyl)-N-alkylamino, N-(alkylaminocarbonyl)-N-alkylamino, N-(alkylaminocarbonyl)-N-phenylamino, phenylaminocarbonylamino, [N-phenyl(alkylamino)]carbonylamino, N-(phenylaminocarbonyl)-N-alkylamino, N-(phenylaminocarbonyl)-N-phenylamino, benzoylaminocarbonylamino, phenylalkylaminocarbonylamino, pyridinylaminocarbonylamino, N-(aminocarbonyl)-N-phenylamino, N-(alkylaminocarbonyl)-N-phenylamino, N-(aminocarbonylaminocarbonyl)-N-phenylamino, N-(pyridinyl)-N-(aminocarbonyl)amino, N-(pyridinyl)-N-(alkylaminocarbonyl)amino, phenylamino, pyridinylamino, diazinylamino or 4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl group,

a saturated, mono- or diunsaturated 5- to 7-membered aza, diaza, triaza, oxaza, thiaza, thiadiaza or S,S-dioxidothiadiaza heterocycle,

whilst the above-mentioned heterocycles may be linked via a carbon or nitrogen atom and

may contain one or two carbonyl groups adjacent to a nitrogen atom,

may be substituted at one of the nitrogen atoms by an alkyl, alkanoyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, phenylalkoxycarbonylalkyl, phenylmethyl or phenyl group,

may be substituted at one or two carbon atoms by a methyl, phenyl, phenylmethyl, naphthyl, biphenylyl, thienyl, pyridinyl or diazinyl group, wherein the substituents may be identical or different,

and wherein a C 3-4 -alkylene group may additionally be attached to the above-mentioned heterocycles via two adjacent carbon atoms or an olefinic double bond of one of the above-mentioned heterocycles may be fused to a thiophene, benzene, pyridine, quinoline or diazine ring,

or, if Y 1 is not a nitrogen atom and R 5 and R 6 together denote an additional bond, R N together with R 7 may also denote a 1,4-butadienylene group or,

if Y 1 denotes a carbon atom, R N together with R 5 with the inclusion of Y 1 may also denote a carbonyl group or a saturated or monounsaturated 5- or 6-membered 1,3-diazaheterocycle which may contain one or two carbonyl groups in the ring adjacent to a nitrogen atom and, if it is unsaturated, may also be benzo-fused at the double bond and may be substituted at one of the nitrogen atoms by a methyl, aminocarbonyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, phenylalkoxycarbonylalkyl, phenylmethyl or phenyl group,

whilst the phenyl, pyridinyl or diazinyl groups contained in the groups mentioned under R N and the thieno-, benzo-, pyrido- or diazino-condensed heterocycles in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by methyl groups, nitro, methoxy, ethoxy, methylsulphonylamino, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, hydroxy, amino, acetylamino, propionylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, hydroxyalkylaminocarbonyl, (4-morpholinyl)carbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1-azepinyl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, methylenedioxy, aminocarbonylamino, aminocarbonylaminoalkyl, methylaminocarbonylamino, acetyl, cyano or trifluoromethoxy groups, whilst the substituents may be identical or different,

and the alkyl groups contained in the above-mentioned radicals may contain 1 to 3 carbon atoms, unless otherwise specified,

X denotes an oxygen atom or 2 hydrogen atoms,

Z denotes a methylene group or the group —NR 1 — wherein

R 1 is a hydrogen atom or a methyl group,

R 11 denotes the hydrogen atom or a methyl or methoxycarbonyl group,

n denotes the number 1 or 2 or, if m is the number 1, n may also denote 0,

m denotes the number 0 or 1,

R 2 denotes a phenyl, 1-naphthyl, 2-naphthyl, 1,2,3,4-tetrahydro-1-naphthyl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl, 1-formyl-1H-indol-3-yl, 1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl, 4-imidazolyl, 1-methyl-4-imidazolyl, 2-thienyl, 3-thienyl, thiazolyl, pyridinyl or quinolinyl group,

wherein the above-mentioned aromatic and heteroaromatic groups may additionally be mono-, di- or trisubstituted in the carbon skeleton by fluorine, chlorine or bromine atoms, by branched or unbranched C 1-5 -alkyl groups, allyl, vinyl, methoxy, ethoxy, propoxy, 1-methylethoxy, dimethylaminoethoxy, trifluoromethyl, hydroxy, nitro, amino, acetylamino, propionylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, acetyl, cyano, methylsulphonyloxy or trifluoromethoxy groups, by tetrazolyl, phenyl pyridinyl, thiazolyl or furyl groups and the substituents may be identical or different, or

A denotes a bond or the divalent group of formula

(linked to the NR 3 R 4 -group of general formula (I) via the carbonyl group)

 wherein

R 8 and R 9 together denote an n-propylene group or

R 8 denotes the hydrogen atom or the methyl group and

R 9 denotes a hydrogen atom or an unbranched C 1-4 -alkyl group which may be substituted in the ω-position

by a hydroxy, amino, methylamino, dimethylamino, hydroxycarbonyl, aminocarbonyl, aminoiminomethylamino, aminocarbonylamino, phenyl or pyridinyl group, wherein the phenyl and pyridinyl group may in turn be substituted in the carbon skeleton by a fluorine, chlorine or bromine atom or by a methyl, methoxy, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl or cyano group and wherein any hydroxy, amino and guanidino groups contained in the groups given for R 9 may be substituted by a protecting group, e.g. the phenylmethoxycarbonyl or tert.butyloxycarbonyl group,

R 3 denotes a hydrogen atom,

a C 1-4 -alkyl group optionally substituted in the ω-position by a cyclohexyl, phenyl, pyridinyl, hydroxy, amino, methylamino, dimethylamino, carboxy, aminocarbonyl, aminocarbonylamino, acetylamino, 1-pyrrolidinyl, 1-piperidinyl or 4-(1-piperidinyl)-1-piperidinyl group,

a phenyl or pyridinyl group,

whilst the above-mentioned phenyl and pyridinyl groups may additionally be substituted in the carbon skeleton by a fluorine, chlorine or bromine atom or by a methyl, methoxy, trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl or cyano group,

R 4 denotes the hydrogen atom or a C 1-2 -alkyl group optionally substituted by a phenyl or pyridinyl group

or R 3 and R 4 together with the enclosed nitrogen atom denote a group of general formula

 wherein

Y 3 denotes a carbon atom or, if R 12 denotes a free pair of electrons, Y 3 may also be a nitrogen atom,

r denotes the number 0, 1 or 2,

q denotes the number 0, 1 or 2,

with the proviso that the sum of the numbers given for r and q is 0, 1, 2 or 3,

R 10 denotes a hydrogen atom, an alkyl, cycloalkyl, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, phenylaminocarbonylamino, alkoxycarbonyl, alkoxycarbonylmethyl, carboxymethyl or carboxy group,

a phenyl, pyridinyl, diazinyl, pyridinylcarbonyl or phenylcarbonyl group which may be mono- or disubstituted in the carbon skeleton by fluorine, chlorine or bromine atoms, or by methyl, ethyl, propyl, methoxy, hydroxy, ω-(dialkylamino)-alkyl, ω-(dialkylamino)hydroxyalkyl or alkanoyl groups, whilst the substituents may be identical or different,

a 1,3-dihydro-2-oxo-2H-imidazolyl, 2,4(1H,3H)-dioxopyrimidinyl or 3,4-dihydro-2(1H)-oxopyrimidinyl group bound via a nitrogen atom, which may be substituted by a phenyl group or may be fused at the double bond to a benzene, pyridine or diazine ring,

a 5- to 7-membered azacycloalkyl group, a 4- to 7-membered oxaza- or diazacycloalkyl group or a 7- to 9-membered azabicycloalkyl group,

wherein the above-mentioned mono- and bicyclic heterocycles are bound via a nitrogen or a carbon atom and

may be substituted by a C 1-7 -alkyl group, or by an alkanoyl, dialkylamino, phenylcarbonyl, carboxyalkanoyl, carboxyalkyl, alkoxycarbonylalkyl or alkoxycarbonyl group having 1 to 4 carbon atoms in the alkoxy moiety, alkylsulphonyl, cycloalkyl or cycloalkylalkyl group or by an azacycloalkylcarbonyl or diazacycloalkylcarbonyl group optionally alkylsubstituted in the ring,

whilst the alicyclic groups contained in these substituents may comprise 3 to 7 ring members and the heteroalicyclic groups may comprise 4 to 7 ring members and

the above-mentioned phenylcarbonyl group may be substituted by a fluorine, chlorine or bromine atom or by a methyl, methoxy, trifluoromethyl, hydroxy, amino or acetylamino group, or

R 10 together with R 12 and Y 3 denotes a 4- to 6-membered cycloaliphatic ring in which a methylene group may be replaced by an —NH— or —N(CH 3 )-group,

whilst a hydrogen atom bound to a nitrogen atom within the group R 10 may be replaced by a protecting group, e.g. the phenylmethoxycarbonyl or tert.butyloxycarbonyl group,

R 12 denotes a hydrogen atom, a C 1-2 -alkyl group which may be substituted in the ω-position by a phenyl, pyridinyl, amino, alkylamino, dialkylamino, 1-pyrrolidinyl, 1-piperidinyl or 4-methyl-1-piperazinyl group,

a methoxycarbonyl or ethoxycarbonyl, cyano or aminocarbonyl group or a free pair of electrons, if Y 3 denotes a nitrogen atom, and

R 13 and R 14 each denote a hydrogen atom or,

if Y 3 is a carbon atom, R 12 together with R 14 also denotes another carbon-carbon bond, wherein R 10 is as hereinbefore defined and R 13 denotes a hydrogen atom, or

if Y 3 is a carbon atom, R 12 together with R 14 also denotes another carbon-carbon bond and R 10 together with R 13 and the enclosed double bond denotes a partially hydrogenated or aromatic 5- or 6-membered mono- or bicyclic carbocycle or heterocycle, containing one or two nitrogen atoms,

whilst all the above-mentioned alkyl and alkoxy groups and the alkyl groups present within the other groups named may contain 1 to 3 carbon atoms, unless otherwise stated, and

all the above-mentioned cycloalkyl groups and the cycloalkyl groups present within the other groups named may contain 5 to 7 carbon atoms, unless otherwise specified,

their tautomers, their diastereomers, their enantiomers, mixtures thereof and the salts thereof.

One subgroup of particularly preferred compounds of general formula I deserving special mention comprises those wherein

A, R 2 , R 3 , R 4 , R 11 , X, Z and m and n are defined as for the particularly preferred compounds of general formula I hereinbefore and

R denotes an unbranched C 1-4 -alkylamino group optionally substituted at the nitrogen atom by a methyl or ethyl group, which may be substituted in the ω-position

by a C 5-7 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or (4-biphenylyl) group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2(1H)-oxoquinolin-3-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl or 1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl group,

by a 5-membered heteroaromatic ring linked via a carbon atom and containing a nitrogen, oxygen or sulphur atom or two nitrogen atoms, whilst a nitrogen atom of an imino group may be substituted by an alkyl group,

or by a pyridinyl group,

whilst a 1,4-butadienylene group may be attached both to the 5-membered heteroaromatic monocyclic rings and also to the pyridinyl group, in each case via two adjacent carbon atoms, and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned hereinbefore for the substitution of the alkylamino groups in the ω-position, as well as optionally any partially hydrogenated mono- and bicyclic heteroaromatic rings, may additionally be mono- or disubstituted in the carbon skeleton by fluorine, chlorine or bromine atoms or by alkyl, nitro, alkoxy, trifluoromethyl, hydroxy, amino, acetylamino, propionylamino, alkanoyl, cyano or trifluoromethoxy groups, whilst the substituents may be identical or different,

whilst all the above-mentioned alkyl and alkoxy groups and the alkoxy groups present within the other named radicals may contain 1 to 3 carbon atoms unless otherwise stated,

their tautomers, their diastereomers, their enantiomers, mixtures thereof and the salts thereof.

Another subgroup of particularly preferred compounds of general formula I which deserves special mention comprises those compounds wherein

R 2 , R 3 , R 4 , R 11 , X, Z and m and n are as hereinbefore defined for the first-mentioned particularly preferred subgroup,

R denotes an unbranched C 1-3 -alkyl group which may be substituted in the ω-position

by a C 5-7 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or (4-biphenylyl) group,

by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 1,3-dihydro-2H-2-oxoimidazol-1-yl or 3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, whilst the latter two groups may be substituted in the carbon skeleton by a phenyl, pyridinyl or diazinyl group,

by a 5-membered heteroaromatic ring linked via a carbon atom and containing a nitrogen, oxygen or sulphur atom or two nitrogen atoms, wherein a nitrogen atom of an imino group may be substituted by an alkyl group,

or by a pyridinyl group,

whilst a 1,4-butadienylene group may be attached both to the 5-membered heteroaromatic monocyclic rings and also to the pyridinyl group via two adjacent carbon atoms in each case and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned hereinbefore for the substitution of the alkyl groups in the ω-position as well as optionally any partially hydrogenated mono- and bicyclic heteroaromatic rings may additionally be mono- or disubstituted in the carbon skeleton by fluorine, chlorine or bromine atoms or by alkyl, nitro, alkoxy, trifluoromethyl, hydroxy, amino, acetylamino, propionylamino, alkanoyl, cyano or trifluoromethoxy groups wherein the substituents may be identical or different,

and A denotes a single bond,

whilst all the above-mentioned alkyl and alkoxy groups and the alkyl groups present within the other groups mentioned may contain 1 to 3 carbon atoms unless otherwise specified,

their tautomers, their diastereomers, their enantiomers and their salts.

More particularly preferred compounds of the above general formula I are those wherein

R denotes an unbranched C 1-3 -alkyl group which may be substituted in the ω-position

by a C 5-7 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or (4-biphenylyl) group, whilst the above-mentioned aromatic groups may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl, methoxy, amino or acetylamino group,

by a 2-pyrrolyl, 3-pyrrolyl, pyridinyl, 1H-indol-3-yl, quinolinyl or isoquinolinyl group,

or an unbranched C 1-4 -alkylamino group which is optionally additionally substituted at the nitrogen atom by a methyl or ethyl group and which may be substituted in the ω-position

by a C 5-7 -cycloalkyl group,

by a phenyl group which may be mono- or disubstituted by fluorine, chlorine or bromine atoms, or by methyl, nitro, methoxy, trifluoromethyl, hydroxy, amino or acetylamino groups, whilst the substituents may be identical or different,

by a 2-pyrrolyl, 3-pyrrolyl, pyridinyl, 1H-indol-3-yl, quinolinyl or isoquinolinyl group,

or the group of formula

 wherein

p denotes the number 1 or 2,

o denotes the number 2 or, if Y 1 and Y 2 are not simultaneously nitrogen atoms, it may also denote the number 1,

Y 1 denotes the nitrogen atom if R 5 denotes a free pair of electrons, or the carbon atom,

Y 2 denotes the nitrogen atom or the group >CH—,

R 5 denotes a free pair of electrons, if Y 1 denotes the nitrogen atom or, if Y 1 denotes the carbon atom, R 5 may denote the hydrogen atom, a C 1-2 -alkyl group or the cyano or phenyl group,

R 6 denotes the hydrogen atom or, provided that Y 1 is not a nitrogen atom, R 6 together with R 5 may also denote an additional bond,

R 7 denotes the hydrogen atom or, provided that Y 1 is not a nitrogen atom and R 5 and R 6 together denote an additional bond, R 7 together with R N may also denote the 1,4-butadienylene group,

R N denotes the hydrogen atom or a C 1-3 -alkyl group, which may be substituted in the ω-position

by one or two phenyl or pyridinyl groups, wherein the substituents may be identical or different,

or by a hydroxy or methoxy group,

a phenyl group which may be mono- or disubstituted by fluorine, chlorine or bromine atoms or by methyl groups, nitro, methoxy, ethoxy, trifluoromethyl, hydroxy or cyano groups, whilst the substituents may be identical or different, or a phenyl group substituted by a methylenedioxy group,

a 2-pyridinyl or 4-pyridinyl group,

an amino, benzoylamino, aminocarbonyl, methylaminocarbonyl, methoxycarbonyl, ethoxycarbonyl, aminocarbonylamino, methylaminocarbonylamino, N-(aminocarbonyl)-N-methylamino, N-(methylaminocarbonyl)-N-methylamino, N-(aminocarbonyl)-N-(4-fluorophenyl)amino, N-(methylaminocarbonyl)-N-phenylamino, phenylaminocarbonylamino, [N-phenyl(methylamino)]carbonylamino, N-(phenylaminocarbonyl)-N-methylamino, N-(phenylaminocarbonyl)-N-phenylamino, benzoylaminocarbonylamino, N-(aminocarbonyl)-N-phenylamino group or a phenylamino group optionally substituted in the phenyl ring by an aminocarbonylamino or methylsulphonylamino group,

a 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, a 1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxobenzimidazol-1-yl, 1,3,3a,4,5,6,7,7a-octahydro-2(2H)-oxobenzimidazol-1-yl, 1H-indol-3-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl, 1,3(2H)-dioxo-1H-isoindol-2-yl, 1H-benzimidazol-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 2(3H)-oxobenzoxazol-3-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-d]pyrimidin-3-yl, 2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl, 3,4-dihydro-2(1H)-oxopyrido[2,3-d]pyrimidin-3-yl, 2(1H)-oxoquinolin-3-yl, 3,4-dihydro-2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 3,4,4a,5,6,7,8,8a-octahydro-2(1H)-oxoquinazolin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl, 1,3-dihydro-5-methyl-4-phenyl-2(2H)-oxoimidazol-1-yl, 2,5-dioxo-4-phenylimidazolidin-1-yl, 2,5-dioxo-4-(phenylmethyl)-imidazolidin-1-yl, 3,4-dihydro-2,2-dioxido-2,1,3-benzothiadiazin-3-yl, 1,3-dihydro-4-(4-biphenylyl)-2(2H)-oxoimidazol-1-yl, 1,3-dihydro-4-(2-naphthyl)-2(2H)-oxoimidazol-1-yl, 1,3-dihydro-4,5-diphenyl-2(2H)-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 4-phenyl-2(1H)-oxopyrimidin-1-yl, 4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl, 3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2[1H]-oxopyrido[4,3-d]pyrimidin-3-yl or 2,3-dihydro-4(1H)-oxoquinazolin-3-yl group,

wherein the above-mentioned mono- and bicyclic heterocycles may be substituted at one of the nitrogen atoms by a methoxycarbonylmethyl group and/or

the above-mentioned mono- and bicyclic heterocycles may be mono-, di- or trisubstituted in the carbon skeleton and/or at the phenyl groups contained in these groups by fluorine, chlorine or bromine atoms, or by methyl, trifluoromethyl, methoxy, hydroxy, amino, nitro, phenyl, phenylmethyl, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, hydroxyethylaminocarbonyl, (4-morpholinyl)carbonyl, (1-piperidinyl)carbonyl or (4-methyl-1-piperazinyl)carbonyl groups wherein the substituents may be identical or different and multiple substitution with the last three substituents is ruled out,

or, provided that Y 1 is not a nitrogen atom and R 5 and R 6 together denote an additional bond, R N together with R 7 also denotes the 1,4-butadienylene group,

or, provided that Y 1 denotes a carbon atom, R N together with R 5 with the inclusion of Y 1 may also denote a carbonyl group or saturated or monounsaturated five- or six-membered 1,3-diaza-heterocycle,

which may contain a carbonyl group in the ring, adjacent to a nitrogen atom,

may be substituted by a phenyl group at one of the nitrogen atoms

and, if it is unsaturated, may also be benzo-condensed at the double bond,

X denotes an oxygen atom or 2 hydrogen atoms,

Z denotes a methylene group or the group —NR 1 , wherein

R 1 denotes a hydrogen atom or a methyl group,

R 11 denotes a hydrogen atom, a methoxycarbonyl, ethoxycarbonyl or methyl group,

n denotes the number 1 and m denotes the number 0 or

n denotes the number 0 and m denotes the number 1,

R 2 denotes a phenyl, 1-naphthyl, 2-naphthyl, 1,2,3,4-tetrahydro-1-naphthyl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl, 1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl, 2-thienyl, 3-thienyl, thiazolyl or alkylthiazolyl group having 1 to 3 carbon atoms in the alkyl moiety, a pyridinyl or quinolinyl group,

wherein the above-mentioned phenyl and naphthyl groups may be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms or by branched or unbranched C 1-5 -alkyl groups, by C 1-3 -alkoxy groups, by vinyl, allyl, trifluoromethyl, methylsulphonyloxy, 2-(dimethylamino)ethoxy, hydroxy, cyano, nitro or amino groups, by tetrazolyl, phenyl, pyridinyl, thiazolyl or furyl groups and the substituents may be identical or different, and multiple substitution with the last five substituents is ruled out,

A denotes a bond or the divalent group of formula

(linked to the group —NR 3 R 4 of formula (I) via the carbonyl group)

 wherein

R 8 and R 9 together denote an n-propylene group or

R 8 denotes the hydrogen atom or the methyl group and

R 9 denotes the hydrogen atom or an unbranched C 1-4 -alkyl group,

which may be substituted in the ω-position by an amino, methylamino, dimethylamino, aminoiminomethylamino or aminocarbonylamino group, whilst in the above-mentioned substituents a hydrogen atom bound to a nitrogen atom may be replaced by a protecting group, e.g. the phenylmethoxycarbonyl or tert.butyloxycarbonyl group,

R 3 denotes a hydrogen atom or

a C 1-4 -alkyl group optionally substituted in the ω-position by an amino, methylamino, dimethylamino- or 4-(1-piperidinyl)-1-piperidinyl group,

R 4 denotes a hydrogen atom or a methyl or ethyl group

or R 3 and R 4 together with the enclosed nitrogen atom denote a group of general formula

 wherein

Y 3 denotes the carbon atom or, if R 12 denotes a free pair of electrons, Y 3 may also denote a nitrogen atom,

r denotes the number 1,

q denotes the number 1,

R 10 denotes the hydrogen atom, an alkyl, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, phenylaminocarbonylamino, alkoxycarbonyl, alkoxycarbonylmethyl, carboxymethyl or carboxy group or a cycloalkyl group having 4 to 7 carbon atoms in the ring,

a benzoyl, pyridinylcarbonyl, phenyl, pyridinyl or diazinyl group, each of which may be substituted in the carbon skeleton by a fluorine, chlorine or bromine atom, or by an acetyl, methyl, ethyl or methoxy group, or by a dimethylaminoalkyl group having 1 to 4 carbon atoms in the alkyl moiety optionally hydroxysubstituted in the alkyl moiety,

a 1,3-dihydro-2-oxo-2H-imidazolyl group bound via a nitrogen atom, which may be fused to a benzene or pyridine ring at the double bond,

a 1-pyrrolidinyl, 1-piperidinyl, 4-(dimethylamino)-1-piperidinyl, 4-piperidinyl or 4-morpholinyl group, wherein the nitrogen atom of the 4-piperidinyl group may be substituted by an alkanoyl- or alkyl group each having 1 to 7 carbon atoms or by a benzoyl, methylsulphonyl, 3-carboxy-propionyl, cyclopropylmethyl, alkoxycarbonylmethyl or carboxymethyl group or by a protecting group, e.g. the phenylmethoxycarbonyl or tert.butyloxycarbonyl group, or it may represent a hexahydro-1H-1-azepinyl, 8-methyl-8-azabicyclo[3,2,1]oct-3-yl, 4-alkyl-1-piperazinyl, hexahydro-4-alkyl-1H-1,4-diazepin-1-yl, 1-alkyl-4-piperidinylcarbonyl or 4-alkyl-1-piperazinylcarbonyl group, or

R 10 together with R 12 and Y 3 denotes a 5-membered cycloaliphatic ring in which a methylene group may be replaced by an —NH— or —N(CH 3 )— group,

R 12 denotes a hydrogen atom, a C 1-2 -alkyl group which may be substituted in the ω-position by a 1-pyrrolidinyl, 1-piperidinyl or 4-methyl-1-piperazinyl group,

a methoxycarbonyl or ethoxycarbonyl or a cyano group,

a free pair of electrons if Y 3 denotes a nitrogen atom, and

R 13 and R 14 each denote a hydrogen atom or,

provided that Y 3 is a carbon atom, R 12 together with R 14 may also denote an additional carbon-carbon bond, wherein R 10 is as hereinbefore defined and R 13 denotes a hydrogen atom or,

provided that Y 3 is a carbon atom, R 12 together with R 14 may also denote an additional carbon-carbon bond and R 10 together with R 13 and the enclosed double bond denotes an indole group fused on via the 5-membered ring,

whilst all the above-mentioned alkyl groups and the alkyl groups present within the other named groups may contain 1 to 3 carbon atoms, unless otherwise specified,

their tautomers, their diastereomers, their enantiomers and their salts.

A subgroup of most particularly preferred compounds of general formula I deserving special mention comprises those wherein

A, R 2 , R 3 , R 4 , R 11 , X, Z and m and n are as hereinbefore defined for the most particularly preferred compounds of general formula I and

R denotes an unbranched C 1-4 -alkylamino group optionally substituted at the nitrogen atom by a methyl or ethyl group, which may be substituted in the ω-position

by a C 5-7 -cycloalkyl group,

by a phenyl group, which may be mono- or disubstituted by fluorine, chlorine or bromine atoms or by methyl, nitro, methoxy, trifluoromethyl, hydroxy, amino or acetylamino groups, wherein the substituents may be identical or different, or

by a 2-pyrrolyl, 3-pyrrolyl, pyridinyl, 1H-indol-3-yl, quinolinyl or isoquinolinyl group,

their tautomers, their diastereomers, their enantiomers, mixtures thereof and salts thereof.

Another subgroup of most particularly preferred compounds of general formula I deserving special mention comprises those wherein

R 2 , R 3 , R 4 , R 11 , X, Z and m and n are as defined hereinbefore for the first-mentioned particularly preferred subgroup,

R denotes an unbranched C 1-3 -alkyl group which may be substituted in the ω-position

by a C 5-7 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or (4-biphenylyl) group, whilst the above-mentioned aromatic groups may be substituted by a fluorine, chlorine or bromine atom or by a methyl, methoxy, amino or acetylamino group,

or by a 2-pyrrolyl, 3-pyrrolyl, pyridinyl, 1H-indol-3-yl, quinolinyl- or isoquinolinyl group,

and A denotes a single bond,

their tautomers, their diastereomers, their enantiomers, mixtures thereof and the salts thereof.

The following are mentioned as examples of most particularly preferred compounds:

(1) 1-[N 2 -[N-[[[2-(2-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(2) 1-[N 2 -[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(3) 1-[N 2 -[N-[[[2-(2,5-Dimethoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(4) 1-[N 2 -[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-arginyl]-4-(4-pyridinyl)-piperazine

(5) 1-[N 2 -[N-[[[2-(2,3-dimethoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(6) 1-[N 2 -[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D,L-tyrosyl]-D,L-lysyl]-4-(1-methyl-4-piperidinyl)-piperazine

(7) 1-[N 2 -[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D,L-tyrosyl]-D,L-lysyl]-4-(4-piperidinyl)-piperazine

(8) 1-[N 2 -[N-[[[2-(3,4-dihydroxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D,L-tyrosyl]-D,L-lysyl]-4-(4-pyridinyl)-piperazine

(9) 1-[N 2 -[N-[4-(2-Methoxyphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(10) 1-[N 2 -[N-[4-(3-Methoxyphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(11) 1-[N 2 -[N-[[(2-Phenylethyl)amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(12) 1-[N 2 -[N-[[[2-(4-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(13) 1-[N 2 -[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3-(1-naphthyl)-D-alanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(14) 1-[N 2 -[N-[[[2-(3-Hydroxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(15) 1-[N 2 -[N-[3-(3-Methoxyphenyl)-1-oxopropyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(16) 1-[N 2 -[N-[[[2-(3-Methoxyphenyl)ethyl]methylamino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(17) 1-[N 2 -[N-(4-Phenyl-1-piperazinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(18) 1-[N 2 -[N-[4-(2-Methylphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(19) 1-[N 2 -[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(20) 1-[N 2 -[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dichloro-D,L-tyrosyl]-D,L-lysyl]-4-(4-pyridinyl)-piperazine

(21) 1-[N 2 -[N-[4-(2-Methoxyphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidin

(22) 1-[N 2 -[N-(4,4-Diphenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(23) 1-[N 2 -[N-(4-Phenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(24) 1-[N 2 -[N-[4-(4-Fluorophenyl)-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(25) 1-[N 2 -[N-[4,4-Diphenyl-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(26) 1-[N 2 -[N-[4-Cyclohexyl-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(27) 1-[N 2 -[N-[4-(4-Acetylamino phenyl)-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(28) 1-[N 2 -[N-[4-(2-Methoxyphenyl)-1-piperazinyl]carbonyl]-3,5-dichloro-D,L-tyrosyl]-D,L-lysyl]-4-(4-pyridinyl)-piperazine

(29) 1-[N 2 -[N-[4-[3-(Trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-3,5-dibromo-D,L-tyrosyl]-D,L-lysyl]-4-(4-pyridinyl)-piperazine

(30) 1-[N 2 -[N-[4-(2-Chlorophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(31) 1-[N 2 -[N-[4-(3,4-Methylenedioxy phenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(32) 1-[N 2 -[N-(4-Methyl-1-piperazinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(33) 1-[N 2 -[N-[4-(2-Hydroxyethyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(34) 1-[N 2 -[N-[4-(4-Pyridinyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(35) 1-[N 2 -[N-[4-(2-Pyridinyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(36) 1-[N 2 -[N-[4-(Diphenylmethyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(37) 1-[N 2 -[N-[4-(Phenylmethyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(38) 1-[N 2 -[N-[4-(4-Nitrophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(39) 1-[N 2 -[N-[4-(Ethoxycarbonyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(40) 1-[N 2 -[N-[[[3-(2-Methoxyphenyl)propyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(41) 1-[N 2 -[N-[[[2-(3-Bromophenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(42) 1-[N 2 -[N-[[[2-(3-Nitrophenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(43) 1-[N 2 -[N-[[[2-(3-Acetylaminophenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(44) 1-[N 2 -[N-[[[2-(3-Bromophenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(45) 1-[N 2 -[N-[(1,2,4,5-Tetrahydro-3H-3-benzazepin-3-yl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(46) 1-[N 2 -[N-[[[2-[3-(Trifluoromethyl)phenyl]ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(47) 1-[N 2 -[N-[[[2-(3-Fluorophenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(48) 1-[N 2 -[N-[4-(2-Methoxyphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-fluorophenyl)-piperazine

(49) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[(2-phenylethyl)amino]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(50) 1-[N 2 -[N-[4-(2-Methoxyphenyl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(51) 1-[N 2 -[N-[4-(3-Methoxyphenyl)-1,2,5,6-tetrahydro-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(52) 1-[N 2 -[N-[4-(2-Methoxyphenyl)-1,2,5,6-tetrahydro-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(53) 1-[N 2 -[N-[(4-Biphenylyl)acetyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(54) 1-[N 2 -[N-[4-(4-Bromophenyl)-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(55) 1-[N 2 -[N-[4-(1H-Indol-3-yl)-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(56) 1-[N 2 -[N-(4,4-Diphenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(57) 1-[N 2 -[N-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(58) 1-[N 2 -[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(59) 1-[N 2 -[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(60) 1-[N 2 -[N-[4-(2-Chlorophenyl)-1-piperazinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(61) 1-[N 2 -[N-[4-(2-Chlorophenyl)-1-piperazinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(62) 1-[N 2 -[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(2-pyridinyl)-piperazine

(63) 1-[N 2 -[N-[[[2-(2-Cyclohexyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(64) 1-[N 2 -[N-[4-(2-Chlorophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(65) 1-[N 2 -[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(66) 1-[N 2 -[N-[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(67) 1-[N 2 -[N-[[[2-(1H-Indol-3-yl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(68) 1-[N 2 -[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-methoxyphenyl)-piperazine

(69) 1-[N 2 -[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-pyridinyl)-piperazine

(70) 1-[N 2 -[N-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-methoxyphenyl)-piperazine

(71) 1-[N 2 -[N-(4,4-Diphenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-pyridinyl)-piperazine

(72) 1-[N 2 -[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D,L-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(73) 1-[N 2 -[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D,L-phenylalanyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(74) 1-[N 2 -[N-[4-(2,3-Dichlorophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(75) 1-[N 2 -[N-[4-(3,5-Dichlorophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(76) 1-[N 2 -[N-[4-(2-Cyanphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(77) 1-[N 2 -[N-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-3,5-dibromo-D,L-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(78) 1-[N 2 -[N-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-3,5-dibromo-D,L-phenylalanyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(79) 1-[N 2 -[N-[4-[4-Chloro-3-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(80) 1-[N 2 -[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(81) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(82) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(83) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(84) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-[1-(1-methylethyl)-4-piperidinyl]-piperidine

(85) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-phenylpiperazine

(86) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-6-methyl-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(87) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-5-methyl-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(88) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-5,6-dichloro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(89) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-3-(methoxycarbonylmethyl)-2(2H)-oxobenzimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(90) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperidine

(91) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3,3a,4,5,6,7,7a-octahydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(92) 1-[4-Amino-3,5-dibromo-N-[[4-(benzoylamino))-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(93) 1-[4-Amino-3,5-dibromo-N-[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(94) 1-[4-Amino-3,5-dibromo-N-[(4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(95) 1-[3,5-Dibromo-N-[[4-(benzoylamino)-1-piperidinyl]caronyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(96) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-6-methyl-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(97) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-5-methyl-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(98) 3,5-Dibromo-N 2 -[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosinamide

(99) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-methylpiperazine

(100) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)piperazine

(101) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-phenylpiperazine

(102) 3,5-Dibromo-N 2 -[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N,N-diethyl-D-tyrosinamide

(103) 3,5-Dibromo-N 2 -[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-[(4-(dimethylamino)butyl]-D-tyrosinamide

(104) 1-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(105) 1-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(106) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]piperazine

(107) 1-[4-Amino-3,5-dibromo-N-[(4-cyan-4-phenyl-1-piperidinyl)carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(108) 1-[3,5-Dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(109) 1-[3,5-Dibromo-N-[(4-cyan-4-phenyl-1-piperidinyl)carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(110) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-pyridinyl)-piperazine

(111) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-pyrimidinyl)-piperazine

(112) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(2-pyridinyl)-piperazine

(113) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4(pyrazinyl)-piperazine

(114) 1-[4-Amino-3,5-dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-phenylalanyl]-4-(2-pyridinyl)-piperazine

(115) 1-[3,5-Dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-tyrosyl]-4-(2-pyridinyl)-piperazine

(116) 1-[4-Amino-3,5-dibromo-N-[[4-(2,4(1H,3H)-dioxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(117) 1-[3,5-Dibromo-N-[[4-(2,4(1H,3H)-dioxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(118) 1-[3,5-Dibromo-N-[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(119) 1-[4-Amino-3,5-dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-phenylalanyl]-4-(pyrazinyl)-piperazine

(120) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(2-pyrimidinyl)-piperazine

(121) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxo-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(122) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(123) cis-1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-cyclohexyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(124) trans-1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-cyclohexyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(125) 1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dimethyl-D,L-tyrosyl]-4-(4-pyridinyl)-piperazine

(126) 1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dimethyl-D,L-tyrosyl]-4-(4-pyridinyl)-piperidine

(127) 1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dimethyl-D,L-tyrosyl]-4-(1-piperidinyl)-piperidine

(128) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-fluorophenyl)-piperazine

(129) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(pyrazinyl)-piperazine

(130) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-methoxyphenyl)-piperazine

(131) 1-[4-Amino-3,5-dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-phenylalanyl]-4-(2-methoxyphenyl)-piperazine

(132) 1-[4-Amino-3,5-dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-phenylalanyl]-4-(4-fluorophenyl)-piperazine

(133) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(2-methoxyphenyl)-piperazine

(134) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(135) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(136) 1-[N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(137) 1-[4-Amino-N-[[4-(1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(138) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3(2H)-dioxo-1H-isoindol-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(139) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(140) 1-[N 2 -[3,5-Dibromo-N-[[4-(2,4(1H,3H)-dioxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(141) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(142) 1-[N 2 -[3,5-Dibromo-N-[[4-(2,4(1H,3H)-dioxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(143) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(144) 1-[3,5-Dibromo-N-[(4′(3′H)-oxospiro[piperidine-4,2′(1′H)-quinazolin]-1-yl)carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(145) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(146) 1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D,L-3-(4-pyridinyl)alanyl]-4-(4-pyridinyl)-piperazine

(147) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine

(148) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(149) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(150) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-5-(methoxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(151) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-5-(hydroxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(152) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxomidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(153) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-5-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(154) 1-[N 2 -[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(155) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorophenyl)-piperazine

(156) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(2-fluorophenyl)-piperazine

(157) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-fluorophenyl)-piperazine

(158) 1-[4-Amino-3,5-dibromo-N-[[4-(phenylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(159) 1-(4-Amino-3,5-dibromo-N-[[4-[N-(aminocarbonyl)-N-phenylamino]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(160) 1-[3,5-Dibromo-N-[[4-(aminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

161) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-4-pyrimidinyl)-piperazine

(162) 1-[3,5-Dibromo-N-[[4-[2(3H)-oxobenzoxazol-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(163) 1-[N-[[4-(Aminocarbonylamino)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(164) 1-[4-Amino-3,5-dibromo-N-[[4-(phenylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(165) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyrimidinyl)-piperazine

(166) 1-[3,5-Dibromo-N-[[4-(methylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(167) 1-[3,5-Dibromo-N-[[4-[N-(aminocarbonyl)-methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(168) 1-[N 2 -[N-[[4-(Aminocarbonylamino)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine

(169) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(3-pyridinyl)-piperazine

(170) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(3-pyridinyl)-piperazine

(171) 1-[3,5-Dibromo-N-[[4-(phenylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(172) 1-[3,5-Dibromo-N-[[4-(phenylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(173) 1-[2,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(4-pyridinyl)-piperidine

(174) 1-[2,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(4-pyridinyl)-piperazine

(175) 1-[3,5-Dibromo-N-[[4-[N-(aminocarbonyl)-N-phenylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(176) 1-[N 2 -[3,5-Dibromo-N-[[4-(methylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine

(177) 1-[N 2 -[3,5-Dibromo-N-[[4-[N-(aminocarbonyl)methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine

(178) 1-[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)-methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(179) 1-[N 2 -[N-[[4-(Aminocarbonylamino)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(180) 1-[N 2 -[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine

(181) 1-[N 2 -[3,5-Dibromo-N-[[4-[N-(aminocarbonyl)methylaminol-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(182) 1-[N 2 -[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)amino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(183) 1-[N 2 -[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(184) 1-[N 2 -[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(185) 1-[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(186) 1-[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(187) 1-[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(188) 1-[N 2 -[N-[[4-[2(3H)-Oxobenzoxazol-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(189) 1-[4-Amino-3,5-dibromo-N-[[4-(1H-indol-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(190) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(191) 1-[N 2 -[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(192) 1-[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(193) 1-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-phenylpiperazine

(194) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-cyclohexyl-4-piperidinyl)-piperazine

(195) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(1-piperidinyl)-piperidine

(196) 1-[N 2 -[N-[[4-(2-Cyanophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(1-piperidinyl)-piperidine

(197) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine

(198) 1-[N 2 -[N-[[4-(2-Cyanophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine

(199) 1-[3,5-Dichloro-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(200) 1-[3,5-Dichloro-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(201) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-6-hydroxy-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(202) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-morpholinyl)-piperidine

(203) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(ethoxycarbonyl)-piperidine

(204) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(dimethylamino)-piperidine

(205) 1-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(206) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-pyrrolidinyl)-piperidine

(207) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(methoxycarbonyl)-4-phenylpiperidine

(208) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-L-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(209) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-L-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine

(210) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine

(211) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hydroxycarbonyl)-piperidine

(212) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 ,N 6 -dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine

(213) 1-[N 2 -[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine

(214) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperazine

(215) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-piperidine

(216) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl)-piperidine

(217) 1-[N 2 -[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(218) 1-[N 2 -[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(219) (R)-1-[2-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-methylamino]-3-(3,5-dibromo-4-hydroxyphenyl)-propyl]-4-(1-piperidinyl)-piperidine (220) (R)-1-[2-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-propyl]-4-(1-piperidinyl)-piperidine

(221) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N 6 ,N 6 -dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine

(222) 3,5-Dibromo-N 2 -[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-[(2-[4-(1-piperidinyl)-1-piperidinyl]ethyl]-D-tyrosinamide

(223) 1-[3,5-Dibromo-N-[[4-[5-[(4-morpholinyl)carbonyl]-1,3-dihydro-2(2H)-oxobenzimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(224) 1-[3,5-Dibromo-N-[[4-[5-[(4-methyl-1-piperazinyl)carbonyl]-1,3-dihydro-2(2H)-oxobenzimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(225) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(226) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(227) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquiazolin-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(228) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(229) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(230) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(231) 1-[4-Amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(232) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(1-piperidinyl)-piperidine

(233) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(234) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(235) 1-[N 2 -[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine

(236) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(237) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(1-piperidinyl)-piperidine

(238) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(239) 1-(3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(240) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine

(241) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(242) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(243) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(244) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine

(245) (R)-1-[2-[N-[[4-(3,4-dihydro-2(1H)-oxopyrido[2,3-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]amino]-3-(4-amino-3,5-dibromophenyl)-propyl]-4-(1-piperidinyl)-piperidine

(246) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,3-dihydro-2(2H)oxobenzimidazol-1-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(247) 1-[N 2 -[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine

(248) 1-[N 2 -[3,5-Dibromo-N-[[4-[2(3H)-oxobenzoxazol-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(249) 1-[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-4-[(1-piperidinyl)methyl]-piperidine

(250) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(251) 1-[N 2 -[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(252) 1-[N 2 -[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-L-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(253) 1-[N 2 -[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(254) 1-[N 2 -[3,5-Dibromo-N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(255) 1-[N 2 -[3,5-Dibromo-N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(256) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(257) 1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-glycyl]-4-(4-pyridinyl)-piperazine

(258) 1-[4-Amino-3,5-dibromo-N-[[4-(benzoylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(259) 1-[4-Amino-3,5-dibromo-N-[[4-(benzoylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(260) 1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-β-alanyl]-4-(4-pyridinyl)-piperazine

(261) 1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N-methylglycyl]-4-(4-pyridinyl)-piperazine

(262) 1-[4-Amino-3,5-dibromo-N-[[4-[N-(phenylaminocarbonyl)-phenylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(263) 1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-[3-(2-thienyl)-D-alanyl]-4-(1-piperidinyl)-piperidine

(264) 4-Amino-3,5-dibromo-N 2 -[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]-D-phenylalaninamide

(265) 1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-glycyl]-4-(1-piperidinyl)-piperidine

(266) 1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-alanyl]-4-(4-pyridinyl)-piperazine

(267) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-[N-(methylaminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-phenylalanyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(1-piperidinyl)-piperidine

(268) 1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-alanyl]-4-(1-piperidinyl)-piperidine

(269) 1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperazinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(270) 1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperazinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(271) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-[N-(methylaminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(1-piperidinyl)-piperidine

(272) 1-[N 2 -[[4-(1,3-Dihydro-2(2H)oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-1-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(1-piperidinyl)-piperidine

(273) 1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N-methylglycyl]-4-(1-piperidinyl)-piperidine

(274) 1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinoxalin-3-yl]-1-piperazinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(275) 1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinoxalin-3-yl]-1-piperazinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(276) 1-[4-Amino-3,5-dibromo-N-[[4-[N-(aminocarbonyl)-N-(4-fluorophenyl)amino]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(277) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-4-methyl-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(278) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-4-methyl-1-piperidinyl]carbonyl]-D-phenylalanyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine

(279) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[3-dimethylamino)propyl]-piperidine

(280) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-4-methyl-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(281) 1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tryptyl]-4-(1-piperidinyl)-piperidine

(282) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)l-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(283) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperazinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine

(284) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(285) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperidine

(286) 3,5-Dibromo-N 2 -[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-[2-(4-methyl-1-piperazinyl)ethyl]-D-tyrosinamide

(287) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(288) 1-[3,5-Dibromo-N-[[4-(7,9-dihydro-6,8-dioxo-1H-purin-9-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(289) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(290) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperidine

(291) (R,S)-1-[2-(4-Amino-3,5-dibromobenzoyl)-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-4-oxobutyl]-4-(4-pyridinyl)-piperidine

(292) (R)-1-[3-(3,5-Dibromo-4-hydroxyphenyl)-2-[N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine

(293) 1-[N 6 -Acetyl-N 2 -[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(294) 1-[N 2 -[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N 6 ,N 6 -dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine

(295) 1-[N 2 -[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 ,N 6 -dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine

(296) (R,S)-1-[2-(4-Amino-3,5-dibromobenzoyl)-4-[4-(3,4-dihydro-2((1H)-oxoquinazolin-3-yl)-1-piperidinyl]-4-oxobutyl]-4-(1-piperidinyl)-piperidine

(297) (R)-1-[3-(4-Amino-3,5-dibromophenyl)-2-[N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine

(298) (R)-1-[3-(4-Amino-3-bromophenyl)-2-[N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine

(299) (R)-1-[3-(4-Amino-3,5-dibromophenyl)-2-[N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine

(300) (R)-1-[3-(4-Amino-3-bromophenyl)-2-[N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine

(301) (R)-1-[3-(3,5-Dibromo-4-hydroxyphenyl)-2-[N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine

(302) (R,S)-1-[2-(4-Amino-3,5-dibromobenzoyl)-4-[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]-4-oxobutyl]-4-(1-piperidinyl)-piperidine

(303) 1-[4-Amino-N-[[4-[2-(aminocarbonylamino)phenylamino]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(304) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(305) 1-[4-Amino-N-[[4-[2-(methylsulphonylamino)phenylamino]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(306) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(307) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(308) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4,4a,5,6,7,8,8a-octahydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(309) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(310) 1-[4-Amino-N-[[4-[7-(aminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(311) 1-[4-Amino-3,5-dibromo-N-[[4-[7-(2-hydroxyethylaminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(312) 1-[4-Amino-N-[[4-[7-(aminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(313) 1-[4-Amino-3,5-dibromo-N-[[4-[7-(2-hydroxyethylaminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(314) 1-[4-Amino-3,5-dibromo-N-[[4-(1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(315) 1-[4-Amino-3,5-dibromo-N-[[4-(1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(316) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(317) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-fluorophenyl)-piperazine

(318) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorophenyl)-piperazine

(319) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-fluorophenyl)-piperazine

(320) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-fluorophenyl)-piperazine

(321) 1-[3,5-Dibromo-N-[[4-(1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(322) trans-1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-cyclohexyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(323) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-6,7-dimethoxy-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(324) 1-[N-[[4-(5-Chloro-3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(325) 1-[3,5-Dibromo-N-[[3-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-pyrrolidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(326) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(327) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(328) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-8-methoxy-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(329) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-(4-methoxyphenyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(330) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(4-methoxyphenyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(331) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(4-methoxyphenyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(332) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(333) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(334) 1-[N-[[4-(1,3-dihydro-4-[3-(trifluoromethyl)-phenyl]-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-3-(4-pyridinyl)-D,L-alanyl]-4-(4-pyridinyl)-piperazine

(335) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(336) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(337) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(338) (R)-1-[3-(4-Amino-3,5-dibromophenyl)-2-[N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine

(339) (R)-1-[3-(4-Amino-3,5-dibromophenyl)-2-[N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine

(340) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine

(341) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1methyl-4-piperidinyl)-piperidine

(342) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(3-thienyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(343) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-(3-thienyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine

(344) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(345) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(346) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(347) 1-[4-Amino-3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(348) 1-[4-Amino-3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(349) 1-[4-Amino-3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(350) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(351) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(352) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(353) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-(3-thienyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(354) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D,L-tyrosyl]-4-(4-pyridinyl)-piperidine

(355) 1-[4-Amino-3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine

(356) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine

(357) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(3-thienyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine

(358) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine

(359) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine

(360) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(361) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine

(362) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(363) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(364) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(365) 1-[N2-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(366) 1-[4-Amino-3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperidine

(367) 1-[4-Amino-3,5 dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperidine

(368) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperidine

(369) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[4-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperazine

(370) 1-[4-Amino-3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperazine

(371) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperazine

(372) 4-(1-Acetyl-4-piperidinyl)-1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-piperidine

(373) 1-[4-Amino-N-[[4-(6-bromo-3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(374) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-5-methyl-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(375) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(3-nitrophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(376) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(377) 1-[4-Amino-N-[[4-[4-(3-bromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(378) 1-[N 2 -[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

(379) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorophenyl)-piperazine

(380) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-fluorophenyl)-piperazine

(381) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(3-pyridinyl)-piperazine

(382) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(3-pyridinyl)-piperazine

(383) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(3-pyridinyl)-piperazine

(384) 1-[3,5-Dibromo-N-[[4-[1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(385) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(3-pyridinyl)-piperazine

(386) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(387) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-pyridinyl)-piperazine

(388) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-pyridinyl)-piperazine

(389) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(phenylaminocarbonylamino)-piperidine

(390) 1-[4-Amino-3,5-dibromo-N-[[4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(391) 1-[3,5-Dibromo-N-[[4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(392) 1-[3,5-Dibromo-N-[[4-[4-phenyl-2(1H)-oxopyrimidin-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(393) 4-Cyano-1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-phenylpiperidine

(394) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyrimidinyl)-piperazine

(395) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyrimidinyl)-piperazine

(396) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyrimidinyl)-piperazine

(397) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyrimidinyl)-piperazine

(398) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(399) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine

(400) 1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(401) 2-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indole

(402) 1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(403) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(404) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-ethylphenyl)-piperazine

(405) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorophenyl)-1,2,5,6-tetrahydropyridine

(406) 1-[3,5-Dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(407) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(408) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(1-oxoethyl)phenyl]-piperazine

(409) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(1-oxoethyl)phenyl]-piperazine

(410) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorobenzoyl)-piperidine

(411) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-cyano-4-phenylpiperidine

(412) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorophenyl)-piperidine

(413) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[(hexahydro-1-methyl-4-pyridinyl)carbonyl]-piperazine

(414) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[3-(dimethylamino)propyl]-piperazine

(415) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[3-(dimethylamino)propyl]-piperazine

(416) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine

(417) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine

(418) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine

(419) 1-[N-[4-[[1,3-Dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine

(420) 1-[3,5-Dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(421) 1-[3,5-Dibromo-N-[[4-[7-(hydroxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(422) 1-[3,5-Dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(423) 1-[3,5-Dibromo-N-[[4-[7-(hydroxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(424) 1-[4-Amino-3,5-dibromo-N-[[4-[7-(methylaminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(425) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-morpholinyl)-piperidine

(426) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(dimethylamino)-piperidine

(427) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-pyrrolidinyl)-piperidine

(428) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-morpholinyl)-piperidine

(429) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(dimethylamino)-piperidine

(430) 1-[4-Amino-3,5-dibromo-N-[[4-[7-[(4-methyl-1-piperazinyl)carbonyl]-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(431) 1-[4-Amino-3,5-dibromo-N-[[4-(2,5-dioxo-4-phenylimidazolidin-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(432) 1-[3,5-Dibromo-N-[[4-(2,5-dioxo-4-phenylimidazolidin-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(433) 1-[4-Amino-3,5-dibromo-N-[[4-[2,5-dioxo-4-(phenylmethyl)-imidazolidin-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(434) 1-[3,5-Dibromo-N-[[4-[2,5-dioxo-4-(phenylmethyl)imidazolidin-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(435) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-pyrrolidinyl)-piperidine

(436) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine

(437) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine

(438) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-cyclohexylpiperazine

(439) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-cyclohexylpiperazine

(440) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2,2-dioxido-2,1,3-benzothiadiazin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(441) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2,2-dioxido-2,1,3-benzothiadiazin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(442) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2,2-dioxido-2,1,3-benzothiadiazin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine

(443) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine

(444) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(445) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine

(446) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine

(447) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine

(448) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(449) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(450) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-N-methyl-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(451) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperazine

(452) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperazine

(453) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperazine

(454) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(455) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(456) 1-[3,4-Dichloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(457) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperidine

(458) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(459) (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(460) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-cycloheptylpiperazine

(461) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-cyclopentylpiperazine

(462) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-4-methoxy-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(463) 1-[3,5-Bis-(trifluoromethyl)-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(4-pyridinyl)-piperazine

(464) 1-[3,5-Bis-(trifluoromethyl)-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(465) 1-[3,5-Bis-(trifluoromethyl)-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(466) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(4-biphenylyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(467) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(2-naphthyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(468) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(2-naphthyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(469) 1-[3-Bromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(470) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(4-biphenylyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(471) 1-[N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(4-biphenylyl)-D,L-alanyl]-4-(1-piperidinyl)-piperidine

(472) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-biphenylyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(473) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(2-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(474) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(2-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(475) 1-[3,5-Bis-(trifluoromethyl)-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(476) 1-[3,5-Bis-(trifluoromethyl)-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine

(477) 1-[3,4-Dichloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(4-pyridinyl)-piperazine

(478) 1-[3-Bromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(479) 1-[3-Bromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(480) 1-[3-Bromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(4-pyridinyl)-piperidine

(481) 1-[4-Amino-3,5-dibromo-N-[[4-[4-(3,4-dichlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(482) 1-[4-Amino-3,5-dibromo-N-[[4-[4-(3,4-dichlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(483) 1-[4-Amino-N-[[4-[4-(3-chlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(484) 1-[4-Amino-N-[[4-[4-(3-chlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(485) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-benzoyl-4-piperidinyl)-piperidine

(486) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methylsulphonyl-4-piperidinyl)-piperidine

(487) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(3-carboxy-1-oxopropyl)-4-piperidinyl]-piperidine

(488) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-hexyl-4-piperidinyl)-piperidine

(489) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-cyclopropylmethyl-4-piperidinyl)-piperidine

(490) 1-[3,5-Dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine

(491) 1-[3,5-Dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(492) 1-[3,5-Dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine

(493) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(ethoxycarbonylmethyl)-4-piperidinyl]-piperidine

(494) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(carboxymethyl)-4-piperidinyl]-piperidine

(495) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4,5-diphenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(496) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[(4-pyridinyl)carbonyl]-piperazine

(497) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-methyl-1-piperazinyl)piperidine

(498) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)piperidine

(499) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)piperidine

(500) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[(1-methyl-4-piperidinyl)carbonyl]-piperazine

(501) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-methyl-1-piperazinyl)piperidine

(502) 1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)piperidine

(503) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)piperidine

(504) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-piperidine

(505) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)carbonyl]-piperidine

(506) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(507) 1-[3-Chloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(508) (R,S)-1-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(509) 1-[4-Amino-3,5-dibromo-N-[[4-[4-(3-bromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine

(510) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine

(511) 1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-methoxy-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(512) 1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-methoxy-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine

(513) 1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-methoxy-D,L-phenylalanyl]-4-(4-pyridinyl)-piperazine

(514) 1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-methoxy-D,L-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine

(515) 1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-methoxy-D,L-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperazine

(516) 1-[N 2 -[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-L-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine

(517) 1-[N 2 -[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine

(518) 1-[N 2 -[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-L-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

(519) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(3-hydroxyphenyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(520) 1-[4-Amino-N-[[4-[4-[3,5-bis-(trifluoromethyl)phenyl]-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(521) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine

(522) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperidine

(523) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-4-(methylsulphonyloxy)-D-phenylalanyl]-4-[1-(methylsulphonyl)-4-piperidinyl]-piperidine

(524) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(methylsulphonyl)-4-piperidinyl]-piperidine

(525) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(cyclopropylmethyl)-4-piperidinyl]-piperidine

(526) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(hydroxycarbonylmethyl)-4-piperidinyl]-piperidine

(527) 1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-(2-methyl-4-thiazolyl)-D,L-alanyl]-4-(1-piperidinyl)-piperidine

(528) 1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-(2-methyl-4-thiazolyl)-D,L-alanyl]-4-(4-pyridinyl)-piperazine

(529) (R,S)-1-[2-[(1-Naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(530) (R,S)-1-[2-[(1-Naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(531) (R,S)-1-[2-[(3-Methoxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(532) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-ethenyl-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(533) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(534) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(535) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperazinyl)-piperidine

(536) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxopyrido[4,3-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(537) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxopyrido[4,3-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine

(538) (R,S)-1-[2-[(1-Naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(539) (R,S)-1-[2-[(1-Naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperazinyl)-piperidine

(540) (R,S)-1-[2-[(1-Naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(541) (R,S)-1-[2-[(3-Ethoxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperazinyl)-piperidine

(542) (R,S)-1-[2-[(3-Ethoxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(543) (R,S)-1-[2-[(3-Ethoxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(544) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(1-methylethoxy)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(545) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(1-methylethoxy)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperazinyl)-piperidine

(546) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(1-methylethoxy)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(547) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(548) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperazinyl)-piperidine

(549) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(550) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-[2-(dimethylamino)ethoxy]phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperazinyl)-piperidine

(551) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazalin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[(1-methyl-4-piperazinyl)carbonyl]-piperidine

(552) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(1-oxoethyl)-1-piperazinyl]-piperidine

(553) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[4-(1-oxoethyl)-1-piperazinyl]-piperidine

(554) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(1-oxoethyl)-1-piperazinyl]-piperidine

(555) 1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[4-(1-oxoethyl)-1-piperazinyl]-piperidine

(556) 1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[(1-methyl-4-piperazinyl)carbonyl]-piperazine

(557) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[(1-methyl-4-piperazinyl)carbonyl]-piperazine

(558) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[(4-pyridinyl)carbonyl]-piperazine

(559) 1-[4-Amino-3,5-dibromo-N-[(4-oxo-1-piperidinyl)carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(560) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-[4-(dimethylamino)butyl]phenyl]-piperazine

(561) 1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-[4-(dimethylamino)butyl]phenyl]-piperazine

(562) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[(1-methyl-4-piperazinyl)carbonyl]-piperazine

(563) 1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[(1-methyl-4-piperazinyl)carbonyl]-piperazine

(564) 1-[4-Amino-N-[(4-amino-1-piperidinyl)carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(565) 1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine

(566) 1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine

(567) 1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine

(568) 1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine

(569) 1-[3,5-Dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-methyl-1-piperazinyl)-piperidine

(570) 1-[N 2 -[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-(1-methyl-4-piperidinyl)-piperidine

(571) 1-[N 2 -[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-(4-methyl-1-piperazinyl)-piperidine

(572) 1-[N 2 -[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-(1-methyl-4-piperidinyl)-piperidine

(573) 1-[N 2 -[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-(4-methyl-1-piperazinyl)-piperidine

(574) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(575) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(576) 1-[N 2 -[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(4-methyl-1-piperazinyl)-piperidine

(577) 1-[N 2 -[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(4-methyl-1-piperazinyl)-piperidine

(578) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromophenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(579) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromophenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(580) 1-[N 2 -[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(1-methyl-4-piperidinyl)-piperidine

(581) 1-[N 2 -[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(1-methyl-4-piperidinyl)-piperidine

(582) 1-[4-Amino-3,5-dibromo-N-[[4-(2,3-dihydro-4(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(583) 1-[N 2 -[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine

(584) 1-[N 2 -[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine

(585) 1-[4-Amino-N-[[4-[4-(4-amino-3,5-dibromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine

(586) 1-[4-Amino-N-[[4-[4-(4-amino-3,5-dibromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine

(587) 1-[N 2 -[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine

(588) 1-[N 2 -[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine

(589) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromo-4-methylphenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(590) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromo-4-methylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(591) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3,4-difluoro-5-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(592) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3,4-difluoro-5-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(593) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(ethoxycarbonyl)-piperidine

(594) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(ethoxycarbonylmethyl)-piperidine

(595) (R,S)-2-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-6-methyl-2,6-diazaspiro[3,4]octane

(596) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(hydroxycarbonylmethyl)-piperidine

(597) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(598) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(599) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(600) (R,S)-1-[4-[4-(Aminocarbonylamino)-1-piperidinyl]-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(601) (R,S)-1-[4-[4-(Aminocarbonylamino)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(602) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromo-4-methoxyphenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(603) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-carboxypiperidine

(604) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromo-4-methoxyphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(605) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-fluor-3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(607) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-fluor-3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(607) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperazine

(608) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine

(609) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(610) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(4-pyridinyl)-piperazine

(611) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(4-pyridinyl)-piperidine

(612) (R,S)-1-[2-[(4-Amino-3,5-dibromophenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(613) 1-[3-Chloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(614) 1-[3-Chloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(615) 1-[3-Chloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(cyclopentyl)-piperazine

(616) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3-methylphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(617) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(hexahydro-1H-1-azepinyl)-piperidine

(618) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine

(619) 1-[3-Bromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(620) 1-[3-cyano-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(621) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-methyl-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(622) 1-[N-[[4-(1,3-Dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-3-methyl-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(623) 1-[3-Methyl-N-[[4-[3,4-dihydro-2(1H)-oxothieno[3,4-d]-pyrimidin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(624) 1-[N-[[4-[1,3-Dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3-methyl-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(625) 1-[N-[[4-[1,3-Dihydro-4-[(3-(trifluoromethyl)-phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3-methyl-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(626) 1-[3-Bromo-N-[[4-[1,3-dihydro-4-[(3-(trifluoromethyl)-phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(627) 1-[3-Bromo-N-[[4-[3,4-dihydro-2(1H)-oxothieno[3,4-d]-pyrimidin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(628) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(629) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperazine

(630) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperazine

(631) (R,S)-4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-4-oxo-2-[[3-(trifluoromethyl)-phenyl]methyl]-N-[2-(4-methyl-1-piperazinyl)ethyl]-butanamide

(632) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(1H-tetrazol-5-yl)-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(633) 1-[3-Bromo-N-[[4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine

(634) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(2-naphthyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(635) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[2-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(636) 1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-nitro-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine

(637) (R,S)-1-[2-[(4-Amino-3,5-dibromophenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(638) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[2-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(639) (R,S)-1-[2-[[3,5-Bis-(trifluoromethyl)phenyl]methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(640) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dimethoxyphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(641) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(2-naphthyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(642) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dimethoxyphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(643) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(4-piperidinyl)-piperidine

(644) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(645) (R,S)-1-[2-[(3-Bromophenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(646) (R,S)-1-[2-[(3-Bromophenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(647) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(1-propen-3-yl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(648) (R,S)-1-[2-[3-(Biphenylyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(649) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(pyridinyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(650) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(2-thiazolyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(651) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(2-furyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(652) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3-propylphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(653) (R,S)-1-[4-(2,4-Dihydro-5-phenyl-3(3H)-oxotriazol-2-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(654) (R,S)-1-[4-[1,3-Dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl]-1-piperidinyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(655) (R,S)-1-[2-[(4-Quinolinyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(656) (R,S)-1-[2-[(4-Quinolinyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(657) 1-[2-[(1,2,3,4-Tetrahydro-1-naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine (mixture of diastereomers)

(658) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dibromophenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(659) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dibromophenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(660) (R,S)-1-[2-[(4-Quinolinyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(661) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(662) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(663) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(664) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-methoxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine

(665) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-methoxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(666) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-methoxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(667) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(1-naphthyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine

(668) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(1-naphthyl)methyl]-1,4-dioxobutyl]-4-(1-methylsulphonyl-4-piperidinyl)-piperidine

(669) (R,S)-1-[2-[3,5-Dibromo-4-methylphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-[4-[4-(dimethylamino)butyl]phenyl]-piperazine

(670) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(671) (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine

(672) (R,S)-1-[2-[(3,4-Dichlorophenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-[4-(dimethylaminomethyl)phenyl]-piperidine

and the salts thereof.

The compounds of general formula I are prepared by methods which are known in principle, particularly using processes derived from peptide chemistry (cf. for example Houben-Weyl, Methoden der Organischen Chemie, Vol. 15/2). The amino protecting groups used may be those described in Houben-Weyl, Methoden der Organischen Chemie, Vol. 15/1, of which urethane protecting groups such as the fluorenylmethoxycarbonyl, phenylmethoxycarbonyl or tert.-butyloxycarbonyl group are preferred. Any functional groups present in the groups R 2 and/or A of the compounds of general formula I or in the precursors thereof are additionally protected by suitable protecting groups in order to prevent side reactions (cf. for example: G. B. Fields et al., Int. J. Peptide Protein Res. 35, 161 (1990); T. W. Greene, Protective Groups in Organic Synthesis). Examples of side-chain-protected amino acids of this kind include, in particular, Arg(NO 2 ), Arg(Mtr), Arg(di-Z), Arg(Pmc) Lys(Boc), Lys(Z), Orn(Boc), Orn(Z), Lys(Cl-Z) which are commercially obtainable, possibly in the form of derivatives. Particular care should be taken to ensure that so-called orthogonal combinations of protecting groups are used to protect the α-amino and the side chain amino group, e.g.:

Protection of the N
(side chain)             N                                                                        α                                                                    -protection
p-Toluenesulphonyl       Phenylmethoxycarbonyl
                         tert.Butyloxycarbonyl
Phenylmethoxycarbonyl    (4-Methoxyphenyl)methoxycarbonyl
                         tert. Butoxycarbonyl
                         Adamantyloxycarbonyl
                         Biphenylylisopropyloxycarbonyl
                         Isonicotinoyloxycarbonyl
                         o-Nitrophenylsulphenyl
                         Formyl
tert. Butoxycarbonyl     Phenylmethoxycarbonyl
                         p-Toluenesulphonyl
                         o-Nitrophenylsulphenyl
                         Biphenylylisopropyloxycarbonyl
                         9-Fluorenylmethoxycarbonyl
Acetyl, Trifluoroacetyl, tert.Butyloxycarbonyl
Formyl, (2-Chlorophenyl)-
methoxycarbonyl, (4-Chloro-
phenyl) methoxycarbonyl,
4-(Nitrophenyl)methoxycar-
bonyl, Phthaloyl

Instead of protecting amino groups in the side chain, amino acids or derivatives thereof which carry precursor functions and in particular are substituted by nitro or cyano in the side chain, such as 5-o-cyanonorvalin may also be used.

The basic functions in the side chains of α-amino acids which are not commercially obtainable and which are characterised, for example, by (aminoiminomethyl) groups, may be protected in the same way as is used for protecting the side chains of arginine and its derivatives (cf. also M. Bodanszky, “Peptide Chemistry”, Springer-Verlag, 1988, p. 94-97); protecting groups which are particularly suitable for the (aminoiminomethyl)- group are the p-toluenesulphonyl, mesitylene sulphonyl—(Mts), methoxytrimethylphenylsulphonyl—(Mtr), 2,2,5,7,8-pentamethylchroman-6-sulphonyl—(Pmc), pentachlorophenoxycarbonyl- and nitro-protecting groups.

For the actual coupling, the methods known from peptide chemistry are used (see Houben-Weyl, for example, Methoden der Organischen Chemie, Vol. 15/2). It is preferable to use carbodiimides such as dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC) or ethyl-(3-dimethylaminopropyl)-carbodiimide, O-(1H-benzotriazol-1-yl)N,N-N′,N′-tetramethyluroniumhexafluorophosphate (HBTU) or tetrafluoroborate (TBTU) or 1H-benzotriazol-1-yloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP). By the addition of 1-hydroxybenzotriazole (HOBt) or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOObt) racemisation may additionally be suppressed, if desired, or the reaction rate may be increased. The couplings are normally carried out with equimolar amounts of the coupling components and the coupling reagent in solvents such as dichloromethane, tetrahydrofuran, acetonitrile, dimethylformamide (DMF), dimethylacetamide (DMA), N-methylpyrrolidone (NMP) or mixtures thereof and at temperatures between −30 and +30° C., preferably between −20 and +20° C. If necessary, N-ethyl-diisopropylamine (DIEA) is preferred as an additional auxiliary base (Hünig base).

The so-called “anhydride method” (cf. also M. Bodanszky, “Peptide Chemistry”, Springer-Verlag 1988, p. 58-59; M. Bodanszky, “Principles of Peptide Synthesis”, Springer-Verlag 1984, p. 21-27) was used as another coupling method for the synthesis of compounds of general formula I. The “mixed anhydride method” is preferred, in the variant according to Vaughan (J. R. Vaughan Jr., J. Amer. Chem.Soc. 73, 3547 (1951)), in which the mixed anhydride is obtained from the optionally N 2 -protected α-amino acid which is to be coupled, and the mono-isobutylcarbonate, using isobutylchlorocarbonate in the presence of base such as 4-methylmorpholine or 4-ethylmorpholine. The preparation of this mixed anhydride and the coupling with amines are carried out in a one-pot process using the above-mentioned solvents at temperatures between −20 and +20° C., preferably between 0 and +20° C.

Any protecting groups present in the side chains of α-amino acid partial structures are finally cleaved, after the formation of the N- and C-terminally substituted amino acid derivative, with suitable reagents which are also known from the literature in principle, specifically arylsulphonyl and hetarylsulphonyl protecting groups, preferably by acidolysis, i.e. by the action of strong acids, preferably trifluoroacetic acid, nitro- and arylmethoxycarbonyl protecting groups are preferably cleaved by hydrogenolysis, e.g. using hydrogen in the presence of palladium black and with glacial acetic acid as solvent. If the substrate contains functions which are sensitive to hydrogenolysis, e.g. halogen atoms such as chlorine, bromine or iodine, a phenylmethanol or hetarylmethanol function or some other benzyl heteroatom bond, particularly a benzyl-oxygen bond, the nitro group may also be cleaved non-hydrogenolytically, e.g. with zinc/2N trifluoroacetic acid (cf. also A. Turan, A. Patthy and S. Bajusz, Acta Chim. Acad. Sci. Hung, Tom. 85 (3), 327-332 [1975]; C.A. 83, 206526y [1975]), with tin(II)-chloride in 60% aqueous formic acid (see also: SUNSTAR KK, JA-A-3271-299), with zinc in the presence of acetic acid (cf. also: A. Malabarba, P. Ferrari, G. Cietto, R. Pallanza and M. Berti, J. Antibiot. 42 (12), 1800-1816 (1989)) or excess aqueous 20% titanium(III)-chloride in aqueous methanol and in the presence of aqueous ammonium acetate buffer at 24° C. (see also: R. M. Freidinger, R. Hirschmann and D. F. Veber, J. Org. Chem. 43 (25), 4800-4803 [1978]).

Any precursor functions which may be present in the side chain of the α-amino acid may also subsequently be converted by hydrogenolysis into the desired amino functions; nitroalkyl groups yield aminoalkyl groups under conditions which will be familiar to the chemist, whilst the cyano group is converted into the aminomethyl group.

Alternatively, nitrile functions may also be reduced with complex hydrides which are selective in relation to other critical functions contained in the molecule, particularly amide groups (cf. also: J. Seyden-Penne, “Reductions by the Alumino- and Borohydrides in Organic Synthesis”, VCH Publishers Inc., 1991, p. 132ff.), e.g. with sodium borohydride in methanol and in the presence of cobalt(II)-chloride, with sodium borohydride in tetrahydrofuran in the presence of trifluoroacetic acid or with tetrakis-(n-butyl)-ammonium borohydride in dichloromethane; the reduction of aliphatic nitro function to the primary amino-function is also possible with sodium borohydride in the presence of tin(II)-chloride or copper(II)-acetylacetonate, without affecting the carboxamide groups present in type I compounds (see also: J. Seyden-Penne, ibid. p. 137ff.).

The following methods are particularly suitable for preparing the compounds of general Formula I according to the invention:

a) In order to prepare compounds of general formula I, wherein

R denotes an unbranched C 1-7 -alkyl group which may be substituted in the ω-position

by a C 4-10 -cycloalkyl group, by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or biphenylyl group,

by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-2H-2-oxoimidazopyridinyl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 1,3-dihydro-2H-2-oxoimidazol-1-yl or 3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, wherein the latter two groups may each be mono- or disubstituted in the 4- and/or 5-position or in the 5- and/or 6-position by lower straight chained or branched alkyl groups, by phenyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl-1-methylpyrazolyl, imidazolyl- or 1-methylimidazolyl-groups and the substituents may be identical or different,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, contains an oxygen, sulphur or additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group,

or by a 6-membered heteroaromatic ring linked via a carbon atom, which contains one, two or three nitrogen atoms,

whilst a 1,4-butadienylene group may be attached both to the above-mentioned 5-membered heteroaromatic monocyclic rings and to the 6-membered heteroaromatic monocyclic rings, in each case via two adjacent carbon atoms, and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group, and

whilst the phenyl, naphthyl and biphenylyl groups mentioned above for the substitution of the alkyl groups in the ω-position and optionally also partially hydrogenated mono- and bi-cyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms or by alkyl groups, C 3-8 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups, wherein the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino and benzoylmethylamino groups may in turn additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino or acetylamino group,

or the group of formula

 wherein

R 5 , R 6 , R 7 , R N , Y 1 , o and p are as hereinbefore defined,

Y 2 denotes a CH— group and

Z denotes an NR 1 — group, wherein R 1 is as hereinbefore defined:

coupling carboxylic acids of general formula VII,

RCO 2 H  (VII)

wherein

R is as hereinbefore defined,

with compounds of general formula VIII,

 wherein

R 2 , R 3 , R 4 , R 11 , A, X, m and n are as hereinbefore defined, and

Z denotes an NR 1 — group, wherein R 1 is as hereinbefore defined, and, if necessary, subsequently cleaving any protecting groups or modifying precursor functions in accordance with the methods described hereinbefore.

The coupling is carried out using the methods known from peptide chemistry described above, particularly using DCC, DIC, HBTU, TBTU or BOP as reagents or using the mixed anhydride method.

b) In order to prepare compounds of general formula I wherein R is defined as in a), Z denotes the NR 1 — group and R 1 , R 2 , R 3 , R 4 , R 11 , A, X, m and n are as hereinbefore defined:

coupling compounds of general formula IX,

R—CO—Nu  (IX)

wherein

R is defined as in a) and

Nu denotes a leaving group, for example a halogen atom such as the chlorine, bromine- or iodine atom, an alkylsulphonyloxy group having 1 to 10 carbon atoms in the alkyl moiety, a phenylsulphonyloxy or naphthylsulphonyloxy group optionally mono-, di- or trisubstituted by chlorine or bromine atoms or by methyl- or nitro groups, wherein the substituents may be identical or different, a 1H-imidazol-1-yl, a 1H-pyrazol-1-yl- optionally substituted by 1 or 2 methyl groups in the carbon skeleton, a 1H-1,2,4-triazol-1-yl, 1H-1,2,3-triazol-1-yl, 1H-1,2,3,4-tetrazol-1-yl, a vinyl, propargyl, p-nitrophenyl, 2,4-dinitrophenyl, trichlorophenyl, pentachlorophenyl, pentafluorophenyl, pyranyl or pyridinyl, a dimethylaminyloxy, 2(1H)-oxopyridin-1-yloxy, 2,5-dioxopyrrolidin-1-yloxy, phthalimidyloxy, 1H-benzotriazol-1-yloxy or azide group,

with compounds of general formula VIII,

 wherein

R 2 , R 3 , R 4 , R 11 , A, X, m and n are as hereinbefore defined and

Z denotes an NR 1 — group, whilst R 1 is as hereinbefore defined,

and, if necessary, subsequently cleaving protecting groups or modifying precursor functions using the methods described above.

The reaction is carried out under Schotten-Baumann- or Einhorn-conditions, i.e. the components are reacted in the presence of at least one equivalent of an auxiliary base at temperatures between −50° C. and +120° C., preferably between −10° C. and +30° C., optionally in the presence of solvents. Auxiliary bases which may be used are preferably alkali- metal and alkaline earth metal hydroxides, e.g. sodium hydroxide, potassium hydroxide or barium hydroxide, alkali metal carbonates, e.g. sodium carbonate, potassium carbonate or cesium carbonate, alkali metal acetate, e.g. sodium- or potassium acetate, as well as tertiary amines, e.g. pyridine, 2,4,6-trimethylpyridine, quinoline, triethylamine, N-ethyl-diisopropylamine, N-ethyl-dicyclohexylamine, 1,4-Diazabicyclo[2,2,2]octane or 1,8-diazabicyclo[5,4,0]undec-7-ene, whilst the solvents which may be used include, for example, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, dimethylformamide, dimethylacetamide, N-methyl-pyrrolidone or mixtures thereof; if alkali metal or alkaline earth metal hydroxides, alkali metal carbonates or -acetates are used as auxiliary bases, water may also be added to the reaction mixture as a cosolvent.

c) In order to prepare compounds of general formula I wherein

R denotes an unbranched C 1-6 -alkylamino group optionally substituted at the nitrogen atom by a C 1-6 -alkyl group or by a phenylmethyl group, which may be substituted in the ω-position

by a C 4-10 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl- or biphenylyl group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or 1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl-group,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, contains an oxygen, sulphur or an additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group, or

by a 6-membered heteroaromatic ring linked via a carbon atom and containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene group may be attached both to the 5-membered and to the 6-membered heteroaromatic monocyclic rings via two adjacent carbon atoms in each case and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned above for the substitution of the alkyl moiety of the alkylamino groups in the ω-position and optionally partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 3-8 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino- and benzoylmethylamino groups in turn may additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino- or acetylamino group,

or the group of formula

 wherein

R 5 , R 6 , R 7 , R N , Y 1 , o and p are as hereinbefore defined,

Y 2 denotes the N-atom and

Z denotes the NR 1 — group, wherein R 1 is as hereinbefore defined:

reacting amines of general formula X

R—H  (X)

wherein

R is as hereinbefore defined, with carbonic acid derivatives of general XI

 X 1 is a nucleofugic group, preferably the 1H-imidazol-1-yl, 1H-1,2,4-triazol-1-yl, trichloromethoxy- or 2,5-dioxopyrrolidin-1-yloxy group,

and with compounds of general formula VIII,

 wherein

R 2 , R 3 , R 4 , R 11 , A, X, m and n are as hereinbefore defined and

Z denotes an NR 1 — group, wherein R 1 is as hereinbefore defined,

and, if necessary, subsequently cleaving any protecting groups or modifying any precursor functions using the method described hereinbefore.

The theoretically two-step reactions are generally carried out as one-pot processes, preferably by reacting one of the two components X or VIII with equimolar amounts of the carbonic acid derivative of general formula XI in a suitable solvent at fairly low temperature, in the first step, and then adding at least equimolar amounts of the other component VIII or X and finishing the reaction at elevated temperature. The reactions with bis-(trichloromethyl)-carbonate are preferably carried out in the presence of at least 2 equivalents (based on bis-(trichloromethyl)-carbonat) of a tertiary base, e.g. triethylamine, N-ethyl-diisopropylamine, pyridine, 1,5-diazabicyclo[4,3,0]non-5-ene, 1,4-diazabicyclo[2,2,2]octane or 1,8-diazabicyclo[5,4,0]undec-7-ene. Examples of solvent, which should be anhydrous, include tetrahydrofuran, dioxane, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone or acetonitrile, if bis-(trichloromethyl)-carbonate is used as the carbonyl component, anhydrous chlorohydrocarbons such as dichloromethane, 1,2-dichloroethane or trichloroethylene are preferred. The reaction temperatures are between −30 and +25° C. for the first step of the reaction, preferably between −5 and +10° C., and between +15° C. and the boiling temperature of the solvent used, preferably between +20° C. and +70° C. for the second step of the reaction (cf. also: H. A. Staab and W. Rohr, “Synthesen mit heterocyclischen Amiden (Azoliden)”, Neuere Methoden der Präparativen Organischen Chemie, Band V, p. 53-93, Verlag Chemie, Weinheim/Bergstr., 1967; P. Majer and R. S. Randad, J. Org. Chem. 59, 1937-1938 (1994); K. Takeda, Y. Akagi, A. Saiki, T. Sukahara und H. Ogura, Tetrahedron Letters 24 (42), 4569-4572 (1983)).

d) In order to prepare compounds of general formula I wherein the carbonyl group linked to the groups R and Z denotes a urea carbonyl group, in which the urea carbonyl is flanked by at least one NH— group, and wherein

R denotes an unbranched C 1-6 -alkylamino group optionally additionally substituted at the nitrogen atom by a C 1-6 -alkyl group or by a phenylmethyl group, which may be substituted in the ω-position

by a C 4-10 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl- or biphenylyl group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or 1,3-dihydro-2H-2-oxoimidazom[4,5-b]pyridin-3-yl-group,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, contains an oxygen, sulphur or an additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group, or

by a 6-membered heteroaromatic ring linked via a carbon atom and containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene group may be attached both to the 5-membered and to the 6-membered heteroaromatic monocyclic rings via two adjacent carbon atoms in each case and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned above for the substitution of the alkyl moiety of the alkylamino groups in the ω-position and optionally partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 3-8 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino- and benzoylmethylamino groups in turn may additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino or acetylamino group,

or the group of formula

 wherein

R 5 , R 6 , R 7 , R N , Y 1 , o and p are as hereinbefore defined and

Y 2 denotes the N-atom,

Z denotes the group NR 1 and

R 1 denotes a hydrogen atom or, provided that, R denotes an unbranched alkylamino group unsubstituted at the nitrogen atom and optionally substituted in the ω-position, R 1 may also denote an alkyl or phenylalkyl group:

Reacting amines of general formula X′,

R—H  (X′)

wherein R is as hereinbefore defined,

with carbonic acid derivatives of general formula XI′,

 wherein

X 2 denotes a phenoxy group, if X 3 is the (1H)-1,2,3,4-tetrazol-1-yl group, the 4-nitrophenoxy group, if X 3 is the 4-nitrophenoxy group, and the chlorine atom if X 3 is the 2,4,5-trichlorophenoxy group, and with compounds of general formula VIII′,

 wherein

R 2 , R 3 , R 4 , R 11 , X, A, m and n are as hereinbefore defined and

R 1 denotes a hydrogen atom or, provided that R is an unbranched alkylamino group unsubstituted at the nitrogen and optionally substituted in the ω-position, R 1 may also denote an alkyl or phenylalkyl group, and

if necessary, subsequently cleaving protecting groups or modifying precursor functions using the methods described hereinbefore.

The reactions are in two steps, in principle, with intermediate formation of urethanes, which can be isolated. However, the reactions may also be carried out as one-pot reactions. Preferably, in the first step, one of the two components X′ or VIII′ is reacted with equimolar amounts of the carbonic acid derivative of general formula XI′ in a suitable solvent at low temperature, then at least equimolar amounts of the other component VIII′ or X′ are added and the reaction is completed at elevated temperature. The reactions are preferably carried out in anhydrous solvents, e.g. in tetrahydrofuran, dioxane, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone, acetonitrile or anhydrous chlorohydrocarbons e.g. dichloromethane, 1,2-dichloroethane or trichloroethylene. The reaction temperatures are between −15 and +40° C., preferably between −10 and +25° C. for the first step, between +20° C. and the boiling temperature of the solvent used, preferably between +20° C. and 100° C. for the second reaction step (cf. also: R. W. Adamiak and J. Stawinski, Tetrahedron Letters 1977, 22, 1935-1936; A. W. Lipkowski, S. W. Tam and P. S. Portoghese, J. Med. Chem. 29, 1222-1225 (1986); J. Izdebski and D. Pawlak, Synthesis 1989, 423-425).

e) In order to prepare compounds of general formula I wherein Z denotes the group NH and

R denotes an unbranched C 1-6 -alkylamino group optionally substituted at the nitrogen atom by a C 1-6 -alkyl group or by a phenylmethyl group, which may be substituted in the ω-position

by a C 4-10 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or biphenylyl group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl or 1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl group,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, contains an oxygen, sulphur or an additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group, or

by a 6-membered heteroaromatic ring linked via a carbon atom and containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene group may be attached both to the 5-membered and to the 6-membered heteroaromatic monocyclic rings via two adjacent carbon atoms in each case and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group, whilst the phenyl, naphthyl and biphenylyl groups mentioned above for the substitution of the alkyl groups in the ω-position and optionally partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 3-8 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino- and benzoylmethylamino groups in turn may additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino or acetylamino group,

or the group of formula

 wherein

R 5 , R 6 , R 7 , R N , Y 1 , o and p are as hereinbefore defined and Y 2 denotes an N-atom:

Reacting isocyanates of general formula XII,

 wherein

R 2 , R 3 , R 4 , R 11 , A, X, m and n are as hereinbefore defined,

with amines of general formula X,

R—H  (X)

wherein

R is as hereinbefore defined and, if necessary, subsequently cleaving protecting groups or modifying precursor functions using the processes described above.

The reaction is carried out at temperatures between 0° C. and 150° C., preferably between 20° C. and 100° C., optionally in the presence of anhydrous solvents, e.g. tetrahydrofuran, 1,4-dioxane, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone or 1,3-dimethyl-2-imidazolidinone or mixtures thereof.

f) In order to prepare compounds of general formula I wherein

R denotes an unbranched C 1-6 -alkylamino group unsubstituted at the nitrogen atom, which may be substituted in the ω-position

by a C 4-10 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl- or biphenylyl group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or 1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl-group,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, contains an oxygen, sulphur or an additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group, or

by a 6-membered heteroaromatic ring linked via a carbon atom and containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene group may be attached both to the 5-membered and to the 6-membered heteroaromatic monocyclic rings via two adjacent carbon atoms in each case and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned above for the substitution of the alkylamino groups in the ω-position and optionally partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 3-8 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino- and benzoylmethylamino groups in turn may additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino- or acetylamino group, and

Z denotes the NR 1 — group wherein R 1 is as hereinbefore defined:

Reacting isocyanates of general formula XIII,

 R═C═O  (XIII)

wherein R is as hereinbefore defined, with compounds of general formula VIII,

wherein R 2 , R 3 , R 4 , R 1 , A, X, m and n are as hereinbefore defined and

Z denotes an NR 1 — group, wherein R 1 is as hereinbefore defined,

and, if necessary, subsequently cleaving any protecting groups or modifying the precursor functions using the methods described hereinbefore.

The reaction is carried out at temperatures between 0 and 150° C., preferably at temperatures between 20 and 100° C., and optionally in the presence of anhydrous solvents, e.g. tetrahydrofuran, 1,4-dioxane, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone or 1,3-dimethyl-2-imidazolidinone.

g) In order to prepare compounds of general formula I wherein R, Z, R 2 , R 3 , R 4 , R 11 , A, m and n have the meanings given hereinbefore and X is as hereinbefore defined, provided that A does not denote a bond or X denotes an oxygen atom, if A denotes a single bond:

Coupling carboxylic acids of general formula XIV,

 wherein

R, Z, R 11 , m and n are as hereinbefore defined,

R 2 ′ has the meanings given for R 2 hereinbefore or denotes a group R 2 substituted by the above-mentioned protecting groups,

A′ has the meanings given for A hereinbefore or, if A denotes the divalent group of an amino acid, it optionally bears in the side chain a precursor group for the group R 9 , e.g. a cyanopropyl group,

to compounds of general formula XV,

H—NR 3 R 4   (XV)

 wherein

R 3 and R 4 are as hereinbefore defined,

and if necessary subsequent cleaving of protective groups or modification of precursor functions using the methods described above.

The coupling is carried out using the methods known from peptide chemistry and described hereinbefore, particularly using DCC, DIC, HBTU, TBTU or BOP as reagents or using the mixed anhydride method.

If the starting compound XIV used is enantiomerically pure, partial racemisation of the C-terminal amino acid must be expected during the coupling step and possibly quantitative racemisation must be expected if triethylamine is used as the auxiliary base and dimethylformamide, dimethylacetamide or N-methyl-pyrrolidone is used as solvent.

h) In order to prepare compounds of general formula I wherein X denotes the oxygen atom:

Coupling carboxylic acids of general formula XVI,

 wherein

R, Z, R 11 , m and n are as hereinbefore defined and

R 2 ′ has the meanings given for R 2 hereinbefore or denotes a group R 2 substituted by the above-mentioned protecting groups,

to compounds of general formula XVII,

 wherein

A′ has the meanings given for A hereinbefore or, if A denotes the divalent group of an amino acid, A′ optionally bears in the side chain a precursor group for the group R 9 , e.g. a cyanopropyl group, and

R 3 and R 4 are as hereinbefore defined,

and if necessary subsequently cleaving protecting groups or modifying precursor functions using the methods described above.

The coupling is carried out using the methods known from peptide chemistry and described above, particularly using DCC, DIC, HBTU, TBTU or BOP as reagents or using the mixed anhydride method.

If the starting compound XVI used is enantiomerically pure, during the coupling step partial racemisation must be expected or, if triethylamine is used as the auxiliary base and dimethylformamide, dimethylacetamide or N-methyl-pyrrolidone is used as solvent, quantitative racemisation must be expected based on the chiral centre of XVI.

i) In order to prepare compounds of general formula I wherein

R denotes an unbranched C 1-6 -alkylamino group optionally substituted at the nitrogen atom by a C 1-6 -alkyl group or by a phenylmethyl group, which may be substituted in the ω-position

by a C 4-10 -cycloalkyl group,

by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or biphenylyl group,

by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl, 2,4(1H,3H)-dioxoquinazolin-1-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl, 2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl, 3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl, 2(1H)-oxoquinoxalin-3-yl, 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, 1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl, 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl, 3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl, 3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or 1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl-group,

by a 5-membered heteroaromatic ring linked via a carbon atom, which contains a nitrogen, oxygen or sulphur atom or, in addition to a nitrogen atom, contains an oxygen, sulphur or an additional nitrogen atom, whilst a nitrogen atom of an imino group may be substituted by an alkyl group, or

by a 6-membered heteroaromatic ring linked via a carbon atom and containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene group may be attached both to the 5-membered and to the 6-membered heteroaromatic monocyclic rings via two adjacent carbon atoms in each case and the bicyclic heteroaromatic rings thus formed may also be bound via a carbon atom of the 1,4-butadienylene group,

whilst the phenyl, naphthyl and biphenylyl groups mentioned above for the substitution of the alkyl moiety of the alkylamino groups in the ω-position and optionally partially hydrogenated mono- and bicyclic heteroaromatic rings in the carbon skeleton may additionally be mono-, di- or trisubstituted by fluorine, chlorine or bromine atoms, by alkyl groups, C 3-8 -cycloalkyl groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino, benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl, alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, whilst the substituents may be identical or different and the above-mentioned benzoyl, benzoylamino and benzoylmethylamino groups in turn may additionally be substituted in the phenyl moiety by a fluorine, chlorine or bromine atom or by an alkyl, trifluoromethyl, amino or acetylamino group,

or the group of formula

 wherein

R 5 , R 6 , R 7 , R N , Y 1 , o and p are as hereinbefore defined and

Y 2 denotes an N-atom,

Z represents the methylene group,

X denotes two hydrogen atoms,

A denotes a single bond,

m denotes the value 1 and

n denotes the value 0:

Coupling carboxylic acids of general formula XVIII,

 wherein

R 2 , R 3 and R 4 are as hereinbefore defined,

with amines of general formula X,

R—H  (X)

wherein R is as hereinbefore defined.

The coupling is carried out using the methods known from peptide chemistry and described above, particularly using DCC, DIC, HBTU, TBTU or BOP as reagents or using the mixed anhydride method.

j) In order to prepare compounds of general formula I wherein R 3 and R 4 have the meanings given hereinbefore with the exception of the hydrogen atoms, Z denotes a methylene group, X denotes two hydrogen atoms, A denotes a single bond, m is the number 1 and n is the number 0:

Reacting secondary amines of general formula XVa,

H—NR 3 ′R 4 ′  (XVa)

 wherein

R 3 ′ and R 4 ′ have the meanings given for R 3 and R 4 hereinbefore with the exception of hydrogen atoms,

with formaldehyde and CH-acid compounds of general formula XIX,

wherein

R is as hereinbefore defined and

 R 2 is as hereinbefore defined, but with the proviso that any acid functions present such as hydroxy groups are appropriately protected by suitable protecting groups.

The reaction is preferably carried out in a slightly acidic medium, using alcohols, e.g. methanol or ethanol, or lower aliphatic carboxylic acids, such as glacial acetic acid, as solvents and at temperatures between room temperature and the boiling point of the solvent in question. In a preferred variant, an inorganic acid salt such as the hydrochloride of a secondary amine of general formula XVa is heated with paraformaldehyde and a ketone of general formula XIX in glacial acetic acid to temperatures between 50° C. and 80° C.

k) In order to prepare compounds of general formula I wherein

R, R 2 , R 3 , R 4 , R 11 , X, Z, m and n are as hereinbefore defined and

A denotes the divalent group of formula III

(linked to the NR 3 R 4 — group via the —CX—0 group)

 wherein

R 8 denotes the hydrogen atom or an alkyl or phenylalkyl group and

R 9 denotes an unbranched C 1-5 -alkyl group substituted in the ω-position by an aminoiminomethylamino group:

Reacting compounds of general formula XX,

 wherein

R, R 2 , R 3 , R 4 , R 11 , X, Z, m and n are as hereinbefore defined,

R 8 denotes a hydrogen atom or an alkyl or phenylalkyl group and

R 9 denotes an unbranched C 1-5 -alkyl group substituted in the ω-position by a primary amino group,

with carbonic acid derivatives of general formula XXI,

 wherein

Nu 2 is a leaving group, e.g. an alkoxy, alkylthio, alkylsulphinyl or alkylsulphonyl group each having 1 to 10 carbon atoms in alkyl moiety, e.g. a methoxy, ethoxy, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, propylsulphinyl, isopropylsulphinyl, methylsulphonyl or ethylsulphonyl group, the chlorine atom, the SO 2 H, SO 3 H— or OPOCl 2 — group, or the group of general formula XXII,

 wherein

R 15 and R 16 , which may be identical or different, denote hydrogen atoms or C 1-3 -alkyl groups.

Occasionally, for example when Nu 2 is an alkoxy group, instead of using the compounds of general formula XXI it is advantageous to use the inorganic acid salts thereof, e.g. the neutral sulphates or hydrochlorides thereof.

The reactions are carried out analogously to methods known from the literature (see G. B. L. Smith, J. Amer. Chem. Soc. 51, 476 [1929]; B. Rathke, Chem. Ber. 17, 297 [1884]; R. Phillips and H. T. Clarke, J. Amer. Chem. Soc. 45, 1755 [1923]; S. J. Angyal and W. K. Warburton, J. Amer. Chem. Soc. 73, 2492 [1951]; H. Lecher and F. Graf, Chem. Ber. 56, 1326 [1923]; J. Wityak, S. J. Gould, S. J. Hein and D. A. Keszler, J. Org. Chem. 52, 2179 [1987]; T. Teraji, Y. Nakai, G. J. Durant, WO-A-81/00109, Chem. Abstr. 94, 192336z [1981]; C. A. Maryanoff, R. C. Stanzione, J. N. Plampin and J. E. Mills, J. Org. Chem. 51, 1882-1884 [1986]; A. E. Miller and J. J. Bischoff, Synthesis 1986, 777; R. A. B. Bannard, A. A. Casselman, W. F. Cockburn and G. M. Brown, Can. J. Chem. 36, 1541 [1958]; Aktieselskabet Grea, Kopenhagen, DE 28 26 452-C2; K. Kim. Y-T. Lin and H. S. Mosher, Tetrah. Letters, 29, 3183-3186 [1988]; H. B. Arzeno et al., Synth. Commun. 20, 3433-3437 [1990]; H. Bredereck and K. Bredereck, Chem. Ber. 94, 2278 [1961]; H. Eilingsfeld, G. Neubauer, M. Seefelder and H. Weidinger, Chem. Ber. 97, 1232 [1964]; P. Pruszynski, Can. J. Chem. 65, 626 [1987]; D. F. Gavin, W. J. Schnabel, E. Kober and M. A. Robinson, J. Org. Chem. 32, 2511 [1967]; N. K. Hart, S. R. Johns, J. A. Lamberton and R. I. Willing, Aust. J. Chem. 23, 1679 [1970]; CIBA Ltd., Belgisches Patent 655 403; Chem. Abstr. 64, 17481 [1966]; R. A. B. Bannard, A. A. Casselman, W. F. Cockburn and G. M. Brown, Can. J. Chem. 36, 1541 [1958]; J. P. Greenstein, J. Org. Chem. 2, 480 [1937]; F. L. Scott and J. Reilly, J. Amer. Chem. Soc. 74, 4562 [1952]; W. R. Roush and A. E. Walts, J. Amer. Chem. Soc. 106, 721 [1984], M. S. Bernatowicz, Y. Wu and G. R. Matsueda, J. Org. Chem. 57, 2497-2502 [1992]; H. Tsunematsu, T. Imamura and S. Makisumi, J. Biochem. 94, 123-128 [1983]) at temperatures between 0° C. and +100° C., preferably between +40° C. and +80° C., using inert solvents, e.g. dichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, dimethylformamide, dimethylacetamide, N-methyl-pyrrolidone or mixtures thereof and, depending on the nature of the Nu 2 — group, frequently in the presence of auxiliary bases, especially alkali metal carbonates such as sodium- or potassium carbonate, or tertiary amines, preferably N-ethyl-diisopropylamine or triethylamine.

The amino acids of general formula I modified according to the invention contain at least one chiral centre. If the group A is also chiral, the compounds may occur in the form of two diastereomeric pairs of antipodes. The invention includes the individual isomers as well as the mixtures thereof.

The diastereomers are separated on the basis of their different physicochemical properties, e.g. by fractional crystallisation from suitable solvents, by high pressure liquid or column chromatography using chiral or preferably achiral stationary phases.

Racemates covered by general formula I may be separated, for example, by HPLC on suitable chiral stationary phases (e.g. Chiral AGP, Chiralpak AD). Racemates which contain a basic or acidic function can also be separated by means of the diastereomeric optically active salts which are formed on reacting with an optically active acid, e.g. (+)- or (−)-tartaric acid, (+)- or (−)-diacetyl tartaric acid, (+)- or (−)-monomethyltartrate or (+)-camphor sulphonic acid or an optically active base such as (R)-(+)-1-phenylethylamine, (S)-(−)-1-phenylethylamine or (S)-brucine.

According to a conventional process for separating isomers, the racemate of a compound of general formula I is reacted with one of the above-mentioned optically active acids or bases in equimolar amounts in a solvent and the crystalline, diastereomeric, optically active salts obtained are separated on the basis of their different solubilities. This reaction may be carried out in solvents of any kind provided that they are sufficiently different in terms of the solubility of the salts. Preferably, methanol, ethanol or mixtures thereof are used, e.g. in a ratio by volume of 50:50. Then each of the optically active salts is dissolved in water, neutralised with a base such as sodium carbonate or potassium carbonate, sodium hydroxide solution or potassium hydroxide solution, and in this way the corresponding free compound is obtained in the (+)- or (−)-form.

The (R)-enantiomer alone or a mixture of two optically active diastereomeric compounds coming within the scope of general formula I may also be obtained by carrying out the syntheses described above with a suitable reaction component in the (R)-configuration.

The starting materials of general formulae VII, IX, X, X′, XI, XII, XIII, XV, XVa, XVII, XXI, XXII required to synthesis the compounds of general formula I as well as the amino acids used are commercially available or may be prepared by methods known from the literature.

Compounds of general formula VIII wherein Z denotes the group NR 1 and those of general formula VIII′ wherein X denotes the oxygen atom may be obtained from commonly available starting materials using methods familiar to peptide chemists.

Isocyanates of general formula XII can easily be obtained from α-amino acid derivatives of general formula VIII′ wherein R 1 denotes a hydrogen atom and the other groups are as hereinbefore defined, or from the hydrochlorides thereof by reacting with phosgene, diphosgene or triphosgene in the presence of pyridine (see also: J. S. Nowick, N. A. Powell, T. M. Nguyen and G. Noronha, J. Org. Chem. 57, 7364-7366 [1992]).

Carboxylic acids of general formulae XIV and XVI may be obtained from the corresponding carboxylic acid esters by saponification, preferably in the presence of lithium hydroxide.

The carboxylic acids of general formula XVIII are obtained by saponifying corresponding carboxylic acid esters which are in turn prepared from suitable secondary amines, 4-aryl-4-oxobutanoic acid esters and formaldehyde by Mannich reaction.

Compounds of general formula XIX may be obtained from suitable 4-oxobutanoic acids and amines of general formula X using conventional methods.

The intermediate compounds of general formula XX come under general formula I and are thus within the scope of the present application. These compounds may be obtained, for example, using processes a) to h) described herein.

The compounds of general formula I may be converted into their physiologically acceptable salts with inorganic or organic acids, particularly for pharmaceutical applications. Examples of suitable acids for this purpose include hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid, methanesulphonic acid, p-toluenesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, mandelic acid, malic acid, citric acid, tartaric acid or maleic acid.

Moreover, if the new compounds of formula I thus obtained contain an acid function, for example a carboxy group, they may if desired be converted into the addition salts thereof with inorganic or organic bases, more particularly for pharmaceutical use, into the physiologically acceptable addition salts thereof. Bases which may be considered include, for example, sodium hydroxide, potassium hydroxide, ammonia, cyclohexylamine, dicyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

The new compounds of general formula I and the physiologically acceptable salts thereof have CGRP-antagonistic properties and exhibit good affinities in CGRP-receptor binding studies. The compounds exhibit CGRP-antagonistic properties in the pharmacological test systems described hereinafter.

The following experiments were carried out to demonstrate the affinity of compounds of general formula I for human CGRP-receptors and their antagonistic properties:

A. Binding studies with SK-N-MC-cells expressing human CGRP-receptor

SK-N-MC-cells are cultivated in Dulbecco's modified Eagle Medium. The medium of confluent cultures is removed. The cells are washed twice with PBS-buffer (Gibco 041-04190 M), detached by the addition of PBS-buffer mixed with 0.02% EDTA and isolated by centrifuging. After resuspension in 20 ml of Balanced Salts Solution [BSS (in mM): NaCl 120, KCl 5.4, NaHCO 3 16.2, MgSO 4 0.8, NaHPO 4 1.0, CaCl 2 1.8, D-Glucose 5.5, HEPES 30, pH7.40] the cells are centrifuged twice at 100×g and resuspended in BSS. After the cell number has been determined the cells are homogenised using an Ultra-Turrax and centrifuged for 10 minutes at 3000×g. The supernatent is discarded and the pellet is recentrifuged and resuspended (1 ml/1000000 cells) in Tris-buffer (10 mM Tris, 50 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, pH 7.40), enriched with 1% bovine serum albumin and 0.1% bacitracin. The homogenate is frozen at −80° C. The membrane preparations are stable for more than 6 weeks under these conditions.

After thawing, the homogenate is diluted 1:10 with assay buffer (50 mM Tris, 150 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, pH 7.40) and homogenised for 30 seconds with an Ultra-Turrax. 230 μl of the homogenate are incubated at ambient temperature for 180 minutes with 50 pM of 125 I-Iodotyrosyl-Calcitonin-Gene-Related Peptide (Amersham) and increasing concentrations of the test substances in a total volume of 250 μl. Incubation is ended by rapid filtration using GF/B-glass fibre filters treated with polyethyleneimine (0.1%) by means of a cell harvester. The protein-bound radioactivity is measured using a gammacounter. The non-specific binding is defined as the radioactivity bound after the presence of 1 μM of human CGRP-alpha during incubation.

The concentration binding curves are analysed using a computer-aided non-linear curve adaptation.

The compounds of general formula I show IC 50 values≦10000 nM in the test described.

B. CGRP-Antagonism in SK-N-MC-cells

SK-N-MC-cells (1 million cells) are washed twice with 250 μl of incubation buffer (Hanks' HEPES, 1 mM 3-isobutyl-1-methylxanthine, 1% BSA, pH 7.4) and pre-incubated at 37° C. for 15 minutes. After the addition of CGRP (10 μl) as agonist in increasing concentrations (10 −11 to 10 −6 M) or additionally of substance in 3 to 4 different concentrations, incubation is continued for a further 15 minutes.

Intracellular cAMP is then extracted by the addition of 20 μl of 1M HCl and centrifugation (2000×g, 4° C. for 15 minutes). The supernatants are frozen in liquid nitrogen and stored at −20° C.

The cAMP contents of the samples are determined by radioimmunoassay (Amersham) and the pA 2 -values of antagonistically acting substances are determined graphically.

The compounds of general formula I display CGRP-antagonistic properties in a dosage range between 10 −11 and 10 −5 M in the in vitro test model described.

In view of their pharmacological properties the compounds of general formula I and the salts thereof with physiologically acceptable acids or bases are thus suitable for acute and prophylactic treatment of headache, particularly migraine and cluster headaches. Moreover, the compounds of general formula I also have a beneficial effect on the following diseases: non-insulin-dependent diabetes mellitis (NIDDM), cardiovascular diseases, skin diseases, particularly thermal and radiation-induced skin damage including sunburn, inflammatory diseases, e.g. inflammatory joint diseases (arthritis), inflammatory lung diseases, allergic rhinitis, asthma, diseases which involve excessive vasodilation and resultant reductions in circulation, e.g. shock and sepsis, as well as morphine tolerance. In addition, the compounds of general formula I have the effect of alleviating pain in general.

The dosage needed to achieve such effects is appropriately 0.0001 to 3 mg/kg of body weight, preferably 0.01 to 1 mg/kg of body weight, by intravenous or subcutaneous route, and 0.01 to 10 mg/kg of body weight, preferably 0.1 to 10 mg/kg of body weight, when administered orally, nasally or by inhalation, in each case 1 to 3 times a day.

For this purpose, the compounds of general formula I prepared according to the invention may be formulated, optionally in combination with other active substances, such as antiemetics, prokinetics, neuroleptics, antidepressants, neurokinin-antagonists, anti-convulsants, histamine-H1-receptor antagonists, antimuscarinics, β-blockers, α-agonists and α-antagonists, ergot alkaloids, mild analgesics, non-steroidal antiphlogistics, corticosteroids, calcium-antagonists, 5-HT 1D -agonists or other antimigraine agents, together with one or more inert conventional carriers and/or diluents, e.g. corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetylstearylalcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, metering aerosol or suppositories.

Thus, additional active substances which may be considered for the above-mentioned combinations include, for example, meloxicam, ergotamine, dihydroergotamine, metoclopramide, domperidon, diphenhydramine, cyclizine, promethazine, chlorpromazine, dexamethasone, flunarizine, dextropropoxyphene, meperidine, propranolol, nadolol, atenolol, clonidine, indoramine, carbamazepine, phenytoin, valproate, amitryptilin, lidocaine, diltiazem or sumatriptan and other 5-HT 1D -agonists such as naratriptan, zolmitriptan, avitriptan, rizatriptan and eletriptan. The dosage for these active substances is appropriately 1/5 of the lowest dose normally recommended up to 1/1 of the normally recommended dosage, i.e. 20 to 100 mg of sumatriptan, for example.

The invention further relates to the use of the compounds of general formula I as valuable auxiliary agents for the production and purification (by affinity chromatography) of antibodies and, after suitable radiolabelling, e.g. by direct labelling with 125 I or 131 I or by tritiation of suitable precursors for example by replacing halogen atoms with tritium, in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

The Examples which follow are intended to illustrate the invention:

Preliminary Remarks

There are satisfactory elementary analyses, IR, UV, 1 H-NMR and generally mass spectra as well, for all the compounds. Unless otherwise specified, Rf values were determined using TLC ready-made plates of silica gel 60 F 254 (E. Merck, Darmstadt, Product No. 5729) without chamber saturation. If there are no details of configuration, it is undecided whether this is the pure enantiomer or whether partial or total racemisation has occurred. The following eluants or eluant mixtures were used for chromatography:

FM1=dichloromethane/cyclohexane/methanol/ammonia 7/1.5/1.5/0.2 (v/v/v/v)

FM2=dichloromethane/methanol/ammonia 7.5/2.5/0.5 (v/v/v)

FM3=dichloromethane/methanol 8/2 (v/v)

FM4=dichloromethane/ethyl acetate/methanol/cyclohexane/conc. aqueous ammonia=59/25/7,5/7,5/1 (v/v/v/v/v)

FM5=ethyl acetate/dichloromethane=7/3 (v/v)

FM6=ethyl acetate/petroleum ether=1/1 (v/v)

FM7=dichloromethane/methanol/conc. aqueous ammonia=80/20/1 (v/v/v)

The following abbreviations were used in the descriptions of the experiments:

Mp.: melting point

(D): (decomposition)

DIEA: N,N-diisopropyl-ethylamine

Boc: (1,1-dimethylethoxy)carbonyl

TBTU: 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate

HOBt: 1-hydroxybenzotriazole-hydrate

CDT: 1,1′-carbonyldi(1,2,4-triazole)

THF: tetrahydrofuran

DMF: dimethylformamide

Fmoc: (9-fluorenylmethoxy)carbonyl

EE: ethyl acetate

PE: petroleum ether

LM: solvent

Lfd. No.: item number

The meanings of the symbols made up of letters and numbers used in the Examples are given in the following summary:

A. PREPARATION OF INTERMEDIATE COMPOUNDS

EXAMPLE A1

Preparation of compounds of the general structure:

1,3-dihydro-4-(3-methoxyphenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

a) 4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-pipieridine

To a mixture of 20.0 g (0.10 mol) of 4-amino-1-(1,1-dimethyl-ethoxycarbonyl)piperidine, 8.2 g (0.1 mol) of anhydrous sodium acetate and 150 ml of dichloromethane was added dropwise, with stirring and whilst maintaining a reaction temperature of from 0° C. to +10° C., a solution of 25.0 g (0.109 mol) of 3-methoxy-phenacylbromide in 50 ml of dichloromethane was added dropwise. The mixture was stirred for 5 hours at room temperature, then 19.5 g (0.296 mol) of sodium cyanate, 18 ml of glacial acetic acid and 10 ml of water were added and stirring was continued for 12 hours at room temperature. The mixture was stirred into 1 l of ice water, the dichloromethane phase was separated off, washed twice with 200 ml of water, 5% aqueous sodium hydrogen carbonate solution, 20% aqueous citric acid solution and once more with water, dried over magnesium sulphate and evaporated down in vacuo. The residue was taken up in methanol. It was left to stand overnight, the precipitate which crystallised out was suction filtered, washed thoroughly with tert. butyl-methylether and after drying in vacuo 11.5 g (30.8% of theory) of colourless crystals were obtained.

MS: M + =373

The following were obtained accordingly:

(1) 4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

R f : 0.51 (FM4)

(2) 4-[1,3-dihydro-4-(4-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 23.8% of theory

(3) 4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

IR(KBr): 1685.7 cm −1 (C═O)

(4) 4-[1,3-dihydro-5-methyl-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-(1,-dimethylethoxycarbonyl)-piperidine

R f : 0.23 (dichloromethane/methanol 9/1 v/v)

IR(KBr): 1687.6 cm −1 (C═O)

MS: M + =357

(5) 4-[1,3-dihydro-4-(3-nitrophenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 29.1% of theory

MS: M + =388

(6) 4-[4-(3-bromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 13.1% of theory

IR(KBr): 1685 cm −1 (C═O)

MS: M + =421/423 (Br)

(7) 4-[1,3-dihydro-4,5-diphenyl-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

IR(KBr): 1680, 1699 cm −1 (C═O)

MS: M + =419

(8) 4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

IR(KBr): 1682 cm −1 (C═O)

MS: M + =388

(9) 4-[4-(4-biphenylyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 21.6% of theory, colourless crystals

R f : 0.6 (ethyl acetate)

IR(KBr): 1681.8 cm −1 (C═O)

(10) 4-[1,3-dihydro-4-(2-naphthyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 30% of theory, crystals

IR(KBr): 1679.9 cm −1 (C═O)

(11) 4-[1,3-dihydro-4-(2-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

R f : 0.86 (FM1)

(12) 4-[4-(3,4-dichlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 62% of theory, colourless crystals

R f : 0.34 (ethyl acetate)

IR(KBr): 1687 cm −1 (C═O)

(13) 4-[4-(3-chlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 21% of theory

R f : 0.6 (ethyl acetate/methanol 9/1 v/v)

(14) 4-[1,3-dihydro-4-(3-hydroxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

Yield: 60% of theory

IR(KBr): 1682 cm −1 (C═O)

MS: M + =359

(15) 4-[4-[3,5-bis-(trifluoromethyl)phenyl]-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

Yield: 3.2% of theory

IR(KBr): 1687.6 cm −1 (C═O)

R f : 0.95 (dichloromethane/methanol 9/1 v/v)

(16) 4-[4-(4-amino-3,5-dibromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

Yield: 4.6% of theory

IR(KBr): 1684 cm −1 (C═O)

R f : 0.48 (FM4; Macherey-Nagel POLYGRAM® SIL G/UV 254 ready-made films for TLC)

b) 1,3-dihydro-4-(3-methoxyphenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

The solution of 11.5 g (0.0308 mol) of 4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine in 150 ml of dichloromethane was mixed with 15 ml of trifluoroacetic acid and then stirred overnight at room temperature. The reaction mixture was evaporated down in vacuo, the residue was taken up in 10 ml of water and made distinctly ammoniacal. The resulting precipitate was suction filtered, washed thoroughly with water and dried overnight at 50° C. in vacuo. 7.0 g (83.1% of theory) of colourless crystals were obtained, R f value 0.2 (dichloromethane/methanol 9/1 v/v).

The following were obtained accordingly:

(1) 1,3-dihydro-4-phenyl-1-(4-piperidinyl)-2H-imidazol-2-one,

R f : 0.22 (FM1; Macherey-Nagel POLYGRAM® SIL G/UV 254 ready-made films for TLC)

IR(KBr): 1672 cm −1 (C═O)

(2) 1,3-dihydro-4-(4-methoxyphenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

IR(KBr): 1670 cm −1 (C═O)

MS: M + =273

(3) 1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-1-(4-piperidinyl)-2H-imidazol-2-one

IR(KBr): 1687.6 cm −1 (C═O)

(4) 1,3-dihydro-5-methyl-4-phenyl-1-(4-piperidinyl)-2H-imidazol-2-one

yield: 76.2% of theory

IR(KBr): 1679.9 cm −1 (C═O)

MS: M + =257

(5) 1,3-dihydro-4-(3-nitrophenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

yield: 94% of theory

IR(KBr): 1677.8 (C═O); 1137.8, 1197.6, 1349.9 (NO 2 ) cm −1

(6) 4-(3-bromophenyl)-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

yield: quantitative

IR(KBr): 1676 cm −1 (C═O)

(7) 1,3-dihydro-4,5-diphenyl-1-(4-piperidinyl)-2H-imidazol-2-one

IR(KBr): 1670 cm −1 (C═O)

MS: M + =319

(8) 1,3-dihydro-4-(4-fluorophenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

yield: 30% of theory

R f : 0.2 (eluant: ethyl acetate/methanol/conc. ammonia 9/1/0.3 v/v/v)

IR(KBr): 1682 cm −1 (C═O)

(9) 4-(4-biphenylyl)-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

yield: quantitative

IR(KBr) of the trifluoroacetate: 1679.9 cm −1 (C═O)

(10) 1,3-dihydro-4-(2-naphthyl)-1-(4-piperidinyl)-2H-imidazol-2-one

yield: 28.2% of theory

R f : 0.03 (FM1)

IR(KBr) of the trifluoroacetate: 1678 cm −1 (C═O)

(11) 7-(2-methoxyphenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

yield: 18.8% of theory

R f : 0.22 (FM1)

IR(KBr) of the trifluoroacetate: 1681.6 cm −1 (C═O)

(12) 4-(3,4-dichlorophenyl)-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

yield: quantitative

IR(KBr) of the trifluoroacetate: 3197 (N—H); 1685 (C═O) cm −1

(13) 4-(3-chlorophenyl)-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

Yield: 98% of theory

R f : 0.25 (eluant: ethyl ethanoate/methanol/conc. ammonia 9/1/0.3 v/v/v)

(14) 1,3-dihydro-4-(3-hydroxyphenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

Yield: 90% of theory

R f : 0.075 (FM1)

IR(KBr): 1670 (C═O) cm −1

MS: M + =259

(15) 4-[3,5-bis-(trifluoromethyl)phenyl]-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

Yield: 71% of theory

R f : 0.15 (FM1)

IR(KBr): 1701 (C═O) cm −1

MS: M + =379

(16) 4-(4-amino-3,5-dibromophenyl)-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

Yield: 44% of theory

R f : 0.71 (FM1; Macherey-Nagel POLYGRAM® SIL G/UV 254 ready-made films for TLC)

IR(KBr): 1676 (C═O) cm −1

EXAMPLE A2

2,4-dihydro-9-phenyl-2-(4-piperidinyl)-3H-1,2,4-triazol-3-one

a) 1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinone-(1,1-dimethylethoxycarbonyl)hydrazone

A mixture of 16.0 g (0.05 mol) of 1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinone, 7.25 g (0.055 mol) of tert. butyl hydrazinoformate and 250 ml of ethanol was refluxed for 1 hour. The solvent was distilled off in vacuo, the oily residue remaining was triturated with diethylether. The crystalline precipitate thus formed was suction filtered and washed with a little diethylether. After the product had been dried in vacuo 21.7 g (99.7% of theory) of colourless crystals were obtained, m.p. 156-158° C. (decomposition).

b) N-(1,1-dimethylethoxycarbonyl)-N′-[1-(9H-fluoren-9-yl-methoxycarbonyl)-4-piperidinyl]-hydrazine

A solution of 21.7 g (0.05 mol) of 1-(9H-fluoren-9-ylmethoxy-carbonyl)-4-piperidinone-(1,1-dimethylethoxycarbonyl)-hydrazone in 200 ml of glacial acetic acid was hydrogenated in the presence of 2.0 g platinum (IV) oxide at room temperature and 3 bar of hydrogen pressure until the calculated volume of hydrogen had been taken up. The catalyst was filtered off, the filtrate was evaporated down in vacuo and the residue was dissolved in a little diethylether. The crystals precipitated after standing for 3 hours at room temperature were suction filtered, washed with a little diethylether and dried in vacuo at room temperature. 21.8 g (99.6% of theory) of colourless crystals of m.p. 135-137° C. and R f =0.235 (eluant 3) were obtained.

ESI-MS: (M+H) + =438

c) [1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinyl]hydrazine-hydrochloride

21.8 g (0.0498 mol) of N-(1,1-dimethylethoxycarbonyl)-N′-[1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinyl]-hydrazine were dissolved in 100 ml of trifluoroacetic acid and stirred for 1 hour at room temperature. The excess trifluoroacetic acid was removed in vacuo, the residue was dissolved in 50 ml of water and made alkaline with 10% aqueous sodium carbonate solution. The solution was extracted thoroughly with dichloromethane, the combined extracts were dried over magnesium sulphate and evaporated down in vacuo. The residue thus obtained was taken up in ethyl acetate and converted into the hydrochloride by the addition of ethereal hydrogen chloride solution. After recrystallisation from anhydrous ethanol 6.2 g (33.3% of theory) of colourless crystals of melting point 160-162° C. were obtained.

C 20 H 23 N 3 O 2 +HCl (373.88) Calculated: C, 64.25; H, 6.47; N, 11.24; Cl, 9.48. Found: 64.14; 6.46; 10.99; 9.46.

d) 2,4-dihydro-5-phenyl-2-[1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinyl]-3H-1,2,4-triazol-3-one

The solutions of 5.56 g (0.0165 mol) of [1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinyl]-hydrazine in 60 ml of tetrahydrofuran and 3.7 g (0.0177 mol) of N-(ethoxycarbonyl)-benzothionamide in 30 ml of tetrahydrofuran were combined and refluxed for 1 hour, whereupon hydrogen sulphide was released. The solvent was distilled off in vacuo, the oily residue remaining was boiled with a little acetonitrile. The mixture was allowed to cool, then additionally cooled from outside with ice water and the resulting precipitate was suction filtered. 4.0 g (52% of theory) of colourless crystals were obtained, melting point 142° C. and R f =0.38 (eluant 4).

IR (KBr): 1685.7 cm −1 (C═O)

e) 2,4-dihydro-5-phenyl-2-(4-piperidinyl)-3H-1,2,4-triazol-3-one

A mixture of 9.0 g (0.0193 mol) of 2,4-dihydro-5-phenyl-2-[1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinyl]-3H-1,2,4-triazol-3-one, 50 ml of tetrahydrofuran and 70 ml of diethylamine was stirred at room temperature until the end of the reaction monitored by thin layer chromatography. The solvent was removed in vacuo, the residue remaining was mixed with 300 ml of water and subjected to ultrasound treatment for 30 minutes. The insoluble matter was separated off by suction filtering and the aqueous filtrate was evaporated down in vacuo. The residue thus obtained was boiled with a little methanol and after cooling it was suction filtered. After drying 0.58 g (12.3% of theory) of colourless crystals of melting point 294° C. (D) and R f =0.1 (eluant 1) were obtained.

IR (KBr): 1681.8 cm −1 (C═O)

EXAMPLE A3

Preparation of compounds of general structure:

3,4-dihydro-3-(4-piperidinyl)-2-(1H)-pyrido[2,3-d]-pyrimidinone

a) N-(2-Pyridinyl)-2,2-dimethylpropanamide

To a solution of 94.1 g (1.0 mol) of 2-aminopyridine and 173 ml (1.25 mol) of triethylamine in 400 ml of dichloromethane were added dropwise, whilst cooling with ice water, 132.5 g (1.099 mol) of pivaloyl chloride in 150 ml of dichloromethane. The mixture was stirred for 2 hours at room temperature and filtered to remove the triethylamine hydrochloride formed. The filtrate was washed with water and twice with 5% aqueous sodium hydrogen carbonate solution, then dried over sodium sulphate. After working up in the usual way 157.5 g (88.4% of theory) of colourless crystals of melting point 74-76° C. were obtained.

The following was obtained in the same way:

N-(4-Pyridinyl)-2,2-dimethylpropanamide

Yield: 74% of theory

Mp. 137-140° C. (diisopropylether)

IR (KBr): 1687 cm −1 (C═O)

b) N-(-formyl-2-pyridinyl)-2,2-dimethylpropanamide

Whilst maintaining a reaction temperature of −78° C., 781 ml (1.25 mol) of a 1.6-molar solution of n-butyllithium in n-hexane were added dropwise to a solution of 89.1 g (0.5 mol) of N-(2-pyridinyl)-2,2-dimethylpropanamide in 300 ml of anhydrous tetrahydrofuran. The mixture was allowed to heat slowly up to 0° C. and stirred for 3 hours at this temperature. Then the mixture was again cooled to −78° C. and whilst maintaining this temperature the solution of 109.6 g (1.5 mol) of dimethyformamide in 150 ml of anhydrous tetrahydrofuran was added dropwise thereto. The mixture was allowed to come up to 0° C. and then stirred into 1 l of ice water. It was initially acidified with 12% aqueous hydrochloric acid, then made alkaline by the addition of solid potassium carbonate and extracted thoroughly with diethylether. The combined ether extracts were dried over sodium sulphate and evaporated down. The crystalline residue, after recrystallisation from diisopropylether, had an m.p. of 83° C. Yield: 94.0 g (91.2% of theory).

The following were obtained in the same way:

(1) N-(4-formyl-3-pyridinyl)-2,2-dimethylpropanamide

Yield: 52% of theory

R f : 0.5 (dichloromethane/methanol/conc. ammonia 90/10/0.1 v/v/v)

IR (KBr) of the hydrochloride: 1695 cm −1 (C═O)

MS: M + =206

(2) N-(3-formyl-4-pyridinyl)-2,2-dimethylpropanamide

The reddish oil obtained in a quantitative yield was further processed without more purification

c) N-[3-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-2-pyridinyl]-2,2-dimethylpropanamide

A solution of 8.2 g (0.0398 mol) of N-(3-formyl-2-pyridinyl)-2,2-dimethylpropanamide and 7.6 g (0.04 mol) of 4-amino-1-(phenylmethyl)piperidine in 80 ml of methanol was combined in batches with a total of 1.7 g (0.045 mol) of sodium borohydride and refluxed for a total of 24 hours. The solvent was removed in vacuo, the residue was distributed between water and ethyl acetate. The organic phase was dried over sodium sulphate and freed from solvent. The residue was triturated with diisopropylether and suction filtered. 6.0 g (39.6% of theory) of colourless crystals of melting point 138° C. were obtained.

The following were obtained in the same way:

(1) N-[4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-3-pyridinyl]-2,2-dimethylpropanamide

Yield: 94% of theory

R f : 0.4 (dichloromethane/methanol/conc. ammonia 90/10/0.1 v/v/v)

The yellowish oil was used in the following stage without further purification

(2) N-[3-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-4-pyridinyl]-2,2-dimethylpropanamide

Yield: 11.6% of theory

IR(KBr): 1689 (C═O) cm −1

d) 2-amino-3-[[[1-(phenylmethyl)-4-piperidinyl]-amino]methyl]pyridine

A mixture of 6.0 g (0.0158 mol) of N-[3-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-2-pyridinyl]-2,2-dimethylpropanamide and 100 ml of conc. hydrochloric acid was refluxed for 3 hours. The mixture was evaporated down in vacuo, the residue remaining was dissolved in a little water and made alkaline by the addition of solid potassium carbonate. It was extracted thoroughly with ethyl acetate, the combined extracts were dried over sodium sulphate and evaporated down in vacuo. The residue was thoroughly triturated with diisopropylether and yielded 4.2 g (89.7% of theory) of colourless crystals of melting point 114° C.

The following were obtained in the same way:

(1) 3-amino-4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]pyridine

Yield: 96% of theory

R f : 0.42 (dichloromethane/methanol/conc. ammonia 90/10/0.1 v/v/v)

The yellowish oil was used in the following stage without further purification

(2) 4-amino-3-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]pyridine

Yield: quantitative

The yellowish oil was used in the following stage without further purification

e) 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-pyrido[2,3-d]-pyrimidinone

A mixture of 4.2 g (0.0142 mol) of 2-amino-3-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-pyridine, 2.4 g (0.0148 mol) of N,N′-carbonyldiimidazole and 50 ml of dimethylformamide was heated to 100° C. for 30 minutes. The still warm mixture was stirred into 300 ml of ice water, the precipitate formed was suction filtered and recrystallised from acetonitrile. After drying in vacuo 4.5 g (98.3% of theory) of colourless crystals of melting point 187° C. were obtained.

The following were obtained in the same way:

(1) 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-pyrido[3,4-d]-pyrimidinone

Colourless crystals

Yield: 33% of theory

IR (KBr): 1676 cm −1 (C═O)

MS: M + =322

(2) 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-pyrido[4,3-d]-pyrimidinone

Mp. 155° C. (D)

Yield: 99% of theory

IR (KBr): 1680 cm −1 (C═O)

f) 3,4-dihydro-3-(4-piperidinyl]-2(1H)-pyrido[2,3-d]-pyrimidinone

A solution of 4.7 g (0.0146 mol) of 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-pyrido[2,3-d]-pyrimidinone in 50 ml of methanol was hydrogenated at a temperature of 50° C. and in the presence of 2.0 g of 20% palladium/charcoal until the uptake of hydrogen ceased. After removal of the catalyst and solvent 3.3 g (97.3% of theory) of a colourless oil of R f =0.35 (FM1) were obtained.

IR (KBr): 1660.6 cm −1 (C═O)

The following were obtained in the same way:

(1) 3,4-dihydro-3-(4-piperidinyl]-2(1H)-pyrido[3,4-d]-pyrimidinone

Colourless crystals

Yield: 95% of theory

IR (KBr): 1662 cm −1 (C═O)

MS: M + =232

(2) 3,4-dihydro-3-(4-piperidinyl]-2(1H)-pyrido[4,3-d]-pyrimidinone

Yellowish resin

Yield: 97% of theory

IR (KBr): 1672 cm −1 (C═O)

R f : 0.12 (FM1)

EXAMPLE A4

Methyl 3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazoline-7-carboxylate

a) (E)-1-(dimethylamino)-2-[4-(methoxycarbonyl)-2-nitrophenyl]ethene

A mixture of 98.3 g (0.504 mol) of methyl 4-methyl-3-nitrobenzoate, 78.0 g (0.655 mol) of N,N-dimethylformamide dimethylacetal and 1 1 of dimethylformamide was heated to 140° C. for 3 hours. The solvent was distilled off in vacuo, the residue was triturated thoroughly with 1 1 methanol. After drying in vacuo 119.5 g (94.7% of theory) of a red amorphous substance was obtained, which was further processed without any more purification.

b) 4-(Methoxycarbonyl)-2-nitrobenzaldehyde

To a mixture of 119.5 g (0.478 mol) of (E)-1-(dimethylamino)-2-[4-(methoxycarbonyl)-2-nitrophenyl]-ethene and 1.3 l of water/tetrahydrofuran mixture (1/1 v/v) were added, in batches, 308.0 g (1.44 mol) of sodium metaperiodate, whilst the reaction temperature was regulated at under +30° C. by external cooling with ice water. The mixture was stirred for a further 2.5 hours at room temperature and then filtered. The precipitate was thoroughly washed with ethyl acetate. The organic phase was separated off, the aqueous phase was thoroughly extracted with ethyl acetate. The combined ethyl acetate phases were dried over sodium sulphate and evaporated down in vacuo. The oil which crystallised after one day was further processed without any more purification. Yield: 87 g (87% of theory).

c) Methyl 4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-3-nitrobenzoate

To a solution of 41.0 g (0.215 mol) of 4-amino-1-(phenylmethyl)-piperidine and 45.0 g (0.215 mol) of 4-(methoxycarbonyl)-2-nitrobenzaldehyde in 1 l methanol were added in batches, at room temperature, 8.3 g (0.22 mol) of sodium borohydride and the mixture was then stirred for 30 minutes at the same temperature. The mixture was stirred into 1 l of ice water and thoroughly extracted with tert. butyl-methylether. The combined extracts were dried over sodium sulphate and evaporated down in vacuo, the residue was dissolved in as little methanol as possible and converted into the hydrochloride by treatment with methanolic hydrogen chloride solution. The crystalline salt was suction filtered, washed with methanol and diethylether, then taken up in water and made alkaline with saturated aqueous potassium carbonate solution. The mixture obtained was extracted thoroughly with ethyl acetate, the combined ethyl acetate extracts were dried over sodium sulphate and evaporated down. 58.2 g (70.6% of theory) of a brownish-yellow oil were obtained, which was further processed without any more purification.

d) Methyl 3-amino-4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-benzoate

A solution of 58.0 g (0.151 mol) of methyl 4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-3-nitrobenzoate in 800 ml of methanol was hydrogenated in the presence of 10 g of 5% rhodium/charcoal for 7 hours at room temperature. The catalyst was filtered off, the filtrate was evaporated down in vacuo. 50.0 g (93.7% of theory) of colourless crystals were obtained, which were further processed without any more purification.

e) Methyl 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-oxoquinazolin-7-carboxylate

Prepared analogously to Example A3e) from methyl 3-amino-4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-benzoate and N,N′-carbonyl-diimidazole in a yield of 66.3% of theory.

Slightly yellowish crystals.

IR (KBr): 1714.6; 1664.5 cm −1 (C═O)

f) Methyl 3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazolin-7-carboxytate

A solution of 35.5 g (0.0936 mol) of methyl 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-oxoquinazolin-7-carboxylate in 400 ml of methanol was hydrogenated in the presence of 5 g of 10% palladium/charcoal for 5 hours at 50° C. The catalyst was filtered off, the filtrate was evaporated down in vacuo. The residue was triturated with 150 ml of ethyl acetate and then suction filtered. After drying in vacuo 20.4 g (75.3% of theory) of colourless crystals were obtained, which were further processed without any more purification.

IR (KBr): 1718.5; 1672.2 cm −1 (C═O)

The following were prepared analogously:

(1) 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone

R f : 0.3 (FM1)

IR (KBr): 1662.5 cm −1 (C═O)

(2) 3,4-dihydro-8-methoxy-3-(4-piperidinyl)-2(1H)-quinazolinone

R f : 0.35 (FM1)

(3) 3,4-dihydro-6,7-dimethoxy-3-(4-piperidinyl)-2(1H)-quinazolinone

R f : 0.40 (FM1)

EXAMPLE A5

3,4-dihydro-3-(4-piperidinyl)-1H-thieno[3,4-d]pyrimidin-2-one-trifluioroacetate

a) Methyl 4-(ethoxycarbonylamino)-thiophene-3-carboxylate

A mixture of 50.0 g (0.258 mol) of methyl 4-aminothiophen-3-carboxylate-hydrochloride, 700 ml of toluene, 26 g (0.257 mol) of triethylamine and 27 ml (0.283 mol) of ethyl chlorocarbonate was refluxed for 5 hours. The insoluble matter was filtered off, the filtrate was evaporated down in vacuo and the residue was crystallised from petroleum ether. 59.0 g (99.8% of theory) of colourless crystals of melting point 52° C. were obtained.

In the same way, crystalline methyl 3-(ethoxycarbonylamino)-thiophen-2-carboxylate was obtained from methyl 3-aminothiophene-2-carboxylate and ethyl chlorocarbonate in a yield of 98.7% of theory.

IR (KBr): 1739.7; 1622 cm −1 (C═O, C═C)

b) 4-(ethoxycarbonylamino)-thiophene-3-carboxaldehyde

Into an ice-cold suspension of 12.9 g (0.34 mol) of lithium aluminium hydride in 800 ml of tert. butyl-methylether was added dropwise, at a reaction temperature of about 0° C., a solution of 59.1 g (0.258 mol) of methyl 4-(ethoxycarbonylamino)-thiophene-3-carboxylate in 200 ml of tert. butyl-methyl-ether, and the mixture was then stirred for a further 2 hours at 10° C. Then 13 ml of water, 13 ml of 2N aqueous sodium hydroxide solution and 39 ml of water were added dropwise one after another and the mixture was stirred for 1 hour at room temperature. It was filtered, and 500 g of activated manganese (IV) oxide were added in batches to the filtrate with stirring. After the completion of the reaction, which could be monitored by thin layer chromatography, the mixture was filtered again and the filtrate was then evaporated down in vacuo. The crystalline residue which solidified was further processed without any more purification. yield: 28.2 g (54.9% of theory).

In the same way 3-(ethoxycarbonylamino)-thiopbene-2-carboxaldehyde was obtained from methyl 3-(ethoxycarbonylamino)-thiophene-2-carboxylate in a yield of 71.9% of theory.

c) 4-[[[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]amino]methyl]-3-(ethoxycarbonylamino)-thiophene

A mixture of 28.2 g (0.142 mol) of 4-(ethoxycarbonyl-amino)-thiophene-3-carboxaldehyde, 28.2 g (0.141 mol) of 4-amino-1-(1,1-dimethyl-ethoxycarbonyl)piperidine and 300 ml of toluene was refluxed using a water separator until water formation had ceased. The solvent was removed in vacuo, the residue was dissolved in 300 ml of methanol and at room temperature combined batchwise with 5.5 g (0.145 mol) of sodium borohydride. The mixture was stirred for a further hour at room temperature, then evaporated down in vacuo and the residue was distributed between water and tert. butyl-methylether. The organic phase was dried over sodium sulphate and freed from solvent in vacuo. The oily residue was further processed without purification.

Yield: 54.0 g (99.9% of theory).

In the same way 2-[[[1,1-dimethylethoxycarbonyl)-4-piperidinyl]amino]methyl]-3-(ethoxycarbonylamino)-thiophene was obtained from 3-(ethoxycarbonylamino)-thiophene-2-carboxaldehyde, 4-amino-1-(1,1-dimethylethoxycarbonyl)piperidine and sodium borohydride in a yield of 100% of theory.

IR (KBr): 1728.1; 1693.4 cm −1 (C═O)

d) 3,4-dihydro-3-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-1H-thieno[3,4-d]pyrimidin-2-one

A solution of 54.0 g (0.141 mol) of 4-[[[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]amino]methyl]-3-(ethoxycarbonylamino)-thiophene in 300 ml of dimethylformamide was refluxed for 4 hours. After the end of the reaction, which could be monitored by thin layer chromatography, the still warm mixture was stirred into 1 l of ice water. The crystalline precipitate was suction filtered and dried at 30° C. in a circulating air drier.

Yield: 47.5 g (99.8% of theory).

In the same way 3,4-dihydro-3-[1-(1,1-dimethyl-ethoxycarbonyl)-4-piperidinyl]-1H-thieno[3,2-d]pyrimidin-2-one was obtained from 2-[[[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]amino]methyl]-3-(ethoxycarbonyl-amino)-thiophene in a yield of 71% of theory. Colourless crystals of melting point 200° C. (acetonitrile).

IR (KBr): 1683.8; 1654.8 cm −1 (C═O)

e) 3,4-dihydro-3-(4-piperidinyl)-1H-thieno[3,4-d]pyrimidin-2-one-trifluoroacetate

A mixture of 10.0 g (0.0296 mol) of 3,4-dihydro-3-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-1H-thieno[3,4-d]pyrimidin-2-one and 50 ml of trifluoroacetic acid was stirred at room temperature for 30 minutes. The residue remaining after removal of the excess trifluoroacetic acid was triturated with diethylether and suction filtered. 5.8 g (55.8% of theory) of colourless crystals were obtained, which were used without further purification.

IR (KBr): 1664.5 cm −1 (C═O)

In the same way, crystalline 3,4-dihydro-3-(4-piperidinyl)-1H-thieno[3,2-d]pyrimidin-2-one-trifluoracetate was obtained from 3,4-dihydro-3-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-1H-thieno-[3,2-d]pyrimidin-2-one and trifluoroacetic acid in a yield of 100% of theory.

IR (KBr): 1685.7; 1656.8 cm −1 (C═O)

EXAMPLE A6

3,4-dihydro-3-(4-piperidinyl)-2(1H)quinolone-hydrochloride

A mixture of 1.1 g (4.949 mmol) of 3-(4-pyridinyl)-2(1H)-quinolone (D. R. Bragg and D. G. Wibberley, J. Chem. Soc. 1961, 5074-5077), 100 ml of ethanol, 5 ml (5 mmol) of iN hydrochloric acid and 0.2 g platinum (IV) oxide was hydrogenated for 4 hours at room temperature. The catalyst was filtered off, the filtrate evaporated down in vacuo and the residue was triturated with isopropanol. The precipitated crystals were suction filtered, washed with isopropanol and diethylether and dried in vacuo. Yield: 0.64 g (56.2% of theory).

IR (KBr): 1666.4 cm −1 (C═O)

MS: M + =230 m/e =146, 84

EXAMPLE A7

3-(4-Piperidinyl)-2(1H)-quinolone

A mixture of 8.6 g (0.0387 mol) of 3-(4-pyridinyl)-2(1H)-quinolone, 1.2 1 of ethanol, 39 ml (0.039 mol) of 1N hydrochloric acid and 8.0 g of 10% palladium/charcoal was hydrogenated at a temperature of 40° C. until about 0.08 mol of hydrogen had been taken up. The mixture was freed from catalyst, the filtrate was evaporated down in vacuo, the residue was taken up in 200 ml of water and made ammoniacal. Common salt was added up to saturation point and the mixture was continuously extracted with dichloromethane using a perforator. The dichloromethane phase was evaporated down, the residue remaining was separated from by-products by chromatography over silica gel using FM1 as eluant. The appropriate fractions were combined, freed from solvent, dissolved in a little isopropanol and converted with ethanolic hydrogen chloride solution into the hydrochloride. Colourless crystals. Yield: 2.68 g (26.2% of theory).

MS: M + =228

IR (KBr): 1651 cm −1 (C═O)

EXAMPLE A8

5-chloro-3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone

An ice-cold solution of 6.3 g (0.0177 mol) of 5-chloro-3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-quinazolinone (prepared analogously to Example A4e)) in 50 ml of dichloromethane was mixed dropwise with 3.34 g (0.0234 mol) of α-chloroethyl chlorocarbonate whilst maintaining a reaction temperature of 0° C., after which the mixture was allowed to come back slowly to room temperature. The reaction mixture was evaporated down in vacuo, the residue was taken up in 50 ml of methanol and refluxed for 4 hours. After cooling, the colourless precipitate formed was suction filtered. Yield: 2.0 g (42.5% of theory).

IR (KBr): 1666.4 cm −1 (C═O)

EXAMPLE A9

6-bromo-3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone-hydrohromide

To a solution of 6.16 g (0.075 mol) of sodium acetate and 11.565 g (0.05 mol) of 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone in a mixture of 150 ml of glacial acetic acid and 35 ml of water a solution of 8.8 g (0.055 mol) of anhydrous bromine in 20 ml of glacial acetic acid was added dropwise, with stirring and whilst maintaining a reaction temperature of 13 to 15° C. The mixture was filtered and the filtrate was evaporated down in vacuo. To remove any inorganic components the residue was taken up five times in 50 ml of dichloromethane, filtered and evaporated down, then triturated with a little acetonitrile, whereupon crystallisation occurred. The crystals were suction filtered, washed with acetonitrile/diethylether (1/1 v/v) and after drying in vacuo 5.5 g of colourless crystals of melting point 288° C. (decomposition) were obtained. By working up the mother liquors a further 4.5 g of material of the same quality was obtained. Total

yield: 10.0 g (51% of theory).

C 13 H 17 Br 2 N 3 O (391.10) Calculated: C, 39.92; H, 4.38; Br, 40.86; N, 10.74. Found: 39.72; 4.36; 41.56; 10.24.

IR (KBr): 1670.3 cm−1 (C═O)

EXAMPLE A10

3 -(4-piperidinyl)-2,4 (1H,3H)-quinazolindione

a)2-amino-N-[1-(phenylmethyl)-4-piperdidinyl]-benzamide

To an ice-cold solution of 28 ml (134 mmol) of 4-amino1-(phenylmethyl)piperidine in 200 ml of tetrahydrofuran were added, batchwise, 21.9 g (134 mmol) of isatoic acid anhydride. The resulting suspension was stirred for 2½ hours at room temperature and 2½ hours at reflux temperature, then freed from solvent. The residue was dissolved in 100 ml of hot ethanol, the resulting solution was filtered whilst hot after the addition of 5 g of activated charcoal. The crystal mass precipitated after cooling was suction filtered, washed with diisopropyl-ether and dried in vacuo at 50° C. 28.3 g of colourless crystals were obtained. A further 5.1 g of a product of the same quality were isolated from the combined mother liquors. Total

yield: 33.4 g (80.6% of theory).

IR (KBr): 1620 cm −1 (C═O)

MS: M + =309

b) 3-[1-(phenylmethyl)-4-piperidinyl]-2,4(1H,3H)-quinazolindione

Prepared analogously to Example A3e) from 2-amino-N-[1-(phenylmethyl)-4-piperidinyl]-benzamide and N,N′-carbonyldiimidazole in a yield of 97.8% of theory. Colourless crystals of melting point 223° C.

IR (KBr): 1720; 1647 cm −1 (C═O)

MS: M + =335

c) 3-(4-piperidinyl)-2,4(1H,3H)-quinazolindione

Prepared analogously to Example A3f) from 3-[1-(phenylmethyl)-4-piperidinyl]-2,4(1H,3H)-quinazolindione by hydrogenolysis in the presence of palladium/charcoal in a yield of 70% of theory.

R f : 0.075 (FM1)

IR (KBr): 1703; 1657 cm −1 (C═O)

EXAMPLE A11

3,4-dihydro-3-[1-(4-piperidinyl)-4-piperidinyl]-2(1H)-quinazolinone

a) 3,4-dihydro-3-[1-[1-(phenylmethyl)-4-piperidinyl]-4-piperidinyl]-2(1H)-qinazolinone

A mixture of 5.75 g (0.0249 mol) of 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone, 4.75 g (0.0251 mol) of 1-(phenylmethyl)-4-piperidinone and 100 ml of ethanol was treated for 30 minutes in an ultrasound bath, then mixed with 9.5 ml (0.031 mol) of titanium (IV) isopropoxide, whereby after 10 minutes a crystal mass was formed. Then heating was continued using the ultrasound bath for a further 2½ hours to a maximum of 35° C., the mixture was allowed to cool to room temperature and 1.05 g (0.0167 mol) of sodium cyanoborohydride were then added in batches, whilst maintaining the pH at 5-6 using dilute methanolic hydrogen chloride solution, and it was then kept for 24 hours at room temperature. After this time another 1.05 g (0.0167 mol) of sodium cyanoborohydride were added and the same procedure was used as above. After a total of 48 hours reaction time the mixture was decomposed by the addition of water and worked up in the usual way. The crude product obtained was purified by column chromatography over silica gel using FM4 as eluant. 7.05 g (70% of theory)of a colourless crystalline substance were obtained.

In the same way exo-4-(8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-1-(phenylmethyl)piperazine was obtained from tropinone and 1-(phenylmethyl)piperazine in a yield of 48.9% of theory. Colourless, amorphous substance, R f =0.36 (FM1).

b) 3,4-dihydro-3-[1-(4-piperidinyl)-4-piperidinyl]-2(1H)-quinazolinone

Prepared analogously to Example A3f) from 3,4-dihydro-3-[1-[1-(phenylmethyl)-4-piperidinyl]-4-piperidinyl]-2(1H)-quinazolinone by hydrogenolysis, but using Pearlman's catalyst, in a yield of 92% of theory. Colourless crystals, R f =0.48 (Macherey-Nagel, POLYGRAM® SIL G/UV 254 ready-made films for TLC; eluant: dichloromethane/methanol/cyclohexane/conc. ammonia 68/20/10/5 v/v/v/v).

IR (KBr): 1660.6 cm −1 (C═O)

MS: M + =314

EXAMPLE A12

3-(4-piperidinyl)-3,4,4a,5,6,7,8,8a-octahydro-2(1H)-quinazolinone-acetate

A solution of 5.0 g (17.17 mmol) of 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone-acetate in 70 ml of methanol was hydrogenated at room temperature and in the presence of 1.0 g rhodium (III) oxide-platinum (IV) oxide hydrate catalyst (46.45% rhodium, 20.15% platinum) until the hydrogen uptake had ceased. The catalyst and solvent were removed, the residue was triturated with 10 ml of diisopropylether and a few drops of isopropanol and the resulting crystals were suction filtered. After drying in vacuo 4.4 g (86.2% of theory) of colourless crystals were obtained, R f =0.3 (eluant: dichloromethane/methanol/conc. ammonia 7.5/2.5/0.5 v/v/v).

IR (KBr): 1641 cm −1 (C═O)

MS: M + =237

EXAMPLE A13

1,1dioxido-2-(4-piperidinyl)-3(4H)-1,2,4-benzothiadiazinone

a) 2-nitro-N-[1-(phenylmethyl)-4-piperidinyl]-benzenesulphonic acid amide

Whilst carrying out external cooling with ice water a solution of 44.3 g (0.2 mol) of 2-nitrobenzenesulphonyl chloride in 250 ml of chloroform was added dropwise to a solution of 38.0 g (0.2 mol) of 4-amino1-(phenylmethyl)piperidine and 22.0 g (0.22 mol) of triethylamine in 250 ml of chloroform. After the cooling was stopped the mixture was stirred for a further 30 minutes at room temperature, the reaction mixture was then extracted twice with 1 l water. The aqueous extracts were extracted once more with 100 ml of dichloromethane, the combined organic phases were then dried over sodium sulphate and evaporated down in vacuo. The highly viscous light-brown substance obtained in a yield of 75.0 g (99.9% of theory) was further processed without any more purification.

IR (KBr): 3363.7 (NH); 1541.0 (NO 2 ); 1365.5 (NO 2 or SO 2 ); 1346.2 (NO 2 or SO 2 ); 1168.8 (SO 2 ) cm −1

b) 2-amino-N-[1-(phenylmethyl)-4-piperidinyl]-benzenesulphonic acid amide

To a solution of 75.0 g (0.2 mol) of 2-nitro-N-[1-(phenylmethyl)-4-piperidinyl]-benzenesulphonic acid amide in 2.0 1 ethanol was added dropwise, at room temperature, a solution of 174.0 g (0.828 mol) of sodium dithionite-dihydrate in 700 ml of water. After the heat of the exothermic reaction had died away the mixture was refluxed for 4.5 hours, then the ethanol was distilled off and the aqueous phase remaining was extracted thoroughly with dichloromethane. The combined dichloromethane extracts were dried over sodium sulphate and evaporated down, the residue remaining was purified by column chromatography over silica gel using dichloromethane/methanol/conc. ammonia 80/20/0.25 (v/v/v) as eluant. 6.5 g (8.6% of theory) of a highly viscous oil were obtained.

IR(KBr): 1319.2, 1153.4 cm −1 (SO 2 )

c) 1,1-dioxido-2-[1-(phenylmethyl)-4-piperidinyl]-3(4H)-1,2,4-benzothiadiazinone

Prepared analogously to Example A3e) from 2-amino-N-[1-(phenylmethyl)-4-piperidinyl]-benzenesulphonic acid amide and N,N′-carbonyldiimidazole in a yield of 78% of theory. Colourless crystals of melting point 169-171° C.

IR(KBr): 1693.4 (C═O); 1359.7, 1340.4, 1188.1 (SO 2 ) cm −1

d) 1,1-dioxido-2-(4-piperidinyl)-3(4H)-1,2,4-benzothiadiazinone

Prepared analogously to Example A3f), but using Pearlman's catalyst instead of palladium/charcoal, in a yield of 90% of theory. Colourless, amorphous substance.

IR(KBr): 1705.0 (C═O) cm −1

EXAMPLE A14

3,4-dihydro-2,2-dioxido-3-(4-piperidinyl)-2,1,3-benzothiadiazine

a) 3,4-dihydro-2,2-dioxido-3-[1-(phenylmethyl)-4-piperidinyl]-2,1,3-benzothiadiazine

A solution of 11.0 g (0.0372 mol) of 2-amino-N-[1-(phenylmethyl)-4-piperidinyl]-benzenemethanamine in 200 ml of pyridine was added dropwise within 1.5 hours and at reflux temperature to a solution of 3.4 g (0.0354 mol) of sulphamide in 200 ml of pyridine and the mixture was then refluxed for 6 hours. The mixture was freed from solvent, the residue was purified by column chromatography using ethyl acetate/methanol 9/1 (v/v) as eluant. 5.5 g (43.5% of theory) of a colourless amorphous substance were obtained.

IR(KBr): 1344.3, 1166.9 cm −1 (SO 2 )

b) 3,4-dihydro-2,2-dioxido-3-(4-piperidinyl)-2,1,3-benzothiadiazine

Prepared analogously to Example A3f) from 3,4-dihydro-2,2-dioxido-3-[1-(phenylmethyl)-4-piperidinyl]-2,1,3-benzothiadiazine by catalytic hydrogenation in the presence of palladium/charcoal in a quantitative yield. Colourless, amorphous substance.

IR(KBr): 1263.3, 1105.1 cm −1 (SO 2 )

EXAMPLE A15

D,L-4-phenyl-1-(4-piperidinyl)-imidazolidine-2,5-dione

a) N 2 -(1,1-dimethylethoxycarbonyl)-N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylglycinamide

A mixture of 10.0 g (0.0398 mol) of N 2 -(1,1-dimethylethoxycarbonyl)-D,L-phenylglycine, 7.57 g (0.0398 mol) of 4-amino-1-(phenylmethyl)piperidine, 10 ml of triethylamine, 12.8 g (0.0399 mol) of TBTU and 5.4 g (0.0353 mol) of N-hydroxybenzotriazole-hydrate in 200 ml of THF-DMF mixture (1/1 v/v) was stirred overnight at room temperature. The residue remaining after removal of the solvent was taken up in ethyl acetate, washed with saturated sodium hydrogen carbonate solution, dried over sodium sulphate and evaporated down in vacuo. 14.8 g (87.8% of theory) of a colourless, amorphous substance were obtained.

IR(KBr): 1701.1, 1676.0, 1652.9 cm −1 (C═O)

Analogously N 2 -(1,1-dimethylethoxycarbonyl)-N-[1-(phenylmethyl)-4-piperidinyl]D,L,-phenylalaninamide was obtained from N 2 -(1,1-dimethylethoxycarbonyl)-D,L-phenylalanine and 4-amino-1-(phenylmethyl)piperidine in a yield of 85% of theory. Colourless, amorphous substance, R f =0.83 (eluant: dichloromethane/cyclohexane/metha-nol/conc. ammonia=70/15/15/2 v/v/v/v).

IR(KBr): 1683.8, 1651.0 cm −1 (C═O)

b) N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylglycinamide-bis-trifluoroacetate

Prepared analogously to Example A5e) from N 2 -(1,1-dimethylethoxycarbonyl)-N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylglycinamide and trifluoroacetic acid in a quantitative yield. Colourless, amorphous substance , R f =0.56 (FM1).

Analogously N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenyalaninamide-bis-trifluoracetate was obtained from N2-(1,1-dimethylethoxycarbonyl)-N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylalaninamide in a yield of 92% of theory.

IR(KBr): 1670.3 cm −1 (C═O)

c) D,L-4-phenyl1-[1-(phenylmethyl)-4-piperidinyl]-imidazolidine-2,5-dione

Prepared analogously to Example A3e) from N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylglycinamide and N,N′-carbonyldiimidazole in a yield of 57.3% of theory. Colourless crystals,

R f =0.68.

IR(KBr): 1774.4, 1712.7 cm −1 (C═O)

Analogously D,L-4-(phenylmethyl)-1-[1-(phenylmethyl)-4-piperidinyl]-imidazolidine-2,5-dione was obtained from N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylalaninamide in a yield of 93% of theory. Colourless, fine crystals, R f =0.6 (eluant: dichloromethane/methanol/cyclohexane/conc. ammonia 7/1.5/1.5/0.2 v/v/v/v).

IR(KBr): 1764.8, 1708.8 cm −1 (C═O)

MS: M + =363

d) D,L-4-phenyl1-(4-piperidinyl)-imidazolidine-2,5-dione

Prepared analogously to Example A3f) from D,L-4-phenyl1-[1-(phenylmethyl)-4-piperidinyl]-imidazolidine-2,5-dione by hydrogenolysis in the presence of palladium/charcoal in a yield of 84.3% of theory. Colourless, amorphous substance, R f =0.5.

IR(KBr): 1766.7, 1706.9 cm −1 (C═O)

Analogously D,L-4-(phenlmethyl)-1-(4-piperidinyl)-imidazolidine-2,5-dione was obtained from D,L-4-(phenylmethyl)-1-[1-(phenylmethyl)-4-piperidinyl]-imidazolidine-2,5-dione. Colourless crystals, R f =0.24 (eluant: dichloromethane/methanol/cyclohexane/conc. ammonia=7/1.5/1.5/0.2 v/v/v/v).

IR(KBr): 1766.7, 1705.0 cm −1 (C═O)

EXAMPLE A16

1,3-dihydro-3-(4-piperidinyl)-2(2H)-imidazo[4,5-c]quinolone

a) 1-[2-(acetlyamino)phenyl]-2-bromoethanorne

45.0 g (0.282 mol) of dry bromine were added dropwise to a boiling solution of 50.0 g (0.282 mol) of 1-[2-(acetylamino)phenyl]ethanone in 400 ml of chloroform at room temperature. The solvent was distilled off, the residue was distributed between dichloromethane and saturated ice-cold sodium hydrogen carbonate solution. The organic phase was dried over sodium sulphate, evaporated down in vacuo, the residue was triturated with diethylether and suction filtered. After drying in vacuo 35.4 g (49% of theory) of colourless crystals were obtained, R f =0.48 (eluant: petroleum ether/ethyl acetate 2/1 v/v).

IR(KBr): 1685.69, 1664.47 cm −1 (C═O)

MS: M + =255/257 (Br)

b) 4-[2-(acetylamino)phenyl]-1,3-dihydro-1-[1-(phenylmethyl)-4-piperidinyl]-2H-benzimidazol-2-one

To a solution of 26.3 g (0.138 mol) of 4-amino1-(phenylmethyl)piperidine and 17.8 g (0.138 mol) of DIEA in 300 ml of dichloromethane was added dropwise a solution of 35.4 g (0.138 mol) of 1-[2-(acetylamino)phenyl]-2-bromoethanone in 150 ml of dichloromethane and the mixture was kept for a further 2 hours at room temperature. With external cooling with ice 13.5 g (0.20 mol) of sodium cyanate and 12 ml of glacial acetic acid were then added and the mixture was stirred overnight in a thawing ice bath. It was washed with water and saturated sodium hydrogen carbonate solution, dried over sodium sulphate and freed from solvent. The residue was triturated with 50 ml of ethyl acetate-methanol mixture (9/1 v/v), the resulting crystals were suction filtered, washed with ethyl acetate and dried in vacuo. 37.0 g (68.7% of theory) of colourless crystals were obtained, R f =0.41 (eluant: dichloromethane/methanol 9/1 v/v)

IR(KBr): 1678 cm −1 (C═O)

MS: M + =390 (Br)

c) 4-(2-aminophenyl)-1,3-dihydro-1-[1-(phenylmethyl)-4-pipleridinyl]-2H-imidazol-2-one

A mixture of 3.0 g (7.68 mmol) of 4-[2-(acetylamino)phenyl]-1,3-dihydro-1-[1-(phenylmethyl)-4-piperidinyl]-2H-imidazol-2-one, 50 ml of 5 N sodium hydroxide solution and 25 ml of ethanol was refluxed for 3 hours. After cooling the organic phase was separated off, dried over sodium sulphate and evaporated down in vacuo. A colourless amorphous substance was obtained in a quantitative yield, R f =0.53 (eluant: dichloromethane/methanol 9/1 v/v).

d) 1,3-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(2H)-imidazo[4,5-c]quinolone

A solution of 2.67 g (7.66 mmol) of 4-(2-aminophenyl)-1,3-dihydro-1-[1-(phenylmethyl)-4-piperidinyl]-2H-imidazol-2-one in 50 ml of chloroform was mixed with 3.0 g of paraformaldehyde and refluxed for 3.5 hours. The residue remaining after evaporation of the solvent was taken up in 100 ml of methanol and acidified with methanolic hydrogen chloride solution. After stirring for one hour at room temperature the mixture was poured into 300 ml of saturated sodium hydrogen carbonate solution. The resulting mixture was extracted thoroughly with ethyl acetate, the combined extracts were dried over sodium sulphate and evaporated down in vacuo. The residue was purified by column chromatography over silica gel using FM4 as eluant. From the appropriate fractions 0.5 g (18.2% of theory) of a colourless, amorphous substance were isolated, R f =0.24 (FM4)

IR(KBr): 1689 cm −1 (C═O)

MS: M + =358 (Br)

e) 1,3-dihydro-3-(4-piperidinyl)-2(2H)-imidazo[4,5-c]quinolone

Prepared analogously to Example A3f) from 1,3-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(2H)-imidazo[4,5-c]quinolone by hydrogenolysis in the presence of palladium/charcoal in a yield of 98.5% of theory. Colourless crystals, R f =0.63 (FM1).

EXAMPLE A17

Preparation of β-(methoxycarbonyl)-arenebutanoic acids

3,5-dibromo-4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid

a) 4-(phenylmethoxy)-benzaldehyde

To a solution of 36.6 g (0.3 mol) of 4-hydroxybenzaldehyde in 100 ml of ethanol were added dropwise, one after another, a solution of 12.0 g (0.3 mol) of sodium hydroxide in 100 ml of water and a solution of 36.5 ml of (0.307 mol) of benzylbromide in 100 ml of ethanol and the mixture was then kept for 1 hour at 50° C. The ethanol was extensively distilled off, finally in vacuo, the remaining aqueous emulsion was divided between water and ethyl acetate. The ethyl acetate phase was dried over sodium sulphate and evaporated down in vacuo. The residue remaining crystallised on trituration with petroleum ether and was recrystallised from diisopropylether. 48.0 g (75.4% of theory) of colourless crystals of melting point 118-122° C. were obtained.

b) 3-(methoxycarbonyl)-4-[(4-phenylmethoxy)phenyl]-3-butenoic acid

To a freshly prepared solution of 2.3 g (0.1 mol) of sodium in 300 ml of anhydrous methanol were added 14.6 g (0.1 mol) of dimethyl succinate and after half an hour's stirring a solution of 21.2 g (0.1 mol) of 4-(phenylmethoxy)-benzaldehyde in 100 ml of anhydrous methanol were added dropwise. Then the mixture was refluxed for 6 hours, the methanol was distilled off under normal pressure and the remaining residue was kept for 30 minutes at a reaction temperature of 80° C. The viscous slurry obtained was stirred into 1 l of a glacial acetic acid-water mixture (1/1 v/v), the resulting mixture was extracted thoroughly with ethyl acetate. The combined ethyl acetate extracts were in turn extracted with saturated potassium carbonate solution. The potassium carbonate extracts were carefully acidified with acetic acid and then extracted thoroughly with ethyl acetate. These extracts were washed with water, dried over sodium sulphate and freed from solvent in vacuo. The residue was purified by column chromatography over silica gel using dichloromethane/petroleum ether/glacial acetic acid 25/74/1 (v/v/v). The colourless, partly crystallised mixture of diastereomers was obtained in a yield of 16.0 g (49% of theory) . R f =0.68 (eluant: ethyl acetate/petroleum ether 1:2 v/v).

IR(KBr): 1699.2 cm −1 (C═O)

The following were obtained analogously:

(1) 3-(methoxycarbonyl)-4-[3-(trifluoromethyl)phenyl]1 -3-butenoic acid was obtained from 3-(trifluoromethyl)benzaldehyde and dimethyl succinate in a yield of 21% of theory.

IR(KBr): 1738, 1726 cm −1 (C═O)

ESI-MS: (M−H) − =287 (M+H) + =289 (M+Na) + =311

(2) 3-(methoxycarbonyl)-4-(1-naphthyl)-3-butenoic acid was obtained from 1-naphthaldehyde and dimethyl succinate in a yield of 60% of theory.

Colourless oil

IR(KBr): 1712 cm −1 (C═O)

MS: M + =270

(3) 3-(methoxycarbonyl)-4-[3,5-dimethyl-4-phenylmethoxyphenyl]-3-butenic acid was obtained from 3,5-dimethyl-4-phenylmethoxybenzaldehyde and dimethyl succinate in a yield of 66% of theory.

Colourless oil which could be further processed without purification.

(4) 4-(4-amino-3,5-dibromophenyl)-3-(methoxycarbonyl)-3-butenoic acid was obtained from 4-amino-3,5-dibromobenzaldehyde and dimethyl succinate in a yield of 21% of theory.

(5) 3-(Methoxycarbonyl)-4-(3-phenylmethoxpheny)-1-3-butenoic acid was obtained from 3-phenylmethoxybenzaldehyde and dimethyl succinate in a yield of 37% of theory.

c) 4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid

Prepared analogously to Example A3f) from 3-(methoxycarbonyl)-4-[(4-phenylmethoxy)phenyl]-3-butenoic acid by hydrogenolysis in the presence of palladium/charcoal in a yield of 96% of theory. Colourless oil, R f =0.5 (eluant: ethyl acetate/petroleum ether/glacial acetic acid 66.3/33.3/0.4 v/v/v).

The following were obtained analogously:

(1) β-(methoxycarbonyl)-3-(trifluoromethyl)-benzenebutanoic acid was obtained from 3-(methoxycarbonyl)-4-[3-(trifluoromethyl)phenyl]-3-butenoic acid in a yield of 80% of theory. R f =0.59 (eluant: ethyl acetate/petroleum ether 1/1/ v/v).

ESI-MS: (M−H) − =289

(2) β-(methoxycarbonyl)-1-naphthalinebutanoic acid was obtained from 3-(methoxycarbonyl)-4-(1-naphthyl)-3-butenoic acid, however using platinum (IV)-oxide as a catalyst, in a yield of 31% of theory.

IR (KBr): 1734, 1711 (C═O) cm −1

MS: M + =272

β-(methoxycarbonyl)-1,2,3,4-tetrahydro-1-naphthaline-butanoic acid was isolated as a by-product in a yield of 8.4% of theory

IR (KBr): 1736, 1712 (C═O) cm −1

MS: M + =276

(3) 3,5-dimethyl-4-hydroxy-β-(methoxycarbonyl)-benzene butanoic acid was obtained from 3-(methoxycarbonyl)-4-[3,5-dimethyl-4-phenylmethoxyphenyl]-3-butenoic acid in a yield of 48% of theory.

R f =0.11 (FM1)

IR (KBr): 1716 (C═O) cm −1

MS: M + =266

(4) 3-Hydroxy-β-(methoxycarhonyl)-benzene butanoic acid was obtained from 3-(Methoxycarbonyl)-4-(3-phenylmethoxyphenyl)-3-butenoic acid in a yield of 59% of theory.

R f =0.24 (petroleum ether/ethyl acetate/glacial acetic acid 6/4/0.2 v/v/v)

IR (KBr): 1714 (C═O) cm −1

MS: M + =238

(5) 4-Amino-β-(methoxycarbonyl)-benzene butanoic acid was obtained from 3-(methoxycarbonyl)-4-(4-amino-3,5-dibromophenyl)-3-butenoic acid and in the presence of triethylamine in a quantitative yield.

R f =0.53 (eluant: dichloromethane/methanol/glacial acetic acid 90/10/1.5 v/v/v))

IR (KBr): 1728 (C═O) cm −1

MS: M + =237

d) 3,5-dibromo-4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid

To a solution of 12.0 g (0.05 mol) of 4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid in 200 ml of glacial acetic acid were added 150 ml of water and 8.0 g sodium acetate and then a solution of 15.58 g (0.0975 mol) of bromine in 60 ml of glacial acetic acid was added dropwise. The mixture was stirred for a further hour at room temperature, then evaporated down to two thirds in vacuo and the residue was divided between water and ethyl acetate. The ethyl acetate extracts were washed with water, dried over sodium sulphate and evaporated down in vacuo. After stirring with diisopropylether a colourless crystal was obtained. Yield: 12.0 g (62.2% of theory). R f =0.4 (eluant: ethyl acetate/petroleum ether/glacial acetic acid 49.8/49.8/0.4 v/v/v).

IR(KBr): 1724 cm −1 (C═O)

MS: M + =394/396/398 (Br 2 )

EXAMPLE A18

1-(3 -pyridinyl)piperazine

a) 1-(phenylmethyl)-3-(3 -pyridinyl)piperazine

To a solution of 5.0 g (0.0515 mol) of 3-fluoropyridine and 43.5 ml of 1-(phenylmethyl)piperazine in 300 ml of anhydrous diethylether was added dropwise, at boiling temperature, within 2.5 hours, 56 ml (0.112 mol) of a 2 molar solution of phenyllithium in a cyclohexane-diethylether mixture (7/3 v/v) and the resulting mixture was then kept at reflux temperature for a further 4 hours. The crude reaction product obtained as an oil after working up in the usual way was purified by column chromatography over silica gel (30-60 μm) using FM1/cyclohexane (7/3 v/v)as eluant. 12.0 g (92% of theory) of a colourless oil were obtained, R f 0.52 (FM4; Macherey-Nagel, POLYGRAM® SIL G/UV 254 Pre-coated plastic sheets for TLC)

MS: M + =253

b) 1-(3-Pyridinyl)piperazine

Prepared analogously to Example A3f) from 1-(phenylmethyl)-3-(3-pyridinyl)piperazine by hydrogenolysis in the presence of palladium/charcoal in a yield of 55% of theory. Colourless oil, R f 0 .35 (FM1).

IR(KBr): 1652.9 cm −1 (C═N)

EXAMPLE A19

1-(1-cyclohexyl-4-piperidinyl)piperazine-tris-trifluoroacetate

a) 1-(1,1-dimethylethoxycarbonyl)-4-[1-(phenylmethyl)-4-peridinyl]piperazine

A solution of 15.0 g (0.8054 mol) of 1-(1,1-dimethylethoxycarbonyl)piperazine and 14.26 ml (0.08053 mol) of 1-(phenylmethyl)-4-piperidinone in 250 ml of methanol was adjusted to a pH of between 5 and 6 by dropwise addition of acetic acid and mixed in batches with a total of 4.13 g (0.0624 mol) of 95% sodium cyanoborohydride, whilst taking care to maintain a pH of 5 to 6 by further dropwise addition of acetic acid. After stirring for 18 hours at room temperature the mixture was evaporated down in vacuo, the residue was made alkaline with soda and divided between water and ethyl acetate. After working up the ethyl acetate phase in the usual way 21.76 g (75.2% of theory) of a highly viscous colourless oil were obtained, R f 0.66 (FM1).

b) 1-(1,1-dimethylethoxycarbonyl)-4-(4-piperidinyl)piperazine

Prepared analogously to Example A3f) from 1-(1,1-dimethylethoxycarbonyl)-4-[1-(phenylmethyl)-4-piperidinyl]piperazine by hydrogenolysis, but using Pearlman's catalyst instead of palladium/charcoal, in a yield of 79.7% of theory.

Colourless crystals, R f =0.3 (FM1).

c) 1-(1,1-dimethylethoxycarbonyl)-4-(1-cyclohexyl-4-piperidinyl)piperazine

Prepared analogously to Example A19a) from 1-(1,1-dimethylethoxycarbonyl)-4-(4-piperidinyl)piperazine and cyclohexanone in a yield of 99% of theory. Colourless, highly viscous oil.

MS: M + =251

d) 1-(1-cyclohexyl-4-piperidinyl)piperazine-tris-trifluoroacetate

Prepared analogously to Example A5e) from 1-(1,1-dimethylethoxycarbonyl)-4-(1-cyclohexyl-4-piperidinyl)piperazine and trifluoroacetic acid in a quantitative yield. Colourless crystals, R f =0.2 (FM1).

EXAMPLE A20

1-(1-ethyl-4-piperidinyl)piperazine-trihydrochloride

a) 1-(1-ethyl-4-piperidinyl)-4-(phenylmethyl)piperazine

Prepared analogously to Example A19

a) from 1-ethyl-4-piperidinone and 1-(phenylmethyl)piperazine in a yield of 71% of theory. Colourless, amorphous substance, R f =0.46 (FM4).

b) 1-(1-ethyl-4-piperidinyl)piperazine-trihydrochloride

A mixture of 36.3 g (0.126 mol) of 1-(1-ethyl-4-piperidinyl)-4-(phenylmethyl)piperazine, 300 ml of 1N hydrochloric acid and 200 ml of methanol was hydrogenated at room temperature and in the presence of 4.0 g of 10% palladium/charcoal until the uptake of hydrogen had ceased. After working up in the usual way 22.9 g (59.3% of theory) of a colourless, crystalline substance was obtained.

MS: M + =197

In the same way exo-1-(8-methyl-8-azabicyclo[3,2,1]oct-3-yl)piperazine-trihydrochloride was obtained from exo-4-(8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-1-(phenylmethyl)piperazine (see Example A11a)) by hydrogenolysis in the presence of palladium/charcoal in a yield of 91% of theory.

MS: M + =209

EXAMPLE A21

1-ethyl-4-(4-piperidinyl)piperidine

a) 1-(phenylmethoxycarbonyl)-4-(4-piperidinyl)piperdine

To a mixture of 72.375 g (0.3 mol) of bipiperidine-dihydrochloride, 1500 ml of methanol, 75 ml of water and 100 mg of bromophenol blue were added dropwise, simultaneously, with stirring and at room temperature, a solution of 51.18 g (0.3 mol) of benzyl chlorocarbonate in 75 ml of toluene and 6 N sodium hydroxide solution (about 80 ml) were added, so that the indicator colour changed continuously. After all had been added, which took about 4 hours, the mixture was diluted with 300 ml of water and the organic solvent was distilled off in vacuo. The aqueous phase remaining was acidified with hydrochloric acid, whilst being externally cooled, extracted thoroughly with diethylether and then made alkaline with 50% potassium hydroxide solution. The mixture was extracted thoroughly with dichloromethane, the combined dichloromethane extracts were dried over magnesium sulphate and evaporated down in vacuo. The colourless, highly viscous, slowly crystallising oil remaining was further processed without any more purification.

Yield: 87.3 g (96.2% of theory).

IR(KEr): 1701.1 cm −1 (C═O)

b) 1-ethyl-4-[1-(phenylmethoxycarbonyl)-4-piperidinyl]piperidine

To a solution of 18.14 g (0.061 mol) of 1-(phenylmethoxycarbonyl)-4-(4-piperidinyl)piperidine in 450 ml of a methanol/water mixture (1/1 v/v) were added, with stirring, whilst maintaining a temperature of 15 to 20° C., 10.05 g (0.152 mol) of 95% sodium cyanoborohydride and 50 mg of bromocresol purple. Then a solution of 10.57 g (0.24 mol) of acetaldehyde in 50 ml of methanol and 1N hydrochloric acid were alternately added dropwise so that the colour of the mixture changed continuously from blue to yellow. After all had been added and the reaction had finished the mixture was adjusted to pH 2 with hydrochloric acid and extracted twice with 200 ml of diethylether. The aqueous phase was then made alkaline and extracted thoroughly with dichloromethane. The combined dichloromethane extracts were dried over magnesium sulphate and evaporated down in vacuo. The colourless crystallising residue remaining was purified by column chromatography over silica gel (30-60 μm) using FM1 as eluant. Yield of colourless crystals of melting point 93-96° C.: 7.9 g (39.26 of theory).

IR(KBr): 1699.2 cm −1 (C═O)

c) 1-ethyl-4-(4-piperidinyl)piperidine

A solution of 7.6 g (0.023 mol) of 1-ethyl-4-[1-(phenylmethoxycarbonyl)-4-piperidinyl]piperidine in a mixture of 70 ml of methanol, 30 ml of water and 10 ml of glacial acetic acid was hydrogenated in the presence of 10% palladium/charcoal at room temperature and 3 bar of hydrogen pressure until the uptake of hydrogen had ceased. After working up in the usual way the desired compound was obtained as a colourless oil in a quantitative yield.

EXAMPLE A22

Hexahydro-1-methyl-4-(4-piperidinyl)-1H-1,4-diazepline

a) Hexahydro-1-methyl-4-[1-(phenylmethyl)-4-piperidinyl]-1H-1,4-diazepine

Prepared analogously to Example A11a) from hexahydro-1-methyl-1H-1,4-diazepine and 1-(phenylmethyl)-4-piperidinone in a yield of 35% of theory. Colourless viscous oil.

MS: M + =287

The following were prepared in the same way:

(1) 1-methyl-4-[1-(phenylmethyl)-4-piperidinyl]-piperazine from 1-methylpiperazine and 1-(phenylmethyl)-4-piperidinone

Yield: 39.9% of theory, colourless viscous oil

(2) 1-acetyl-4-[1-(phenylmethyl)-4-piperidinyl]piperazine from 1-acetylpiperazine and 1-(phenylmethyl)-4-piperidinone

Yield: 24.2% of theory, colourless viscous oil

R f : 0.46 (eluant: ethyl acetate/methanol/conc. ammonia 50/50/2 v/v/v)

IR(KBr): 1647 cm −1 (C═O)

MS: M + =301

(3) 4-(dimethylamino)-1-[1-(phenylmethyl)-4-piperidinyl]piperidine from 4-(dimethylamino)piperidine and 1-(phenylmethyl)-4-piperidinone

Yield: 28.9% of theory; colourless viscous oil

R f : 0.58 (eluant: ethyl acetate/methanol/conc. ammonia 50/50/2 v/v/v)

MS: M + =301

(4) 1-(1,1-dimethylethoxycarbonyl)-4-[4-(phenylmethyl)-1-piperazinyl]piperidine from 1-(1,1-dimethylethoxycarbonyl)-4-piperidinone and 1-(phenylmethyl)piperazine

Yield: 86.6% of theory. Colourless, amorphous substance

R f : 0.58 (eluant: dichloromethane/methanol 9/1 v/v)

b) Hexahydro-1-methyl-4-(4-piperidinyl)-1H-1,4-diazepine

Prepared analogously to Example A3f) from hexahydro-1-methyl-4-[1-(phenylmethyl)-4-piperidinyl]-1H-1,4-diazepine by hydrogenolysis but using Pearlman's catalyst instead of palladium/charcoal, in a quantitative yield. Colourless viscous oil.

MS: M + =197

The following were obtained in the same way:

(1) 1-methyl-4-(4-piperidinyl)piperazine from 1-methyl-4-[1-(phenylmethyl)-4-piperidinyl]piperazine in a quantitative yield. Colourless viscous oil.

MS: M + =183

(2) 1-acetyl-4-(4-piperidinyl)piperazine from 1-acetyl-4-[1-(phenylmethyl)-4-piperidinyl]piperazine in a yield of 81.90 of theory. Colourless crystals.

IR(KBr): 1631 cm −1 (C═O)

(3) 4-(dimethylamino)-1-(4-piperidinyl)piperidine from 4-(dimethylamino)-1-[1-(phenylmethyl)-4-piperidinyl]piperidine in a yield of 76.8% of theory. Colourless, amorphous substance.

(4) 1-(1,1-dimethylethoxycarbonyl)-4-(1-piperazinyl)piperidine-hydrochloride from 1-(1,1-dimethylethoxycarbonyl)-4-[4-(phenylmethyl)-1-piperazinyl]piperidine-hydrochloride.

Yield: 96% of theory. Colourless crystals

R f : 0.23 (eluant: dichloromethane/methanol 9/1 v/v)

EXAMPLE A23

4-[(4-methyl-1-piperazinyl)carbonyl]-piperidine-bis-trifluoroacetate

a) 1-(1,1-dimethyethoxycarbonyl)-4-piperidinecarboxylic acid

To a mixture of 25.9 g (0.2 mol) of piperidine-4-carboxylic acid, 200 ml (0.2 mol) of iN sodium hydroxide solution and 200 ml of tetrahydrofuran were added 48.0 g (0.22 mol) of di-tert.-butyl pyrocarbonate and the mixture was stirred overnight at room temperature. The tetrahydrofuran was distilled off, finally in vacuo, and the remaining aqueous solution was acidified with citric acid. The colourless crystals precipitated were suction filtered and dried at 40° C. in a circulating air drier.

Yield: 45.5 g (99.2% of theory).

IR(KBr): 1733.9, 1662.5 cm −1 (C═O)

b) 1-(1,1-dimethylethoxycarbonyl)-4-[(4-methyl-1-piperazinyl)carbonyl]piperidine

Prepared analogously to Example A15a) from 1-(1,1-dimethylethoxycarbonyl)-4-piperidinecarboxylic acid and 1-methylpiperazine in the presence of TBTU in a yield of 76% of theory. Colourless, amorphous substance, R f =0.64 (eluant: dichloromethane/methanol/conc. ammonia 50/50/1 v/v/v).

IR(KBr): 1693, 1678 cm −1 (C═O)

The following were prepared in the same way:

(1) 1-methyl-4-[[4-(1,1-dimethylethoxycarbonyl)-1-piperazinyl]carbonyl]1-piperidine from 1-methyl-4-piperidinecarboxylic acid and 1-(1,1-dimethylethoxycarbonyl)piperazine in a yield of 97% of theory. Colourless crystals.

IR(KBr): 1683.8, 1629.8 cm −1 (C═O)

(2) 1-(1,1-dimethylethoxycarbonyl)-4-(isonicotinoyl)piperazine from 1-(1,1-dimethylethoxycarbonyl)-piperazine and 4-pyridinecarboxylic acid in a yield of 76.8% of theory. Colourless crystals of melting point 139.2-140.2° C. and R f =0.84 (eluant: dichloromethane/methanol/conc. ammonia 90/10/1 v/v/v).

IR(KBr): 1689.5, 1625.9 cm −1 (C═O)

c) 4-[(4-methyl-1-piperazinyl)carbonyl]-piperidine-bis-trifluoroacetate prepared analogously to Example A5e) from 1-(1,1-dimethylethoxycarbonyl)-4-[(4-methyl1-piperazinyl)carbonyl]-piperidine and trifluoroacetic acid in a yield of 89% of theory. Colourless, amorphous substance.

The following were prepared in the same way:

(1) 1-methyl-4-[(1-piperazinyl)carbonyl]-piperidide from 1-methyl-4-[[4-(1 1 1-dimethylethoxycarbonyl)-1-piperazinyl]carbonyl]-piperidine and trifluoroacetic acid in a yield of 57% of theory. Colourless, amorphous substance.

IR(KBr): 1679.9, 1645.2 cm −1 (C═O)

MS: M + =211

(2) 4-(isonicotinoyl)piperazine-trifluoroacetate from 1-(1,1-dimethylethoxycarbonyl)-4-(isonicotinoyl)piperazine and trifluoroacetic acid in a yield of 98.3% of theory. Colourless, amorphous substance.

IR(KBr): 1676.0 cm − (C═O)

EXAMPLE 24

Preparation of compounds of the general structure:

Boc-A-NR 3 R 4

1-[N 2 -(1,1-dimethylethoxycarbonyl)-N 6 -(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine

To a mixture of 18.8 g (0.0494 mol) of Boc-Lys(Z)-OH, 6.5 g (0.05 mol) of DIEA, 16 g (0.05 mol) of TBTU, 6.6 g (0.049 mol) of HOBt and 100 ml of dimethylformamide were added dropwise, with stirring, 8.1 g (0.0494 mol) of 1-(4-pyridinyl)piperazine, dissolved in 40 ml of DMF, and the mixture was stirred overnight at room temperature. The solvent was removed in vacuo and the residue was taken up in ethyl acetate. The ethyl acetate phase was then washed three times successively with 70 ml of saturated aqueous sodium hydrogen carbonate solution and once with 70 ml of saturated aqueous saline solution, dried over sodium sulphate and evaporated down in vacuo. 24.2 g (93.2% of theory) of a yellowish oil were obtained, which was used for the following reactions without further purification.

IR (KBr): 1650, 1713 cm −1 (C═O)

R f (FM1): 0.59

The following were prepared analogously:

A	NR 3 R 4	Remarks	% Yield	R f	Eluant	IR [cm −1 ]
A9	C1	THF as LM	63.2	0.4	FM1	(KBr): C═O
		KHSO 4 /				1705.0; 1649
		NaCl soln
A4	C1		93.2	0.59	FM1	(KBr): C═O
						1647.7; 1712.7
A5	C1		66	0.55	FM1	(KBr): C═O
						1655; 1709
A5	C8		54	0.8	FM1	(KBr): C═O
						1653; 1713
A6	C8		91	0.8	FM1	(KBr): C═O
						1645; 1710.8
A10	C1		63	0.5	FM1	(KBr): C═O
						1665; 1695
A10	C8		30	0.41	FM4	(KBr): C═O
						1662; 1699

EXAMPLE A25

Preparation of compounds of general formula:

Cbz-A-NR 3 R 4

1-[N 2 -(phenylmethoxycarbonyl)-N 6 -(1,1-dimethyl-ethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine

To a mixture of 100 g (0.263 mol) of Z-Lys(Boc)-OH, 86.1 g (0.268 mol) of TBTU and 36.3 g (0.263 mol) of HOBt in 600 ml of 15 dimethylformamide were added 43.0 g (0.263 mol) of 1-(4-pyridinyl)-piperazine and 47.2 ml (0.268 mol) of DIEA with stirring and the mixture was stirred overnight at room temperature. The reaction mixture was evaporated down in vacuo and the residue divided between ethyl acetate and aqueous saturated sodium hydrogen carbonate solution. The aqueous phase was extracted twice more with a mixture of ethyl acetate/methanol (10/1, v/v) and the combined organic phases were washed once with saturated sodium hydrogen carbonate solution. The organic phase was, after drying over sodium sulphate, evaporated down in vacuo and the residue was taken up in 750 ml of ethyl acetate and washed four times with 100 ml of water, six times with 100 ml of 1% potassium hydrogen sulphate solution, once with 100 ml of water, twice with 100 ml of 3% aqueous ammonia solution and twice with 100 ml of water. The organic phase was evaporated down after drying over sodium sulphate. 120 g (87% of theory) of the desired product were obtained as an oil, which was used without further purification for the subsequent reactions.

IR (KBr): 1709 cm −1 (C═O)

R f (FM1): 0.59

EI-MS: M + =525

The following were prepared analogously:

A	NR 3 R 4	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
A3	C4		100
A3	C3	Triethylamine as	100		0.8	FM1	(KBr): C═O
		base					1643.3; 1710.8
A11	C1		98.8		0.5	FM1	(KBr): C═O
							1705.0; 1643.3
A3	C1		81	EI: M+ = 525	0.59	FM1	(KBr): C═O
							1708.8;
A3	C5	LC/SiO 2 /FM4	95	YED: M = 525	0.67	FM4
A3	C6	THF,LC/SiO 2 /FM4	92		0.82	FM4	(KBr): C═O
							1710.8; 1641.3
A3	C8	Further reacted as	100
		crude product

EXAMPLE A26

Preparation of compounds of general formula:

H-A-NR 3 R 4

1-[N 6 -(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine

To a mixture of 24.2 g (46 mmol) of 1-[N 2 -(1,1-dimethylethoxycarbonyl)-N 6 -(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine and 150 ml of methylene chloride were added 50 ml of trifluoroacetic acid and the reaction mixture was stirred overnight at room temperature. The reaction mixture was neutralised by the addition of saturated aqueous sodium hydrogen carbonate solution, the organic phase was dried and evaporated down in vacuo. 12 g (62% of theory) of the desired compound were obtained as a colourless oil.

IR (KBr): 1648 cm −1 (C═O)

R f (FM1): 0.5

The following were prepared analogously:

			%
A	NR 3 R 4	Remarks	Yield	R f	Eluant	IR [cm −1 ]
A9	C1		100	0.4	FM2	(KBr): C═O
						1676.0; 1645.2
A4	C1		61.5	0.48	FM1	(KBr): C═O
						1647.7; 1712.7
A5	C1		55	0.42	FM1	(KBr): C═O
						1651
A5	C8	further reacted	100	0.19	FM1
		as crude
		product
A6	C1		82	0.3	FM1	(KBr): C═O
						1647; 1676
A6	C8	further reacted	100	0.23	FM1	(KBr): C═O
		as crude				1674
		product
A10	C1		38	0.55	FM1	(KBr): C═O
						1643
A10	C8	further reacted	100	0.15	FM1
		as crude
		product

EXAMPLE A27

Preparation of compounds of general formula:

H-A-NR 3 R 4

1-[N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine

A solution of 120 g (0.228 mol) of 1-[N 2 -(phenylmethoxycarbonyl)-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine in 1000 ml of methanol and 240 ml of 1M aqueous potassium hydrogen sulphate solution was hydrogenated in the presence of 30 g palladium on charcoal (100) at 20° C. and 3 bar of hydrogen pressure until the uptake of hydrogen had ceased. The catalyst was filtered off, the filtrate evaporated down in vacuo, the residue was taken up in isopropanol/methanol and adjusted to pH 7-8 by the addition of a concentrated aqueous ammonia solution. The solution was filtered and evaporated to dryness. 87 g (97% of theory) of an oil were obtained.

IR (KBr): 1634, 1701 cm −1 (C═O)

R f : 0.79 (ethyl acetate/methanol/conc. aqueous ammonia=6/4/1 (v/v/v)

The following were prepared analogously:

A	NR 3 R 4	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
A3	C4		93	ESI: M + H = 391	0.6	FM1	(KBr): C═O
				(M + Na = 413)			1637.5; 1706.9
A3	C3		100		0.3	FM1	(KBr): C═O
							1641.3; 1705
A11	C1		78.5		0.2	FM1	(KBr): C═O
							1701.1; 1641.3
A7	C1	without KHSO 4	80.2		0.2	FM7
A3	C1		97		0.79	ethyl	(KBr): C═O
						acetate/methanol/	1633.6; 1701.1
						conc. aqueous
						ammonia 6/4/1
						(v/v/v)
A3	C5	without KHSO 4	53		0.39	FM4	(KBr): C═O
							1733.9; 1624.0
A3	C6	without KHSO 4	89		0.38	FM4	(KBr): C═O
							1706.9; 1645.2
A3	C8	further reacted as	100		0.3	FM1
		crude product

EXAMPLE A28

Preparation of compounds of general formula:

1-[N 2 -[N-(1,1-dimethylethoxycarbonyl)-3,5-dibromo-D-tyrosyl]-N 6 -(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

To a mixture of 2.58 g (5.88 mmol) of N-[(1,1-dimethylethoxy)-carbonyl]-3,5-dibromo-D-tyrosine, 1.03 g (8 mmol) of DIEA, 1.93 g (6 mmol) of TBTU, 0.79 g (5.8 mmol) of HOBt and 100 ml of dimethylformamide were added dropwise, 2.5 g (5.88 mmol) of 1-[N6-[(phenylmethoxy)-carbonyl]-L-lysyl]-4-(4-pyridinyl)piperazine, dissolved in 50 ml of dimethylformamide, with stirring. The reaction mixture was stirred overnight at room temperature, then evaporated down in vacuo and the residue was taken up in ethyl acetate. The organic phase was washed twice with aqueous saturated sodium hydrogen carbonate solution and once with aqueous saturated saline solution, dried and evaporated down in vacuo. The purification was carried out by column chromatography (aluminium oxide, activity stage III (6% water content) (ICN Biomedicals), eluant: ethyl acetate/methanol/ammonia=8/2/0.5 (v/v/v), followed by methanol/ammonia =7/3 (v/v)). 4.0 g (80% of theory) of an amorphous substance were obtained.

IR (KBr): 1643, 1709 cm −1 (C═O)

R f : 0.52(FM1)

ESI-MS: (M+H) + =845/847/849 (Br 2 )

The following were prepared analogously (in each case n=1)

R 2	A	NR 3 R 4	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
AS7	A0	C4	LM: THF;	100
			reacted as
			crude product
AS1	A0	C11	reacted as	69
			crude product
AS4	A0	C20		59	ESI: (M + H) + =			(KBr): C═O
					600/2/4 (Br 2 )			1639; 1707
AS1	A0	C4		71
AS4	A0	C11		53		0.5	FM1
AS7	A0	C1	reacted as	100				(KBr): C═O
			crude product					1644
AS4	A7	C1	NEt 3 as base;	100		0.4	FM8
			reacted as
			crude product
AS1	A4	C1		80	ESI: (M + H) + =	0.52	FM1	(KBr): C═O
					845/7/9 (Br 2 )			1643.3; 1708.8
AS4	A0	C5	Boc-AS4	83	EI: M + =	0.69	FM5	(KBr): C═O
			LC/SiO 2 /FM5		581/3/5 (Br 2 )			1706.9; 1641.3
AS4	A0	C15	LC/SiO 2 /FM4	86	EI: M + =	0.83	FM4	(KBr): C═O
					382/4/6 (Br 2 )			1706.9; 1641.3
AS1	A0	C5	LC/SiO 2 /FM5	81		0.5	FM5	(KBr): C═O
								1705.0; 1637.5
AS4	A0	C16	LC/SiO 2 /FM4	85	EI: (M + H) + =	0.42	FM4	(KBr): C═O
			THF		582/4/6 (Br 2 )			1706.9; 1643.3
AS1	A0	C15	THF	76		0.53	FM4	(KBr): C═O
			LC/SiO 2 /FM4					1701.1; 1637.5
AS4	A0	C3	LC/SiO 2 /FM6	83	ESI: (M + H) + =	0.71	FM6	(KBr): C═O
					598/600/2 (Br 2 )			1706.9; 1641.3
AS1	A0	C16	LC/SiO 2 /FM4	85		0.35	FM1	(KBr): C═O
								1705; 1641.3
AS1	A0	C6	LC/SiO 2 /FM6	84		0.54	FM6	(KBr): C═O
								1701.1; 1635.5
AS4	A0	C18	LC/SiO 2 /FM4	95		0.66	FM4	(KBr): C═O
								1705; 1641.3
AS1	A0	C37		90		0.43	FM1	(KBr): C═O
								1645; 1714.5
AS4	A0	C37		95		0.51	FM4	(KBr): C═O
								1643.3; 1705
AS4	A0	C22		75				(KBr): C═O
								1635.5; 1708.8
AS4	A0	C21		92	M + =	0.42	FM4	(KBr): C═O
					582/4/6 (Br 2 )			1643; 1705
AS4	A5	C1		69	ESI: (M + H) + =			(KBr): C═O
					939/41/43 (Br 2 )			1653; 1709
AS4	A0	C23		85				(KBr): C═O
								1645; 1709
AS4	A10	C1		65	M + : 652/4/6			(KBr):C═O
								1649; 1707
AS4	A0	C24		79	M + : 589/91/93			(KBr): C═O
								1643; 1707
AS4	A5	C8		76				(KBr): C═O
								1643; 1713
AS4	A6	C1		95				(KBr): C═O
								1645; 1710.8
AS4	A6	C8		88	M + : 657/9/61			(KBr): C═O
								1628; 1713
AS4	A10	C8		46	ESI: (M + H) + =			(KBr): C═O
					858/60/62 (Br 2 )			1647; 1707
AS4	A0	C26		46				(KBr): C═O
								1637.5; 1707
AS1	A0	C1	further reacted as	100
			crude product
AS1	A0	C8		55		0.3	dichloromethane/	(KBr): C═O
							methanol 9/1	1632
AS1	A0	C18		84	ESI: (M + H) + =	0.4	FM4	(KBr): C═O
					613/5/7 (Br 2 )			1641; 1707
AS1	A0	C3		81				(KBr): C═O
								1638; 1701
AS1	A0	C21		70		0.28	FM4	(KBr): C═O
								1643; 1707
AS4	A0	C6		47				(KBr): C═O
								1639; 1707
AS4	A0	C19		90				(KBr): C═O
								1639; 1707
AS9	A0	C1	further reacted as	47
			crude product
AS1	A7	C1	NEt 3 as base;	83		0.28	FM1
			further reacted as
			crude product
AS4	A0	C38		67		0.5	FM1
AS4	A0	C37		84
AS4	A0	C39		100		0.68	FM1
				(raw)
AS4	A0	C40		36
AS1	A0	C42		90		0.43	FM1	(KBr): C═O
								1645/1715
AS4	A0	C42		100		0.51	FM4	(KBr): C═O
								1643/1705
AS1	A0	C43		78		0.9	EE/MeOH	(KBr): C═O
							95/5	1636/1676/1659
AS1	A0	C44		47		0.9	EE/MeOH	(KBr): C═O
							95/5	1638/1701
AS1	A0	C45		72	EI: M + =	0.9	EE/MeOH	(KBr): C═O
					591/3/5 (Br 2 )		9/1	1638/1695
AS1	A0	C47		80	EI: M + =	0.95	EE/MeOH	(KBr): C═O
					596/98/600 (Br 2 )		9/1	1636/1705
AS1	A0	C49		89		0.9	EE/MeOH	(KBr): C═O
							9/1	1636/1684
AS4	A0	C44		69		0.9	EE/MeOH	(KBr): C═O
							9/1	1643/1707;
								CN 2235
AS1	A0	C50		93	EI: M + =	0.9	EE/MeOH	(KBr): C═O
					598/600/602 (Br 2 )		9/1	1636/1705
AS1	A0	C51		100		0.1	EE/MeOH/	(KBr): C═O
							NH 4 OH 5/5/0.1	1638/1707
AS4	A0	C52		63		0.56	FM1	(KBr): C═O
								1641/1705
AS4	A0	C53		83	EI: M + =			(KBr): C═O
					601/3/5 (Br 2 )			1638/1705
AS4	A0	C64		41	ESI: (M + H) + =			(KBr): C═O
					610/12/14 (Br 2 )			1639/1701
AS1	A0	C53		66		0.45	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH 4 OH 70/30/1	1639/1709
AS4	A0	C51		88		0.35	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH 4 OH 50/50/0.5	1641/1691
AS4	A0	C66		77	EI: M + =	0.75	CH 2 Cl 2 /MeOH/	(KBr): C═O
					629/31/33 (Br 2 )		NH 4 OH 9/1/0.1	1641/1707
AS16	A0	C8		100		0.8	FM1
AS16	A0	C1		56		0.5	EE/MeOH/	(KBr): C═O
							NH 4 OH 9/1/1	1695
AS4	A0	C8		100
AS1	A0	C53		70.0	EI: M + =	0.10	CH 2 Cl 2 /MeOH/	(KBr): C═O
					502/4/6 (Br 2 )		NH4OH 70/30/1	1676
AS4	A0	C70		47.0				(KBr): C═O
								1645/1707
AS1	A0	C64		31.0		0.50	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH4OH 90/10/1	1639/1707
AS1	A0	C70		20.0
AS4	A0	C72		50.0		0.50	CH 2 Cl 2 /MeOH/
							NH4OH 90/10/1
AS19	A0	C8		98.0
AS35	A0	C8		92.0		0.70	FM1
AS36	A0	C8		65.0

EXAMPLE A29

Preparation of compounds of general formula:

1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(4-pyridinyl)piperazine

A mixture of 39 g (0.089 mol) of 4-amino-3,5-dibromo-N-[(1,1-dimethylethoxy)carbonyl]-D-phenylalanine, 35.7 g (0.111 mol) of TBTU, 12.3 g (0.089 mol) of HOBt, 14.5 g (0.089 mol) of 1-(4-pyridinyl)-piperazine and 19.6 ml of (0.111 mol) of DIEA in 1000 ml of tetrahydrofuran was stirred overnight at room temperature. The reaction mixture was extracted once with saturated aqueous saline solution and twice with saturated aqueous sodium hydrogen carbonate solution. The combined aqueous phases were extracted once with tetrahydrofuran and the combined tetrahydrofuran phases were washed once with saturated aqueous saline solution. After drying the organic phase with sodium sulphate it was evaporated down in vacuo and the residue was taken up in ethyl acetate. The ethyl acetate phase was filtered after drying again and evaporated down in vacuo. 52.5 g of the intermediate compound were obtained as a viscous oil, which was then mixed with 300 ml of methylene chloride and 80 ml of trifluoroacetic acid and stirred overnight at room temperature. The reaction mixture was evaporated down in vacuo, the residue formed was triturated with ether. 45.8 g (72% of theory) of the desired product were obtained as a white amorphous solid.

IR (KBr): 1643, 1674 cm −1 (C═O)

R f : 0.36 (ethyl acetate/methanol =6/4 (v/v))

The following were prepared analogously (in each case n=1)

R 2	A	NR 3 R 4	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
AS7	A0	C8	Crude product;	84
			Boc-cleaving
			with pure TFA
AS4	A0	C8		63	ESI: (M + H) + =			(KBr): C═O
					486/88/90 (Br 2 )			1632
AS4	A0	C4		63	ESI: (M + H) + =			(KBr): C═O
					481/3/5 (Br 2 )			1620
AS1	A9	C1		55		0.25	FM2	(KBr): C═O
								1674.1; 1643.3
AS4	A0	C8		81	ESI: (M + H) + =	0.6	FM2	(KBr): C═O
					486/8/90 (Br 2 )			1629.8
AS4	A0	C1		72		0.38	ethyl acetate/	(KBr): C═O
							methanol = 6/4 (v/v)	1643.3; 1674.1
AS1	A0	C20		30
AS4	A0	C65		41	EI: M + =			(KBr): C═O
					515/17/19 (Br 2 )			1618
AS1	A0	C65		15	ESI: (M + H) + =	0.08	FM1	(KBr): C═O
					517/19/21 (Br 2 )			1635
AS4	A0	C78		77.0	ESI: (M + H) + =	0.30	CH 2 Cl 2 /MeOH/	(KBr): C═O
					529/31/33 (Br 2 )		NH4OH = 90/10/1	1674
AS1	A0	C78		60.0	ESI: (M + H) + =	0.10	CH 2 Cl 2 /MeOH/	(KBr): C═O
					531/33/35 (Br 2 )		NH 4 OH = 80/20/1	1670
AS4	A0	C71		43.0		0.20	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH 4 OH = 90/10/1	1678
AS31	A0	C20		39.0	EI: M + = 382	0.30	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH 4 OH = 80/20/1	1678
AS31	A0	C53		83.0	EI: M + = 383			(KBr): C═O
								1678

EXAMPLE A30

Preparation of compounds of general formula:

1-[N 2 -[N-(9-fluorenylmethoxycarbonyl)-3,5-dibromo-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine

A mixture of 63 g (0.1123 mol) of N-[(9-fluorenylmethoxy)carbonyl]-3,5-dibromo-D-tyrosine, 44 g (0.1123 mol) of 1-[N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine, 39.7 g (0.1235 mol) of TBTU, 15.5 g (0.1123 mol) of HOBt, 21.7 ml (0.1235 mol) of DIEA and 600 ml of dimethylformamide was stirred for 20 hours at room temperature. The reaction mixture was evaporated down in vacuo and the residue divided between ethyl acetate/methanol (10/1 v/v) and saturated aqueous sodium hydrogen carbonate solution. The organic phase was washed once with saturated aqueous sodium hydrogen carbonate solution and after drying evaporated down in vacuo. The residue was recrystallised twice from isopropanol (22.6g; 22% of theory), the mother liquors were combined, evaporated down and purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM; eluant: ethyl acetate/methanol=8/2 (v/v)). A further 28.0 g (26.7% of theory)of the desired end product were obtained. Total yield: 49% of theory.

IR (KBr): 1641, 1705 cm −1 (C═O)

R f : 0.46 (ethyl acetate/methanol =6/4 (v/v))

ESI-MS: (M+H) + =933/935/937 (Br 2 )

The following were prepared analogously:

R 2	A	NR 3 R 4	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
AS1	A3	C1		48	ESI: (M + H) + =	0.46	Ethyl acetate/	(KBr): C═O
					933/5/7 (Br 2 )		methanol = 6/4 (v/v)	1641.3; 1705.5
AS1	A3	C5	THF/SiO 2 /FM4	80	ESI: (M + H) + =	0.72	FM1	(KBr): C═O
					933/5/7 (Br 2 )			1701.1; 1635.5
AS1	A3	C6	THF	60	ESI: M − =	0.47	FM4	(KBr): C═O
					960/2/4 (Br 2 )			1712.7; 1631.7
AS5	A3	C1	THF	61	ESI: (M + H) + =	0.36	FM4	(KBr): C═O
			LC/SiO 2 /FM4		917/19/21 (Br 2 )			1708.8; 1645.2
			Diastereomers
AS10	A0	C1	THF	90		0.52	FM4
AS1	A3	C18		73		0.46	FM1	(KBr): C═O
								1635.5; 1712.7
AS10	A3	C1	THF	85				(KBr): C═O
								1643.3; 1708.8
AS10	A3	C4	THF	82				(KBr): C═O
								1639.4; 1710.8
AS10	A3	C1	THF	85				(KBr): C═O
								1643; 1709
AS4	A3	C18		94	ESI: (M + H) + =			(KBr): C═O
					963/5/7 (Br 2 )			1633.6; 1711
AS15	A0	C8		90				(KBr): C═O
								1635.5; 1617.5
AS12	A0	C8		44	ESI: (M + H) + =			(KBr): C═O
					577			1630; 1714.6
AS10	A0	C4		88		0.49	FM4	(KBr): C═O
								1635.5; 1716.5
AS1	A3	C1		70		0.7	FM7

EXAMPLE A31

Preparation of compounds of general formula:

1-[N 2 -(3,5-dibromo-D-tyrosyl)-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

To a mixture of 63 g (0.1123 mol) of N-[(9-fluorenylmethoxy)carbonyl]-3,5-dibromo-D-tyrosine, 44 g (0.1123 mol) of 1-[N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine, 39.7 g (0.1235 mol) of TBTU, 15.5 g (0.1123 mol) of HOBt and 1500 ml of tetrahydrofuran were slowly added dropwise 21.7 ml (0.1235 mol) of DIEA and the reaction mixture was then stirred for 2 hours at room temperature. After the addition of 200 ml of diethylamine the mixture was again stirred overnight at room temperature. The reaction mixture was mixed with 1000 ml of saturated saline solution, stirred thoroughly and the aqueous phase was separated off. After extracting the aqueous phase three times with 500 ml of tetrahydrofuran and combining the organic phases the mixture was washed three times with 500 ml of saturated aqueous saline solution, three times with 200 ml of saturated aqueous sodium hydrogen carbonate solution and once with 500 ml of saturated aqueous saline solution. The organic phase was dried and then evaporated down in vacuo. The residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol/conc. aqueous ammonia=8/1/0.25 (v/v/v)). 40.0 g (50% of theory)of the desired end product were obtained.

IR (KBr): 1641, 1699 cm −1 (C═O)

R f : 0.2 (ethyl acetate/methanol/conc. aqueous ammonia=6/4/1 (v/v/v))

ESI-MS: (M+H) + =711/713/715 (Br 2 )

The following were prepared analogously (in each case n=1)

R 2	A	NR 3 R 4	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
AS4	A3	C8	crude	43
AS4	A3	C1	crude	100		0.4	FM1
AS4	A3	C4		79	ESI: (M + H) + =	0.7	FM7	(KBr): C═O
					709/11/13 (Br 2 )			1637.5; 1705
AS4	A0	C69		82	ESI: (M + H) + =			(KBr): C═O
					587/9/81 (Br 2 )			1618/1645/1690
AS4	A0	C46		38		0.55	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH 4 OH 90/10/1	1614/1639
AS4	A0	C48		54	EI: M + =	0.52	CH 2 Cl 2 /MeOH/	(KBr): C═O
					522/4/6 (Br 2 )		NH 4 OH 90/10/2	1638
AS11	A0	C53		71.0	EI: M + = 469	0.20	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH 4 OH 90/10/1	1637/1732
AS11	A0	C20		45.0	EI: M + = 468	0.40	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH 4 OH 90/10/1	1635/1732
AS31	A0	C72		100.0	EI: M + = 411	0.45	FM1	(KBr): C═O
								1664
AS11	A0	C72		33.0	EI: M + = 497	0.30	FM1	(KBr): C═O
								1630/1641

EXAMPLE A32

Preparation of compounds of general formula:

1-[N 2 -(3,5-dibromo-D-tyrosyl)-N 6 -(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

To a mixture of 4 g (4.7 mmol) of 1-[N 2 -[N-(1,1-dimethylethoxycarbonyl)-3,5-dibromo-D-tyrosyl]-N 6 -(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine and 80 ml of methylene chloride were added 20 ml of trifluoroacetic acid and the reaction mixture was stirred overnight at room temperature. The reaction mixture was neutralised by the addition of saturated aqueous sodium hydrogen carbonate solution, the organic phase was dried over sodium sulphate and evaporated down in vacuo. 2.2 g (64% of theory) of an amorphous solid were obtained.

IR (KBr): 1643, 1680 cm −1 (C═O)

R f : 0.5 (FM1)

ESI-MS: (M+H) + =745/747/749 (Br 2 )

The following were prepared analogously (in each case n=1)

R 2	A	NR 3 R 4	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]	Mp. (° C.)
AS7	A0	C4	crude product;	51		0.30	FM1
			pure TFA
AS1	A0	C11		95	ESI: (M + H) + =			(KBr): C═O
					503/5/7 (Br 2 )			1676
AS4	A0	C20		100	ESI: (M + H) + =
					500/2/4 (Br 2 )
AS1	A0	C4		100	ESI: (M + H) + =			(KBr): C═O
					481/3/5 (Br 2 )			1678
AS4	A0	C11		74
AS7	A0	C1	reacted as	100
			crude product
AS4	A7	C1	reacted as	100		0.40	EE/MeOH
			crude product				7/3 v/v
AS1	A4	C1		64	ESI: (M + H) + =	0.50	FM1	(KBr): C═O
					745/7/9 (Br 2 )			1643.3; 1679.9
AS4	A0	C5		89		0.32	FM4	(KBr): C═O
								1637.5
AS4	A0	C15		93		0.33	FM4	(KBr): C═O
								1618.2
AS1	A0	C5		89		0.25	FM4	(KBr): C═O	154-157
								1639.4
AS4	A0	C16	LC/SiO 2 /FM4	90		0.30	FM4	(KBr): C═O
								1635.5
AS1	A0	C15		89		0.20	FM4	(KBr): C═O	160-164
								1639.4
AS4	A0	C3	LC/SiO 2 /FM4	98		0.37	FM4	(KBr): C═O
								1683.8;
AS4	A0	C6		89		0.28	FM4	(KBr): C═O
								1637.5
AS1	A0	C16		95		0.57	FM1	(KBr): C═O
								1683.8
AS1	A0	C6	LC/SiO 2 /FM4	56	EI: M + =	0.24	FM4	(KBr): C═O
					511/3/5 (Br 2 )			1637.5
AS4	A0	C18		90	EI: M + =	0.50	FM1	(KBr): C═O
					512/4/6 (Br 2 )			1624.0
AS4	A0	C37		93		0.24	FM4	(KBr): C═O
								1635.5; 1684
AS4	A0	C22		88	M + =			(KBr): C═O
					502/4/6 (Br 2 )			1618.2
AS4	A0	C21		52	M + =	0.55	FM1	(KBr): C═O
					482/4/6 (Br 2 )			1681.8
AS1	A0	C37		89		0.32	FM1	(KBr): C═O
								1681.8
AS4	A5	C1		crude				(KBr): C═O
								1645; 1676
AS4	A0	C23		88				(KBr): C═O
								1643
AS4	A10	C1		47	ESI: (M + H) + =			(KBr): C═O
					553/5/7 (Br 2 )			1653
AS4	A5	C8		67	M + =			(KBr): C═O
					543/5/7			1645
AS4	A6	C1		59				(KBr): C═O
								1643
AS4	A0	C24		94	M + =			(KBr): C═O
					489/91/93			1618; 1637.5
AS4	A6	C8		70				(KBr): C═O
								1639.4
AS4	A10	C8		82	M + =			(KBr): C═O
					557/9/61			1651
AS4	A0	C26		88				(KBr): C═O
								1626
AS1	A0	C1		96	ESI: (M + H) + =	0.18	FM1	(KBr): C═O
					483/5/7 (Br 2 )			1680
AS1	A0	C8	crude	69
AS1	A0	C18		82		0.27	FM1	(KBr): C═O
								1684
AS1	A0	C3		100		0.38	FM1	(KBr): C═O
								1682
AS1	A0	C21		89		0.26	FM1	(KBr): C═O
								1595; 1615
AS4	A0	C3		99		0.37	FM4	(KBr): C═O
								1618; 1636; 1683
AS4	A0	C19		98	ESI: (M + H) + =	0.47	FM4	(KBr): C═O
					498/500/502 (Br 2 )			1638; 1682
AS9	A0	C1	Crude product	96
AS1	A7	C1		37		0.42	FM7
AS4	A0	C38		80		0.25	FM1
AS4	A0	C37		86
AS4	A0	C39		73
AS4	A0	C40		92	EI: M + =			(KBr): C═O
					515/7/9			1674
AS1	A0	C42		100		0.32	FM1	(KBr): C═O
				crude				1682
AS4	A0	C42		95		0.24	FM4	(KBr): C═O
								1636/1684
AS1	A0	C43		66		0.1	FM7	(KBr): C═O
								1659
AS1	A0	C44		59		0.15	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH 4 OH 90/10/1	1676
AS1	A0	C45		82	ESI: (M + H) + =	0.10	EE/MeOH 9/1	(KBr): C═O
					492/4/6 (Br 2 )			1678
AS1	A0	C47		89		0.52	FM7	(KBr): C═O
								1634/1666
AS1	A0	C49		84		0.15	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH 4 OH	1678
AS4	A0	C44		93	EI: M + =	0.45	EE/MeOH 9/1	(KBr): C═O
					504/6/8 (Br 2 )			1653; CN 2239
AS1	A0	C50		100	EI: M + =	0.10	EE/MeOH 9/1	(KBr): C═O
					498/500/502 (Br 2 )			1636
AS1	A0	C51		100	EI: M + =	0.05	EE/MeOH/	(KBr): C═O
					530/2/4 (Br 2 )		NH4OH 5/5/0.1	1678
AS4	A0	C52		97		0.15	FM1	(KBr): C═O
								1620/1688
AS4	A0	C53		58	ESI: (M + H) + =	0.05	EE/MeOH/	(KBr): C═O
					502/4/6 (Br 2 )		NH 4 OH 5/5/0.1	1678
AS4	A0	C64		100				(KBr): C═O
								1647/1678
AS1	A0	C53		70	EI: M + =	0.15	CH 2 Cl 2 /MeOH/	(KBr): C═O
					502/4/6 (Br 2 )		NH 4 OH 70/30/1	1676
AS4	A0	C51		100		0.05	CH 2 Cl 2 /MeOH/	(KBr): C═O
							NH 4 OH	1680
AS4	A0	C66		100		0.27	CH 2 Cl 2 /MeOH/
							NH 4 OH
AS16	A0	C8		76		0.40	FM1
AS16	A0	C1		28		0.20	EE/MeOH/
							NH 4 OH 9/1/1
AS4	A0	C70		96		0.20	EE/MeOH/	(KBr): C═O
							NH 4 OH 80/20/10.5	1676
AS1	A0	C64		100	EI: M + =			(KBr): C═O
					510/1214			1674
AS1	A0	C70		100				(KBr): C═O
								1674
AS4	A0	C72		100	ESI: (M + H) + =	0.10	CH 2 Cl 2 /MeOH/	(KBr): C═O
					530/2/4 (Br 2 )		NH 4 OH 80/20/1	1678
AS19	A0	C8		100
AS35	A0	C8		72		0.60	FM1
AS36	A0	C8		80		0.52	FM1	(KBr): C═O
								1674

EXAMPLE A33

4-(4-pyridinyl)-1-[3-(4-pyridinyl)-D,L-alanyl]-piperazine-hydrochloride

16.4 g (0.04 mol) of 1-[N-[(1,1-dimethylethoxy)carbonyl]-3-(4-pyridinyl)-D,L-alanyl]-4-(4-pyridinyl)-piperazine, dissolved in 100 ml of methanol, were mixed with 20 ml of ethereal hydrochloric acid and the reaction mixture was heated to 40° C. The desired compound crystallised out of the reaction mixture.

yield: 9.2 g (60% of theory)

R f : 0.1 (FM1)

Mp.: 198-200° C.

EXAMPLE A34

Preparation of compounds of general formula:

1-[N 2 -(3,5-dibromo-D-tyrosyl)-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

A mixture of 50 g (53.5 mmol) of 1-[N 2 -[N-(9-fluorenylmethoxycarbonyl)-3,5-dibromo-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine and 300 ml of diethylamine was heated to 60° C. with stirring. 100 ml of methanol were added and stirring was continued for a further 5 hours at 60° C. The reaction mixture was evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol=6/4 (v/v)). 26 g (68% of theory) of a white foam were obtained.

IR (KBr): 1641, 1691 cm −1 (C═O)

R f : 0.2 (ethyl acetate/methanol/conc. aqueous ammonia=6/4/1 (v/v/v))

ESI-MS: (M+H) + =710/712/714 (Br 2 )

The following were prepared analogously:

R 2	A	NR 3 R 4	n	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
AS1	A3	C4	1		85	ESI: M + H =	0.2	FM1	(KBr): C═O
						710/2/4 (Br 2 )			1635.5; 1695.3
AS1	A3	C8	1		98				(KBr): C═O
									1635; 1705
AS1	A3	C1	1		68	EI: M + =	0.2	ethyl acetate/	(KBr): C═O
						710/2/4 (Br 2 )		methanol/NH 4 OH =	1641.3; 1691.5
								6/4/1 (v/v/v)
AS1	A3	C5	1	THF as solvent; purified by	56	ESI: M + H =	0.3	FM1	(KBR):C═O
				column chromatography:		711/3/5 (Br 2 )			1695.3; 1635.5
				silica gel/FM1
AS1	A3	C6	1	THF as solvent; purified by	90	EI: M + =	0.49	FM1	(KBr): C═O
				column chromatography:		739/41/43 (Br 2 )			1695.3; 1629.8
				silica gel/FM1
AS5	A3	C1	1	THF as solvent; purified by	93		0.25/	FM4	(KBr): C═O
				column chromatography:			0.37		1705.0; 1643.3
				silica gel/FM4;
				diastereomers
AS10	A0	C1	1		71		0.5	FM1	(KBr): C═O
									1641.3
AS1	A3	C18	1		94				(KBr): C═O
									1647; 1722.5
AS10	A3	C1	1		49	M + =			(KBr): C═O
						694/6/8 (Br 2 )			1643; 1703
AS10	A3	C4	1		46	ESI: M + H =			(KBr): C═O
						694/6/8 (Br 2 )			1639.4; 1705
AS10	A3	C4	1		46	ESI: M + H =			(KBr): C═O
						694/6/8 (Br 2 )			1639.4; 1705
AS10	A3	C1	1		49	M + =			(KBr): C═O
						694/68/70 (Br 2 )			1643; 1703
AS4	A3	C18	1		46	ESI: M + H =			(KBr):C═O
						741/3/5 (Br 2 )			1641.3; 1705
AS15	A0	C8	1		100	M + : 321			(KBr): C═O
									1637.5
AS12	A0	C8	1		81				(KBr): C═O
									1630
AS10	A0	C4	1	THF as solvent	68		0.38	FM4	(KBr): C═O
									1635.5
AS1	A3	C1	0	crude product	100		0.3	FM7

EXAMPLE A35

1-[N 2 -[N-[[[2-(2-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-N 6 -(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinl)-piperazine

To a solution of 1.0 g (1.34 mmol) of 1-[N 2 -(-3,5-dibromo-D-tyrosyl)-N 6 -(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine in 80 ml of tetrahydrofuran were added 0.28 g (1.6 mmol) of 2-methoxyphenethyl isocyanate and the mixture was stirred for 3 days at room temperature. The reaction mixture was evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: methylene chloride/methanol/cyclohexane/ammonia=350/75/75/10 (v/v/v/v)). 0.5 g (40% of theory) of a colourless amorphous solid was obtained.

IR(KBr): 1639 cm −1 (C═O)

R f : 0.49 (FM1)

ESI-MS: (M+H) + =922/924/926 (Br 2 )

EXAMPLE A36

Preparation of compounds of general formula:

methyl 4-amino-3,5-dibromo-N 2 -[[(2-phenylethyl)amino]carbonyl]-D-phenylalanine

A mixture of 1.27 g (7.73 mmol) of CDT in 150 ml of tetrahydrofuran was mixed, whilst cooling with ice, with 0.72 ml (5.15 mmol) of triethylamine and 2.0 g (5.15 mmol) of methyl-4-amino-3,5-dibromo-D-phenylalanine-hydrochloride, stirred for a further 30 minutes whilst cooling with ice and stirred for 1 hour at room temperature. Then 0.82 ml (6.44 mmol) of benzene ethanamine were added and the mixture was refluxed for 5 hours. The reaction mixture was evaporated down in vacuo, the residue was taken up in ethyl acetate and washed with saturated aqueous sodium hydrogen carbonate solution. After drying the organic phase the solvent was removed in vacuo, the residue was stirred with ether and the precipitate was filtered off. 1.69 g (66% of theory) of an amorphous solid were obtained.

IR(KBr): 1632, 1732 cm −1 (C═O)

R f : 0.63 (ethyl acetate)

ESI-MS: (M+H) + =498/500/502 (Br 2 )

The following were prepared in the same way (in each case n=1):

RCO	R 2	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
N6	AS1	further reacted	100		0.60	FM1
		as crude product
N15	AS6	DMF/THF = 1/1	100	ESI: (M + H) + =	0.65	FM1	(KBr): C═O
		(v/v) as solvent		517/9 (Br)			1745.5; 1676.0
N2	AS1		99		0.53	FM1	(KBr): C═O
							1716.5
N8	AS4		66	ESI: (M + H) + =	0.63	ethyl acetate	(KBr): C═O
				498/500/502 (Br 2 )			1631.7; 1732.0
N15	AS4		92		0.85	ethyl acetate/	(KBr): C═O
						methanol = 8/2 (v/v)	1620.1; 1737.8
N23	AS4		95	EI: M + =	0.86	ethyl acetate/	(KBr): C═O
				572/4/6/8 (Br 2 .Cl)		methanol = 8/2 (v/v)	1732.0; 1641.3
N2	AS2		100	EI: M + =406	0.86	FM1	(KBr):C═O
							1629.8; 1722.3; 1741.6
N15	AS1	DIEA	47		0.75	FM1
N15	AS3		38		0.60	t.-butyl-	(KBr): C═O
						methylether/	1695.5
						petroleum ether =
						9/1 (v/v)
N66	AS21		76		0.60	EE	(KBr): C═O
							1662/1734
N66	AS1		100
N66	AS4		63		0.56	FM1
N122	AS1		95
N122	AS4		88
N66	AS17		22	ESI: (M + H) + =	0.25	FM1	(KBr): C═O
				623/5/7 (Br 2 )			1663/1740
N66	AS18		65		0.53	EE
N66	AS19		79		0.50	FM1	(KBr): C═O
							1663/1734
N66	AS5		90	ESI: (M + H) + =	0.78	FM1	(KBr): C═O
				607/09/11 (Br 2 )			1637/1663/1740
N66	AS22		68		0.74	FM1
N66	AS23		100				(KBr): C═O
							1738/1662
N66	AS25		100	ESI: (M + H) + =	0.52	FM1
				472
N66	AS49		100		0.80	FM1

EXAMPLE A37

Preparation of compounds of general formula:

4-amino-3,5-dibromo-N 2 -[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-D-phenylalanine

To a solution of 2.8 g (4.9 mmol) of methyl 4-amino-3,5-dibromo-N 2 -[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-D-phenylalanine in a mixture of 30 ml of methanol and 20 ml of water were added 0.25 g (10.0 mmol) of lithium hydroxide and the mixture was then stirred for 3 hours at room temperature. After the addition of 2.0 g (50 mmol) of sodium hydroxide the mixture was diluted with 50 ml of water. The reaction mixture was stirred for 15 minutes in an ultrasound bath, then stirred overnight at room temperature and evaporated down in vacuo. The residue was mixed with 100 ml of water and the aqueous phase was extracted twice with 50 ml of ether. By the addition of 2 M aqueous hydrochloric acid the aqueous phase was adjusted to a pH of 3-4 and extracted three times with ethyl acetate. The combined ethyl acetate phases were washed once with water, then dried and evaporated down in vacuo. 1.6 g (58% of theory) of a yellowish-brown oil were obtained.

IR(KBr): 1616, 1724 cm −1 (C═O)

R f : 0.33 (ethyl acetate/methanol=8/2 (v/v))

ESI-MS: (M+H) + =557/559/561/563 (Br 2 , Cl)

The following were prepared in the same way (in each case n=1):

RCO	Z	R 2	Remarks	% Yield	MS	R f	Eluant	IR [cm −1]
N8	N—H	AS4		62	ESI: (M − H) − =	0.61	Ethyl acetate/	(KBr): C═O
					482/4/6 (Br 2 )		methanol = 6/4 (v/v)	1612.4, 1724.3;
								—OH, —NH—
								3386.8; 3483.2
N15	N—H	AS4		64	ESI: (M − H) − =	0.10	Ethyl acetate/	(KBr): C═O
					578/80/82 (Br 2 );		methanol = 8/2 (v/v)	1703.0
					(M + H) + =
					580/2/4 (Br 2 );
					(M + Na) + =
					602/4/6 (Br 2 )
N23	N—H	AS4		58	ESI: (M − H) − =	0.33	Ethyl acetate/	(KBr): C═O
					557/59/61/63 (Br 2 ,Cl)		methanol = 8/2 (v/v)	1616.3; 1724.3
N15	N—H	AS1	No addition	59	ESI: (M − H) − =	0.72	EE/MeOH/	(KBr): C═O
			of sodium		579/81/83 (Br 2 )		NH 4 OH = 6/4/1	1695.3
			hydroxide				(v/v/v)
N66	N—H	AS21		95		0.48	EE/AcOH	(KBr): C═O
							10/0.02 (v/v)	1639
N66	CH 2	AS1		85		0.38	CH 2 Cl 2 /MeOH/
							AcOH 9/1/0.15
							(v/v/v)
N71	CH 2	AS1		66.6	ESI: (M + H) + =	0.38	CH 2 Cl 2 /MeOH/	(KBr): C═O
					606/08/10 (Br 2 )		AcOH 9/1/0.15	1622/1680
							(v/v/v)
N66	N—H	AS18		100	ESI: (M − H) − =	0.26	EE/AcOH 9/0.01
					557		(v/v)
N66	N—H	AS19		98		0.22	CH 2 Cl 2 /MeOH/	(KBr): C═O
							AcOH 9/1/0.15	1665/1740
							(v/v/v)
N66	N—H	AS5		73	ESI: (M − H) − =	0.23	FM1	(KBr): C═O
					577/79/81 (Br 2 )			1632/1705
N66	N—H	AS22		78		0.30	FM1	(KBr): C═O
								1668/1739
N66	CH 2	AS21		79		0.34	EE/AcOH 9/0.01	(KBr): C═O
							(v/v)	1643/1703
N66	CH 2	AS1		90		0.30	EE/MeOH 9/1
							(v/v)
N15	CH 2	AS1		78	ESI: (M − H) − =	0.30	EE/AcOH 9/0.01	(KBr): C═O
					578/80/82 (Br 2 )		(v/v)	1728/1672
N66	N—H	AS25		99
N66	CH 2	AS2		100				(KBr): C═O
								1645/1712
N66	CH 2	AS23		70
N139	CH 2	AS2		59				(KBr): C═O
								1630/1662/1707
N66	CH 2	AS27		93		0.20	FM1
N66	CH 2	AS28	LiOH	100		0.30	FM1
N66	CH 2	AS4		72		0.53	FM1	(KBr): C═O
								1639/1701
N66	CH 2	AS36		74	ESI: (M − H) − =	0.36	FM1	(KBr): C═O
					434			1645/1701
N66	CH 2	AS38		69
N66	CH 2	AS48		47	EI: M + = 489	0.30	FM1	(KBr): C═O
								1645
N66	N—H	AS49		47		0.10	FM1
N66	CH 2	AS18		60		0.15	EE
N66	CH 2	AS39		96
N109	CH 2	AS21		81
N113	CH 2	AS21		76		0.20	EE/AcOH
							99/1
N134	CH 2	AS21		89		0.15	EE/AcOH
							99/1
N66	CH 2	AS47		100	ESI: (M + H) + =			(KBr): C═O
					476			1645/1716
N66	CH 2	AS7		60		0.20	FM1	(KBr): C═O
								1649/1722
N66	CH 2	AS52		95	ESI: (M + H) + =	0.15	FM1	(KBr): C═O
					480			1643/1722

EXAMPLE A38

Preparation of compounds of general formula:

3,5-dibromo-N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-D-tyrosine

A mixture of 24 g (46.3 mmol) of methyl 3,5-dibromo-N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-D-tyrosine and 5.0 g (50 mmol) of lithium hydroxide in 200 ml of water was stirred for 1 hour at 60 C. The solid product was suction filtered and the filtrate was washed with 200 ml of ethyl acetate. By the addition of 1 M aqueous hydrochloric acid the aqueous phase was adjusted to a pH of 3-4 and extracted 3 times with 150 ml of ethyl acetate. The combined ethyl acetate phases were washed once with water, dried over sodium sulphate and evaporated down in vacuo. The residue was triturated with ether. 9.1 g (38% of theory) of a colourless solid were obtained.

IR(KBr): 1719 cm −1 (C═O)

R f : 0.57 (ethyl acetate/methanol/glacial acetic acid=9.5/0.5/0.2 (v/v/v))

The following were prepared in the same way (in each case n=1):

RCO	Z	R 2	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
N6	N—H	AS1		100		0.20	FM1	(KBr): C═O
								1625.9; 1730
N15	N—H	AS6	H 2 O/MeOH =	85	ESI: (M − H) − =	0.53	EE/MeOH/AcOH =	(KBr): C═O
			1/1 (v/v) as solvent		501/3 (Br)		9/1/0.1 (v/v/v)	1695.3
N2	N—H	AS1		75		0.57	EE/methanol/glacial	(KBr): C═O
							acetic acid =	1718.5
							9.5/0.5/0.2 (v/v/v)
N2	N—H	AS2		71		0.20	FM1	(KBr): C═O
								1625.9; 1693.4; 1718.5;
								—NH— 3357.9
N15	N—H	AS3	H 2 O/MeOH =	57		0.30	EE/MeOH =	(KBr): C═O
			1/1 (v/v) as solvent				1/1 (v/v)	1693.4
N66		AS1		75		0.05	EE/MeOH 8/2
N66		AS4		85
N122		AS1		44
N122		AS4		85
N66	N—CH 3	AS1		58	ESI: (M − H) − =	0.20	EE	(KBr): C═O
					607/09/11 (Br 2 )			1607/1655/1711
N66	N—H	AS17		55		0.03	FM1
N15	CH 2	AS1		78	ESI: (M − H) − =	0.30	EE/MeOH 9/1	(KBr): C═O
					578/80/82 (Br 2 )		(v/v)	1672/1728
N66	N—H	AS23		79.0		0.22	FM1	(KBr): C═O
								1738/1664

EXAMPLE A39

methyl N 6 -[(1,1-dimethylethoxy)carbonyl]-N 2 -[N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysine

To a mixture of 10 g (19.4 mmol) of 3,5-dibromo-N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-D-tyrosine, 2.6 g (20 mmol) of DIEA, 6.4 g (20 mmol) of TBTU, 2.64 g (19.5 mmol) of HOBt and 200 ml of dimethylformamide was added dropwise, with stirring, a solution of 5.04 g (19.4 mmol) of H-Lys(Boc)-OMe in 50 ml of dimethylformamide and the mixture was stirred overnight at room temperature. The reaction mixture was evaporated down in vacuo and the residue was taken up in 250 ml of ethyl acetate. The ethyl acetate phase was then washed twice with 100 ml of saturated aqueous sodium hydrogen carbonate solution, once with 100 ml of 20% aqueous citric acid solution and finally once with 100 ml of saturated aqueous saline solution. The organic phase was dried with sodium sulphate, evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/petroleum ether=2/1 (v/v)). After removal of the solvent in vacuo the residue was triturated with ether, the amorphous solid obtained (9.5 g; 66% of theory) was suction filtered and dried.

IR(KBr): 1632; 1657, 1682, 1734 cm −1 (C═O)

R f : 0.64 (ethyl acetate)

ESI-MS: (M+H) + =757/759/761 (Br 2 ) (M+Na) + =779/781/783 (Br 2 )

EXAMPLE A40

N 6 -[(1,1-dimethylethoxy)carbonyl]-N 2 -[N-[[[2-(3-methoxy-phenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysine

A mixture of 7.75 g (10.4 mmol) of methyl N 6 -[(1,1-dimethyl-ethoxy)carbonyl]-N 2 -[N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysine, 3.5 g (140 mmol) of lithium hydroxide and 150 ml of water was stirred overnight at room temperature. The aqueous phase was washed once with ethyl acetate, acidified by the addition of 1 M aqueous potassium hydrogen sulphate solution and then extracted with ethyl acetate. The organic phase was dried over sodium sulphate and evaporated down in vacuo. 6.9 g (91% of theory) of a yellowish oil were obtained.

IR(KBr): 1653 cm −1 (C═O)

R f : 0.7 (ethyl acetate/methanol/glacial acetic acid=9/0.5/0.5 (v/v/v))

ESI-MS: (M−H) − =741/743/745 (Br 2 )

EXAMPLE A41

1-[N 2 -[N-(phenylmethoxycarbonyl)-3,5-dichloro-D-tyrosyl]-N 6 -(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

A mixture of 5 g (13.0 mmol) of 3,5-dichloro-N-[(phenylmethoxy)carbonyl]-D-tyrosine, 5.1 g (13.0 mmol) of 1-[N 6 -[(1,1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, 1.81 g (14 mmol) of DIEA, 4.17 g (13 mmol) of TBTU, 1.75 g (13.0 mmol) of HOBt and 200 ml of tetrahydrofuran was stirred at room temperature overnight. The reaction mixture was evaporated down in vacuo, the residue was taken up in ethyl acetate/methanol (95/5) and washed twice with saturated aqueous sodium hydrogen carbonate solution. The organic phase was dried, evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol=6/4 (v/v)). 6.0 g (61% of theory) of a yellowish oil were obtained.

R f : 0.47 (FM1)

ESI-MS: (M+H) + =757/759/761 (Cl 2 )

EXAMPLE A42

Preparation of compounds of general formula:

1-[N 2 -[N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-N6-[(1,1-dimethylethoxy)-carbonyl]-L-lysyl]-4-(1-methyl-4-piperidinyl)-piperazine

To a mixture of 1.1 g (1.5 mmol) of N 6 -[(dimethylethoxy)-carbonyl]-N 2 -[N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysine, 0.79 g (6.1 mmol) of DIEA, 0.52 g (1.6 mmol) of TBTU, 0.2 g (1.5 mmol) of HOBt and 100 ml of dimethylformamide was added dropwise a solution of 0.44 g (1.5 mmol) of 1-(1-methyl-4-piperidinyl)-piperazine in 30 ml of dimethylformamide at room temperature, the mixture was then stirred overnight and evaporated down in vacuo. The residue was taken up in ethyl acetate/methanol (95/5), washed twice with 70 ml of aqueous saturated sodium hydrogen carbonate solution, dried over sodium sulphate and evaporated down in vacuo. 1.1 g (81% of theory) of a colourless foam were obtained.

R f : 0.34 (ethyl acetate/methanol/conc. aqueous ammonia=7/2/1 (v/v/v))

The following was prepared analogously (n=1):

				Re-	%		Elu-
RCO	R 2	A	NR 3 R 4	marks	Yield	R f	ant	IR [cm −1 ]
N15	AS1	A11	C1	KHSO 4	70	0,40	FM3	(KBr):
				solution				C═O
								1697.3;
								1641.3

EXAMPLE A43

1-[N 2 -(3,5-dichloro-D-tyrosyl)-N 6 -[(1,1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

A solution of 6 g (7.9 mmol) of 1-[N 2 -[N-[(phenylmethoxy)carbonyl]-3,5-dichloro-D-tyrosyl]-N 6 -[(1,1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine in a mixture of 200 ml of methanol and 20 ml of aqueous 1 M potassium hydrogen sulphate solution was hydrogenated in the presence of 0.5 g palladium black as catalyst at room temperature under 3 bar of hydrogen pressure for 40 minutes. The catalyst was filtered off, the reaction mixture was evaporated to dryness in vacuo and the residue adjusted to a pH of about 10 by the addition of 2 ml of concentrated aqueous ammonia solution. The product was extracted several times with isopropanol, the combined isopropanel extracts were evaporated down in vacuo and the residue was purified by column chromatography (LiChroprep, Si60 particle size: 20-40 μm, Messrs. Merck (Darmstadt); eluant: methylene chloride/methanol/ammonia=350/75/75/10 (v/v/v/v)). 2.5 g (51% of theory) of a colourless amorphous solid substance were obtained.

IR(KBr): 1641, 1705 cm −1 (C═O)

R f : 0.27 (FM1)

EXAMPLE A44

Preparation of compounds of general formula:

Fmoc-A-NR 3 R 4

1-[N 2 -[(9-fluorenylmethoxy)carbonyl]-N G -(2,2,5,7,8-pentamethylchroman-6-sulphonyl)-L-arginyl]-4-(4-pyridinyl)-piperazine

To a mixture of 7.0 g (10.6 mmol) of Fmoc-Arg(Pmc)-OH, 1.42 g (11.0 mmol) of DIEA, 3.53 g (11.0 mmol) of TBTU, 1.35 g (11.0 mmol) of HOBt and 50 ml of DMF was added dropwise with stirring a solution of 1.74 g (10.6 mmol) of 1-(4-pyridinyl)-piperazine in 20 ml of DMF. The reaction mixture was stirred for a further 3.5 hours at room temperature and then evaporated down at 40° C. in a high vacuum. The residue was dissolved in ethyl acetate, the organic phase was washed twice with saturated aqueous sodium hydrogen carbonate solution, dried over sodium sulphate and evaporated down in vacuo. The residue was triturated with diethylether, suction filtered and dried. 7.85 g (96% of theory) of the desired end product were obtained, which was reacted without further purification.

R f : 0.5 (FM1)

The following was prepared analogously:

			%
	A	NR 3 R 4	Yield	R f	Eluant	IR [cm −1 ]
	A3	C18	60	0.55	FM4	(KBr): C═O
						1643; 1711

EXAMPLE A45

Preparation of compounds of general formula:

H-A-NR 3 R 4

1-[N G -(2,2,5,7,8-pentamethylchroman-6-sulphonyl)-L-arginyl]-4-(4-pyridinyl)-piperazine

A solution of 8.5 g (11.1 mmol) of 1-[N 2 -[(9-fluorenylmethoxy)carbonyl]-N G -(2,2,5,7,8-pentamethylchroman-6-sulphonyl)-L-arginyl]-4-(4-pyridinyl)-piperazine in 100 ml of THF was mixed with 16 ml of diethylamine and then stirred for 2.5 hours at room temperature. The reaction mixture was evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: FM1). 3.3 g (54% of theory) of an amorphous solid were obtained.

R f :=0.19(FM1)

IR(KBr) 1637 cm −1 (C=O)

The following was prepared analogously:

			%
	A	NR 3 R 4	Yield	R f	Eluant	IR [cm −1 ]
	A3	C18	80			(KBr): C═O
						1637.5; 1705

EXAMPLE A46

1-[N 6 ,N 6 -dimethyl-N 2 -[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

9.6 g (18.3 mmol) of 1-[N 6 -[(1,1-dimethylethoxy)carbonyl]-N 2 -[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine were stirred overnight in 200 ml of a 5% solution of trifluoroacetic acid in dichloromethane. The reaction mixture was then evaporated down in vacuo. 13.47 g (97% of theory) of the desired 1-[N 2 -[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine were obtained as the trifluoroacetate salt. Then 7.0 g (9.1 mmol) of the crude product were dissolved in 200 ml of water and 4.1 ml of a 40% formaldehyde solution (45.6 mmol) were added whilst cooling with an ice bath. The reaction mixture was stirred for 10 minutes at room temperature, carefully mixed with 1.5 g (40 mmol) of sodium borohydride whilst cooling with an ice bath, then mixed with 4.1 ml of a 40% formaldehyde solution (45.6 mmol) whilst cooling externally with ice, after which the reaction mixture was stirred for a further 10 minutes at room temperature and again mixed with 1.5 g (40 mmol) of sodium borohydride whilst cooling with an ice bath. The pH of the reaction mixture was monitored continuously during the reaction and kept between pH 3 and pH 6 by dropwise addition of trifluoroacetic acid. The mixture was then stirred for 30 minutes at 5° C., adjusted to pH 10 by the addition of potassium carbonate and extracted four times with 50 ml of ethyl acetate. The combined organic phases were dried, evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol/conc. aqueous ammonia=6.5/3/0.3 (v/v/v)). 2.3 g (56% of theory) of a colourless oil were obtained.

IR(KBr): 1711, 1649 cm −1 (C═O)

R f : 0.2 (FM7)

ESI-MS: (M+H) + =454

EXAMPLE A47

Preparation of compounds of general formula:

methyl (R,S)-4-amino-3,5-dibromo-γ-oxo-β-[[4-(4-pyridinyl)-1-piperidinyl]methyl]-benzenebutanoate

A mixture of 10 g (27 mmol) of methyl 4-amino-3,5-dibromo-γ-oxo-benzenebutanoate, 5.4 g (27 mmol) of 4-(4-pyridinyl)-piperidine and 1.5 g (45 mmol) of paraformaldehyde was suspended in 20 ml of glacial acetic acid and heated with stirring in an oil bath (bath temperature: 100° C.). After 3 hours a further 1.5 g (45 mmol) of paraformaldehyde were added and the mixture was stirred for a further 3 hours at 100° C. and then for 1 hour at 125° C. The solvent was removed in vacuo and the residue was taken up in 800 ml of water. The aqueous phase was made alkaline by the addition of sodium carbonate and extracted twice with 500 ml of ethyl acetate. The combined ethyl acetate extracts were dried, evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol=9:1)). 1.0 g (6.8% of theory) of the desired end product were obtained as an oil.

IR(KBr): 1716.5 cm−1

R f : 0.7 (FM1)

The following was prepared analogously:

		%
A	NR 3 R 4	Yield	R f	Eluant	IR [cm −1 ]
AS4	C8	35	0.68	FM1	(KBr): C═O
					1672.2; 1733.9

EXAMPLE A48

Preparation of compounds of general formula:

(R,S)-4-amino-3,5-dibromo-γ-oxo-β-[[4-(4-pyridinyl)-1-piperidinyl]methyl]-benzenebutanoic acid

A mixture of 1.0 g (1.9 mmol) of methyl (R,S)-4-amino-3,5-dibromo-γ-oxo-β-[[4-(4-pyridinyl)-1-piperidinyl]methyl]-phenylbutanoate, 5 ml of 1 N sodium hydroxide solution and 50 ml of dioxane was stirred overnight at room temperature and for 1 hour at 60° C. The reaction mixture was then neutralised by the addition of 5 ml of 1 N hydrochloric acid, evaporated down in vacuo and the residue was dried in a vacuum drying chamber. 0.97 g (100% of theory) of the desired product was obtained, which was further reacted without any purification.

R f : 0.15 (FM1)

The following was prepared analogously:

			%
	A	NR 3 R 4	Yield	R f	Eluant	IR [cm −1 ]
	AS4	C8	96	0.2	FM1	(KBr): C═O
						1660

EXAMPLE A49

3,5-dibromo-4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid

To a solution of 12 g (0.043 mol) of 4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid in 200 ml of acetic acid were added 150 ml of water and 8 g of sodium acetate, a solution of 5 ml of bromine in 60 ml of acetic acid was added dropwise with stirring, then the reaction mixture was extensively evaporated down in vacuo and the residue was stirred into water. The aqueous phase was repeatedly extracted with ethyl acetate, and the combined organic phases were washed with water. The organic extracts were dried, evaporated down in vacuo and the solid residue was recrystallised from diisopropylether. 12 g (70% of theory) of the desired end product were obtained.

R f : 0.4 (ethyl acetate/petroleum ether/glacial acetic acid=5/5/0.4 (v/v/v)

ESI-MS: (M+H) + =394/6/8 (Br 2 )

EXAMPLE A50

Preparation of compounds of general formula:

methyl (R,S)-2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]-4-oxo-butanoate

A solution of 2.0 g (5 mmol) of 3,5-dibromo-4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid in 80 ml of THF was mixed with 1.6 g (5 mmol) of TBTU, 0.76 g (5 mmol) of HOBt, 1.25 g (5 mmol) of 4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)piperidine and 1.03 g (8 mmol) of DIEA with stirring. The reaction mixture was stirred for 6 hours at room temperature and then evaporated down in vacuo. The residue was mixed with saturated aqueous sodium hydrogen carbonate solution and extracted several times with ethyl acetate. The combined organic extracts were washed successively with saturated aqueous sodium hydrogen carbonate solution and water, dried over sodium sulphate and evaporated down in vacuo. 3.0 g (50% of theory) of the desired product was obtained, which was further reacted without purification.

IR(KBr): 1714.8 cm −1 (C═O)

R f : 0.7 (ethyl acetate/petroleum ether=7/3 (v/v))

The following were prepared analogously:

RCO	R 2	% Yield	MS	R f	Eluant	IR [cm −1 ]
N66	AS1	98		0.66	FM1
N66	AS2	100		0.77	FM1	(KBr): C═O
						1664/1734
N139	AS2	100	EI: M + =	0.30	FM1	(KBr): C═O
			486			1643/1672/1732
N66	AS4	28	EI: M + =	0.33	FM4	(KBr): C═O
			606/08/10			1666/1734
			(Br 2 )
N66	AS36	63		0.56	FM4
N66	AS38	92
N66	AS48	100		0.68	FM1
N66	AS18	22
N66	AS39	100
N109	AS21	39		0.35	EE	(KBr): C═O
						1639/1734
N113	AS21	57		0.15	EE/PE
					95/5
N134	AS21	80		0.15	EE
N66	AS7	100		0.75	FM1
N66	AS53	40

EXAMPLE A51

(R)-1-[2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propyl]-4-(1-piperidinyl)-piperidine

To a suspension of 3.8 g (100 mmol) of lithium aluminium hydride in 400 ml of THF were added in batches, with stirring and at room temperature, 14.4 g (20 mmol) of 1-(3,5-dibromo-D-tyrosyl)-4-(1-piperidinyl)-piperidine within 30 minutes. The reaction mixture was kept for 30 minutes at room temperature and refluxed for 2 hours and then neutralised by the careful addition of 1 ml of water and 5.1 ml of concentrated aqueous hydrochloric acid. After the addition of 100 ml of methanol the solid precipitate was suction filtered and the filtrate was evaporated down in vacuo. The residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: methylene chloride/methanol/conc. aqueous ammonia=8/2/0.2 (v/v/v)). 5.4 g (57% of theory) of the desired product was obtained as an amorphous solid.

IR (KBr): 3420 cm −1 (NH 2 )

R f : 0.4 (FM2)

ESI-MS: M + =473/475/477 (Br 2 )

The following was prepared analogously:

(R)-1-[2-amino-3-(4-amino -3,5-dibromophenyl)propyl]-4-1-piperidinyl)-piperidine from 1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(1-piperidinyl)-piperidine in a yield of 56.5%. of theory, R f 0.12 (eluant: dichloromethane/methanol/cyclohexane/conc. ammonia 7/1.5/1.5/0.2 (v/v/v/v)).

EXAMPLE A52

(R)-1-[3-(4-amino-3,5-dibromophenyl)-2-[N-[(1,1-dimethylethoxy)carbonyl]amino]propyl]-4-(1-piperidinly)-piperidne

To a solution of 10 g (0.017 mol) of 1-[4-amino-3,5-dibromo-N-[(1,1-dimethylethoxy)carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine in 350 ml of dioxane were added 3.1 g (0.082 mol) of sodium borohydride and the reaction mixture was cooled to 5° C. Then a solution of 4.92 g (0.082 mol) of acetic acid in 100 ml of dioxane was added dropwise with stirring. The reaction mixture was stirred for a further hour at room temperature and for 3 hours at 85° C. Then ice water was added, the organic solvent was removed in vacuo and the aqueous residue was repeatedly extracted with methylene chloride. The combined organic phases were dried, evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: methylene chloride/methanol/cyclohexane/conc. aqueous ammonia=3600/150/150/20 (v/v/v/v). 4.1 g (42% of theory) of a colourless foam were obtained.

IR(KBr): 1705 cm −1 (C═O)

EXAMPLE A53

(R)-1-[2-amino-3-(4-amino-3,5-dibromophenyl)propyl]-4-(1-piperdinyl)-piperidine

To a mixture of 4 g (7 mmol) of (R)-1-[3-(4-amino-3,5-dibromophenyl)-2-[N-[(1,1-dimethylethoxy)carbonyl]-amino]propyl]-4-(1-piperidinyl)-piperidine and 100 ml of methylene chloride, 40 ml of trifluoroacetic acid were slowly added dropwise, with stirring, at 10° C. The reaction mixture was stirred for 2 hours at room temperature and then evaporated down in vacuo. The residue was mixed with ice water, made basic by the addition of concentrated aqueous ammonia solution and extracted three times with 200 ml of diethylether. The combined ether extracts were dried and evaporated down in vacuo. 3.4 g (100% of theory) of an amorphous solid were obtained.

IR(KBr): 1683.8, 1616.3 (C═O)

R f : 0.02 (FM 4)

EXAMPLE A54

methyl (R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[[3-(trifluoromethyl)phenyl]-methyl]-butanoate

Prepared analogously to Example A15a) from methyl (R,S)-3-carboxy-2-[[3-(trifluoromethyl)phenyl]methyl]-propanoate and 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone in a yield of 27.3% of theory. Colourless, amorphous substance, R f =0.25 (eluant: ethyl acetate).

MS: M + =503

The following was obtained in the same way:

methyl (R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-butanoate from methyl (R,S)-3-carboxy-2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-propanoate and 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone in a yield of 98% of theory, R f =0.66 (eluant: dichloromethane/cyclohexane/methanol conc. ammonia 7/1.5/1.5/0.2 (v/v/v/v)).

EXAMPLE A55

(R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-butanoic acid

A mixture of 3.0 g (4.92 mmol) of methyl (R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-butanoate, 30 ml (30 mmol) of 1N sodium hydroxide solution and 20 ml of methanol was stirred for 3 hours at room temperature, then diluted with 100 ml of water and 30 ml of 1N hydrochloric acid were added dropwise. The precipitate was suction filtered and dried at 50° C. in a circulating air drier. Colourless, amorphous substance , R f =0.38 (eluant: dichloromethane/methanol/glacial acetic acid 9/1/0.15 (v/v/v)). Yield: 2.5 g (85.4% of theory).

The following was obtained in the same way:

(R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl-4-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-butanoic acid from methyl (R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-butanoate in a yield of 79% of theory, R f =0.34 (eluant: ethyl acetate/glacial acetic acid 99.8/0.2 (v/v)).

IR(KBr): 1703, 1643 cm −1 (C═O)

EXAMPLE A56

Methyl 3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-1-N-methyl-D-tyrosine

a) 1-(chlorocarbonyl)-4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]piperidine

To a mixture of 7.0 ml (about 14 mmol) of a 20% solution of phosgene in toluene and 2.02 g (20 mmol) of triethylamine in 300 ml of tetrahydrofuran was added in batches, while maintaining a reaction temperature of about 0° C., a suspension of 1.5 g (5.60 mmol) of 4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]piperidine-hydrochloride in 100 ml of tetrahydrofuran. The mixture was stirred for another hour at a temperature between 0° C. and +5° C., filtered to remove the resulting triethylamine-hydrochloride and the filtrate was freed from solvent. The residue was triturated with diisopropyl ether and suction filtered. After drying in vacuo 0.7 g (42.6% of theory) of colourless crystals were obtained, R f =0.17 (eluant: dichloromethane/acetone 9.5/0.5 (v/v)), which was further processed without any further purification.

b) Methyl 3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-N-methyl-D-tyrosine

To a solution of 4.9 g (13.3 mmol) of methyl 3,5-dibromo-N-methyl-D-tyrosine and 4.04 g (40 mmol) of triethylamine in 500 ml of tetrahydrofuran was added dropwise, at room temperature, within 3 hours, a solution of 3.92 g (13.34 mmol) of 1-(chlorocarbonyl)-4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]piperidine in 1 l tetrahydrofuran. The mixture was then heated for 12 hours to reflux temperature, left to cool and filtered to remove the precipitated triethylamine. The filtrate was evaporated down, the residue was divided between ethyl acetate and 20% aqueous citric acid. The organic phase was dried over sodium sulphate, again evaporated down in vacuo, the residue was purified by column chromatography over silica gel using ethyl acetate/petroleum ether 9/1 (v/v) as eluant. Working up the appropriate fractions yielded 3.2 g (38.5% of theory) of a colourless, amorphous substance, R f =0.45 (eluant: ethyl acetate).

IR(KBr): 1739.7, 1660.6 cm −1 (C═O)

ESI-MS: (M+H) + =623/625/627 (Br 2 ) (M+Na) + =645/647/649 (Br 2 ) (M+K) + =661/663/665 (Br 2 )

EXAMPLE A57

Methyl 3,5-dibromo-4-methoxy-D-phenylalanine

To a mixture of 5.5 g (14.12 mmol) of 3,5-dibromo-4-methoxy-D-phenylalanine-hydrochloride and 55 ml of methanol were added 150 ml of a saturated methanolic hydrogen chloride solution and the mixture was stirred for 20 hours at room temperature. The residue remaining after evaporation of the solvent was stirred with 50 ml of water and adjusted to pH 8 with saturated sodium hydrogen carbonate solution. The precipitate was suction filtered, stirred with 10 ml of isopropanol and left to stand overnight. The insoluble matter was filtered off and the filtrate was evaporated down in vacuo. The residue was further reacted as a crude product. Yield: 1.0 g (28.7% of theory) of a colourless oil , R f =0.55 (eluant: dichloromethane/ethyl acetate/cyclohexane/methanol/conc. ammonia=300/80/25/25/3 (v/v/v/v/v)).

EXAMPLE A58

1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(4-pyrimidinyl)piperazine

a) 1-(2-chloro-4-pyrimidinyl)-4-(phenylmethyl)piperazine

A mixture of 9.9 g (0.0664 mol) of 2,4-dichloropyrimidine, 200 ml of water and 11.7 ml (0.0673 mol) of 1-(phenylmethyl)piperazine was heated to 40° C. for 2 hours in an ultrasound bath. After cooling the mixture was made alkaline with potassium carbonate and extracted thoroughly with ethyl acetate. The crude product obtained after working up in the usual way was purified by column chromatography over silica gel (30-60 μm) using FM2 and FM4 (2/1 v/v) as eluant. Working up the appropriate fractions yielded 7.4 g (38.6% of theory) of a colourless oil, R f =0.51 (FM4; Macherey-Nagel POLYGRAMO® SIL G/UV 254 , ready-made films for TLC).

MS: M + =288/290 (Cl)

b) 1-(4-pyrimidinyl)piperazine

A solution of 7.4 g (0.0256 mol) of 1-(2-chloro-4-pyrimidinyl)-4-(phenylmethyl)piperazine in 100 ml of ethanol was hydrogenated in the presence of 2 g of 10% palladium/charcoal for 4 hours at 40° C. under 5 bar of hydrogen pressure. The crude product obtained after conventional working up was purified by column chromatography over silica gel (30-60 μm) using FM1/cyclohexane 9/1 (v/v) as eluant. Colourless crystals, R f =0.3 (FM1/cyclohexane 9/1 (v/v)); Macherey-Nagel POLYGRAM® SIL G/UV 254 , ready-made films for TLC). Yield: 1.7 g (40.7% of theory).

c) 1-[4-amino-3,5-dibromo-N-(1,1-dimethylethoxycarbonyl)-D-phenylalanyl)-4-(4-pyrimidinyl)piperazine

Prepared analogously to Example A15a) from 4-amino-3,5-dibromo-N-(1,1-dimethylethoxycarbonyl)-D-phenylalanine and 1-(4-pyrimidinyl)piperazine in the presence of TBTU in a yield of 92% of theory. Colourless, amorphous substance, R f =0.42 (FM4; Macherey-Nagel POLYGRAM® SIL G/UV 254 , ready-made films for TLC).

IR(KBr): 1705.0, 1643.3 cm −1 (C═O)

MS: M + =582/584/586 (Br 2 )

d) 1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(4-pyrimidinyl)piperazine

Prepared analogously to Example A1b) from 1-[4-amino-3,5-dibromo-N-(1,1-dimethylethoxycarbonyl)-D-phenylalanyl)-4-(4-pyrimidinyl)piperazine in a yield of 52% of theory. Colourless, amorphous substance, R f =0.55 (FM1; Macherey-Nagel POLYGRAM® SIL G/UV 254 , ready-made films for TLC).

IR(KBr): 1681.8 cm −1 (C═O)

MS: M + =482/484/486 (Br 2 )

EXAMPLE A59

Preparation of compounds of general formula:

(R,S)-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidin]-2-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-oxobutanoic acid

A mixture of 4.8 g (8.3 mMol) of ethyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-(1,1-dimethylethyl)phenyl]methyl]-2-(ethoxycarbonyl)-4-oxobutanoate, 200 ml of ethanol and 41.5 ml of 1N sodium hydroxide solution was refluxed for 3 hours. The ethanol was removed in vacuo, then the residue was diluted with 50 ml of water and adjusted to pH 3 with 1N aqueous hydrochloric acid. The precipitated substance was suction filtered, thoroughly washed with water and then dried in vacuo. 3.8 g (96% of theory) of colourless crystals of Mp. 139 141° C. were obtained, R f =0.65 (eluant: EE/MeOH/glacial acetic acid 90/10/1 v/v/v).

IR(KBr): 1724, 1647 cm −1 (C═O)

MS: no M + , m/e=246, 231, 147

The following were prepared analogously:

R 2	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
AS29		100
AS16		17	ESI: (M + H) + =	0.30	EE/MeOH/
			488/90/92 (Cl 2 )		AcOH 80/10/1
AS5		62		0.60	CH 2 Cl 2 /MeOH/
					NH 4 OH 90/10/1
AS32		100	ESI: (M + Na) + =	0.67	EE/MeOH/	(KBr): C═O
			614/6/8 (Br 2 )		AcOH 90/10/1	1645/1728
AS33		90	EI: M + = 525	0.20	EE/MeOH/	(KBr): C═O
					AcOH 90/10/1	1643/1701
AS31		100		0.20	CH 2 Cl 2 /MeOH/
					NH 4 OH 80/20/1
AS17		100	ESI: (M + H) + =	0.50	EE/MeOH/	(KBr): C═O
			608/10/12 (Br 2 )		AcOH 90/10/1	1643
AS34		76	ESI: (M − H) − =	0.65	EE/MeOH/
			506		AcOH 90/10/1
AS19		70		0.46	EE/MeOH/	(KBr): C═O
					AcOH 9/1/0.5	1643/1701
AS46		78	ESI: (M − H) − =	0.20	FM1	(KBr): C═O
			471			1647
AS50		97		0.05	EE
AS2	LiOH instead	86	ESI: (M + H) + =			(KBr): C═O
	of NaOH		472			1643/1705
AS29		100	ESI: (M − H) − =			(KBr): C═O
			448			1645/1705
AS31		87

EXAMPLE A60

Preparation of compounds of general formula:

Ethyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-(1,1-dimethylethyl)phenyl]methyl]-2-(ethoxycarbonyl)-4-oxobutanoate

A mixture of 2.31 g (10 mMol) of 4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-piperidine, 3.64 g (10 mMol) of β,β-bis(ethoxycarbonyl)-4-(1,1-dimethylethyl)-benzenebutanoic acid, 5 ml of triethylamine, 3.5 g (11 mMol) of TBTU, 200 ml of tetrahydrofuran and 20 ml dimethylformamide was stirred for 5 hours at room temperature. The solvent was removed in vacuo and the residue taken up in dichloromethane, the resulting solution was dried over sodium sulphate and freed from the solvent. After purification by column chromatography on 400 g of silica gel (Amicon, 35-70 μm, ethyl acetate as eluant), 4.8 g (83% of theory) of a colourless, amorphous substance were obtained, R f =0.63 (eluant: EE).

IR(KBr): 1734, 1668, 1653 cm −1 (C═O)

MS: M + =577 (Br 2 )

The following were prepared analogously:

	%
R 2	Yield	MS	R f	Eluant	IR [cm −1 ]
AS29	75		0.8	FM1
AS16	59		0.5	EE
AS5	65	EI: M + =	0.7	FM4	(KBr): C═O
		677/79/81			1649/1668/
		(Br 2 )			1734
AS32	74		0.5	FM4	(KBr): C═O
					1647/1668/
					1734
AS33	85		0.5	EE	(KBr): C═O
					1649/1734
AS31	82	EI: M + = 574	0.5	CH 2 Cl 2 /MeOH/	(KBr): C═O
				NH 4 OH 90/10/1	1658/1741
AS17	93	EI: M + =	0.5	EE	(KBr): C═O
		707/09/11			1645/1666/
		(Br 2 )			1736/1759
AS34	75	EI: M + = 607	0.8	EE	(KBr): C═O
					1649/1668/
					1736
AS19	67		0.8	FM1	(KBr): C═O
					1647/1668/
					1734
AS46	80	EI: M + = 572	0.8	FM1	(KBr): C═O
					1737
AS50	78	EI: M + =	0.6	EE	(KBr): C═O
		677/9/81 (Br 2 )			1645/1666/
					1730
AS2	51

EXAMPLE A61

Preparation of compounds of general formula:

β,β-bis-(ethoxycarbonyl)-1-methyl-1H-indol-3-butanoic acid

Produced analogously to Example A1b) from tert.-butyl β,β-bis(ethoxycarbonyl)-1-methyl-1H-indol-3-butanoate through the action of trifluoroacetic acid in dichloromethane in a yield of 63.5% of theory. Colourless crystals of Mp. 127-130° C. (diisopropylether).

IR(KBr): 1738, 1712 cm −1 (C═O)

The following were prepared analogously:

R 2	% Yield	MS	R f	Eluant	IR [cm −1 ]
AS29	100
AS16	100		0.7	EE/MeOH/
				AcOH
				97.5/2.2/0.25
AS5	100		0.5	PE/EE 2/1
AS32	100		0.58	PE/EE 2/1	(KBr): C═O
					1759/1711
AS33	100				(KBr): C═O
					1736
AS17	52				(KBr): C═O
					1707/1726/
					1755
AS34	90		0.8	EE/MeOH/	(KBr): C═O
				AcOH	1705/1743
				97.5/2.5/0.25
AS19	100		0.76	PE/EE/	(KBr): C═O
				AcOH 6/3/1	1738
AS46	92		0.35	FM1	(KBr): C═O
					1732
AS50	71				(KBr): C═O
					1712/1734/
					1759
AS2	31	EI: M + = 272	0.42	PE/EE/	(KBr): C═O
				AcOH 6/4/0.2	1711/1734

EXAMPLE A62

Preparation of compounds of general formula:

Tert.-butyl β,β-bis-(ethoxycarbonyl)-3,5-dimethylbenzene-butanoate

To a solution of 13.8 g (50.2 mMol) of diethyl [(1,1-dimethylethoxycarbonyl)methyl]-malonoate in 400 ml of anhydrous tetrahydrofuran, 2.3 g (52.7 mMol) of sodium hydride was added whilst being externally cooled with iced water. After stirring for 30 minutes, and maintaining a reaction temperature of 0 to +5° C., the solution of 10.0 g (50.2 mMol) of 3,5-dimethylbenzylbromide in 80 ml tetrahydrofuran was added dropwise and the mixture allowed to warm to room temperature within 14 hours. The reaction mixture was freed from the solvent in vacuo, 200 ml of 10% citric acid was added to the residue and the resulting mixture was thoroughly extracted with ethyl acetate. After the usual working up, the combined extracts yielded 19.7 g (100% of theory) of a colourless oil of R f =0.67 (eluant: dichloromethane), which was used in the following steps without further purification.

The following were prepared analogously:

R 2	Remarks	% Yield	MS	R f	Eluant	IR [cm −1 ]
AS29		100
AS16		62		0.6	CH 2 Cl 2
AS5		91	ESI: (M + H) + =	0.8	PE/EE	(KBr): C═O
			521/3/5 (Br 2 )		2/1	1734
AS32		96		0.76	PE/EE	(KBr): C═O
					2/1	1734
AS33		78		0.55	CH 2 Cl 2	(KBr): C═O
						1736
AS31	with use of 3-	74	EI: M + = 417	0.7	toluene/	(KBr): C═O
	(dimethylaminomethyl)-				t-BME 4/1	1734
	1-methyl-1H-indol-
	methoiodide
AS17		70	EI: M + =	0.5	CH 2 Cl 2	(KBr): C═O
			550/52/54 (Br 2 )			1734
AS34		93	EI: M + = 450	0.5	CH 2 Cl 2 /	(KBr): C═O
					PE 1/1	1736
AS19		87		0.89	CH 2 Cl 2	(KBr): C═O
						1736
AS46		54	EI: M + = 415	0.7	FM4
AS50		60	EI: M + =	0.7	CH 2 Cl 2	(KBr): C═O
			520/22/24 (Br 2 )			1734

EXAMPLE A63

(phenylmethyl)-β,β-bis-(ethoxycarbonyl)-4-(1,1-dimethylethyl)benzenebutanoate

Prepared analogously to Example A62 from diethyl[(phenylmethoxycarbonyl)methyl]-malonoate and 4-(1,1-dimethylethyl)benzylbromide in the presence of sodium hydride in a yield of 53% of theory.

Colourless oil of R f =0.21 (eluant: dichloromethane/petroleum ether 2/1 v/v).

IR(KBr): 1738 cm −1 (C═O)

EXAMPLE A64

Methyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(1-methylethoxy)phenyl]methyl]-4-oxobutanoate

To a solution of 2.0 g (4.43 mMol) of methyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3-hydroxyphenyl)methyl]-4-oxobutanoate in 30 ml of anhydrous dimethylformamide, 0.2 g (4.4 mMol) of a 55% suspension of sodium hydride in paraffin oil was added. After stirring for 30 minutes at room temperature, 0.5 ml (4.8 mMol) of isopropyliodide was added dropwise, and kept for two hours each at room temperature and at 70° C. The residue remaining after removal of the volatile constituents was divided between water and ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried over magnesium sulphate and was again evaporated down. The raw product was purified by column chromatography on silica gel (60 μm), first using dichloromethane, later methanol/conc. ammonia (9/1 v/v) as eluants. Yield was 0.9 g (42% of theory) of a colourless, amorphous substance of R f =0.32 (FM4).

IR(KBr): 1734, 1668 cm −1 (C═O)

MS: M + =493

In the same way, methyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3-ethoxyphenyl)methyl]-4-oxobutanoate was obtained from methyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3-hydroxyphenyl)methyl]-4-oxobutanoate and ethyliodide in a yield of 67% of theory. Colourless, amorphous substance of R f =0.29 (FM4).

IR(KBr): 1734, 1666 cm −1 (C=O)

MS: M + =479

EXAMPLE A65

β,β-bis-(ethoxycarbonyl)-4-(1,1-dimethylethyl)-benzenebutanoic acid

Prepared analogously to example A58b) from phenyl methyl β,β-bis-(ethoxycarbonyl)-4-(1,1-dimethylethyl)-benzenebutanoate by catalytic hydrogenation in the presence of palladium/charcoal in a yield of 95% of theory. Colourless, highly-viscous oil of R f =0.16 (eluant: dichloromethane).

IR(KBr): 1739 cm −1 (C═O)

EXAMPLE A66

1-methyl-4-[(1-piperazinyl)carbonyl]-piperazine-bis-(trifluoroacetate)

a) 4-[[4-(1,1-dimethylethoxycarbonyl)-1-piperazinyl]carbonyl]-1-methylpiperazine

To a solution of 1.1 g of triphosgene (3.7 mMol) in 20 ml of dichloromethane, a mixture of 1.2 g (10 mMol) of 1-methyl-piperazine, 0.38 ml (22 mMol) of DIEA and 35 ml of dichloromethane was added dropwise at room temperature within 30 minutes, and then the solution of 1.9 g (10 mMol) of 1-(1,1-dimethylethoxycarbonyl)piperazine and 0.38 ml of DIEA in 20 ml dichloromethane were added. After stirring for an hour at room temperature, insoluble matter was filtered off and the filtrate evaporated down in vacuo. After purification of the raw product on silica gel (Amicon, 35-70 μm), using dichloromethane/methanol/conc. ammonia(80/20/1 v/v/v) for elution, 700 mg (22% of theory) of colourless crystals were obtained of Mp. 130° C.

IR(KBr): 1691, 1641 cm −1 (C═O)

b) 1-methyl-4-[(1-piperazinyl)carbonyl]-piperazine-bis-(trifluoroacetate)

Prepared analogously to Example A1b), but omitting the treatment with aqueous ammonia, from 4-[[4-(1,1-dimethylethoxycarbonyl)-1-piperazinyl]carbonyl]-1-methylpiperazine and trifluoroacetic acid in a yield of 99.6% of theory. Colourless, amorphous substance of R f =0.17 (eluant: dichloromethane/methanol/conc. ammonia 50/50/0.5).

IR(KBr): 1678 cm −1 (C═O)

MS: M + =212

EXAMPLE A67

1-[4-[4-(dimethylamino)butyl]phenyl]-piperazine-dihydrochloride

a) N,N-dimethyl-4-fluoro-γ-oxobenzenebutanoic acid amide

To a solution of 30.5 g (0.155 Mol) of 4-fluoro-γ-oxobenzenebutanoic acid in 470 ml tetrahydrofuran, 35.0 g (0.216 Mol) of N,N′-carbonyldiimidazole was added with stirring and at room temperature and held at room temperature for a further 2.5 hours. Then, 13.7 g (0.304 Mol) of dimethylamine was added under strong external cooling by means of an ice-ethanol mixture. After the mixture had stood at room temperature for 12 hours, the solvent was removed in vacuo, the residue was divided between dichloromethane and 10% aqueous citric acid solution, the organic phase was dried over sodium sulphate and once again evaporated down in vacuo. After purification by column chromatography (eluant: ethyl acetate) on silica gel the crude product yielded 30.22 g (87% of theory) of colourless crystals of

R f =0.31 (eluant: ethyl acetate/glacial acetic acid 99.99/0.01).

IR(KBr): 1680, 1647 cm −1 (C═O)

b) N,N-dimethyl-γ-oxo-4-[4-(phenylmethyl)-1-piperazinyl]-benzenebutanoic acid amide

The mixture of 33.48 g (0.15 Mol) of N,N-dimethyl-4-fluoro-γ-oxobenzenebutanoic acid amide, 29.6 g (0.168 Mol) of 1-(phenylmethyl)piperazine and 6 ml of DIEA was refluxed for 6 hours. Another 30 g (0.17 Mol) of (phenylmethyl)piperazine was added, and the mixture was refluxed for a further 7 hours. The mixture was taken up in a little dichloromethane, and purified by column chromatography on silica gel, using dichloromethane/methanol/conc. ammonia 99/1/0.5 for elution. The residue obtained from the appropriate fractions was stirred with diisopropylether, the formed crystals were then recrystallised from ethanol. 42.22 g (74% of theory) of colourless crystals were obtained, R f =0.69 (eluant: dichloromethane/methanol/conc. ammonia 95/5/0.5 v/v/v).

IR(KBr): 1662, 1643 cm −1 (C═O)

c) 4-[4-[4-(dimethylamino)-1-hydroxybutyl]phenyl]-1-(phenylmethyl)piperazine

Prepared analogously to example A51 from N,N-dimethyl-γ-oxo-4-[4-(phenylmethyl)-1-piperazinyl]-benzenebutanoic acid amide by reduction with lithium aluminium hydride in a yield of 61% of theory. Colourless, amorphous substance of R f =0.62 (eluant: ethyl acetate/methanol 1/1 v/v).

MS: M + =367

d) 1-[4-[4-(dimethylamino)butyl]phenyl]-piperazine-dihydrochloride

Prepared analogously to example A20b) from 4-[4-[4-(dimethyl-amino)-1-hydroxybutyl]phenyl]-1-(phenylmethyl)piperazine by catalytic hydrogenation in the presence of palladium/charcoal and hydrochloric acid in a quantitative yield. Colourless, amorphous substance of Rf 0.37 (eluant: ethyl acetate/methanol 50/50/0.5 v/v/v).

B. PREPARATION OF THE FINAL COMPOUNDS

EXAMPLE 1

Preparation of compounds of general formula:

1-[N-[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-4-(4-pyridinyl)-piperazine (No. 83)

A mixture of 2 g (3.44 mmol) of 3,5-dibromo-N 2 -[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]-carbonyl]-D-tyrosine, 0.59 g (3.6 mmol) of 1-(4-pyridinyl)-piperazine, 1.27 g (3.96 mmol) of TBTU, 0.47 g (3.44 mmol) of HOBt, 0.7 ml (3.96 mmol) of DIEA and 100 ml tetrahydrofuran was stirred overnight at ambient temperature. The reaction mixture was extracted once with saturated aqueous saline solution, twice with saturated aqueous sodium hydrogen carbonate solution and again with saturated aqueous saline solution. The organic phase was dried, evaporated down in vacuo and the crude product was then purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol=9/1/(v/v/)). 550 mg (22% of theory) of an amorphous solid were obtained.

IR(KBr): 1601, 1636, 1696 cm −1 (C═O)

R f : 0.67 (FM2)

ESI-MS: (M+H) + =726/728/730 (Br 2 )

The following were prepared analogously (in each case n=1):

							%
No.	RCO	Z	R 2	A	NR 3 R 4	Remarks	Yield	MS	R f	Eluant	IR [cm −1 ]
	N6	N—H	AS1	A3	C4		88	ESI: (M + H) + =	0.8	FM1	(KBr): C═O
								928/30/32 (Br 2 )			1629.8; 1708.8
193	N15	N—H	AS6	A0	C7	DMF as solvent	26	ESI: (M + H) + =	0.9	EE/MeOH/AcOH	(KBr): C═O
								647/9 (Br)		75/23/2 v/v/v	1693.4; 1622.0
194	N66	N—H	AS1	A0	C67		49	ESI: (M + H) + =	0.33	FM1	(KBr): C═O
								828/30/32 (Br 2 )			1622/1664
202	N15	N—H	AS1	A0	C36	DMF as solvent;	9	ESI: (M + H) + =	0.49	FM1	(KBr): C═O
						DIEA		733/5/7 (Br 2 )			1695.3;1622.0
											NH 3417.7
203	N15	N—H	AS1	A0	C29	DMF as solvent;	41	ESI: (M − H) − =	0.58	EE/MeOH	(KBr): C═O
						DIEA		718/20/22 (Br 2 )		9/1 v/v	1695.3
204	N15	N—H	AS1	A0	C30	DMF as solvent;	27	ESI: (M + H) + =	0.1	FM1	(KBr): C═O
						DIEA		691/3/5 (Br 2 )			1695.3; 1624.0
205	N15	N—H	AS6	A0	C8	DMF as solvent;	23	ESI: (M + H) + =	0.46	FM1	(KBr): C═O
						DIEA		653/5 (Br)			1695.3; 1622.0
206	N15	N—H	AS1	A0	C31	DMF as solvent;	33	ESI: (M + H) + =	0.25	FM1	(KBr): C═O
						DIEA		717/19/21 (Br 2 )			1695.3; 1624.0
207	N15	N—H	AS1	A0	C32	DMF as solvent;	55	ESI: (M − H) − =	0.46	FM1	(KBr): C═O
						DIEA		780/2/4 (Br 2 )			1690; 1650
212	N15	N—H	AS1	A7	C1	DMF as solvent;	37	ESI: (M + H) + =	0.27	FM1	(KBr): C═O
						DIEA		882/4/6 (Br 2 )			1697.3; 1639.4
											NH 3423.4
217	N15	N—H	AS6	A3	C1		51		0.9	FM1	(KBr): C═O
											1693.4; 1641.3
222	N15	N—H	AS1	A0	C27	THF/DMF 1/1	10	ESI: (M + H) + =	0.35	FM1	(KBr): C═O
						as solvent;		774/6/8 (Br 2 )			1695.3
						NEt 3 as base
286	N15	N—H	AS1	A0	C28	THF/DMF 1/1	9	ESI: (M + H) + =	0.4	FM1	(KBr): C═O
						as solvent;		706/8/10			1699.2
						NEt 3 as base		(Br 2 )
81	N15	N—H	AS4	A0	C4		64	ESI: (M + H) + =	0.75	FM1	(KBr): C═O
								724/6/8 (Br 2 );			1618.2; 1703.0
								(M + Na) + =
								746/48/50 (Br 2 )
82	N15	N—H	AS4	A0	C1		53	ESI: (M + H) + =	0.55	FM3	(KBr): C═O
								725/7/9 (Br 2 )			1620.1; 1703.0
84	N66	N—H	AS21	A0	C68		31	ESI: (M + H) + =	0.52	FM1	(KBr): C═O
								683			1608/1628/1666
85	N15	N—H	AS4	A0	C7		42	ESI: (M + H) + =	0.8	FM1	(KBr): C═O
								724/6/8 (Br 2 );			1618.2; 1697.3;
								(M + Na) + =			—NH—, —NH 2 3379.1
								746/48/50 (Br 2 )
90	N15	N—H	AS1	A0	C8		40	ESI: (M + H) + =	0.78	FM2	(KBr): C═O
								731/3/5 (Br 2 )			1624.0; 1697.3
	N2	N—H	AS2	A3	C1	DMF as solvent;	73	ESI: (M + H) + =	0.42	FM1	(KBr): C═O
						DIEA		766			1654.2; 1708.8
354	N15	N—H	AS1	A0	C4		21	ESI: (M + H) + =	0.76	FM2	(KBr): C═O
								725/7/9 (Br 2 );			1622.0; 1695.3;
								(M + Na) + =			—OH, —NH— 3417.7
								747/49/51 (Br 2 )
98	N15	N—H	AS1	A0	C9		60	ESI: (M + H) + =	0.41	FM2	(KBr): C═O
								580/2/4 (Br 2 ):			1624.0; 1685.7;
								(M − H) − =			—OH, —NH— 3421.5
								578/80/82 (Br 2 );
								(M + Na) + =
								602/4/6 (Br 2 )
102	N15	N—H	AS1	A0	C12		43	ESI: (M + H) + =	0.76	FM2	(KBr): C═O
								636/38/40 (Br 2 );			1622.0; 1695.3;
								(M + Na) + =
								658/60/62 (Br 2 )
99	N15	N—H	AS1	A0	C10		54	ESI: (M + H) + =	0.61	FM2	(KBr): C═O
								663/5/7 (Br 2 )			1622.9; 1700.9;
											—OH,—NH— 3421.5
100	N15	N—H	AS1	A0	C11		54	ESI: (M + H) + =	0.5	FM2	(KBr): C═O
								746/48/50 (Br 2 )			1624.0; 1695.3;
											—NH—, —OH 3423.4;
101	N15	N—H	AS1	A0	C7		62	ESI: (M + H) + =	0.82	FM2	(KBr): C═O
								725/7/9 (Br 2 );			1622.0; 1695.3;
								(M + Na) + =			—OH, —NH— 3253.7
								747/49/51 (Br 2 )
103	N15	N—H	AS1	A0	C13		37	ESI: (M + H) + =	0.72	FM2	(KBr): C═O
								679/81/83 (Br 2 )			1625.9; 1693.4; 1666.4;
											—OH, —NH— 3409.9
106	N15	N—H	AS1	A0	C14		72	ESI: (M + H) + =	0.66	FM1	(KBr): C═O
								832/4/6 (Br 2 );			1674.1; 1689.5
								(M + Na) + =
								854/6/8 (Br 2 )
104	N15	N—H	AS6	A0	C4		36	ESI: (M + H) + =	0.71	FM1	(KBr): C═O
								647/9 (Br);			1695.3
								(M + Na) + =
								669/71 (Br);
								(M − H) − =
								645/7 (Br)
105	N15	N—H	AS6	A0	C1		25	ESI: (M + H) + =	0.25	FM3	(KBr): C═O
								648/50 (Br)			1695.3
	N2	N—H	AS1	A12	C1	DMF as solvent;	72	ESI: (M + H) + =	0.4	FM1	KBr: C═O
						DIEA		1082/4/6 (Br 2 )			1641
199	N15	N—H	AS3	A0	C8	THF/DMF =	86	ESI: (M + H) + =	0.37	ethyl acetate/	KBr: C═O
						9/1 (v/v)		643/5/7 (Br 2 )		methanol/	1697; 1624
						as solvent				petroleum ether =
										1/2/1 (v/v/v)
200	N15	N—H	AS3	A0	C1		40	ESI: (M + H) + =	0.45	ethyl acetate/	KBr: C═O
								638/40/42 (Br 2 )		methanol/	1695; 1636
										petroleum ether =
										1/2/1 (v/v/v)
419	N66	N—H	AS21	A0	C38		28	ESI: (M + H) + =	0.1	FM1	(KBr): C═O
								682			1628/1662
425	N66	N—H	AS1	A0	C36		42	ESI: (M + H) + =	0.4	FM1	(KBr): C═O
								747/49/51 (Br 2 )			1624/1657
426	N66	N—H	AS4	A0	C30		66	ESI: (M + H) + =	0.45	FM1	(KBr): C═O
								704/6/8 (Br 2 )			1618/1663
427	N66	N—H	AS1	A0	C31		38	ESI: (M + H) + =	0.2	FM1	(KBr): C═O
								731/3/5 (Br 2 )			1630/1653
428	N66	N—H	AS4	A0	C36		40	ESI:(M + H) + =	0.6	FM1	(KBr): C═O
								746/48/50 (Br 2 )			1618/1662
429	N66	N—H	AS1	A0	C30		47	ESI: (M + H) + =	0.15	FM1	(KBr): C═O
								705/7/9 (Br 2 )			1635/1653
435	N66	N—H	AS4	A0	C31		20	ESI: (M + H) + =	0.55	FM1	(KBr): C═O
								730/2/4 (Br 2 )			1608/1631
436	N66	N—H	AS1	A0	C11		15	ESI: (M + H) + =	0.1	FM1	(KBr): C═O
								760/2/4 (Br 2 )			1624/1653
437	N66	N—H	AS4	A0	C11		25	ESI: (M + H) + =	0.5	FM1	(KBr): C═O
								759/61/63 (Br 2 )			1622/1661
438	N66	N—H	AS4	A0	C54		13	ESI: (M + H) + =	0.7	FM1	(KBr): C═O
								744/6/8 (Br 2 )			1620/1660
439	N66	N—H	AS1	A0	C54		31	ESI: (M + H) + =	0.5	FM1	(KBr): C═O
								745/7/9 (Br 2 )			1626/1661
443	N122	N—H	AS1	A0	C11		44	ESI: (M + H) + =	0.1	FM1	(KBr): C═O
								790/2/4 (Br 2 )			1624/1680
444	N122	N—H	AS1	A0	C8		62	ESI: (M + H) + =	0.18	FM1	(KBr): C═O
								775/7/9 (Br 2 )			1624/1678
445	N122	N—H	AS1	A0	C1		60	ESI: (M + H) + =	0.2	FM1	(KBr): C═O
								770/2/4 (Br 2 )			1630/1680
446	N122	N—H	AS1	A0	C20		59	ESI: (M + H) + =	0.15	FM1	(KBr): C═O
								789/91/93 (Br 2 )			1622/1680
447	N122	N—H	AS4	A0	C1		54	ESI: (M + H) + =	0.6	FM1	(KBr): C═O
								769/71/73 (Br 2 )			1622/1682
448	N122	N—H	AS4	A0	C20		68	ESI: (M + H) + =	0.5	FM1	(KBr): C═O
								788/90/92 (Br 2 )			1620/1682
449	N122	N—H	AS4	A0	C8		59	ESI: (M + H) + =	0.58	FM1	(KBr): C═O
								774/6/8 (Br 2 )			1620/1682
450	N66	N—CH 3	AS1	A0	C4		36	ESI: (M + H) + =	0.39	FM1	(KBr): C═O
								753/5/7 (Br 2 )			1653
451	N66	CH 2	AS1	A0	C1		20	ESI: (M + H) + =	0.3	FM1	(KBr): C═O
								739/41/43 (Br 2 )			1638
452	N71	CH 2	AS1	A0	C1		16	ESI: (M + H) + =	0.4	FM1	(KBr): C═O
								751/53/55 (Br 2 )			1638/1680
453	N66	CH 2	AS1	A0	C11		17	ESI: (M + H) + =	0.13	FM1	(KBr): C═O
								758/60/62 (Br 2 )			1636
454	N66	CH 2	AS1	A0	C20		33	ESI: (M + H) + =	0.23	FM1	(KBr): C═O
								757/59/61 (Br 2 )			1632
455	N71	CH 2	AS1	A0	C8		35	EI: M + =	0.42	FM1	(KBr): C═O
								755/7/9 (Br 2 )			1624/1684
457	N71	CH 2	AS1	A0	C4		49	ESI: (M + H) + =	0.77	FM1	(KBr): C═O
								750/2/4 (Br 2 )			1626/1682
458	N71	CH 2	AS1	A0	C37		25	ESI: (M + H) + =	0.2	FM1	(KBr): C═O
								769/71/73 (Br 2 )			1638/1682
459	N66	CH 2	AS1	A0	C37		50	EI: M + =	0.2	FM1	(KBr): C═O
								757/59/61 (Br 2 )			1636
460	N66	N—H	AS1	A0	C55		72	ESI: (M + H) + =	0.27	EE/MeOH/	(KBr): C═O
								759/61/63 (Br 2 )		NH 4 OH =	1626/1661
										8/1.5/0.1 v/v/v
461	N66	N—H	AS1	A0	C56		77	ESI: (M + H) + =	0.77	FM1	(KBr): C═O
								731/3/5 (Br 2 )			1626/1661
462	N66	N—H	AS17	A0	C8		51	ESI: (M + H) + =	0.44	FM1	(KBr): C═O
								759/61/63 (Br 2 )			1628/1663
463	N66	N—H	AS18	A0	C1		59	ESI: (M + H) + =	0.7	FM1	(KBr): C═O
								704			1661
464	N66	N—H	AS18	A0	C8		51	ESI: (M + H) + =	0.76	FM1	(KBr): C═O
								709			1628/1663
465	N66	N—H	AS18	A0	C37		73	ESI: (M + H) + =	0.7	FM1	(KBr): C═O
								723			1628/1663
469	N66	N—H	AS19	A0	C8		34	ESI: (M + H) + =	0.34	FM1	(KBr): C═O
								651/53 (Br)			1626/1664
471	N66	N—H	AS20	A0	C8		41	ESI: (M + H) + =	0.68	FM1	(KBr): C═O
								649			1624/1684
472	N66	N—H	AS5	A0	C8		26	ESI: (M + H) + =	0.73	FM1	(KBr): C═O
								729/31/33 (Br 2 )			1626/1664
475	N66	N—H	AS18	A0	C20		58	ESI: (M + H) + =	0.22	FM1	(KBr): C═O
								723			1628/1664
476	N66	N—H	AS18	A0	C11		44	ESI: (M + H) + =	0.27	MeOH	(KBr): C═O
								724			1630/1662
478	N66	N—H	AS19	A0	C37		62	ESI: (M + H) + =	0.8	FM1	(KBr): C═O
								665/7 (Br)			1626/1662
479	N66	N—H	AS19	A0	C20		55	ESI: (M + H) + =	0.64	FM1	(KBr): C═O
								665/7 (Br)			1664
480	N66	N—H	AS19	A0	C4		55	ESI: (M + H) + =	0.77	FM1	(KBr): C═O
								645/7 (Br)			1628/1662
506	N66	N—H	AS21	A0	C20		46	ESI: (M + H) + =	0.75	FM1	(KBr): C═O
								655			1626/1664
507	N66	N—H	AS22	A0	C8		65	ESI: (M + H) + =	0.78	FM1	(KBr): C═O
								607/9 (Cl)			1624/1664
508	N66	CH 2	AS21	A0	C20		15	ESI: (M + H) + =	0.15	MeOH	(KBr): C═O
								654			1639/1670
246	N15	CH 2	AS1	A0	C8		19	ESI: (M + H) + =	0.35	EE/MeOH/	(KBr): C═O
								730/2/4 (Br 2 )		NH 4 OH	1635/1707
										9/1/0.5 v/v/v
285	N15	CH 2	AS1	A0	C4		42	ESI: (M + H) + =	0.45	EE/MeOH/	(KBr): C═O
								724/6/8 (Br 2 )		NH 4 OH	1684/1711
										9/1/0.5 v/v/v
289	N66	CH 2	AS1	A0	C8		40	ESI: (M + H) + =	0.38	EE/MeOH/	(KBr): C═O
								744/6/8 (Br 2 )		NH 4 OH	1635/1668
										9/1/0.5 v/v/v
290	N66	CH 2	AS1	A0	C4		30	ESI: (M + H) + =	0.45	EE/MeOH/	(KBr): C═O
								738/40/42 (Br 2 )		NH 4 OH	1634/1664
										9/1/0.5 v/v/v
511	N66	N—H	AS23	A0	C8	DMF	80	ESI: (M + H) + =	0.57	FM1	(KBr): C═O
								603			1664/1626
512	N66	N—H	AS23	A0	C11	DMF	60	ESI: (M + H) + =	0.30	FM1	(KBr): C═O
								618			1645
513	N66	N—H	AS23	A0	C1	DMF	54	ESI: (M + H) + =	0.50	FM1	(KBr): C═O
								598			1662/1712
514	N66	N—H	AS23	A0	C38	DMF	65	ESI: (M + H) + =	0.20	FM1	(KBr): C═O
								644			1664/1626/1712
515	N66	N—H	AS23	A0	C40	DMF	7	ESI: (M + H) + =	0.40	FM1	(KBr): C═O
								632			1630/1662
527	N66	N—H	AS25	A0	C8		49	ESI: (M + H) + =	0.48	FM1	(KBr): C═O
								594			1647
528	N66	N—H	AS25	A0	C1		29	ESI: (M + H) + =	0.48	FM1	(KBr): C═O
								589			1646
529	N66	CH 2	AS2	A0	C8		27	ESI: (M + H) + =	0.50	FM1	(KBr): C═O
								622			1635/1668/1716
530	N66	CH 2	AS2	A0	C20		5	EI: M + = 635	0.49	FM1	(KBr): C═O
											1637/1668/1714
531	N66	CH 2	AS23	A0	C8		30	EI: M + = 601	0.50	FM1
	N66	CH 2	AS23				95
538	N139	CH 2	AS2	A0	C20		49	EI: M + = 636	0.30	FM1	(KBr): C═O
											1635/1674
539	N139	CH 2	AS2	A0	C53		52	EI: M + = 637	0.30	FM1	(KBr): C═O
											1637/1674
540	N139	CH 2	AS2	A0	C8		60		0.37	FM1	(KBr): C═O
											1635/1674
541	N66	CH 2	AS27	A0	C53		32	EI: M + = 630	0.65	FM1	(KBr): C═O
											1639/1670
542	N66	CH 2	AS27	A0	C8		32	EI: M + = 615	0.80	FM1	(KBr): C═O
											1639/1670
543	N66	CH 2	AS27	A0	C20		21	EI: M + = 629	0.59	FM1	(KBr): C═O
											1639/1672
544	N66	CH 2	AS28	A0	C20		35	EI: M + = 643	0.50	FM1	(KBr): C═O
											1641/1670
545	N66	CH 2	AS28	A0	C53		54	EI: M + = 644	0.50	FM1	(KBr): C═O
											1639/1670
546	N66	CH 2	AS28	A0	C8		53	EI: M + = 629	0.60	FM1	(KBr): C═O
											1639/1672
547	N66	CH 2	AS29	A0	C8		14	EI: M + = 599	0.53	FM1	(KBr): C═O
											1630
548	N66	CH 2	AS29	A0	C53		12	EI: M + = 614	0.48	FM1
549	N66	CH 2	AS29	A0	C20		15	EI: M + = 613	0.48	FM1	(KBr): C═O
											1637/1668
550	N66	CH 2	AS30	A0	C53		4		0.48	FM1
574	N66	CH 2	AS16	A0	C20		55	EI: M + =	0.80	CH 2 Cl 2 /MeOH/	(KBr): C═O
								653/5/7 (Cl 2 )		NH4OH 80/20/1	1635/1670
575	N66	CH 2	AS16	A0	C53		54	EI: M + =	0.20	EE/MeOH/	(KBr): C═O
								654/6/8 (Cl 2 )		NH 4 OH 70/30/3	1635/1668
578	N66	CH 2	AS5	A0	C53		32	EI: M + =	0.30	FM5	(KBr): C═O
								742/4/6 (Br 2 )			1637/1670
579	N66	CH 2	AS5	A0	C20		37	EI: M + =	0.50	FM5	(KBr): C═O
								741/3/5 (Br 2 )			1635/1670
589	N66	CH 2	AS32	A0	C53		49	EI: M + =	0.33	FM5	(KBr): C═O
								756/58/60 (Br 2 )			1639/1670
590	N66	CH 2	AS32	A0	C20		36	EI: M + =	0.47	FM5	(KBr): C═O
								755/7/9 (Br 2 )			1658/1672
591	N66	CH 2	AS33	A0	C20		43	EI: M + = 689	0.40	EE/MeOH/	(KBr): C═O
										NH 4 OH 50/50/0.5	1637/1670
592	N66	CH 2	AS33	A0	C53		52	EI: M + = 690	0.20	EE/MeOH/	(KBr): C═O
										NH 4 OH 70/30/5	1633/1668
593	N66	CH 2	AS16	A0	C29		11	EI: M + =	0.65	EE/MeOH	(KBr): C═O
								628/30/32 (Cl 2 )		9/1	1606/1637/
											1668/1728
594	N66	CH 2	AS16	A0	C73		48	EI: M + =	0.50	EE/MeOH	(KBr): C═O
								628/30/32 (Cl 2 )		9/1	1637/1668/1736
595	N66	CH 2	AS16	A0	C74		10	EI: M + =	0.30	EE/MeOH
								597/99/601 (Cl 2 )		NH 4 OH 50/50/0.5
597	N66	CH 2	AS31	A0	C53		25	EI: M + = 639	0.30	CH 2 Cl 2 /MeOH/	(KBr): C═O
										NH 4 OH 90/10/1	1635/1668
598	N66	CH 2	AS31	A0	C20		31	EI: M + = 638	0.10	CH 2 Cl 2 /MeOH/	(KBr): C═O
										NH 4 OH 90/10/0.3	1635/1668
600	N73	CH 2	AS31	A0	C20		10	ESI: (M + H) + =	0.15	CH 2 Cl 2 /MeOH/	(KBr): C═O
								551		NH 4 OH 90/10/1	1628
602	N66	CH 2	AS17	A0	C53		56	EI: M + =	0.25	EE/MeOH/	(KBr): C═O
								772/4/6 (Br 2 )		NH 4 OH 50/50/0.5	1637/1668
603	N66	CH 2	AS16	A0	C33		93	EI: M + =	0.75	EE/MeOH/	(KBr): C═O
								600/02/04 (Br 2 )		AcOH 70/30/1	1635/1716
604	N66	CH 2	AS17	A0	C20		47	EI: M + =	0.20	EE/MeOH/	(KBr): C═O
								771/3/5 (Br 2 )		NH 4 OH 50/50/0.5	1635/1668
605	N66	CH 2	AS34	A0	C53		70	EI: M + = 672	0.25	EE/MeOH/	(KBr): C═O
										NH 4 OH 60/40/0.5	1633/1666
606	N66	CH 2	AS34	A0	C20		45	EI: M + = 671	0.15	EE/MeOH/	(KBr): C═O
										NH 4 OH 50/50/0.5	1635/1668
607	N66	N—H	AS21	A0	C40		27	ESI: (M + H) + =	0.65	FM1	(KBr): C═O
								670			1608/1628/1664
608	N66	N—H	AS21	A0	C11		34	ESI: (M + H) + =	0.50	FM1	(KBr): C═O
								656			1606/1628/1664
609	N66	N—H	AS21	A0	C8		30	ESI: (M + H) + =	0.80	FM1	(KBr): C═O
								641			1626/1664
610	N66	N—H	AS21	A0	C1		55	ESI: (M + H) + =	0.80	FM1	(KBr): C═O
								636			1635/1662
611	N66	N—H	AS21	A0	C4		80	ESI: (M + H) + =	0.70	FM1	(KBr): C═O
								635			1606/1628/1664
612	N66	CH 2	AS4	A0	C8		43	EI: M + =	0.85	FM1	(KBr): C═O
								742/4/6 (Br 2 )			1668/1631/1606
613	N66	N—H	AS22	A0	C20		62	ESI: (M + H) + =	0.73	FM1	(KBr): C═O
								621/23 (Cl)			1626/1664
614	N66	N—H	AS22	A0	C37		55	ESI: (M + H) + =	0.68	FM1	(KBr): C═O
								621/23 (Cl)			1626/1664
615	N66	N—H	AS22	A0	C56		77	ESI: (M + H) + =	0.76	FM1	(KBr): C═O
								593			1628/1664
616	N66	CH 2	AS36	A0	C8		32	ESI: (M + H) + =	0.76	FM1	(KBr): C═O
								585			1637/1668
617	N66	CH 2	AS21	A0	C37		15	EI: M + = 653	0.15	MeOH	(KBr): C═O
											1639/1670
618	N66	CH 2	AS21	A0	C38		24	EI: M + = 680	0.10	MeOH	(KBr): C═O
											1639/1670
628	N66	CH 2	AS21	A0	C8		31	EI: M + = 639	0.25	MeOH	(KBr): C═O
											1639/1670
629	N66	CH 2	AS21	A0	C11		43	EI: M + = 654	0.10	MeOH	(KBr): C═O
											1641/1668
630	N66	CH 2	AS21	A0	C1		74	EI: M + = 634	0.10	MeOH	(KBr): C═O
											1641/1668
631	N66	CH 2	AS21	A0	C28		63	EI: M + = 614	0.30	MeOH	(KBr): C═O
											1666
634	N66	CH 2	AS38	A0	C8		35	ESI: (M + H) + =	0.25	MeOH	(KBr): C═O
								622			1635/1668
635	N66	CH 2	AS48	A0	C8		40	EI: M + = 639	0.68	FM1	(KBr): C═O
											1643/1670
636	N66	N—H	AS49	A0	C20		25	ESI: (M + H) + =	0.40	EE/MeOH/	(KBr): C═O
								632		NH 4 OH 9/1/0.5	1664
637	N66	CH 2	AS4	A0	C20		11	ESI: (M + H) + =	0.60	FM1	(KBr): C═O
								757/59/61 (Br 2 )			1635/1668
638	N66	CH 2	AS48	A0	C20		11	ESI: (M + H) + =	0.66	FM1	(KBr): C═O
								654			1641/1668
639	N66	CH 2	AS18	A0	C20		4	EI: M + = 721	0.10	MeOH	(KBr): C═O
											1637/1670
640	N66	CH 2	AS39	A0	C20		38	EI: M + = 645	0.80	CH 2 Cl 2 /MeOH/	(KBr): C═O
										NH 4 OH 8/2/0.3	1635/1670
641	N66	CH 2	AS38	A0	C20		49	EI: M + = 635	0.80	CH 2 Cl 2 /MeOH/	(KBr): C═O
										NH 4 OH 8/2/0.3	1635/1668
642	N66	CH 2	AS39	A0	C8		45	EI: M + = 631	0.10	EE/MeOH/	(KBr): C═O
										NH 4 OH 9/1/0.3	1635/1670
	N66	CH 2	AS21	A0	C69		70	EI: M + = 739			(KBr): C═O
											1684
644	N109	CH 2	AS21	A0	C20		46	ESI: (M + H) + =	0.10	MeOH	(KBr): C═O
								659			1643
645	N66	CH 2	AS19	A0	C20		21	EI: M + =	0.53	FM1	(KBr): C═O
								763/5 (Br)			1669/1634
646	N66	CH 2	AS19	A0	C8		45	EI: M + =	0.60	FM1	(KBr): C═O
								649/651 (Br)			1637/1668
653	N113	CH 2	AS21	A0	C20		55	EI: M + = 666	0.60	FM1	(KBr): C═O
											1630/1701
654	N134	CH 2	AS21	A0	C20		22	EI: M + = 690	0.60	FM1	(KBr): C═O
											1714
655	N66	CH 2	AS46	A0	C20		43	EI: M + = 636	0.50	FM1	(KBr): C═O
											1630/1664
656	N66	CH 2	AS46	A0	C8		71	EI: M + = 622	0.60	FM1	(KBr): C═O
											1635
657	N66	CH 2	AS47	A0	C20		63	EI: M + = 639	0.50	FM1	(KBr): C═O
											1635/1668/1716
658	N66	CH 2	AS50	A0	C20		70	ESI: (M + H) + =	0.20	EE/MeOH/	(KBr): C═O
								741/3/5 (Br 2 )		NH 4 OH 50/50/0.5	1635/1668
659	N66	CH 2	AS50	A0	C53		60	ESI: (M + H) + =	0.20	EE/MeOH/	(KBr): C═O
								743/5/7 (Br 2 )		NH 4 OH 50/50/0.5	1635/1668
660	N66	CH 2	AS46	A0	C53		41	EI: M + =637	0.65	FM1	(KBr): C═O
											1630
661	N66	CH 2	AS7	A0	C8		75	EI: M + = 615	0.70	FM1	(KBr): C═O
											1626/1660
662	N66	CH 2	AS7	A0	C53		41	EI: M + = 630	0.55	FM1	(KBr): C═O
											1628/1662
663	N66	CH 2	AS7	A0	C20		78	EI: M + = 629	0.60	FM1	(KBr): C═O
											1628/1662
664	N66	CH 2	AS52	A0	C8		66	EI: M + = 629	0.75	FM1	(KBr): C═O
											1635
665	N66	CH 2	AS52	A0	C53		37	EI: M + = 644	0.70	FM1	(KBr): C═O
											1633/1664
666	N66	CH 2	AS52	A0	C20		61	EI: M + = 643	0.80	FM1	(KBr): C═O
											1635/1664
667	N66	CH 2	AS2	A0	C53		47	EI: M + = 636	0.60	FM1	(KBr): C═O
											1630/1664
	N66	CH 2	AS2	A0	C69		78		0.75	FM1
669	N66	CH 2	AS32	A0	C71		44	EI: M + =	0.20	EE/MeOH/	(KBr): C═O
								834/6/8 (Br 2 )		NH 4 OH 50/50/0.5	1641/1670
670	N66	CH 2	AS51	A0	C20	Preliminary	47	EI: M + = 641	0.15	EE/MeOH/	(KBr): C═O
						stage special				NH 4 OH 50/50/0.5	1635/1664
						cases
671	N66	CH 2	AS51	A0	C53		45	EI: M + = 642	0.15	EE/MeOH/	(KBr): C═O
										NH 4 OH 50/50/0.5	1637/1670
672	N66	CH 2	AS16	A0	C76		55	EI: M + =	0.66	FM1	(KBr): C═O
								689/91/93 (Cl 2 )			1635

EXAMPLE 2

Preparation of compounds of general formula:

1-[N 2 -[4-amino-N-[[4-(2-chlorophenyl)-1-piperazinyl]-carbonyl]-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)piperazine-bis-(trifluoroacetate) (No. 61)

A mixture of 0.56 g (1.0 mmol) of 4-amino-N 2 -[[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-3.5-dibromo-D-phenylalanine, 0.41 g (1.05 mmol) of 1-[N 6 -(1.1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine, 0.35 g (1.10 mmol) of TBTU, 0.14 g (1.0 mmol) of HOBt, 0.2 ml (1.10 mmol) of DIEA and 100 ml of dimethylformamide was stirred overnight at ambient temperature. The reaction mixture was evaporated down in vacuo and divided between methylene chloride and saturated aqueous sodium hydrogen carbonate solution. The organic phase was then extracted once with saturated aqueous sodium hydrogen carbonate solution and with water, dried and evaporated down in vacuo. The crude product was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol=8/2 (v/v/)), taken up in 30 ml of methylene chloride and stirred with 3 ml of trifluoroacetic acid for 3 hours at ambient temperature. The reaction mixture was evaporated down in vacuo, the residue was triturated with ether and the obtained amorphous solid (0.43 g, 37% of theory) was suction filtered.

IR (KBr): 1643, 1678 cm −1 (C═O)

R f : 0.6 (FM1)

ESI-MS: (M+H) + =832/834/836/838 (Br 2 ,Cl)

The following were prepared analogously (in each case n=1):

No.	RCO	R 2	A	NR 3 R 4	% Yield	MS	R f	Eluant	IR [cm −1 ]
48	N6	AS1	A1	C3	79	ESI: M + H =	0.3	FM1	(KBr): C═O
						946/48/50			1652.9; 1674.1
						(Br 2 )
213	N15	AS6	A1	C8	14.7	ESI: M + H =	0.45	FM2	(KBr): C═O
						781/3 (Br)			1691.5; 1629.8
49	N8	AS4	A1	C1	57.14	ESI: M + H =	0.5	FM1	(KBr):C═O
						757/59/61			1643.3; 1676.0
						(Br 2 )
58	N15	AS4	A1	C4	21	ESI: M + H =	0.57	FM1	(KBr): C═O
						852/4/6 (Br 2 )			1635.5; 1695.3
59	N15	AS4	A1	C1	45.6	ESI: M + H =	0.44	FM1	(KBr): C═O
						853/5/7 (Br 2 )			1635.5; 1695.3
60	N23	AS4	A1	C4	19.2	ESI: M + H =	0.65	FM1	(KBr): C═O
						831/3/5/7			1633.6
						(Br 2 , Cl)
61	N23	AS4	A1	C1	36.6	ESI: M + H =	0.6	FM1	(KBr): C═O
						832/4/6/8			1643.3; 1678.0
						(Br 2 , Cl)

EXAMPLE 3

Preparation of compounds of general formula:

1-[N 2 -[3,5-dibromo-N-[[[(2-methoxyphenyl)methyl]amino]-carbonyl]-D,L-tyrosyl]-N 6 -(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

A tetrahydrofuran solution (50 ml) of 1.0 g (1.34 mmol) of 1-[N 2 -(3,5-dibromo-D-tyrosyl)-N 6 -(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine was added dropwise over a period of 40 minutes to a suspension of 0.33 g (2.01 mmol) of CDT in 50 ml of tetrahydrofuran cooled to −10 ° C. and stirred. The reaction mixture was then stirred for 2 hours at ambient temperature and mixed with 0.22 ml (1.675 mmol) of 2-methoxybenzenethanamine. Then the mixture was refluxed for 2 hours and stirred overnight at ambient temperature. The reaction mixture was evaporated down in vacuo, the residue was triturated with ether and the solid obtained (1.1 g; 90% of theory) was suction filtered and dried.

IR (KBr): 1641, 1717 cm −1 (C═O)

ESI-MS: (M+H) + =908/910/912 (Br 2 ) (M+H+Na) ++ =466.7 (Br 2 )

The following were prepared analogously:

%

Mp.

No.

RCO

R 2

n

X

A

NR 3 R 4

Remarks

Yield

MS

R f

Eluant

IR [cm −1 ]

(° C.)

195

N15

AS1

1

O

A3

C8

21

ESI: (M + H) + =

0.8

FM7

(KBr): C═O

959/61/63

1699.2

(Br 2 )

1635.5

196

N51

AS1

1

O

A3

C8

26.1

ESI: (M + H) + =

0.85

FM7

(KBr): C═O

929/31/33

1710; CN

(Br 2 )

2219.8

201

N101

AS4

1

O

A0

C8

DIEA

34

ESI: (M + H) + =

0.58

FM1

(KBr): C═O

746/8/50

1693.4

(Br 2 )

1618.2

215

N15

AS1

1

O

A0

C34

NEt 3 as

92

ESI: (M − H) − =

0.36

FM1

(KBr): C═O

base

778/80/82

1695.3

(Br 2 )

216

N15

AS1

1

O

A0

C35

NEt 3 as

69

ESI: (M − H) − =

0.3

FM1

(KBr): C═O

base

779/81/82

1701.1

(Br 2 )

221

N15

AS4

1

O

A7

C1

NEt 3 as

39

ESI: (M + H) + =

0.38

FM1

(KBr): C═O

base

881/3/5

1697.3;

(Br 2 )

1637.5

288

N85

AS1

1

O

A0

C8

THF/DMF

30

ESI: (M + H) + =

0.3

MeOH

(KBr): C═O

as solvent;

749/51/53

1683.8;

NEt 3 as

(Br 2 )

1624.0

base

OH 3429.2

293

N66

AS1

1

O

A9

C1

DIEA

11

ESI: (M + H) + =

0.4

FM1

(KBr): C═O

910/2/4

1645.2

(Br 2 )

295

N66

AS1

1

O

A7

C1

NEt 3 as

70

ESI: (M + H) + =

0.45

FM1

(KBr): C═O

base

896/8/900

1716.5

(Br 2 )

1647.1

303

N86

AS4

1

O

A0

C8

DIEA

20

ESI: (M + H) + =

0.7

FM 2

(KBr): C═O

747/9/51

1618.2

(Br 2 )

304

N87

AS4

1

O

A0

C8

THF as

30

ESI: (M + H) + =

0.75

FM1

(KBr): C═O

solvent;

802/4/6

1720.4

NEt 3 as

(Br 2 )

1668.3;

base

1620.1

NH, NH 2

3431.2;

3379.1

305

N88

AS4

1

O

A0

C8

DIEA

45

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

782/4/6

1616; SO2

(Br 2 )

1323.1

1151.4

308

N90

AS4

1

O

A0

C8

DIEA

27

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

750/2/4

1637.5

(Br 2 )

80

N15

AS1

1

O

A3

C1

62

ESI: (M + H) + =

0.8

FM2

(KBr): C═O

954/6/8

1697.3;

(Br 2 )

1639.4

N8

AS1

1

O

A3

C1

66

ESI: (M + H) + =

0.22

EtOAc/

(KBr): C═O

858/60/62

methanol =

1641.3

(Br 2 )

6/4 (v/v)

N9

AS1

1

O

A3

C1

59

ESI: (M + H) + =

0.22

EtOAc/

(KBr): C═O

888/90/92

methanol =

1652.9

(Br 2 )

6/4 (v/v)

N2

AS1

1

O

A4

C1

40

ESI: (M + H) + =

0.45

FM1

(KBr): C═O

922/4/6 (Br 2 );

1641.3;

(M + Na) + =

1710.8;

944/6/8 (Br 2 )

OH, NH

3396.4

N4

AS1

1

O

A4

C1

73

ESI: (M + H) + =

0.13

FM1

(KBr): C═O

952/4/6 (Br 2 )

1641.3;

1714.6

62

N15

AS1

1

O

A3

C5

purified by

65

ESI: (M + H) + =

0.27

FM1

(KBR): C═O

column

1003/5/7 (Br 2 );

1685.7;

chromato-

(M + Na) + =

1635.5; OH,

graphy: silica

1025/7/9 (Br 2 )

NH: 3419.6

gel/FM4

N15

AS1

1

O

A3

C6

purified by

86

ESI: (M + H) + =

0.45

FM1

(KBr): C═O

column

983/5/7 (Br 2 )

1695.3,

chromato-

1633.6

graphy: silica

gel/FM4

73

N15

AS5

1

O

A3

C1

purified by

64

ESI: (M + H) + =

0.75

FM1

(KBr):

column

938/40/42 (Br 2 )

C═O 1699.2;

chromato-

1641.3

graphy: silica

gel/FM4;

diastereo-

mers

78

N45

AS5

1

O

A3

C1

purified by

44

ESI: (M + H) + =

0.73

FM1

(KBr): C═O

column

952/4/6 (Br 2 )

1712.7,

chromato-

1637.5; —NH—

graphy: silica

3300.0

gel/FM4;

diastereo-

mers

110

N15

AS4

1

O

A0

C5

purified by

82

ESI: (M + H) + =

0.79

FM1

(KBr): C═O

column

725/7/9 (Br 2 )

1620.1;

chromato-

1514.0

graphy: silica

gel/FM4

111

N15

AS4

1

O

A0

C15

purified by

58

ESI: M + =

0.77

FM1

(KBr): C═O

column

726/28/30 (Br 2 )

1697.3;

chromato-

1620.1

graphy: silica

gel/FM4

114

N45

AS4

1

O

A0

C5

purified by

75

ESI: (M + H) + =

0.78

FM1

(KBr): C═O

column

739/41/43 (Br 2 )

1710.8;

chromato-

1620.1

graphy: silica

gel/FM4

112

N15

AS1

1

O

A0

C5

purified by

45

ESI: (M + H) + =

0.33

FM1

(KBr): C═O

column

726/28/30 (Br 2 )

1695.3;

chromato-

1624.0

graphy: silica

gel/FM4

115

N45

AS1

1

O

A0

C5

purified by

28

ESI: (M + H) + =

0.35

FM1

(KBr): C═O

column

740/2/4 (Br 2 )

1710.8;

chromato-

1622

graphy: silica

gel/FM4

113

N15

AS4

1

O

A0

C16

purified by

56

ESI: (M + H) + =

0.68

FM1

(KBr): C═O

173-176

column

726/8/30 (Br 2 )

1699.2;

chromato-

1618.2

graphy: silica

gel/FM4

119

N45

AS4

1

O

A0

C16

purified by

81

ESI: (M + H) + =

0.69

FM1

(KBr): C═O

148-152

column

762/4/6 (Br 2 )

1710.8;

chromato-

1618.2

graphy: silica

gel/FM4

120

N15

AS1

1

O

A0

C15

purified by

27

ESI: (M + H) + =

0.31

FM1

(KBr): C═O

173-175

column

749/51/53 (Br 2 )

1695.3

chromato-

graphy: silica

gel/FM4

128

N15

AS4

1

O

A0

C3

purified by

61

ESI: (M + Na) + =

0.72

FM1

(KBr): C═O

174-177

column

764/6/8 (Br 2 )

1699.2;

chromato-

1618.2

graphy: silica

gel/FM4

130

N15

AS4

1

O

A0

C6

purified by

60

ESI: (M + H) + =

0.7

FM1

(KBr): C═O

150-154

column

754/6/8 (Br 2 )

1703

chromato-

1620.1

graphy: silica

gel/FM4

129

N15

AS1

1

O

A0

C16

purified by

18

ESI: (M − H) − =

0.27

FM1

(KBr): C═O

173-176

column

725/7/9 (Br 2 )

1693.4;

chromato-

1627.8

graphy: silica

gel/FM4

131

N45

AS4

1

O

A0

C6

purified by

69

ESI: (M + H) + =

0.73

FM1

(KBr): C═O

159-162

column

768/70/72 (Br 2 )

1712.7;

chromato-

1620.1

graphy: silica

gel/FM4

132

N45

AS4

1

O

A0

C3

purified by

27

ESI: (M + Na) + =

0.72

FM1

(KBr): C═O

142-146

column

778/80/2 (Br 2 )

1712.7;

chromato-

1618.2

graphy: silica

gel/FM4

133

N15

AS1

1

O

A0

C6

purified by

24

ESI: (M + H) + =

0.33

FM1

(KBr): C═O

161-164

column

755/7/9 (Br 2 )

1697.3;

chromato-

1624.0

graphy: silica

gel/FM4

134

N15

AS4

1

O

A0

C18

purified by

69

ESI: (M + H) + =

0.59

FM1

(KBr): C═O

171-174

column

756/8/60 (Br 2 )

1699.2;

chromato-

1618.2

graphy: silica

gel/FM4

135

N15

AS1

1

O

A0

C18

Purified by

17

ESI: (M + H) + =

0.25

FM1

(KBr): C═O

74-77

column

757/9/61 (Br 2 )

1691.5; 1625.9

chromato-

graphy: silica

gel/FM4

N29

AS1

1

O

A3

C1

61

ESI: (M + H) + =

0.62

FM7

(KBr): C═O

903/5/7 (Br 2 )

1641.3

N36

AS1

1

O

A3

C1

33

ESI: (M + H) + =

0.49

FM7

(KBr): C═O

915/7/9 (Br 2 )

1641.3

44

N34

AS1

1

O

A3

C1

35

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

936/38/40/42

1641.3

(Br 3 )

378

N15

AS1

0

O

A3

C1

30

ESI: (M + H) + =

0.13

FM1

(KBr): C═O

940/2/4 (Br 2 )

1701.1; 1641.3

N48

AS1

1

O

A3

C1

52

0.58

FM7

(KBr): C═O

1641.3

N77

AS1

1

O

A3

C4

32

ESI: (M + H) + =

(KBr): C═O

955/7/9 (Br 2 )

1645; 1713

294

N66

AS4

1

O

A7

C1

NEt 3 as base

31

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

895/7/9 (Br 2 )

1653; 1772.5;

1716.5

323

N104

AS1

1

O

A0

C4

DIEA

18

ES: (M + H) + =

0.4

FM1

(KBr): C═O

799/801/803

1624

(Br 2 )

324

N105

AS1

1

O

A0

C4

DIEA

24

ESI: (M + H) + =

0.38

FM1

(KBr): C═O

773/5/7/9

1624/1667

(Br 2 /Cl)

325

N106

AS1

1

O

A0

C4

DIEA

22

ESI: (M + H) + =

0.35

FM1

(KBr): C═O

725/7/9 (Br 2 )

1626/1662.5

326

N71

AS1

1

O

A0

C1

DIEA

20

ESI: (M + H) + =

0.16

FM1

(KBr): C═O

752/4/6 (Br 2 )

1624/1680

327

N71

AS4

1

O

A0

C4

DIEA

24

ESI: (M + H) + =

0.48

FM1

(KBr): C═O

750/2/4 (Br 2 )

1618/1682

328

N107

AS1

1

O

A0

C4

DIEA

17

ESI: (M + H) + =

0.38

FM1

(KBr): C═O

769/71/73 (Br 2 )

1651

329

N108

AS4

1

O

A0

C4

DIEA

16

ESI: (M + H) + =

0.31

FM1

(KBr): C═O

781/83/85 (Br 2 )

1620/1674

330

N108

AS4

1

O

A0

C1

DIEA/DMF

15

ESI: (M + H) + =

0.45

FM1

(KBr): C═O

781/83/85 (Br 2 )

1620/1678

331

N108

AS4

1

O

A0

C20

DIEA/DMF

15

ESI: (M + H) + =

0.4

FM1

(KBr): C═O

800/802/804

1616/1680

(Br 2 )

332

N109

AS1

1

O

A0

C4

DIEA/DMF

39

ESI: (M + H) + =

0.32

FM1

(KBr): C═O

745/7/9 (Br 2 )

1665

333

N110

AS1

1

O

A0

C4

DIEA/DMF

52

ESI: (M + H) + =

0.34

FM1

(KBr): C═O

745/7/9 (Br 2 )

1636

334

N111

AS14

1

O

A0

C1

DIEA/DMF

18

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

649

1626/1688

335

N109

AS4

1

O

A0

C4

DIEA/DMF

46

ESI: (M + H) + =

0.47

FM1

(KBr): C═O

744/6/8 (Br 2 )

1618

336

N110

AS1

1

O

A0

C8

DIEA/DMF

25

ESI: (M + H) + =

0.22

FM1

(KBr): C═O

751/3/5 (Br 2 )

1645

337

N109

AS1

1

O

A0

C8

DIEA/DMF

32

ESI: (M + H) + =

0.21

FM1

(KBr): C═O

751/3/5 (Br 2 )

1645

338

N109

AS4

1

H2

A0

C8

DIEA/

38

ESI: (M + H) + =

0.44

FM1

(KBr): C═O

DMF

736/8/40 (Br 2 )

1653

339

N110

AS4

1

H2

A0

C8

DIEA/

39

ESI: (M + H) + =

0.44

FM1

(KBr): C═O

DMF

736/8/40 (Br 2 )

1653

340

N66

AS1

1

O

A0

C20

DIEA/

33

ESI: (M + H) + =

0.12

FM1

(KBr): C═O

DMF

759/61/63 (Br 2 )

1618/1657

341

N71

AS1

1

O

A0

C20

DIEA/

31

ESI: (M + H) + =

0.1

FM1

(KBr): C═O

DMF

771/3/5 (Br 2 )

1620/1680

342

N112

AS4

1

O

A0

C20

DIEA/

27

ESI: (M + H) + =

0.47

FM1

(KBr): C═O

DMF

776/8/80 (Br 2 )

1618/1682

343

N112

AS1

1

O

A0

C20

DIEA/

26

ESI: (M + H) + =

0.11

FM1

(KBr): C═O

DMF

777/9/81 (Br 2 )

1624/1678

344

N71

AS1

1

O

A0

C37

DIEA/

52

ESI: (M + H) + =

0.65

FM1

(KBr): C═O

DMF

771/3/5 (Br 2 )

1622/1680

345

N66

AS1

1

O

A0

C37

DIEA/

50

ESI: (M + H) + =

0.7

FM1

(KBr): C═O

DMF

759/61/63 (Br 2 )

1626/1659

346

N71

AS4

1

O

A0

C37

DIEA/

37

ESI: (M + H) + =

0.75

FM1

(KBr): C═O

DMF

770/72/74 (Br 2 )

1620/1682

347

N6

AS4

1

O

A0

C37

DIEA/

45

ESI: (M + H) + =

0.8

FM1

(KBr): C═O

DMF

758/60/62 (Br 2 )

1620/1663

348

N113

AS4

1

O

A0

C20

DIEA/

24

ESI: (M + H) + =

0.8

FM1

(KBr): C═O

DMF

771/3/5 (Br 2 )

1616/1701

349

N113

AS4

1

O

A0

C8

DIEA/

40

ESI: (M + H) + =

0.8

FM1

(KBr): C═O

DMF

757/59/61 (Br 2 )

1616/1699

350

N111

AS4

1

O

A0

C20

33

ESI: (M + H) + =

0.63

FM1

(KBr): C═O

838/40/42 (Br 2 )

1620/1688

351

N111

AS4

1

O

A0

C8

39

ESI: (M + H) + =

0.64

FM1

(KBr): C═O

824/6/8 (Br 2 )

1620/1688

352

N111

AS1

1

O

A0

C8

36

ESI: (M + H) + =

0.37

FM1

(KBr): C═O

825/7/9 (Br 2 )

1644/1688

353

N112

AS1

1

O

A0

C8

24

ESI: (M + H) + =

0.28

FM1

(KBr): C═O

763/5/7 (Br 2 )

1624/1684

355

N113

AS4

1

O

A0

C11

DIEA/

6

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

DMF

772/4/6 (Br 2 )

1620/1697

356

N66

AS4

1

O

A0

C38

DIEA/

31

ESI: (M + H) + =

0.23

FM1

(KBr): C═O

DMF

785/7/9 (Br 2 )

1624/1664

357

N112

AS4

1

O

A0

C11

DIEA/

5

ESI: (M + H) + =

0.37

FM1

DMF

777/79/81 (Br 2 )

358

N111

AS1

1

O

A0

C11

DIEA/

13

ESI: (M + H) + =

0.09

FM1

(KBr): C═O

DMF

840/42/44 (Br 2 )

1624/1686

359

N111

AS4

1

O

A0

C11

DIEA/

24

0.39

FM1

(KBr): C═O

DMF

1622/1686

360

N109

AS4

1

O

A0

C8

DIEA/

25

ESI: (M + H) + =

0.7

FM1

(KBr): C═O

DMF

750/52/54 (Br 2 )

1618/1657

361

N110

AS4

1

O

A0

C11

DIEA/

35

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

DMF

750/52/54 (Br 2 )

1622/1649

362

N110

AS4

1

O

A0

C8

DIEA/

24

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

DMF

750/52/54 (Br 2 )

1649

363

N111

AS4

1

O

A0

C37

DIEA/

25

0.53

FM1

(KBr): C═O

DMF

1622/1688

364

N111

AS1

1

O

A0

C37

DIEA/

24

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

DMF

839/41/43 (Br 2 )

1624/1686

366

N66

AS4

1

O

A0

C39

67

ESI: (M + H) + =

0.53

FM1

(KBr): C═O

772/4/6 (Br 2 )

1618/1665

367

N71

AS4

1

O

A0

C39

DIEA/

12

ESI: (M + H) + =

0.52

FM1

(KBr): C═O

DMF

784/6/8 (Br 2 )

1618/1684

368

N111

AS4

1

O

A0

C39

DIEA/

37

ESI: (M + H) + =

0.8

FM1

(KBr): C═O

DMF

852/4/6 (Br 2 )

1618/1686

369

N114

AS4

1

O

A0

C8

15

ESI: (M + H) + =

0.58

FM1

(KBr): C═O

824/6/8 (Br 2 )

1618/1686

370

N66

AS4

1

O

A0

C40

DIEA/

35

ESI: (M + H) + =

0.44

FM1

(KBr): C═O

DMF

773/5/7 (Br 2 )

1622/1660

371

N111

AS4

1

O

A0

C40

DIEA/

58

ESI: (M + H) + =

0.44

FM1

(KBr): C═O

DMF

853/5/7 (Br 2 )

1622/1687

373

N115

AS4

1

O

A0

C8

DIEA/

43

ESI: (M + H) + =

0.7

FM1

(KBr): C═O

DMF

822/4/6/8 (Br 3 )

1620/1670

374

N116

AS4

1

O

A0

C20

27

ESI: (M + H) + =

0.53

FM1

(KBr): C═O

784/6/8 (Br)

1618/1680

375

N117

AS4

1

O

A0

C20

23

ESI: (M + H) + =

0.52

FM1

(KBr): C═O

815/7/9 (Br)

1620/1687

376

N118

AS4

1

O

A0

C20

30

0.56

FM1

(KBr): C═O

1620/1684

377

N119

AS4

1

O

A0

C20

74

ESI: (M + H) + =

0.61

FM1

(KBr): C═O

848/50/52/54

1616/1685

(Br 3 )

418

N111

AS4

1

O

A0

C38

DIEA/

23

ESI: (M + H) + =

0.27

FM1

(KBr): C═O

DMF

865/7/9 (Br)

1622/1687

490

N113

AS1

1

O

A0

C20

DIEA/

37

ESI: (M + H) + =

0.1

FM1

(KBr): C═O

DMF

772/4/6 (Br 2 )

1622/1699

491

N113

AS1

1

O

A0

C8

DIEA/

94

ESI: (M + H) + =

0.37

FM1

(KBr): C═O

DMF

758/60/62 (Br 2 )

1624/1691

492

N113

AS1

1

O

A0

C11

DIEA/

42

ESI: (M + H) + =

0.1

FM1

(KBr): C═O

DMF

773/5/7 (Br 2 )

1678

495

N133

AS4

1

O

A0

C20

45

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

846/48/50 (Br 2 )

1620/1682

379

N71

AS1

1

O

A0

C3

39

ESI: (M + H) + =

0.41

FM4

(KBr): C═O

769/71/73 (Br 2 )

1680

380

N71

AS4

1

O

A0

C3

40

ESI: (M + H) + =

0.47

FM4

(KBr): C═O

768/70/72 (Br 2 )

1618/1682

381

N71

AS1

1

O

A0

C42

11

ESI: (M + H) + =

0.53

FM1

(KBr): C═O

752/54/56 (Br 2 )

1624/1682

382

N66

AS1

1

O

A0

C42

18

ESI: (M + H) + =

0.16

FM4

(KBr): C═O

740/42/44 (Br 2 )

1630/1653

383

N66

AS4

1

O

A0

C42

47

ESI: (M + H) + =

0.25

FM4

(KBr): C═O

739/41/43 (Br 2 )

1626/1659

384

N93

AS1

1

O

A0

C1

11

ESI: (M + H) + =

0.20

FM7

(KBr): C═O

790/92/94 (Br 2 )

1636/1705

385

N71

AS4

1

O

A0

C42

37

ESI: (M + H) + =

0.30

FM4

(KBr): C═O

751/53/55 (Br 2 )

1620/1680

386

N71

AS4

1

O

A0

C18

26

ESI: (M + H) + =

0.27

FM4

(KBr): C═O

782/4/6 (Br 2 )

1620/1682

387

N66

AS4

1

O

A0

C5

62

ESI: (M + H) + =

0.38

FM4

(KBr): C═O

739/41/43 (Br 2 )

1626/1663

388

N71

AS4

1

O

A0

C5

55

ESI: (M + H) + =

0.39

FM4

(KBr): C═O

751/3/5 (Br 2 )

1618/1684

389

N66

AS1

1

O

A0

C43

59

ESI: (M + H) + =

0.32

CH 2 Cl 2 /MeOH/

(KBr): C═O

796/98/800

NH 4 OH 9/1/0.1

1653

(Br 2 )

390

N135

AS4

1

O

A0

C18

5

ESI: (M + H) + =

0.71

FM1

(KBr): C═O

853/5/7 (Br 2 )

1622/1653

391

N135

AS1

1

O

A0

C18

6

ESI: (M + H) + =

0.54

FM1

(KBr): C═O

854/6/8 (Br 2 )

1659

392

N120

AS1

1

O

A0

C4

12

ESI: (M + H) + =

0.41

CH 2 Cl 2 /MeOH/

(KBr): C═O

763/5/7 (Br 2 )

NH 4 OH 9/1/0.1

1618/1639

393

N66

AS1

1

O

A0

C44

28

ESI: (M + H) + =

0.50

CH 2 Cl 2 /MeOH/

(KBr): C═O

763/5/7 (Br 2 )

NH 4 OH 9/1/0.1

1659

394

N66

AS4

1

O

A0

C21

37

ESI: (M + H) + =

0.35

EE/MeOH/

(KBr): C═O

740/42/44 (Br 2 )

AcOH 75/25/0.5

1659

396

N71

AS1

1

O

A0

C21

49

ESI: (M + H) + =

0.30

EE/MeOH/

(KBr): C═O

753/5/7 (Br 2 )

AcOH 75/25/0.5

1622/1678

397

N66

AS1

1

O

A0

C21

62

ESI: (M + H) + =

0.35

EE/MeOH/

(KBr): C═O

741/3/5 (B 2 )

AcOH 75/25/0.5

1649

398

N121

AS4

1

O

A0

C8

80

ESI: (M + H) + =

0.55

CH 2 Cl 2 /MeOH/

(KBr): C═O

743/5/7 (Br 2 )

NH 4 OH 9/1/0.1

1618/1668

399

N122

AS4

1

O

A0

C18

40

ESI: (M + H) + =

0.62

FM1

(KBr): C═O

800/2/4 (Br 2 )

1622/1682

400

N136

AS4

1

O

A0

C8

11

ESI: (M + H) + =

0.65

FM1

(KBr): C═O

741/3/5 (Br 2 )

1622/1653

401

N66

AS1

1

O

A0

C45

19

ESI: (M + H) + =

0.65

CH 2 Cl 2 /MeOH/

(KBr): C═O

749/51/53 (Br 2 )

NH 4 OH 9/1/0.1

1659

402

N136

AS4

1

O

A0

C1

10

ESI: (M + H) + =

0.42

CH 2 Cl 2 /MeOH/

(KBr): C═O

736/8/40 (Br 2 )

NH 4 OH 9/1/0.1

1649

403

N121

AS4

1

O

A0

C1

25

ESI: (M + H) + =

0.43

CH 2 Cl 2 /MeOH/

(KBr): C═O

738/40/42 (Br 2 )

NH 4 OH 9/1/0.1

1626/1676

404

N66

AS4

1

O

A0

C46

58

ESI: (M + H) + =

0.29

CH 2 Cl 2 /MeOH/

(KBr): C═O

766/8/70 (Br 2)

NH 4 OH 9/1/0.1

1624/1663

405

N66

AS1

1

O

A0

C47

40

ESI: (M − H) =

0.3

EE/MeOH 9/1

(KBr): C═O

752/4/6 (Br 2 )

1659

406

N136

AS1

1

O

A0

C1

16

ESI: (M + H) + =

0.34

FM7

(KBr): C═O

737/39/41 (Br 2 )

1645

407

N121

AS1

1

O

A0

C1

15

ESI: (M + H) + =

0.36

FM7

(KBr): C═O

739/41/43 (Br 2 )

1638

408

N71

AS4

1

O

A0

C48

47

ESI: (M + H) + =

0.17

CH 2 Cl 2 /MeOH/

(KBr): C═O

792/4/6 (Br 2 )

NH 4 OH 9/1/0.1

1620/1680

409

N66

AS4

1

O

A0

C48

31

ESI: (M + H) + =

0.43

CH 2 Cl 2 /MeOH/

(KBr): C═O

780/2/4 (Br 2 )

NH 4 OH 9/1/0.1

1665/1736

410

N66

AS1

1

O

A0

C49

51

0.24

EE/MeOH 9/1

(KBr): C═O

1661

411

N71

AS4

1

O

A0

C44

45

ESI: (M + Na) + =

0.35

EE/MeOH 9/1

(KBr): C═O

796/98/800

1728

(Br 2 )

412

N66

AS1

1

O

A0

C50

58

ESI: (M + H) + =

0.47

EE/MeOH 9/1

(KBr): C═O

756/58/60 (Br 2 )

1642/1661

413

N66

AS1

1

O

A0

C51

16

ESI: (M + H) + =

0.47

EE/MeOH/

(KBr): C═O

788/90/92 (Br 2 )

NH 4 OH 5/5/0.1

1631

414

N66

AS4

1

O

A0

C52

34

ESI: (M + H) + =

0.54

FM1

(KBr): C═O

747/49/51 (Br 2 )

1622/1662

415

N71

AS4

1

O

A0

C52

35

ESI: (M + H) + =

0.52

FM1

(KBr): C═O

759/61/63 (Br 2 )

1620/1682

416

N66

AS4

1

O

A0

C53

53

ESI: (M + H) + =

0.45

CH 2 Cl 2 /MeOH/

(KBr): C═O

759/61/63 (Br 2 )

NH 4 OH 9/1/0.1

1620/1664

417

N71

AS4

1

O

A0

C53

39

ESI: (M + H) + =

0.43

(KBr): C═O

771/3/5 (Br 2 )

1620/1684

496

N66

AS4

1

O

A0

C64

57

0.5

CH 2 Cl 2 /MeOH/

(KBr): C═O

NH 4 OH 9/1/0.1

1635

497

N66

AS1

1

O

A0

C53

60

ESI: (M + H) + =

0.31

CH 2 Cl 2 /MeOH/

(KBr): C═O

760/2/4 (Br 2 )

NH 4 OH

1676

50/50/0.5

498

N66

AS4

1

O

A0

C65

60

ESI: (M + H) + =

0.39

FM1

(KBr): C═O

760/2/4 (Br 2 )

1676

499

N71

AS4

1

O

A0

C65

53

ESI: (M + H) + =

0.39

FM1

(KBr): C═O

785/7/9 (Br 2 )

1618/1684

500

N66

AS4

1

O

A0

C51

71

ESI: (M + H) + =

0.15

CH 2 Cl 2 /MeOH/

(KBr): C═O

787/89/91 (Br 2 )

NH 4 OH 9/1/0.1

1628

501

N71

AS1

1

O

A0

C53

71

ESI: (M + H) + =

0.25

CH 2 Cl 2 /MeOH/

(KBr): C═O

772/4/6 (Br 2 )

NH 4 OH

1676

50/50/0.5

502

N66

AS1

1

O

A0

C65

42

ESI: (M + H) + =

0.15

FM1

(KBr): C═O

774/6/8 (Br 2 )

1626/1657

503

N71

AS1

1

O

A0

C65

48

ESI: M + H) + =

0.12

FM1

(KBr): C═O

786/88/90 (Br 2 )

1620/1682

504

N66

AS4

1

O

A0

C66

67

ESI: (M + H) + =

0.65

CH 2 Cl 2 /MeOH/

(KBr): C═O

787/89/91 (Br 2 )

NH 4 OH

1624

50/50/0.5

297

N71

AS4

1

H2

A0

C8

9

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

742/4/6 (Br 2 )

1684

298

N71

AS13

1

H2

A0

C8

6

ESI: (M + H) + =

0.16

FM1

(KBr): C═O

664/6 (Br)

1622/1682

299

N66

AS4

1

H2

A0

C8

21

ESI: (M + H) + =

0.25

FM1

(KBr): C═O

730/2/4 (Br 2 )

1666

300

N66

AS13

1

H2

A0

C8

14

ESI: (M + H) + =

0.19

FM1

(KBr): C═O

652/4 (Br)

1666

301

N71

AS1

1

H2

A0

C8

26

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

743/5/7 (Br 2 )

1682

420

N87

AS1

1

O

A0

C4

45

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

797/99/801

1624/1665/

(Br 2 )

1719

422

N87

AS1

1

O

A0

C8

35

ESI: (M + H) + =

9.54

FM1

(KBr): C═O

805/7/9 (Br 2 )

1628/1668/

1720

431

N125

AS4

1

O

A0

C8

89

ESI: (M + H) + =

0.75

FM1

(KBr): C═O

772/4/6 (Br 2 )

1713/1773

432

N125

AS1

1

O

A0

C4

59

ESI: (M + H) + =

0.65

FM1

(KBr): C═O

767/69/71 (Br 2 )

1622/1711/

1773

433

N126

AS4

1

O

A0

C4

33

ESI: (M + H) + =

0.65

FM1

(KBr): C═O

780/2/4 (Br 2 )

1709/1769

434

N126

AS1

1

O

A0

C8

53

ESI: (M + H) + =

0.53

FM1

(KBr): C═O

787/89/91 (Br 2 )

1626/1707

440

N127

AS4

1

O

A0

C8

67

ESI: (M + H) + =

0.67

FM1

(KBr): C═O

780/2/4 (Br 2 )

1618

441

N127

AS4

1

O

A0

C20

89

ESI: (M + H) + =

0.24

EE/MeOH/

(KBr): C═O

794/6/8 (Br 2 )

NH 4 OH

1618

8/1.5/0.3

442

N127

AS4

1

O

A0

C4

83

ESI: (M + H) + =

0.37

EE/MeOH/

(KBr): C═O

774/6/8 (Br 2 )

NH 4 OH

1616/1732

8/1.5/0.3

456

N66

AS16

1

O

A0

C8

83

ESI: (M + H) + =

0.32

EE/MeOH/

(KBr): C═O

641/3/5 (Cl 2 )

NH 4 OH

1624/1665

8/1.5/0.1

466

N128

AS4

1

O

A0

C8

13

ESI: (M + H) + =

0.63

FM1

(KBr): C═O

832/4/6 (Br 2 )

1684

467

N129

AS4

1

O

A0

C8

16

ESI: (M + H) + =

0.63

FM1

(KBr): C═O

806/08/10 (Br 2 )

1618/1682

468

N129

AS1

1

O

A0

C8

28

ESI: (M + H) + =

0.29

FM1

(KBr): C═O

807/09/11 (Br 2 )

1630/1680

470

N128

AS1

1

O

A0

C8

81

ESI: (M + H) + =

0.63

FM1

(KBr): C═O

835/7/9 (Br 2 )

1684

473

N130

AS1

1

O

A0

C8

40

ESI: (M + H) + =

0.51

FM1

(KBr): C═O

787/89/91 (Br 2 )

1624/1678

474

N130

AS4

1

O

A0

C8

17

ESI: (M + H) + =

0.71

FM1

(KBr): C═O

786/88/90 (Br 2 )

1618/1684

477

N66

AS16

1

O

A0

C1

33

ESI: (M + H) + =

0.53

EE/MeOH/

(KBr): C═O

636/38/40 (Cl 2 )

NH 4 OH 9/1/1

1661

(v/v/v)

481

N131

AS4

1

O

A0

C37

30

ESI: (M + H) + =

0.15

CH 2 Cl 2 /

(KBr): C═O

838/40/42/44

MeOH 7/3

1618/1685

(Br 2 ; Cl 2 )

(v/v)

482

N131

AS4

1

O

A0

C20

24

ESI: (M + H) + =

0.15

CH 2 Cl 2 /

(KBr): C═O

838/40/42/44

MeOH 7/3

1618/1685

(Br 2 ; Cl 2 )

(v/v)

483

N132

AS4

1

O

A0

C20

62

ESI: (M + H) + =

0.55

FM1

(KBr): C═O

804/6/8/10

1684

(Br 2 ; Cl)

484

N132

AS4

1

O

A0

C37

85

ESI: (M + H) + =

0.60

FM1

(KBr): C═O

804/6/8/10

1616/1686

(Br 2 ; Cl)

505

N134

AS4

1

O

A0

C8

81

ESI: (M + H) + =

0.74

FM1

(KBr): C═O

781/3/5 (Br 2 )

1616/1714

292

N66

AS1

1

H2

A0

C8

6

ESI: (M + H) + =

0.25

FM1

(KBr): C═O

731/3/5 (Br 2 )

1607/1664

245

N72

AS4

1

H2

A0

C8

19

ESI: (M + H) + =

0.30

FM1

(KBr): C═O

731/3/5 (Br 2 )

1668

220

N15

AS1

1

H2

A0

C8

6

ESI: (M + H) + =

0.30

FM1

(KBr): C═O

717/19/21 (Br 2 )

1697.3

307

N87

AS4

1

O

A0

C4

27

ESI: (M + H) + =

0.50

FM1

(KBr): C═O

796/98/800

1618/1670/

(Br 2 )

1718

178

N74

AS1

1

O

A0

C4

33

ESI: (M + H) + =

0.60

EE/MeOH/

(KBr): C═O

679/81/83 (Br 2 )

AcOH

1624

50/50/1

(v/v/v)

395

N71

AS4

1

O

A0

C21

22

ESI: (M + H) + =

0.25

EE/MeOH/

752/4/6 (Br 2 )

AcOH

50/25/0.5

(v/v/v)

509

N119

AS4

1

O

A0

C38

DMF

45

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

875/7/9/81

1687/1618

(Br 3 )

510

N118

AS4

1

O

A0

C38

DMF

34

ESI: (M + H) + =

0.4

FM1

(KBr): C═O

827/29/31 (Br 2 )

1682/1620

519

N137

AS4

1

O

A0

C20

THF/

62

ESI: (M + H) + =

0.1

FM1

(KBr): C═O

DMF

786/88/90 (Br 2 )

1618/1678

520

N138

AS4

1

O

A0

C20

THF/DMF

31

ESI: (M + H) + =

0.45

FM1

(KBr): C═O

906/08/10

1693

(Br 2 )

N66

AS4

1

O

A0

C69

DMF

100

533

N139

AS1

1

O

A0

C8

44

ESI: (M + H) + =

0.1

FM5

(KBr): C═O

746/48/50

1628

(Br 2 )

534

N139

AS4

1

O

A0

C20

60

ESI: (M + H) + =

0.2

FM5

(KBr): C═O

759/61/63

1618/1672

(Br 2 )

535

N139

AS1

1

O

A0

C53

34

ESI: (M + H) + =

0.1

FM5

(KBr): C═O

761/63/65

1624/1670

(Br 2 )

536

N140

AS4

1

O

A0

C8

40

ESI: (M + H) + =

0.37

FM1

(KBr): C═O

745/7/9

1616/1676

(Br 2 )

537

N140

AS1

1

O

A0

C8

33.4

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

746/48/50

1614/1672

(Br 2 )

551

N66

AS1

1

O

A0

C66

41

ESI: (M + H) + =

0.3

EE/MeOH/

(KBr): C═O

788/90/92

NH 4 OH

1628

(Br 2 )

50/50/0.5

552

N66

AS4

1

O

A0

C78

83

ESI: (M + H) + =

0.6

CH 2 Cl 2 /MeOH/

(KBr): C═O

787/89/91

NH 4 OH

1620

(Br 2 )

80/20/1

553

N66

AS1

1

O

A0

C78

30

ESI: (M + H) + =

0.5

CH 2 Cl 2 / MeOH/

(KBr): C═O

788/90/92

NH 4 OH

1626

(Br 2 )

80/20/1

554

N71

AS4

1

O

A0

C78

67

ESI: (M + H) + =

0.5

CH 2 Cl 2 /MeOH/

(KBr): C═O

799/801/803

NH 4 OH

1622/1684

(Br 2 )

80/20/1

555

N71

AS1

1

O

A0

C78

26

ESI: (M + H) + =

0.5

CH 2 Cl 2 /MeOH/

(KBr): C═O

800/02/04

NH 4 OH

1624/1684

(Br 2 )

80/20/1

556

N66

AS4

1

O

A0

C70

71

ESI: (M + H) + =

0.6

CH 2 Cl 2 /MeOH/

(KBr): C═O

788/90/92

NH 4 OH

1653

(Br 2 )

50/50/0.5

557

N71

AS4

1

O

A0

C70

27

ESI: (M + H) + =

0.8

CH 2 Cl 2 /MeOH/

800/02/04

NH 4 OH

(Br 2 )

50/50/0.5

558

N66

AS1

1

O

A0

C64

61

ESI: (M + H) + =

0.3

CH 2 Cl 2 /MeOH/

(KBr): C═O

790/92/94

NH 4 OH

1635

(Br 2 )

90/10/1

559

N141

AS4

1

O

A0

C20

80

ESI: (M + H) + =

0.3

CH 2 Cl 2 /MeOH/

(KBr): C═O

626/28/30

NH 4 OH

1618/1714

(Br 2 )

90/10/1

560

N66

AS4

1

O

A0

C71

59

ESI: (M + H) + =

0.3

CH 2 Cl 2 /MeOH/

(KBr): C═O

837/39/41

NH 4 OH

1628/62

(Br 2 )

90/10/1

561

N71

AS4

1

O

A0

C71

56

ESI: (M + H) + =

0.2

CH 2 Cl 2 /

(KBr): C═O

849/51/53 (Br 2 )

MeOH/

1618/1684

NH 4 OH

90/10/1

562

N66

AS1

1

O

A0

C70

15

ESI: (M + H) + =

0.6

CH 2 Cl 2 /

(KBr): C═O

789/91/93 (Br 2 )

MeOH/

1676

NH 4 OH

50/50/0.5

563

N71

AS1

1

O

A0

C70

27

ESI: (M + H) + =

0.6

CH 2 Cl 2 /

(KBr): C═O

80/3/5 (Br 2 )

MeOH/

1678

NH 4 OH

70/30/1

565

N66

AS4

1

O

A0

C72

51

ESI: (M + H) + =

0.2

CH 2 Cl 2 /

(KBr): C═O

787/89/91 (Br 2 )

MeOH/

1622/1658

NH 4 OH

80/20/1

566

N71

AS4

1

O

A0

C72

65

ESI: (M + H) + =

0.2

CH 2 Cl 2 /

(KBr): C═O

799/801/803

MeOH/

1620/1682

(Br 2 )

NH 4 OH

80/20/1

567

N136

AS4

1

O

A0

C53

65

ESI: (M + H) + =

0.5

CH 2 Cl 2 /

(KBr): C═O

756/58/60 (Br 2 )

MeOH/

1641

NH 4 OH

80/20/1

568

N136

AS4

1

O

A0

C72

76

ESI: (M + H) + =

0.2

CH 2 Cl 2 /

(KBr): C═O

784/6/8 (Br 2 )

MeOH/

1637

NH 4 OH

80/20/1

569

N136

AS1

1

O

A0

C53

63

ESI: (M + H) + =

0.4

CH 2 Cl 2 /

(KBr): C═O

757/59/61 (Br 2 )

MeOH/

1643

NH 4 OH

80/20/1

570

N66

AS31

1

O

A0

C20

85

ESI: (M + H) + =

0.6

CH 2 Cl 2 /

(KBr): C═O

640

MeOH/

1622/1664

NH 4 OH

80/20/1

571

N66

AS31

1

O

A0

C53

82

ESI: (M + H) + =

0.8

CH 2 Cl 2 /

(KBr): C═O

641

MeOH/

1664

NH 4 OH

80/20/1

572

N71

AS31

1

O

A0

C20

100

ESI: (M + H) + =

0.4

CH 2 Cl 2 /

(KBr): C═O

652

MeOH/

1620/1684

NH 4 OH

80/20/1

573

N71

AS31

1

O

A0

C53

48

ESI: (M + H) + =

0.4

CH 2 Cl 2 /

(KBr): C═O

653

MeOH/

1622/1684

NH 4 OH

80/20/1

576

N66

AS11

1

O

A0

C53

35

ESI: (M + H) + =

0.65

CH 2 Cl 2 /

(KBr): C═O

727

MeOH/

1664/1732

NH 4 OH

80/20/1

577

N71

AS11

1

O

A0

C53

73

ESI: (M + H) + =

0.18

EE/

(KBr): C═O

739

MeOH/

1684/1734

NH 4 OH

50/50/0.5

580

N66

AS11

1

O

A0

C20

65

ESI: (M + H) + =

0.5

CH 2 Cl 2 /

(KBr): C═O

706

MeOH/

1664/1732

NH 4 OH

80/20/1

581

N71

AS11

1

O

A0

C20

38

ESI: (M + H) + =

0.2

CH 2 Cl 2 /

(KBr): C═O

738

MeOH/

1684/1734

NH 4 OH

90/10/1

582

N143

AS4

1

O

A0

C20

61

ESI: (M + H) + =

0.5

CH 2 Cl 2 /

(KBr): C═O

758/60/62

MeOH/

1615

NH 4 OH

90/10/1

583

N66

AS31

1

O

A0

C72

50

ESI: (M + H) + =

0.35

FM1

(KBr): C═O

669

1664

584

N71

AS31

1

O

A0

C72

68

ESI: (M + H) + =

0.35

FM1

(KBr): C═O

681

1622/1684

585

N144

AS4

1

O

A0

C8

50

ESI: (M + H) + =

0.43

FM5

(KBr): C═O

927/29/31/33

1616/1684

(Br 4 )

586

N144

AS4

1

O

A0

C53

85

ESI: (M + H) + =

0.67

FM1

(KBr): C═O

942/4/6/8 (Br 4 )

1680

587

N66

AS11

1

O

A0

C72

37

ESI: (M + H) + =

0.35

FM1

(KBr): C═O

755

1622/1658/

1732

588

N71

AS11

1

O

A0

C72

81

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

767

1684/1732

619

N71

AS19

1

O

A0

C8

27.9

0.3

EE/MeOH/

(KBr): C═O

NH 4 OH

1622/1684

9/1/0.3

620

N66

AS35

1

O

A0

C8

36

ESI: (M − H) − =

0.25

MeOH

(KBr): C═O

598

1628/1664

621

N66

AS36

1

O

A0

C8

32

ESI: (M − H) − =

0.56

FM1

(KBr): C═O

587

1626/1666

622

N71

AS36

1

O

A0

C8

32

ESI: (M − H) − =

0.44

FM1

(KBr): C═O

599

1622/1684

623

N109

AS36

1

O

A0

C8

37

ESI: (M − H) − =

0.6

FM1

(KBr): C═O

593

1626/1649

624

N118

AS36

1

O

A0

C8

55

ESI: (M − H) − =

0.6

FM1

(KBr): C═O

629

1622/1684

625

N111

AS36

1

O

A0

C8

47

ESI: (M − H) − =

0.61

FM1

(KBr): C═O

667

1624/1687

626

N111

AS19

1

O

A0

C8

20

ESI: (M − H) − =

0.28

EE/MeOH/

(KBr): C═O

731/3 (Br)

NH 4 OH

1624/1687

9/1/0.3

627

N109

AS19

1

O

A0

C8

16

ESI: (M − H) − =

0.28

EE/MeOH/

(KBr): C═O

657/9 (Br)

NH 4 OH

1653

9/1/0.3

633

N118

AS19

1

O

A0

C8

20

ESI: (M + H) + =

0.18

EE/MeOH/

(KBr): C═O

693/5 (Br)

NH 4 OH

1622/1684

9/1/0.3

N66

AS1

1

O

A0

C69

100

0.3

FM4

(KBr): C═O

1668

EXAMPLE 4

Preparation of compounds of general formula:

1-[4-amino-3,5-dibromo-N-[4-(1,3,3a,4,5,6,7,7a-octahydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine (No. 91)

A mixture of 0.35 g (2.1 mmol) of CDT, 1.0 g (1.4 mmol) of 4-(1,3,3a,4,5,6,7,7a-octahydro-2(2H)-oxobenzimidazol-1-yl)-piperidine, 0.5 ml of (2.8 mmol) of DIEA and 100 ml of tetra-hydrofuran was stirred for 1 hour whilst cooling with ice and then for 30 minutes at ambient temperature. With stirring 0.46 g (1.75 mmol) of 1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(4-pyridinyl)piperazine and 0.32 ml of (1.8 mmol) of DIEA were added and refluxed for 3 hours. The reaction mixture was diluted with 100 ml of ethyl acetate and the organic phase was washed twice with aqueous saturated sodium hydrogen carbonate solution. The combined aqueous phases were then extracted once with ethyl acetate/tetrahydrofuran=1/1 (v/v) and the combined organic phases were washed once with saturated aqueous saline solution. After drying the organic phase and eliminating the solvent in vacuo the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol=9/1 (v/v)). 120 mg (12% of theory) of a colourless foam were obtained.

IR (KBr): 1626. 1686 cm −1 (C═O)

R f : 0.62 (FM3)

ESI-MS: (M+H) + =731/733/735 (Br 2 ) (M+H+Na) ++ =377/378/379 (Br 2 )

The following were prepared analogously (in each case n=1):

%

M.p.

No.

RCO

R 2

A

NR 3 R 4

n

Remarks

Yield

MS

R f

Eluant

IR [cm −1 ]

(° C.)

N16

AS1

A3

C1

1

NEt 3 as base

31

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

974/6/8 (Br 2 )

1641.3;

1695.3

86

N53

AS4

A0

C1

1

DMF as solvent

23

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

739/41/43 (Br 2 )

1641.3;

1697.3

87

N54

AS4

A0

C1

1

DMF als

81

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

Lösemittel

739/41/43 (Br 2 )

1620.1;

1697.3

92

N57

AS4

A0

C1

1

DMF as solvent

60

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

712/4/6 (Br 2 )

1597; 1635.5

93

N47

AS4

A0

C1

1

23

ESI: (M + H) + =

0.4

FM1

(KBr): C═O

636/8/40 (Br 2 )

1622; 1675

94

N45

AS4

A0

C1

1

45

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

739/41/43 (Br 2 )

1598.9;

1620.1

95

N57

AS1

A0

C1

1

DMF as solvent

13

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

713/5/7 (Br 2 )

1637.5

96

N53

AS1

A0

C1

1

DMF as solvent

15

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

740/2/4 (Br 2 )

1633.6;

1687.6

97

N54

AS1

A0

C1

1

DMF as solvent

31

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

740/2/4 (Br 2 )

1635.5;

1695.3

107

N59

AS4

A0

C1

1

76

ESI: (M + H) + =

0.7

FM1

(KBr): C═O

694/6/8 (Br 2 )

1597; 1635.5

108

N45

AS1

A0

C1

1

37

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

740/2/4 (Br 2 )

1633.6;

1708.8

109

N59

AS1

A0

C1

1

30

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

695/7/9 (Br 2 )

1647.4

116

N60

AS4

A0

C1

1

DMF as solvent

80

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

753/5/7 (Br 2 )

1623.7;

1676.1;

1712.7

117

N60

AS1

A0

C1

1

DMF as solvent

50

ESI: (M + H) + =

0.4

FM1

(KBr): C═O

754/6/8 (Br 2 )

1617; 1650;

1670; 1712.7

118

N47

AS1

A0

C1

1

29

ESI: (M + H) + =

0.1

FM1

(KBr): C═O

637/9/41 (Br 2 )

1639.4

121

N61

AS1

A0

C1

1

12.4

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

727/9/31 (Br 2 )

1635.5; 1705

122

N61

AS4

A0

C1

1

42

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

726/8/30 (Br 2 )

1620.1;

1706.9

125

N15

AS7

A0

C1

1

NEt 3 as base

4.4

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

598

1708.8

126

N15

AS7

A0

C4

1

NEt 3 as base

57

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

188.0

597

1622; 1708.8

127

N15

AS7

A0

C8

1

NEt 3 as

16

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

168-

base

603

1622;

170

1697.3

137

N94

AS4

A0

C4

1

42

ESI: (M + H) + =

0.8

FM1

(KBr): C═O

708/10/12 (Br 2 )

1618

138

N95

AS4

A0

C8

1

NEt 3 as

29

ESI: (M + H) + =

0.8

FM1

(KBr): C═O

base

743/5/7 (Br 2 )

1713

139

N61

AS1

A3

C1

1

41

ESI: (M + H) + =

0.4

FM1

(KBr): C═O

955/7/9 (Br 2 )

1640; 1709

140

N60

AS1

A3

C1

1

66

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

982/4/6 (Br 2 )

1645; 1712

143

N66

AS1

A0

C4

1

DMF as

69

ESI: (M + H) + =

0.4

FM1

(KBr): C═O

solvent

739/41/43 (Br 2 )

1624; 1659

144

N96

AS1

A0

C4

1

54

ESI: (M + H) + =

0.54

FM1

(KBr): C═O

725/7/9 (Br 2 )

1616

145

N61

AS1

A0

C4

1

48

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

724/6/8 (Br 2 )

1624; 1709

146

N15

AS14

A0

C1

1

DMF as

53

ESI: (M + H) + =

0.15

FM1

(KBr): C═O

solvent

555

1636; 1701

147

N61

AS4

A0

C11

1

30

ESI: (M + H) + =

0.7

FM1

(KBr): C═O

746/48/50 (Br 2 )

1620; 1713

148

N66

AS1

A0

C8

1

THF/DMF

58

ESI: (M + H) + =

0.68

FM1

(KBr): C═O

as solvent

745/7/9 (Br 2 )

1628; 1663

149

N69

AS1

A0

C4

1

THF/DMF

61

ESI: (M + H) + =

0.68

FM1

(KBr): C═O

as solvent

739/41/43 (Br 2 )

1624; 1675

150

N97

AS1

A0

C4

1

THF/DMSO

32

ESI: (M + H) + =

0.4

FM1

(KBr): C═O

as solvent

783/85/87 (Br 2 )

1709

152

N71

AS1

A0

C4

1

40

ESI: (M + H) + =

0.68

FM1

(KBr): C═O

751/53/55 (Br 2 )

1622; 1684

153

N65

AS1

A0

C4

1

51

ESI: (M + H) + =

0.68

FM1

(KBr): C═O

751/53/55 (Br 2 )

1626; 1678

N66

AS1

A3

C1

1

37

225

N66

AS1

A0

C1

1

THF/DMF

48

ESI: (M + H) + =

0.35

FM1

(KBr): C═O

as solvent

740/42/44 (Br 2 )

1650; 1670

226

N66

AS4

A0

C8

1

THF/DMF

88

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

as solvent

744/6/8 (Br 2 )

1618; 1661

227

N69

AS4

A0

C8

1

THF/DMF

72

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

as solvent

744/6/8 (Br 2 )

1618; 1680

228

N69

AS1

A0

C8

1

THF/DMF

69

ESI: (M + H) + =

0.45

FM1

(KBr): C═O

as solvent

745/7/9 (Br 2 )

1628

229

N70

AS1

A0

C4

1

THF/DMF

39

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

as solvent

727/29/31 (Br 2 )

1730

230

N66

AS4

A0

C20

1

49

ESI: (M + H) + =

0.55

FM1

(KBr): C═O

758/60/62 (Br 2 )

1614

231

N99

AS4

A0

C8

1

THF/DMF as

68

ESI: M + H) + =

0.6

FM1

(KBr): C═O

solvent

758/60/62 (Br 2 )

1624

239

N71

AS1

A0

C8

1

THF/DMF as

59

ESI: (M + H) + =

0.45

FM1

(KBr): C═O

solvent

757/59/61 (Br 2 )

1626; 1680

240

N71

AS4

A0

C11

1

35

ESI: (M + H) + =

0.68

FM1

(KBr): C═O

771/3/5 (Br 2 )

1615; 1684

241

N71

AS4

A0

C8

1

88

ESI: (M + H) + =

0.68

FM1

(KBr): C═O

756/58/60 (Br 2 )

1620; 1682

242

N71

AS4

A0

C1

1

40

ESI: (M + H) + =

0.64

FM1

(KBr): C═O

751/3/5 (Br 2 )

1615; 1684

243

N71

AS4

A0

C20

1

38

ESI: (M + H) + =

0.65

FM1

(KBr): C═O

770/2/4 (Br 2 )

1618; 1684

244

N71

AS1

A0

C11

1

36

ESI: (M + H) + =

0.35

FM1

(KBr): C═O

772/4/6 (Br 2 )

1622; 1684

N5

AS1

A3

C1

1

NEt 3 as base

24

ESI: (M + H) + =

0.06

FM1

(KBr): C═O

890/2/4 (Br 2 )

1641.3

N10

AS1

A3

C1

1

NEt 3 as base

55

ESI: (M + H) + =

0.38

FM1

(KBr): C═O

874/6/8 (Br 2 )

1641.3

N12

AS1

A3

C1

1

NEt 3 as base

35480

ESI: (M + H) + =

0.43

FM1

(KBr): C═O

902/4/6 (Br 2 )

1639.4

N22

AS1

A3

C1

1

NEt 3 as base

35.5

0.5

FM1

N23

AS1

A3

C1

1

NEt 3 as base

31

0.5

FM1

N24

AS1

A3

C1

1

NEt 3 as base

35607

0.5

FM1

N46

AS1

A3

C1

1

NEt 3 as base

36.2

0.5

FM1

(KBr): C═O

1641.3

83

N15

AS1

A0

C1

1

36.7

ESI: (M + H) + =

0.62

FM2

(KBr): C═O

726/28/30 (Br 2 )

1641.3;

1695.3

84

N15

AS1

A0

C4

1

36.3

ESI: (M + H) + =

0.69

FM2

(KBr): C═O

725/7/9 (Br 2 );

1624.0;

(M + Na) + =

1699.2

747/49/51 (Br 2 )

88

N55

AS4

A0

C1

1

93.6

ESI: (M + H) + =

0.75

FM3

(KBr): C═O

793/5/7/9

1641.3;

(Br 2 ; Cl 2 )

1708.8

89

N56

AS4

A0

C1

1

30

ESI: (M + H) + =

0.81

FM1

(KBr): C═O

797/799/801

1641.3;

(Br 2 )

1697.3;

1749.3

136

N15

AS9

A0

C1

1

14.6

ESI: (M + H) + =

0.55

FM3

(KBr): C═O

570

1635.5;

1701.1

91

N64

AS4

A0

C1

1

11.7

ESI: (M + H) + =

0.62

FM3

(KBr): C═O

731/733/735

1625.9;

1685.7

N16

AS1

A3

C5

1

Purification

74

ESI: (M + H) + =

0.48

FM4

(KBr): C═O

by column

974/976/978

1685.7;

chromato-

(Br 2 )

1635.5

graphy: silica

gel/FM4

155

N15

AS1

A0

C3

1

34

ESI: (M + H) + =

0.45

FM1

(KBr): C═O

165-9

743/5/7 (Br 2 )

1626; 1695

156

N15

AS1

A0

C19

1

40

ESI: (M + H) + =

0.47

FM1

(KBr): C═O

155-9

743/5/7 (Br 2 )

1624; 1695

157

N15

AS4

A0

C19

1

54

ESI: (M + H) + =

0.79

FM1

(KBr): C═O

151-4

742/4/6 (Br 2 )

1616; 1697

158

N79

AS4

A0

C1

1

15

ESI: (M + H) + =

0.63

FM1

(KBr): C═O

132-5

727/29/31 (Br 2 )

1616; 1695;

1732

159

N77

AS4

A0

C8

1

34

ESI: (M + H) + =

0.63

FM1

(KBr): C═O

732/4/6 (Br 2 )

1632

160

N73

AS1

A0

C4

1

12

ESI: (M − H) − =

0.14

FM1

(KBr): C═O

649/651/653

1626

(Br 2 )

170

N15

AS4

A0

C37

1

62

ESI: (M − H) − =

0.45

FM1

(KBr): C═O

165-70

725/7/9 (Br 2 )

1620; 1701

171

N79

AS1

A0

C1

1

60

ESI: (M + H) + =

0.21

FM1

(KBr): C═O

193-7

728/30/32 (Br 2 )

1637.5

172

N79

AS1

A0

C8

1

27

ESI: (M + H) + =

0.32

FM1

(KBr): C═O

163-9

733/5/7 (Br 2 )

1622

185

N77

AS4

A0

C4

1

66

ESI: (M + H) + =

0.49

FM1

(KBr): C═O

726/28/30 (Br 2 )

1624

186

N77

AS4

A0

C1

1

76

ESI: (M + H) + =

0.63

FM1

(KBr): C═O

727/29/31 (Br 2 )

1635.5

187

N77

AS1

A0

C4

1

67

ESI: (M + H) + =

0.33

FM1

(KBr): C═O

727/29/31 (Br 2 )

1627.8

188

N78

AS1

A3

C1

1

63

ESI: (M + H) + =

0.45

FM1

(KBr): C═O

955/7/9 (Br 2 )

1637.5;

1774.4; 1701

189

N103

AS4

A0

C8

1

50

ESI: (M + H) + =

0.71

FM1

(KBr): C═O

713/5/7 (Br 2 )

1616.3

192

N77

AS1

A0

C1

1

47

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

728/30/32 (Br 2 )

1643.3

247

N15

AS10

A3

C4

1

60

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

937/39/41 (Br 2 )

1639.4; 1701

249

N15

AS4

A0

C22

1

52

ESI: (M + H) + =

0.59

FM1

(KBr): C═O

744/6/8 (Br 2 )

1695.3

161

N15

AS4

A0

C21

1

32

ESI: (M + H) + =

0.61

FM1

(KBr): C═O

163-7

726/28/30 (Br 2 )

1622: 1701

162

N78

AS1

A0

C4

1

15

ESI: (M + H) + =

0.48

FM1

(KBr): C═O

726/28/30 (Br 2 )

1624; 1772.5

163

N73

AS1

A0

C1

1

43

ESI: (M + H) + =

0.07

FM1

(KBr): C═O

752/4/6 (Br 2 )

1637.5

164

N79

AS4

A0

C8

1

48

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

127-32

732/4/6 (Br 2 )

1616.3

165

N15

AS1

A0

C21

1

27

ESI: (M + H) + =

0.26

FM1

(KBr): C═O

184-9

727/29/31 (Br 2 )

1697.3

166

N76

AS1

A0

C4

1

17

ESI: (M + H) + =

0.23

FM1

(KBr): C═O

665/7/9 (Br 2 )

1616; 1734

167

N75

AS1

A0

C4

1

20

ESI: (M + H) + =

0.18

FM1

(KBr): C═O

665/7/9 (Br 2 )

1624

168

N73

AS1

A3

C4

1

39

ESI: (M + H) + =

0.15

FM1

(KBr): C═O

879/81/83 (Br 2 )

1631.7

169

N15

AS1

A0

C37

1

17

ESI: (M + H) + =

0.31

FM1

(KBr): C═O

156-61

726/28/30 (Br 2 )

1627.8; 1697.3

173

N15

AS10

A0

C4

1

66

ESI: (M + H) + =

0.68

FM1

(KBr): C═O

283-4

709/11/13 (Br 2 )

1627.8; 1656.8;

1695.3

174

N15

AS10

A0

C1

1

42

ESI: (M + H) + =

0.61

FM1

(KBr): C═O

266-9

710/2/4 (Br 2 )

1706.9

175

N77

AS1

A0

C8

1

36

ESI: (M + H) + =

0.24

FM1

(KBr): C═O

733/5/7 (Br 2 )

1641.3

176

N76

AS1

A3

C4

1

47

ESI: (M + H) + =

0.21

FM1

(KBr): C═O

893/5/7 (Br 2 )

1635.5

177

N75

AS1

A3

C4

1

53

ESI: (M + H) + =

0.14

FM1

(KBr): C═O

893/5/7 (Br 2 )

1637.5

180

N74

AS1

A3

C4

1

44

ESI: (M + H) + =

0.26

FM1

(KBr): C═O

907/9/11 (Br 2 )

1631.7; 1689.5

190

N15

AS1

A3

C18

1

44

ESI: (M + H) + =

0.38

FM1

(KBr): C═O

985/7/9 (Br 2 )

1635.5; 1695.3

191

N15

AS10

A3

C1

1

64

ESI: (M + H) + =

0.56

FM1

(KBr): C═O

938/40/42 (Br 2 )

1645.2; 1701

N15

AS10

A3

C4

1

91

ESI: (M + H) + =

(KBr): C═O

937/39/41 (Br 2 )

1643.3; 1701

N15

AS10

A3

C1

1

64

ESI: (M + H) + =

(KBr): C═O

938/40/42 (Br 2 )

1645; 1701

254

N77

AS1

A3

C1

1

37

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

956/8/60 (Br 2 )

1641

N15

AS4

A3

C18

1

90

ESI: (M + H) + =

(KBr): C═O

984/6/8 (Br 2 )

1641.3; 1699

257

N15

AS4

A5

C1

1

17

ESI: (M + H) + =

0.53

FM1

(KBr): C═O

782/4/6 (Br 2 )

1643; 1697

258

N100

AS4

A0

C1

1

69

ESI: (M + H) + =

0.54

FM1

(KBr): C═O

755/7/9 (Br 2 )

1627.8; 1705

259

N100

AS4

A0

C8

1

70

ESI: (M + H) + =

0.54

FM1

(KBr): C═O

760/2/4 (Br 2 )

1695

260

N15

AS4

A0

C23

1

39

ESI: (M + H) + =

0.36

FM1

(KBr): C═O

796/798/800

1635.5; 1699

(Br 2 )

261

N15

AS4

A10

C1

1

26

ESI: (M + H) + =

0.38

FM1

(KBr): C═O

796/798/800

1631.4; 1701

(Br 2 )

265

N15

AS4

A5

C8

1

20

ESI: (M + H) + =

0.41

FM1

(KBr): C═O

787/9/91 (Br 2 )

1635.5; 1697

266

N15

AS4

A6

C1

1

24

ESI: (M + H) + =

0.43

FM1

(KBr): C═O

796/798/800

1647; 1689.5

(Br 2 )

262

N80

AS4

A0

C1

1

25

ESI: (M + H) + =

0.54

FM1

(KBr): C═O

803/5/7 (Br 2 )

1637.5

263

N15

AS15

A0

C8

1

64

ESI: (M + H) + =

0.43

FM1

(KBr): C═O

565

1627.8; 1707

264

N15

AS4

A0

C24

1

62

ESI: (M + H) + =

0.4

FM1

(KBr): C═O

733/5/7 (Br 2 )

1622; 1701

267

N81

AS4

A3

C8

1

46

ESI: (M + H) + =

0.55

FM1

(KBr): C═O

974/6/8 (Br 2 )

1641; 1707

268

N15

AS4

A6

C8

1

27

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

801/3/5 (Br 2 )

1633.6; 1697

269

N82

AS4

A0

C8

1

86

ESI: (M + H) + =

0.66

FM1

(KBr): C═O

742/4/6 (Br 2 )

1620; 1649

270

N82

AS4

A0

C1

1

56

ESI: (M + H) + =

0.59

FM1

(KBr): C═O

737/39/41 (Br 2 )

1641

272

N15

AS11

A0

C8

1

76

ESI: (M + H) + =

0.6

FM1

(KBr): C═O

698

1627.8;

1714.6

273

N15

AS4

A10

C8

1

68

ESI: (M + H) + =

0.52

FM1

(KBr): C═O

801/3/5 (Br 2 )

1637.5; 1701

274

N102

AS4

A0

C1

1

76

ESI: (M + H) + =

0.56

FM1

(KBr): C═O

738/40/42 (Br 2 )

1664.5

275

N102

AS4

A0

C8

1

55

ESI: (M + H) + =

0.59

FM1

(KBr): C═O

743/5/7 (Br 2 )

1618; 1664.5

276

N83

AS4

A0

C1

1

30

ESI: (M + H) + =

0.48

FM1

(KBr): C═O

745/7/9 (Br 2 )

1633.6

277

N84

AS4

A0

C8

1

63

ESI: (M + H) + =

0.54

FM1

(KBr): C═O

744/6/8 (Br 2 )

1616; 1691.5

278

N84

AS4

A3

C4

1

88

ESI: (M + H) + =

0.53

FM1

(KBr): C═O

966/8/70 (Br 2 )

1633.6;

1691.5

279

N15

AS4

A0

C26

1

75

ESI: (M + H) + =

0.44

FM1

(KBr): C═O

732/4/6 (Br 2 )

1618; 1709

281

N15

AS12

A0

C8

1

21

ESI: (M + H) + =

0.42

FM1

(KBr): C═O

598

1697

282

N66

AS1

A0

C18

1

19

ESI: (M + H) + =

0.51

FM1

(KBr): C═O

770/2/4 (Br 2 )

1624; 1660.6;

1734

284

N66

AS1

A0

C18

1

29

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

771/3/5 (Br 2 )

1630; 1655

314

N93

AS4

A0

C8

1

81

ESI: (M + H) + =

0.5

FM1

(KBr): C═O

794/6/8 (Br 2 )

1618; 1701

315

N93

AS4

A0

C1

1

77

ESI: (M + H) + =

0.49

FM1

(KBr): C═O

789/91/93 (Br 2 )

1627.6; 1705

316

N65

AS1

A0

C18

1

15

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

783/5/7 (Br 2 )

1624; 1681.8

317

N66

AS4

A0

C3

1

51

ESI: (M + H) + =

0.62

FM1

(KBr): C═O

778/80/82 (Br 2 )

1627.6;

1662.5

318

N66

AS1

A0

C3

1

40

ESI: (M + H) + =

0.41

FM1

(KBr): C═O

557/579/561

1659

(Br 2 )

319

N66

AS4

A0

C19

1

55

ESI: (M + H) + =

0.68

FM1

(KBr): C═O

778/780/782

1664.5

(Br 2 )

320

N65

AS4

A0

C19

1

61

ESI: (M + H) + =

0.62

FM1

(KBr): C═O

768/70/72 (Br 2 )

1618; 1682

321

N93

AS1

A0

C4

1

29

ESI: (M + H) + =

0.35

FM1

(KBr): C═O

789/91/93 (Br 2 )

1622; 1705

N15

AS1

A3

C5

1

47

0.32

FM1

N19

AS1

A3

C1

1

80

ESI: (M + H) + =

(KBr): C═O

933/5/7 (Br 2 )

1641.3

EXAMPLE 5

Preparation of compounds of general formula:

1-[N 2 -[N-(4-phenyl-1-piperazinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (No. 17)

To a solution of 800 mg (0.86 mmol) of 1-[N 2 -[N-(4-phenyl-1-piperazinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-N 6 -[(1,1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine in methanol were added 2 ml of methanol saturated with hydrogen chloride and the mixture was stirred overnight at ambient temperature. The reaction mixture was mixed with ethyl acetate until the hydrochloride was totally precipitated and the precipitate formed was filtered off. After washing the precipitate with water it was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol/conc. aqueous ammonia=5/5/0.5 (v/v/v)). 0.38 g (55% of theory) of an amorphous solid were obtained.

IR (KBr): 1639 cm −1 (C═O)

R f : 0.55 (FM2)

ESI-MS: (M+H) + =799/801/803 (Br 2 ) (M+2H) ++ =400/401/402 (Br 2 )

The following were prepared analogously (in each case n=1):

No.	RCO	R 2	A	n	NR 3 R 4	% Yield	MS	R f	Elaunt	IR [cm −1 ]
11	N8	AS1	A1	1	C1	70	ESI: (M + H) + =	0.43	FM2	(KBr): C═O
							758/60/62 (Br 2 )			1656.8
12	N9	AS1	A1	1	C1	60	ESI: (M + H) + =	0.46	FM2	(KBr): C═O
							788/90/92 (Br 2 )			1643.3
8	N5	AS1	A1	1	C1	53.7	ESI: (M + H) + =	0.2	methanol/	(KBr): C═O
							790/2/4 (Br 2 )		glacial acetic	1641.3
									acid/water =
									9/1/1 (v/v/v)
15	N11	AS1	A1	1	C1	56	ESI: (M + H) + =	0.4	FM2
							773/5/7 (Br 2 )
6	N2	AS1	A1	1	C11	66.4	ESI: (M + H) + =	0.39	FM2	(KBr): C═O
							808/10/12 (Br 2 )			1656.8
7	N2	AS1	A1	1	C2	46.2	ESI: (M + H) + =	0.13	FM2	(KBr): C═O
							794/6/8 (Br 2 )			1637.5
13	N2	AS2	A1	1	C1	84.7	ESI: (M + H) + =	0.46	FM2	(KBr): C═O
							666			1641.3

EXAMPLE 6

Preparation of compounds of general formula:

1-[4-amino-3,5-dibromo-N 2 -[N-[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine-bis-trifluoroacetate) (No. 61)

To a mixture of 0.42 g (0.45 mmol) of 1-[4-amino-3,5-dibromo-N 2 -[N-[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-D-phenylalanyl]-N6-[(1.1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine in 30 ml of methylene chloride were added 3 ml of trifluoroacetic acid. The reaction mixture was stirred for 3 hours at ambient temperature and then evaporated down in vacuo. The remaining residue was triturated with ether and the resulting beige amorphous solid (0.43 g; 37% of theory) was suction filtered.

IR (KBr): 1643, 1678 cm −1 (C═O)

R f : 0.6 (FM1)

ESI-MS: (M+H) + =832/834/836/838 (Br 2 , Cl)

The following were prepared analogously:

%

No.

RCO

Z

R 2

A

NR 3 R 4

n

Remarks

Yield

MS

R f

Eluant

IR [cm −1 ]

21

N6

N—H

AS1

A1

C4

1

65

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

828/30/32 (Br 2 )

1635.5

22

N16

N—H

AS1

A1

C1

1

98

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

874/6/8 (Br 2 )

1643.3; 1676

141

N61

N—H

AS1

A1

C1

1

46

ESI: (M + H) + =

0.1

FM1

(KBr): C═O

855/7/9 (Br 2 )

1634; 1705

142

N60

N—H

AS1

A1

C1

1

50

ESI: (M + H) + =

0.1

FM1

(KBr): C═O

882/4/6 (Br 2 )

1643; 1711

154

N66

N—H

AS1

A1

C1

1

60

ESI: (M + H) + =

0.1

FM1

(KBr): C═O

868/70/72 (Br 2 )

1645; 1653

197

N15

N—H

AS1

A1

C8

1

21

ESI: (M + H) + =

0.18

FM7

(KBr): C═O

859/61/63 (Br 2 )

1678;

1201.6; CF3

1180.4;

1134.1

198

N51

N—H

AS1

A1

C8

1

27

ESl: (M + H) + =

0.22

FM7

(KBr): C═O

829/31/33 (Br 2 )

1676; CN

2221.9; CF3

1203.5;

1180.4; 1132

218

N15

N—H

AS6

A1

C1

1

25.7

ESI: (M + H) + =

0.45

FM1

(KBr): C═O

776/8 (Br)

1695.3;

1635.5

287

N15

N—H

AS1

A8

C1

1

36.5

ESI: (M + H) + =

0.5

FM2

(KBr): C═O

840/2/4 (Br 2 )

1695.3;

1637.5

19

N15

N—H

AS1

A1

C1

1

44

ESI; (M + H) + =

0.43

FM2

(KBr): C═O

854/6/8 (Br 2 )

1695.3;

1637.5

14

N10

N—H

AS1

A1

C1

1

25.5

ESI: (M + H) + =

0.33

FM2

(KBr): C═O

774/6/8 (Br 2 )

1683.8

16

N12

N—H

AS1

A1

C1

1

64.4

ESI: (M + H) + =

0.55

FM2

(KBr): C═O

802/4/6 (Br 2 )

1639.4

29

N22

N—H

AS1

A1

C1

1

91.2

ESI: (M + H) + =

0.5

FM2

(KBr): —NH—

867/69/71 (Br 2 )

3427.3; C═O

1643.3;

1678.0

30

N23

N—H

AS1

A1

C1

1

83.3

ESI: (M + H) + =

0.5

FM2

(KBr): C═O

833/5/7/9 (Br 2 , Cl)

1643.3;

1676.0

31

N24

N—H

AS1

A1

C1

1

100

ESI: (M + H) + =

0.51

FM2

(KBr): C═O

843/5/7 (Br 2 )

1645.2;

1676.0

63

N46

N—H

AS1

A1

C1

1

100

ESI: (M + H) + =

0.58

FM2

(KBr): C═O

764/6/8 (Br 2 )

1643.3;

1676.0

68

N15

N—H

AS1

A1

C6

1

80

ESI: (M + H) + =

0.18

FM1

(KBr): C═O

833/5/7 (Br 2 )

1683.8

69

N15

N—H

AS1

A1

C5

1

74

ESI: (M + H) + =

0.18

FM1

(KBr): C═O

854/6/8 (Br 2 )

1683.8; 1639.4

70

N45

N—H

AS1

A1

C6

1

89

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

897/9/901 (Br 2 )

1695.3; 1676.0

71

N16

N—H

AS1

A1

C5

1

82

ESI: (M + H) + =

0.22

FM1

(KBr): C═O

874/6/8 (Br 2 )

1678.0;

1639.4

72

N15

N—H

AS5

A1

C1

1

97

ESI: (M + H) + =

0.16/0.2

FM1

(KBr): C═O

838/40/42 (Br 2 )

1685.7;

1643.3

77

N45

N—H

AS5

A1

C1

1

66

ESI: (M + H) + =

0.33/0.4

FM1

(KBr): C═O

852/4/6 (Br 2 )

1683.8; 1645.2

NH 3 3427.3

24

N18

N—H

AS1

A1

C1

1

94

ESI: (M + H) + =

0.11

FM1

(KBr): C═O

775/7/9 (Br 2 )

1676.0;

1643.3

25

N19

N—H

AS1

A1

C1

1

92

ESI: (M + H) + =

0.13

FM1

(KBr): C═O

833/5/7 (Br 2 )

1676.0;

1643.3

26

N20

N—H

AS1

A1

C1

1

98

EI: M + = 762/4/6

0.11

FM1

(KBr): C═O

(Br 2 )

1676.0;

1643.3

27

N21

N—H

AS1

A1

C1

1

98

ESI: (M + H) + =

0.04

FM1

(KBr): C═O

814/6/8 (Br 2 )

1676.0;

1645.2

41

N34

N—H

AS1

A1

C1

1

97

ESI: (M + H) + =

0.08

FM1

(KBr): C═O

835/38/40/42

1676.0;

(Br 3 )

1643.3

42

N35

N—H

AS1

A1

C1

1

83

ESI: (M + H) + =

0.09

FM1

(KBr): C═O

803/5/7 (Br 2 )

1676.0;

1643.3

43

N36

N—H

AS1

A1

C1

1

87

ESI: (M + H) + =

0.04

FM1

(KBr): C═O

815/7/9 (Br 2 )

1676.0;

1645.2

53

N42

N—H

AS1

A1

C1

1

89

ESI: (M + H) + =

0.11

FM1

(KBr): C═O

805/7/9 (Br 2 )

1676.0;

1634.3

54

N43

N—H

AS1

A1

C1

1

84

ESI: (M + H) + =

0.11

FM1

(KBr): C═O

835/7/9/41 (Br 3 )

1678.0;

1643.3

55

N44

N—H

AS1

A1

C1

1

95

ESI: (M + H) + =

0.07

FM1

(KBr): C═O

796/8/800 (Br 2 )

1676.0;

1643.3

67

N48

N—H

AS1

A1

C1

1

90

ESI: (M + H) + =

0.06

FM1

(KBr): C═O

797/99/801 (Br 2 )

1682.9;

1643.3

184

N77

N—H

AS1

A1

C4

1

88

ESI: (M + H) + =

0.11

FM1

(KBr): C═O

855/7/9 (Br 2 )

1637.5; 1676

248

N78

N—H

AS1

A1

C1

1

97

ESI: (M + H) + =

0.14

FM1

(KBr): C═O

855/7/9 (Br 2 )

1643.3; 1676;

1772.5

181

N75

N—H

AS1

A1

C4

1

95

ESI: (M + H) + =

0.04

FM1

(KBr): C═O

793/5/7 (Br 2 )

1637.5; 1676

182

N76

N—H

AS1

A1

C4

1

93

ESI: (M + H) + =

0.04

FM1

(KBr): C═O

793/5/7 (Br 2 )

1637.5; 1678

183

N74

N—H

AS1

A1

C4

1

91

ESI: (M + H) + =

0.08

FM1

(KBr): C═O

807/9/11 (Br 2 )

1635.5; 1678

250

N15

N—H

AS1

A1

C18

1

98

ESI: (M + H) + =

0.14

FM1

(KBr): C═O

885/7/9 (Br 2 )

1633.6; 1680

251

N15

N—H

AS10

A1

C4

1

84

ESI: (M + H) + =

0.27

FM1

(KBr): C═O

837/39/41 (Br 2 )

1635.5;

1693.4

252

N15

N—H

AS10

A1

C4

1

87

ESI: (M + H) + =

0.31

FM1

(KBr): C═O

837/39/41 (Br 2 )

1637.5;

1685.7

253

N15

N—H

AS10

A1

C1

1

82

ESI: (M + H) + =

0.18

FM1

(KBr): C═O

838/40/42 (Br 2 )

1690

255

N77

N—H

AS1

A1

C1

1

94

ESI: (M + H) + =

0.08

FM1

(KBr): C═O

856/8/60 (Br 2 )

1645; 1676

256

N15

N—H

AS4

A1

C18

1

74

ESI: (M + H) + =

0.28

FM1

(KBr): C═O

884/6/8 (Br 2 )

1633.6;

1683.8

271

N81

N—H

AS4

A1

C8

1

76

ESI: (M + H) + =

0.2

FM1

(KBr): C═O

874/6/8 (Br 2 )

1674

280

N84

N—H

AS4

A1

C4

1

66

ESI: (M + H) + =

0.26

FM1

(KBr): C═O

866/8/70 (Br 2 )

1635.5;

1685.7

N15

N—H

AS1

A1

C1

0

98

ESI: (M + H) + =

0.2

ButOH/

(KBr): C═O

840/2/4 (Br 2 )

ACOH/H2O =

1643; 1680

4/1/1

(v/v/v)

179

N73

N—H

AS1

A1

C4

1

86

ESI: (M + H) + =

0.03

FM1

(KBr): C═O

779/81/83 (Br 2 )

1642.8; 1676

N66

N—H

AS4

A0

1

75

ESI: (M + H) + =

0.3

FM1

(KBr): C═O

744/6/8 (Br 2 )

1620/1666

516

N66

N—H

AS1

A1

C1

1

Isomer to

82

0.1

FM1

No. (154)

517

N66

N—H

AS1

A1

C1

1

Isomer to

80

0.1

FM1

No. (154)

518

N66

N—H

AS1

A1

C1

1

Isomer to

89

0.1

FM1

No. (154)

521

N66

N—H

AS4

A0

C17

1

THF/DMF

75

ESI: (M + H) + =

0.15

FM1

(KBr): C═O

744/6/8 (Br 2 )

1666/1620

522

N66

N—H

AS1

A0

C17

1

THF/DMF

100

ESI: (M + H) + =

0.15

FM1

(KBr): C═O

745/7/9 (Br 2 )

1624/1655

643

N66

CH 2

AS21

A0

C17

1

53

ESI: (M + H) + =

0.35

FM1

(KBr): C═O

640

1635/1668

N66

CH 2

AS2

A0

C17

1

100

EI: M + = 621

0.35

FM1

(KBr): C═O

1670

EXAMPLE 7

Preparation of compounds of general formula:

1-[N 2 -[N-[[[(2-methoxyphenyl)methyl]amino]carbonyl]-3,5-dibromo-D,L-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

A mixture of 910 mg (1.0 mmol) of 1-[N 2 -[N-[[[2-(2-methoxy-phenyl)methyl]amino]carbonyl]-3,5-dibromo-D,L-tyrosyl]-N 6 -[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, 50 ml of glacial acetic acid, 25 ml of a 33% solution of hydrogen bromide in glacial acetic acid and 2 ml of anisole was stirred overnight at ambient temperature. The reaction mixture was stirred into diethylether and the sticky precipitate formed was suction filtered. The crude product was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol/conc. aqueous ammonia=8/2/0.2 (v/v/v)). 0.37 g (48% of theory) of an amorphous solid were obtained.

IR (KBr): 1630 cm −1 (C═O)

ESI-MS: (M+H) + =774/776/778 (Br 2 ) (M+2H) ++ =387.7/388.7/389.7 (Br 2 )

The following were prepared analogously (in each case n=1):

					%
No.	RCO	R 2	A	NR 3 R 4	Yield	MS	R f	Eluant	IR [cm −1 ]
1	N1	AS1	A1	C1	46.9	ESI: (M + H) + =	0.36	FM1	(KBr): C═O
						788/90/92 (Br 2 )			1627.8
2	N2	AS1	A1	C1	100	ESI: (M + H) + =	0.48	FM2	(KBr): C═O
						788/90/92 (Br 2 )			1641.3; NH,
									NH + 3419.6
4	N4	AS1	A1	C1	2.8	ESI: (M + H) + =	0.52	FM2
						818/20/22 (Br 2 )

EXAMPLE 8

Preparation of compounds of general formula:

1-[N 2 -[N-[4-(4-fluorophenyl)-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-N 6 -[(1.1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

To a solution of 0.18 g (0.001 mol) 4-(4-fluorophenyl)-butanoic acid in a mixture of 4 ml of dimethylformamide and 10 ml of tetrahydrofuran was added with stirring a mixture of 0.71 g (0.001 mol) 1-[N2-(3,5-dibromo-D-tyrosyl)-N 6 -[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, 0.32 g (0.001 mol) TBTU and 0.13 g (0.001 mol) DIEA and the mixture was stirred in a nitrogen atmosphere for 2 days. The reaction mixture was then evaporated down in vacuo and the remaining residue was taken up in dichloromethane. The organic phase was with 20% aqueous citric acid solution and then extracted with 10% aqueous sodium hydrogen carbonate solution, dried over sodium sulphate, filtered and evaporated down in vacuo. After stirring the residue with ether 0.68 g (77% of theory) of the desired product remain as an amorphous residue.

IR (KBr): 1641, 1676 cm −1 (C═O)

R f : 0.65 (FM2)

ESI-MS: (M+H) + =875/877/879 (Br 2 ) (M+H+Na) ++ =449/450/451 (Br 2 )

The following were prepared analogously (in each case n=1):

						%
No.	RCO	R 2	A	NR 3 R 4	Remarks	Yield	MS	R f	Eluant	IR [cm −1 ]
123	N62	AS1	A0	C1	DMF/THF as	20	ESI: (M + H) + =	0.3	FM1	(KBr): C═O
					solvent		725/7/9 (Br 2 )			1641.3;
										1691.5
124	N63	AS1	A0	C1	DMF/THF as	53	ESI: (M + H) + =	0.2	FM1	(KBr): C═O
					solvent		725/7/9 (Br 2 )			1641.3;
										1691.5
322	N63	AS1	A0	C8	DMF/THF as	19	EI: M + =	0.3	FM1	(KBr): C═O
					solvent		729/31/33 (Br 2 )			1629.8;
										1695.3
	N11	AS1	A3	C1		46	ESI: (M + H) + =			(KBr): C═O
							873/5/7 (Br 2 )			1625.9;
										1645.2
	N18	AS1	A3	C1	THF/DMF as	77	ESI: (M + H) + =	0.78	FM7	(KBr): C═O
					solvent		875/7/9 (Br 2 )			1641.3
	N20	AS1	A3	C1	THF/DMF as	88	ESI: (M + H) + =	0.67	FM7	(KBr): C═O
					solvent		863/5/7 (Br 2 )			1643.3
	N21	AS1	A3	C1	THF/DMF as	78	ESI: (M + H) + =	0.47	FM7	(KBr): C═O
					solvent		917/6/8 (Br 2 )			1643.3
	N46	AS1	A3	C1	THF/DMF as	80	ESI: (M + H) + =	0.65	FM7	(KBr): C═O
					solvent		905/7/9 (Br 2 )			1643.3
	N43	AS1	A3	C1	THF/DMF as	75		0.75	FM7	(KBr): C═O
					solvent					1645.2
	N44	AS1	A3	C1	THF/DMF as	79	ESI: (M + H) + =	0.65	FM7	(KBr): C═O
					solvent		896/98/900			1629.8
							(Br 2 )

EXAMPLE 9

Preparation of compounds of general formula:

1-[N 2 -[N-[[[(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dichloro-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine-bis-(trifluoroacetate (No. 20)

To a suspension of 0.33 g (2 mmol) of CDT and 1 ml of triethylamine in about 30 ml of tetrahydrofuran, cooled to −10° C., was added dropwise, with stirring, a solution of 1.0 g (1.6 mmol) of 1-[N 2 (-3.5-dichloro-D-tyrosyl]-N 6 -[(1.1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine in 50 ml of tetrahydrofuran within 60 minutes. The reaction mixture was stirred for 1 hour at 0° C., then stirred for 2 hours at ambient temperature, mixed with a tetrahydrofuran solution of 0.24 g (1.6 mmol) of (3-methoxyphenyl)-ethanamine, refluxed for 3 hours and stirred overnight at ambient temperature. After elimination of the solvent in vacuo the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: FM1). The resulting intermediate compound was stirred in a mixture of 5 ml of trifluoroacetic acid and 80 ml of dichloromethane overnight, the solvent was eliminated in vacuo and the residue triturated with ether. 709 mg (43% of theory) of the desired compound as an amorphous solid.

IR (KBr): 1643, 1676 cm −1 (C═O)

R f : 0.41 (FM2)

ESI-MS: (M+H) + =700/702/704 (Br 2 ) (M+2H) ++ =350.7/351.7/352.7 (Br 2 )

The following were prepared analogously (in each case n=1):

						%
No.	RCO	R 2	A	NR 3 R 4	Remarks	Yield	MS	R f	Eluant	IR [cm −1 ]
23	N17	AS1	A1	C1	NEt 3 as base	55	ESI: (M + H) + =	0.2	FM1	(KBr): C═O
							798/800/802 (Br 2 )			1643.3;
										1676
47	N39	AS1	A1	C1	NEt 3 as base	69.4	ESI: (M + H) + =	0.1	FM1	(KBr): C═O
							676/78/80 (Br 2 )			1645.2;
										1676
50	N64	AS1	A1	C1	NEt 3 as base	76	ESI: (M + H) + =	0.2	FM1	(KBr): C═O
							828/830/832 (Br 2 )			1643.3;
										1678
51	N40	AS1	A1	C1	NEt 3 as base;	79.7	ESI: (M + H) + =	0.2	FM1	(KBr): C═O
					dehydration		826/828/30 (Br 2 )			1643.3;
										1678
52	N41	AS1	A1	C1	NEt 3 as base;	21.8	ESI: (M + H) + =	0.2	FM1	(KBr): C═O
					dehydration		826/828/30 (Br 2 )			1645.2;
										1679.9
56	N16	AS1	A1	C4	NEt 3 as base	5	ESI: (M + H) + =	0.3	FM1	(KBr): C═O
							873/75/77 (Br 2 )			1637.5;
										1676
57	N45	AS1	A1	C4	NEt 3 as base	32	ESI: (M + H) + =	0.2	FM1	(KBr): C═O
							867/9/71 (Br 2 )			1635.5;
										1678
66	N47	AS1	A1	C4	NEt 3 as base	28.4	ESI: (M + H) + =	0.1	FM1	(KBr): C═O
							764/6/8 (Br 2 )			1635.5;
										1676
46	N38	AS1	A1	C1	NEt 3 as base	86	ESI: (M + H) + =	0.35	FM1	(KBr): C═O
							826/28/30 (Br 2 )			1645.2;
										1684
232	N66	AS4	A1	C8		69	ESI: (M + H) + =	0.33	FM1	(KBr): C═O
							872/4/6 (Br 2 )			1645
233	N66	AS4	A1	C1	THF/DMF as	16	ESI: (M + H) + =	0.32	FM1	(KBr): C═O
					solvent		867/69/71 (Br 2 )			1653
234	N66	AS4	A1	C4		68	ESI: (M + H) + =	0.42	FM1	(KBr): C═O
							867/69/71 (Br 2 )			1645
235	N66	AS1	A1	C8		26	ESI: (M + H) + =	0.27	FM1	(KBr):C═O
							873/5/7 (Br 2 )			1645
236	N71	AS1	A1	C1		30	ESI: (M + H) + =	0.22	FM1	(KBr): C═O
							880/2/4 (Br 2 )			1636; 1678
237	N71	AS4	A1	C8		28	ESI: (M + H) + =	0.25	FM1
							884/6/8 (Br 2 )
238	N71	AS4	A1	C1		20	ESI: (M + H) + =	0.3	FM1	(KBr): C═O
							879/81/83 (Br 2 )			1641; 1682
18	N14	AS1	A1	C1	Cleaving of Boc	26.3	ESI: (M + H) + =	0.55	FM2	(KBr): C═O
					protecting group with		813/5/7 (Br 2 )			1641.3;
					methanolic HCl					1716.5
					solution
17	N13	AS1	A1	C1	Cleaving of Boc	55.2	ESI: (M + H) + =	0.55	FM2	(KBr): C═O
					protecting group with		799/801/803 (Br 2 )			1639.4
					methanolic HCl
					solution
9	N6	AS1	A1	C1	Cleaving of Boc	41.3	ESI: (M + H) + =	0.44	FM2	(KBr): C═O
					protecting group with		829/31/33 (Br 2 )			1639.4
					methanolic HCl
					solution
10	N7	AS1	A1	C1	Cleaving of Boc	57.6	ESI: (M + H) + =	0.32	FM2	(KBr): C═O
					protecting group with		829/31/33 (Br 2 )			1639.4
					methanolic HCl
					solution
20	N2	AS3	A1	C1		43	ESI: (M + H) + =	0.41	FM2	(KBr): C═O
							700/2/4 (Br 2 )			1643.3;
										1676.0
283	N102	AS4	A3	C4	NEt 3 as base	65	ESI: (M + H) + =	0.24	FM1	(KBr): C═O
							864/6/8 (Br 2 )			1637.5;
										1676

EXAMPLE 10

Preparation of compounds of general formula:

1-[N 2 -[N-[4-(2,3-dichlorophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine-tris-(trifluoroacetate) (No. 74)

To a solution of 0.35 g (2.1 mmol) of CDT in 50 ml of tetrahydrofuran were added with cooling (0° C.) and stirring 1.0 g (1.4 mmol) of 1-[N 2 -(3,5-dibromo-D-tyrosyl)-N 6 -[(1,1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine and the mixture was stirred for 30 minutes at 0° C. and for a further 30 minutes at ambient temperature. After the addition of 0.47 g (1.75 mmol) of 1-(2,3-dichlorophenyl)piperazine-hydrochloride and 0.25 ml of triethylamine the reaction mixture was refluxed for 5 hours and after cooling mixed with 70 ml of saturated aqueous sodium hydrogen carbonate solution. The organic phase was separated off, the aqueous phase was extracted twice with 50 ml of tetrahydrofuran. The combined organic phases were washed with saturated aqueous saline solution, dried over magnesium sulphate, filtered and evaporated down in vacuo. The residue was triturated with ether, suction filtered and then stirred for 2 hours with a mixture of 50 ml of dichloromethane and 5 ml of trifluoroacetic acid. After evaporation of the reaction mixture in vacuo and trituration of the residue with ether, 0.8 g (47% of theory) of an amorphous solid are left.

IR (KBr): 1643.3, 1676 cm −1 (C═O)

R f : 0.78 (FM7)

ESI-MS: (M+H) + =867/869/871/873/875 (Br 2 , Cl 2 ) (M+2H) ++ =434/435/436/437 (Br 2 , Cl 2 )

The following were prepared in the same way (in each case n=1):

					%
No.	RCO	R 2	A	NR 3 R 4	Yield	MS	R f	Eluant	IR [cm −1 ]
36	N29	AS1	A1	C1	17.3	ESI : (M + H) + =	0.35	MeOH/NH 4l OH =	(KBr): C═O
						889/91/93 (Br 2 )		9/1 (v/v)	1643.3;
									1674.1
208	N15	AS1	A1	C1	53.5	ESI: (M + H) + =	0.43	FM2	(KBr): C═O
						854/6/8 (Br 2 )			1691.5;
									1635.5
209	N15	AS1	A1	C1	47.7	ESI: (M + H) + =	0.55	FM2	(KBr): C═O
						854/6/8 (Br 2 )			1695.3;
									1637.5
210	N15	AS1	A1	C1	28	ESI: (M + H) + =	0.48	FM2	(KBr): C═O
						854/6/8 (Br 2 )			1689.5;
									1639.4
75	N50	AS1	A1	C1	16.5	ESI: (M + H) + =	0.63	FM2	(KBr): C═O
						867/69/71/73/75			1643.3;
						(Br 2 , Cl 2 )			1676.0;
74	N49	AS1	A1	C1	47	ESI: (M + H) + =	0.65	FM2	(KBr): C═O
						867/69/71/73/75			1643.3;
						(Br 2 , Cl 2 )			1676.0
76	N51	AS1	A1	C1	13.4	ESI: (M + H) + =	0.58	FM2	(KBr): C═O
						824/6/8 (Br 2 )			1643.3;
									1676.0; CN
									2219.9
79	N52	AS1	A1	C1	11.4	ESI: (M + H) + =	0.59	FM2	(KBr): C═O
						901/3/5/7 (Br 2 ,			1645.2;
						Cl)			1676.3
45	N37	AS1	A1	C1	43	ESI: (M + H) + =	0.6	FM2	(KBr): C═O
						784/6/8 (Br 2 )			1643.3;
									1678.0
39	N32	AS1	A1	C1	48.3	ESI: (M + H) + =	0.57	FM2	(KBr): C═O
						795/7/9 (Br 2 )			1643.3;
									1678.0
38	N31	AS1	A1	C1	54.1	ESI: (M + H) + =	0.6	FM2	(KBr): C═O
						844/6/8 (Br 2 )			1643.3;
									1678.0; NO2
									1543.0
37	N30	AS1	A1	C1	61.6	ESI: (M + H) + =	0.6	FM2	(KBr): C═O
						813/5/7 (Br 2 )			1643.3;
									1676.0
35	N28	AS1	A1	C1	74.8	ESI: (M + H) + =	0.55	FM2	(KBr): C═O
						800/2/4 (Br 2 )			1639.4;
34	N27	AS1	A1	C1	36.8	ESI: (M + H) + =	0.43	FM2	(KBr): C═O
						800/2/4 (Br 2 )			1641.3;
									1714.6; NH +
									3409.9
32	N25	AS1	A1	C1	50.0	ESI: (M + H) + =	0.44	FM2	(KBr): C═O
						737/39/41 (Br 2 )			1645.2;
									1678.3
33	N26	AS1	A1	C1	42	ESI: (M + H) + =	0.33	FM2	(KBr): C═O
						767/69/71 (Br 2 )			1676.0
40	N33	AS1	A1	C1	14.5	ESI: (M + H) + =	0.58	FM2	(KBr): C═O
						802/4/6 (Br 2 )			1643.3;
									1676.0
28	N6	AS3	A1	C1	67.2	ESI: (M + H) + =	0.43	FM2	(KBr): C═O
						741/3/5 (Cl 2 )			1641.3;
									1716.5
64	N23	AS1	A1	C4	39	ESI: (M + H) + =	0.68	FM2	(KBr): C═O
						832/4/6/8			1627.8;
						(Br 2 , Cl)			1678.0
65	N15	AS1	A1	C4	41	ESI: (M + H) + =	0.61	FM2	(KBr): C═O
						853/5/7 (Br 2 )			1631.7;
									1695.3
365	N111	AS1	A1	C1	36.9	ESI: (M + H) + =	0.09	FM1	(KBr): C═O
						839/41/43 (Br 2 )			1626/1676

EXAMPLE 11

1-[N2-[N-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]carbonyl]-3,5 dibromo-D,L-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (No. 3)

A mixture of 0.8 g (0.84 mmol) of 1-[N 2 -[N-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-N 6 -[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, 50 ml of glacial acetic acid, 25 ml of a 33% solution of hydrogen bromide in glacial acetic acid and 2 ml of anisole was stirred for 12 hours at ambient temperature. The reaction mixture was stirred into diethylether and the resulting precipitate was suction filtered. The solid residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol/conc. aqueous ammonia=8/2/0.2 (v/v/v)). 0.3 g (44% of theory) of the desired product was obtained as an amorphous solid.

IR (KBr): 1643.3 cm −1 (C═O)

R f : 0.17 (ethyl acetate/methanol/conc. aqueous ammonia=6/4/1)

ESI-MS: (M+H) + =818/820/822 (Br 2 ) (M+2H) ++ =409.5/410.5/411.5 (Br 2 )

EXAMPLE 12

1-[N 2 -[3,5-dibromo-N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-D-tyrosyl]-L-arginyl]-4-(4-pyridinyl)-piperazine-bis-(trifluoroacetate) (No. 4)

A stirred mixture of 20 ml of trifluoroacetic acid, 1.3 ml of anisole and 0.9 ml of ethanedithiol was mixed with 2.1 g (1.9 mmol) of solid 1-[N 2 -[3,5-dibromo-N-[[[2-(3-methoxyphenyl)-ethyl]amino]carbonyl]-N G -(2,2,5,7,8-pentamethylchroman-6-sulphonyl)-D-tyrosyl]-L-arginyl]-4-(4-pyridinyl)-piperazine whilst cooling with ice and stirred for a further 45 minutes whilst cooling with ice, then for 3 hours at ambient temperature. The resulting precipitate was suction filtered and discarded, the filtrate was evaporated down in vacuo, the residue remaining was mixed with toluene and again evaporated down in vacuo. The resulting solid residue was triturated with a mixture of diethylether and acetone and the white solid formed was suction filtered and dried. 1.7 g (65% of theory) of the desired title compound were obtained.

IR (KBr): 1674, 1645 cm −1 (C═O)

R f : 0.15 (FM: BuOH/AcOH/H 2 O 4/1/1 (v/v/v))

ESI-MS: (M+H) + =816/818/820 (Br 2 ) (M+2H) ++ =408.6/409.6/410.6 (Br 2 )

EXAMPLE 13

Preparation of compounds of general formula:

(R,S)-1-[2-(4-amino-3,5-dibromobenzoyl)-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-4-oxobutyl]-4-(4-pyridinyl)-piperidine (No. 291)

A mixture of 0.97 g (1.8 mmol) of (R,S)-4-amino-3,5-dibromo-γ-oxo-β-[[4-(4-pyridinyl)-1-piperidinyl]methyl]-benzenebutanoic acid, 0.48 g (1.8 mmol) of 4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-piperidine, 2 ml of triethylamine, 0.58 g (1.8 mmol) of TBTU, 0.24 g (1.8 mmol) of HOBt, 25 ml of THF and 25 ml of DMF was stirred for 4 hours at ambient temperature. The reaction mixture was evaporated down in vacuo, the residue was taken up in a mixture of ethyl acetate and methanol (95/5 (v/v)) and washed with saturated aqueous sodium hydrogen carbonate solution. The organic phase was dried and evaporated down in vacuo. The residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol=9/1 (v/v); then MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: methylene chloride/ethanol=9/1 (v/v)). 0.2 g (15% of theory) of the desired product were obtained as a white amorphous solid.

IR (KBr): 1668.3 cm −1 (C═O)

R f : 0.5 (FM2)

ESI-MS: (M+H) + =737/739/741 (Br 2 ) (M+Na) + =759/761/763 (Br 2 )

The following were prepared analogously:

				%
No.	RCO	R 2	NR 3 R 4	Yield	MS	R f	Eluant	IR [cm −1 ]
291	N66	AS4	C4	15	ESI: (M + H) + =	0,36	CH 2 Cl 2 /	(KBr): C═O
					737/39/41 (Br 2 )		EtOH	1668
296	N66	AS4	C8	14	ESI: (M + H) + =	0,66	FM1	(KBr): C═O
					743/5/7 (Br 2 )			1668
302	N71	AS4	C8	19	ESI: (M + H) + =	0,54	FM1	(KBr): C═O
					755/7/9 (Br 2 )			1682

EXAMPLE 14

1-[4-amino-N-[[4-[7-(aminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine (No. 312)

a) 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine (No. 307)

Prepared analogously to Example 3 from methyl 3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazoline-7-carboxylate, 1-[4-amino-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine and CDT in a yield of 27.2% of theory. Colourless, amorphous substance, Rf 0.5 (eluant: dichloromethane/cyclohexane/methanol/conc. ammonia=7/1.5/1.5/0.2 (v/v/v/v)).

IR(KBr): 1718.5, 1670.3, 1618.2 cm −1 (C═O)

ESI-MS: (M+H) + =796/798/800 (Br 2 ) (M+Na) + =818/820/822 (Br 2 )

The following were obtained accordingly:

From methyl-3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazoline-7-carboxylate, 1-[4-amino-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine and CDT in a yield of 30.3% of theory: 1-4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl -D-phenyl-alanyl]-4-(1-piperidinyl)-piperidine (No. 304), R f =0.75 (FM1).

IR(KBr): 1720.4, 1668.3, 1620.1 cm −1 (C═O)

ESI-MS: (M+H) + =802/804/806 (Br 2 ) (M+Na) + =824/826/828 (Br 2 )

From methyl-3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazoline-7-carboxylate, 1-(3,5-dibromo-D-tyrosyl)-4-(1-piperidinyl)-piperidine and CDT in a yield of 35% of theory: 1-[3,5-dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine (No. 422), R f 0.54 (eluant: dichloromethane/cyclohexane/methanol/conc. ammonia=7/1.5/1.5/0.2 (v/v/v/v)).

IR(KBr): 1720.4, 1668.3, 1627.8 cm −1 (C═O)

ESI-MS: (M+H) + =803/805/807 (Br 2 ) (M+Na) + =825/827/829 (Br 2 )

From methyl-3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazoline-7-carboxylate, 1-(3,5-dibromo-D-tyrosyl)-4-(4-pyridinyl)-piperidine and CDT in a yield of 45% of theory: 1-[3,5-dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine (No. 420), R f 0.56 (FM1).

IR(KBr): 1718.5, 1664.5, 1624.0 cm −1 (C═O)

ESI-MS: (M+H) + =797/799/801 (Br 2 ) (M+Na) + =819/821/823 (Br 2 )

b) 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine (No. 309)

Prepared analogously to Example A37) from 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)piperidine by saponification with lithium hydroxide in a yield of 95% of theory. Colourless, amorphous substance, R f 0.25 (eluant: dichloromethane/methanol/conc. ammonia=7.5/2.5/0.5 (v/v/v)).

IR(KBr): 1666.4, 1614.3 cm −1 (C═O)

ESI-MS: (M-H) − =780/782/784 (Br 2 )

The following were obtained accordingly:

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine in a yield of 60.2% of theory: 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-pIperidinyl]carbonyl]-D-phenlalanyl]-4-(1-piperidinyl)-piperidin (No. 306), R f 0.15 (FM1).

IR(KBr): 1635.5 cm −1 , broad (C═O)

ESI-MS: (M+H) + =788/790/792 (Br 2 ) (M+Na) + =810/812/814 (Br 2 )

From 1-[3,5-dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine in a yield of 62% of theory: 1-[3,5-dibromo-N-[[4-[7-(hydroxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine (No. 423), R f 0.03 (eluant: dichloromethane/cyclohexane/methanol/conc. ammonia=7/1.5/1.5/0.2 (v/v/v/v)).

IR(KBr): 1635.5 cm −1 , broad (C═O)

ESI-MS: (M+H) + =789/791/793 (Br 2 )

From 1-[3,5-dibromo-N-[[4-(1,3-dihydro-5-(methoxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine in a yield of 80% of theory: 1-[3,5-dibromo-N-[[4-(1,3-dihydro-5-(hydroxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine (No. 151). Colourless, amorphous substance.

IR(KBr): 1701.1, 1625.9 cm −1 (C═O)

ESI-MS: (M+H) + =767/769/771 (Br 2 ) (M+2H) ++ =383/384/385 (Br 2 )

From 1-[3,5-dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine in a yield of 82% of theory: 1-[3,5-dibromo-N-[[4-[7-(hydroxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine (No. 421), R f 0.03 (FM1). Colourless, amorphous substance.

IR(KBr): 1625 wide cm −1 (C═O)

ESI-MS: (M+H) + =783/785/787 (Br 2 ) (M+Na) + =805/807/809 (Br 2 )

c) 1-[4-amino-N-[[4-[7-(aminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine (No. 312)

Prepared analogously to Example 1 from 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine and ammonium carbonate in the presence of TBTU in a yield of 40.6% of theory. Colourless, amorphous substance, R f 0.8 (eluant: dichloromethane/methanol/conc. ammonia=7.5/2.5/0.5 (v/v/v)).

IR(KBr): 1670.3, 1616.3 cm −1 (C═O)

ESI-MS: (M+H) + =781/783/785 (Br 2 ) (M+Na) + =803/805/807 (Br 2 )

The following were obtained accordingly:

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine and ethanolamine in a yield of 34.6% of theory: 1-[4-amino-3,5-dibromo-N-[[4-[7-(2-hydroxyethylaminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenyalanyl]-4-(4-pyridinyl)-piperidine, (No. 313) R f =0.7 (eluant: dichloromethane/methanol/conc. ammonia=7.5/2.5/0.5 v/v/v).

IR(KBr): 1662.5, 1618.2 cm −1 (C═O)

ESI-MS: (M+H) + =825/827/829 (Br 2 ) (M+Na) + =847/849/851 (Br 2 ) (M+2H) ++ =413/414/415 (Br 2 ) (M+H+Na) ++ =424/425/426 (Br 2 )

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine and 1-methylpiperazine in a yield of 44.9% of theory: 1-[4-amino-3,5-dibromo-N-[[-4-[7-[(4-methyl-1-piperazinyl)carbonyl]-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine, (No. 430) R f =0.28 (eluant: ethyl acetate/methanol/conc. ammonia=8/1.5/0.3 v/v/v).

IR(KBr): 1618.2 cm −1 (C═O)

ESI-MS: (M+H) + =864/866/868 (Br 2 ) (M+Na) + =886/888/890 (Br 2 ) (M+2H) ++ =432/433/434.7 (Br 2 )

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine and methylammonium chloride in a yield of 37% of theory: 1-[4-amino-3,5-dibromo-N-[[4-[7-(methylaminocarbonyl)-3,4-dihydro-2(1H)-onoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine, (No. 424) R f =0.49 (FM1)

IR(KBr): 1662.5, 1622 cm −1 (C═O)

ESI-MS: (M+H) + =795/797/799 (Br 2 ) (M+Na) + =817/819/821 (Br 2 )

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2((1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl)]-4-(1-piperidinyl)-piperidine and ammonium carbonate in a yield of 12% of theory: 1-[4-amino-N-[[4-[7-(aminocarbonyl)-3,4-dihydro-2(1H)-oxquinazolin-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1)-piperidinyl)-piperidine (No. 310), R f =0.7 (eluant: dichloromethane/methanol/conc. ammonia=7.5/2.5/0.5 (v/v/v)).

IR(KBr): 1670.3, 1618.2 cm −1 (C═O)

ESI-MS: (M+H) + =787/789/791 (Br 2 )

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine and ethanolamine in a yield of 11.4% of theory: 1-[4-amino-3,5-dibromo-N-[[4-[7-(2-hydroxyethylaminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine (No. 311), R f =0.65 (eluant: dichloromethane/methanol/conc. ammonia=7.5/2.5/0.5 (v/v/v)).

IR(KBr): 1660.6, 1620.1 cm −1 (C═O)

ESI-MS: (M+H) + =831/833/835 (Br 2 ) (M+2H) ++ =416/417/418 (Br 2 ) (M+H+Na) ++ =427/428/429 (Br 2 )

EXAMPLE 15

4-(1-acetyl-4-piperidinyl)-1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-phenylalanyl]-piperidine (No. 372)

a) 1-[4-amino-3,5-dibromo-D-phenylalanyl]-4-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-piperidine

A mixture of 5.60 g (0.01 mol) of 4-amino-3,5-dibromo-N 2 -(9-fluorenylmethoxycarbonyl)-D-phenylalanine, 1.35 g (0.01 mol) HOBt, 3.21 g (0.01 mol) TBTU, 1.29 g (0.01 mol) DIEA, 2.68 g (0.01 mol) 4-[1-(1,1-dimethylethyl-oxycarbonyl)-4-piperidinyl]-piperidine and 150 ml of tetrahydrofuran was stirred for 2 hours at room temperature. After the reaction was complete 20 ml of diethylamine were added and the mixture was stirred for a further 18 hours at room temperature. The reaction mixture was evaporated down in vacuo, the residue was taken up in 200 ml of dichloromethane and washed successively with 100 ml of saturated sodium chloride solution and saturated sodium hydrogen carbonate solution and dried over magnesium sulphate. The reddish oil remaining after elimination of the solvent was purified by column chromatography on silica gel (30-60 μm) using firstly dichloromethane, then FM4 as eluant. The title compound was obtained in the form of a colourless amorphous substance and in a yield of 4.31 g (73.3% of theory).

IR(KBr): 1687.6 cm −1 (C═O)

MS: M + =586/588/590 (Br 2 )

b) 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-piperidine

Prepared analogously to Example 4 from 1-[4-amino-3,5-dibromo-D-phenylalanyl]-4-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-piperidine, CDT and 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone in a quantitative yield. Colourless, amorphous substance.

IR(KBr): 1676 cm −1 (C═O)

MS: (M+H) + =844/846/848 (Br 2 ) (M+Na) + =866/868/870 (Br 2 )

c) 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine (No. 521)

Prepared analogously to Example A1b), but using sodium hydroxide solution instead of ammonia, from 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-phenylalanyl]-4-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-piperidine by treating with trifluoroacetic acid in a yield of 75% of theory. Colourless, amorphous substance.

IR(KBr): 1666.4, 1620.1 cm −1 (C═O)

MS: (M+H) + =744/746/748 (Br 2 ) (M+2H) ++ =372/373/374.5 (Br 2 )

d) 4-(1-acetyl-4-piperidinyl)-1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl-piperidine (No. 372)

A solution of 0.372 g (0.499 mmol) of 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine and 0.07 g (5.5 mmol) of DIEA in 50 ml of dichloromethane was mixed with 0.043 g (5.48 mmol) of acetylene chloride dropwise whilst cooling externally with ice-water and then stirred for 1 hour at room temperature. The solvent was eliminated in vacuo, the residue was stirred with water and filtered. The filter residue was dried in vacuo and purified by column chromatography on silica gel (30-60 μm) using FM4 as eluant. The suitable eluates were evaporated down, the residue was triturated with diethylether and suction filtered. 230 mg (58.5% of theory) of colourless crystals were obtained.

IR(KBr): 1622 cm −1 (C═O)

MS: (M+H) + =786/788/790 (Br 2 ) (M+Na) + =808/810/812 (Br 2 )

The following were obtained accordingly:

1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-benzoyl-4-piperidinyl)-piperidine (No. (485).

Colourless crystals

R f 0.74 (FM1)

IR(KBr): 1626, 1668 cm −1 (C═O)

ESI-MS: (M+H) + =848/850/852 (Br 2 )

EXAMPLE 16

1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methylsulphonyl-4-piperidinyl)-piperidine (No. 486)

A solution of 0.372 g (0.499 mmol) of 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine and 0.07 g (5.5 mmol) of DIEA in 50 ml of dichloromethane was mixed dropwise with 0.063 g (5.5 mmol) of methanesulphonylchloride whilst cooling externally with ice-water and then stirred for 1 hour at room temperature. The solvent was eliminated in vacuo, the residue was stirred with water and filtered. The filter residue was dried in vacuo and purified by column chromatography over silica gel (30-60 μm) using initially dichloromethane, then FM4 as eluant. The suitable eluates were evaporated down, the residue was triturated with diethylether and suction filtered. 220 mg (53.5% of theory) of colourless crystals were obtained.

IR(KBr): 1668, 1618 cm −1 (C═O)

MS: (M+H) + =822/824/826 (Br 2 ) (M+Na) + =844/846/848 (Br 2 ) (M+K) + =860/862/864 (Br 2 )

The following were obtained accordingly:

(1) 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-4-(methylsulphonyloxy)-D-phenylalanyl]-4-[1-(methylsulphonyl)-4piperidinyl]-piperidine (No. (523)) in a yield of 12% of theory.

R f 0.54 (FM1)

IR(KBr): 1628, 1665 cm −1 (C═O)

ESI-MS: (M+H) + =901/903/905 (Br 2 )

(2) 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(methylsulphonyl)-4-piperidinyl]-piperidine (No. (524) in a yield of 12% of theory.

R f 0.50 (FM1)

ESI-MS: (M+H) + =823/825/827 (Br 2 )

(3) (R,S)-1-[4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(1-naphthyl)methyl]-1,4-dioxobutyl]-4-(1-methylsulphonyl-4-piperidinyl)-piperidine (No. (668) in a yield of 56% of theory.

R f 0.70 (FM1)

IR(KBr): 1630, 1666 cm −1 (C═O)

MS: M + =699

EXAMPLE 17

1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(3-carboxy-1-oxopropyl)-4-piperidinyl]-piperidine (No. 487)

A mixture of 0.372 g (0.499 mmol) of 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine, 0.11 g (1.1 mmol) of succinic anhydride and 150 ml of tetrahydrofuran was refluxed for 1 hour. The reaction mixture was freed from solvent in vacuo, the residue was purified by column chromatography on silica gel (30-60 μm) using FM1 as eluant. The suitable eluates were evaporated down, the residue was triturated with diethylether and suction filtered. 175 mg (41.5% of theory) of colourless crystals were obtained.

IR(KBr): 1668, 1608 cm −1 (C═O)

MS: (M−H) − =842/844/846 (Br 2 ) (M+Na) + =868/870/872 (Br 2 )

EXAMPLE 18

1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-hexyl-4-piperidinyl)-piperidine (No. 488)

A mixture of 0.372 g (0.499 mmol) of 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine, 0.05 g (0.499 mmol) of hexanal, 0.03 g (0.5 mmol) of glacial acetic acid and 150 ml of tetrahydrofuran was stirred for 1 hour at room temperature. After the addition of 0.116 g (0.52 mmol) of 95% sodium triacetoxyborohydride the mixture was kept for a further 2.5 hours at room temperature. The solvent was eliminated in vacuo, the residue was divided between 20% aqueous sodium carbonate solution and dichloromethane, the organic phase was dried over magnesium sulphate and evaporated down. The residue was purified by column chromatography on silica gel (30-60 μm) using FM4 as eluant. The suitable eluates were evaporated down, the residue was triturated with diethylether and suction filtered. 100 mg (24.2% of theory) of colourless crystals were obtained.

IR(KBr): 1666, 1620 cm −1 (C═O)

MS: (M+H) + =828/830/832 (Br 2 ) (M+Na) + =850/852/854 (Br 2 )

The following were obtained accordingly:

(1) 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperdinyl]carbonyl]-D-pbenylalanyl]-4-(1-cyclopropylmethyl-4-piperidinyl)-piperidine (No. (489) in a yield of 23% of theory.

R f 0.65 (FM1)

IR(KBr): 1622, 1666 cm −1 (C═O)

ESI-MS: (M+H) + =798/800/802 (Br 2 )

(2) 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(ethoxycarbonylmethyl)-4-piperidinyl]-piperidine (No. (493) in a yield of 43% of theory.

R f 0.72 (FM1)

IR(KBr): 1620, 1666 cm −1 (C═O)

ESI-MS: (M+H) + =730/732/734 (Br 2 )

(3) 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(cyclopropylmethyl)-4-piperidinyl]-piperidine (No. (525) in a yield of 46.5% of theory.

R f 0.50 (FM1)

IR(KBr): 1622, 1662 cm −1 (C═O)

ESI-MS: (M+H) + =799/801/803 (Br 2 )

EXAMPLE 19

Preparation of compounds of general formula:

1-[N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-ethenyl-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine (No. 532)

The mixture of 200 mg (3 mmol) 1-[3-bromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine, 108 mg (0.33 mMol) vinyl-tributyl tin (ALDRICH No. 27143-8), 50 mg tetrakis-(triphenylphosphine)-palladium (Merck No. 818193), a trace of 2,6-di-tert.-butyl-4-methylphenol and 10 ml anhydrous toluene was refluxed for 5 hours. The cooled reaction mixture was filtered over an activated charcoal filter, the filtrate was evaporated in a vacuum. The residue was purified for elution by column chromatography over silica gel, initially using pure dichloromethane, then methanol/conc. ammonia (9/1 v/v). The suitable eluates were triturated and suction filtered with tert.-butyl-methylether. Yield was 60 mg (32.6% of theory) of colourless crystals of R f 0.25 (FM1)

MS: M + =612

The following were prepared analogously: (in each case, n=1):

						%
No.	RCO	Z	R 2	A	NR 3 R 4	Yield	MS	Eluant	R f	IR [cm −1 ]
647	N66	CH 2	AS40	A0	C8	75	EI: M + = 611	FM1	0.6	(KBr): C═O
										1639/1668
648	N66	CH 2	AS41	A0	C8	56	EI: M + = 647	FM1	0.7	(KBr): C═O
										1639/1668
649	N66	CH 2	AS42	A0	C8	8	EI: M + = 648	FM1	0.6	(KBr): C═O
										1635/1668
650	N66	CH 2	AS43	A0	C8	11	EI: M + = 654	FM1	0.6	(KBr): C═O
										1635/1666
651	N66	CH 2	AS44	A0	C8	84	EI: M + = 637	FM1	0.6	(KBr): C═O
										1633/1664
652	N66	CH 2	AS45	A0	C8	83	EI: M + = 613	FM1	0.6	(KBr): C═O
										1637/1667

EXAMPLE 20

Preparation of compounds of general formula:

(R,S)-1-[4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidin (No. 599)

Produced analogously to Example 1 from (R,S)-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-4-oxobutanoic acid, 4-(4-methyl-1-piperazinyl)piperidine and TBTU in a yield of 10% of theory. Colourless, amorphous substance of R f =0.2 (dichloromethane/methanol/conc. ammonia 90/10/1 v/v/v).

IR(KBr): 1722, 1662, 1637 cm −1 (C═O)

MS: M + =711

Accordingly, (R,S)-1-[4-[4-(aminocarbonylamino)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine (No. 601) was obtained from (R,S)-4-[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-4-oxobutanoic acid, 4-(4-methyl-1-piperazinyl)piperidine and TBTU in a yield of 20% of theory. Colourless, amorphous substance of R f =0.25 (dichloromethane/methanol/conc. ammonia 90/10/1 v/v/v).

ESI-MS: (M+H) + =624 (M+Na) + =646 (M+H+Na) ++ =323.8

EXAMPLE 21

1-[3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hydroxycarbonyl)-piperidine (No. 211)

Produced analogously to Example A38 from 1-[3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(ethoxycarbonyl)-piperidine and aqueous lithium hydroxide solution in a yield of 79% of theory. Colourless, amorphous substance of R f 0.54 (ethyl ethanoate/methanol/glacial acetic acid 9/1/0.3 v/v/v).

IR(KBr): 1691.5, 1622.0 cm −1 (C═O)

ESI-MS: (M-H) − =690/2/4 (Br 2 )

EXAMPLE 22

1-[3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperazine (No. 214)

Produced analogously to Example A24 from 3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosine, 1-(1,1-dimethylethoxycarbonyl)-4-(1-piperazinyl)piperidine and TBTU, and additional conversion of the obtained intermediate product with trifluoroacetic acid (in accordance with Example A1b) in a yield of 4.2% of theory. Colourless, amorphous substance of R f 0.25 (FM1)

IR(KBr): 1624.0 cm −1 (C═O)

ESI-MS: (M+H) + =732/4/6 (Br 2 )

EXAMPLE 23

(R)-1-[2-[N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-methylamino]-3-(3,5-dibromo-4-hydroxyphenyl)-propyl]-4-(1-piperidinyl)-piperidine (No.219)

a) 1-(chlorocarbonyl)-4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-piperidine

To a solution of 3.0 g (13.8 mmol) 4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)piperidine and 2.7 ml (15 mMol) DIEA in 100 ml toluene, a solution of 1.8 ml (14.9 mMol) diphosgene in 15 ml toluene was added dropwise under external cooling with iced water, and the mixture was additionally kept at room temperature for 17 hours. The precipitate was suction filtered, washed with petroleum ether and dissolved in 50 ml dichloromethane. The obtained solution was agitated twice each with 50 ml 7% aqueous sodium hydrogen carbonate solution, dried over sodium sulphate and evaporated in a vacuum. Yield was 3.0 g (78% of theory) of a colourless substance of R f 0.25 (dichloromethane/acetone 9/1 v/v), which was further processed without more purification.

b) (R)-1-[3-(3,5-dibromo-4-hydroxyphenyl)-2-(N-methylamino)-propyl]-4-(1-piperidin)-piperidine

To a suspension of 2.3 g (60 mmol) lithium aluminium hydride in 100 ml anhydrous tetrahydrofuran, a solution of 11.0 g (18.66 mmol) 1-[3,5-dibromo-N-(1,1-dimethylethoxycarbonyl)-D-tyrosyl]-4-(1-piperidinyl)piperidine in 100 ml anhydrous tetrahydrofuran was added dropwise at room temperature whilst being stirred. It was stirred for a further 15 minutes at room temperature and then refluxed for 3 hours. 3 ml 20% aqueous ammonium chloride solution was added to the cooled mixture, then it was dried with magnesium sulphate. The filter cake was filtered and washed with 300 ml of an ethyl ethanoate-methanol mixture (1/1 v/v), and the combined filtrates were evaporated in a vacuum. The residue was purified by column chromatography over silica gel using ethyl ethanoate/methanol (8/2 v/v) for elution.

1. 2.9 g (31% of theory) of a colourless substance of R f 0.13 (eluant: methanol) was isolated from the suitable fractions, which was identified as 1-(3,5-dibromo-N-methyl-D-tyrosyl)-4-(1-piperidinyl)piperidine:

IR(KBr): 1668.3 cm −1 (C═O)

MS: M + =501/3/5 (Br 2 ) and

2. 1.8 g (20% of theory) of a colourless substance of R f 0.05 (eluant: methanol), which was identified as the sought compound:

ESI-MS: (M+H) + =488/490/492 (Br 2 ) (M+2H) ++ =244/245/246.5 (Br 2 )

c) (R)-1-[2-[N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-methylamino]-3-(3,5-dibromo-4-hydroxy-phenyl)-propyl]-4-(1-piperidinyl)-piperidine (No. 219)

A solution of 0.57 g (2.02 mmol) 1-(chlorocarbonyl)-4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-piperidine in 30 ml dimethylformamide was added dropwise to the mixture of 0.9 g (1.84 mmol) (R)-1-[3-(3,5-dibromo-4-hydroxyphenyl)-2-(N-methylamino)-propyl]-4-(1-piperidinyl)-piperidine and 0.65 ml (3.7 mmol) DIEA in a mixture of 50 ml tetrahydrofuran and 20 ml dimethylformamide. It was stirred overnight at room temperature and the deposit was evaporated in a vacuum. The residue was treated with 300 ml of a tetrahydrofuran ethyl ethanoate mixture (1/1 v/v) and the resulting solution was agitated twice each with 100 ml of a saturated aqueous solution of sodium hydrogen carbonate, dried over sodium sulphate and evaporated in a vacuum. The residue was purified over silica gel by column chromatography using dichloromethane/methanol (8.5/1.5 v/v) for elution. 390 mg (29% of theory) of a colourless substance of R f 0.46 (dichloromethane cyclohexane/methanol/conc. ammonia 75/15/15/2 v/v/v/v) were isolated from the suitable fractions:

IR(KBr): 1695.3, 1624.0 cm −1 (C═O)

ESI-MS: (M+H) + =731/3/5 (Br 2 )

EXAMPLE 24

1-[3,5-dibromo-N-[[4-[5-[(4-morpholinyl)carbonyl]-1,3-dihydro-2(2H)-oxobenzimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine (No. 223)

100 mg (0.6 mMol) N,N′-carbonyldiimidazole was added to a solution of 400 mg (0.5 mMol) 1-[3,5-dibromo-N-[[4-(1,3-dihydro-5-(hydroxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine in 10 ml anhydrous tetrahydrofuran at room temperature, heated to 50° C. for 30 minutes and then 90 mg (1 mMol) morpholine was added. After heating to 50-60° C. for two hours, the solution was removed in a vacuum and the residue was purified over silica gel(30-60 μm) by column chromatography, initially using dichloromethane, then dichloromethane/methanol 9/1 (v/v), and finally dichloromethane/methanol/conc. ammonia 9/1/0.2 (v/v/v) as eluants. 250 mg (60% of theory) of an amorphous, colourless substance was yielded from the suitable extracts.

IR(KBr): 1712.7, 1625.9 cm −1 (C═O)

ESI-MS: (M+H) + =838/840/842 (Br 2 ) (M+2H) ++ =419/420/421.5 (Br 2 )

The following were obtained accordingly:

1-[3,5-dibromo-N-[[4-[5-[(4-methyl-1-piperazinyl)carbonyl]-1,3-dihydro-2 (2H)-oxobenzimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine (No. 224) from 1-[3,5-dibromo-N-[[4-(1,3-dihydro-5-(hydroxycarbonyl)-2(2H)-oxobenzimi-dazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine, 1-methylpiperazine and N,N′-carbonyldiimidazole in a yield of 52% of theory. Colourless, amorphous substance.

IR(KBr): 1710.8, 1625.9 cm −1 (C═O)

ESI-MS: (M+H) + =851/853/855 (Br 2 ) (M+2H) ++ =426/427/428 (Br 2 )

EXAMPLE 25

1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(carboxymethyl)-4-piperidinyl]-piperidine (No. 494)

Produced analogously to Example A37, but using tetrahydrofuran instead of methanol, from 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(ethoxycarbonylmethyl)-4-piperidinyl]-piperidine by the action of aqueous lithium hydroxide solution in a yield of 51% of theory. Colourless, amorphous substance.

ESI-MS: (M−H) − =800/802/804 (Br 2 ) (M+H) + =802/804/806 (Br 2 ) (M+Na) + =824/826/828 (Br 2 )

EXAMPLE 26

1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(hydroxycarbonylmethyl)-4-piperidinyl]-piperidine (No. 526)

Produced analogously to Example 18 from 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperidine, ethyl glyoxylate and sodium triacetoxyborhydride and additional saponification with soda lye of the 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(ethoxycarbonylmethyl)-4-piperidinyl]-piperidine, obtained as an intermediate product but not characterised, according to Example A55. A colourless, amorphous substance is obtained in a yield of 35% of theory.

IR(KBr): 1625.9 wide cm −1 (C═O)

ESI-MS: (M+H) + =803/805/807 (Br 2 ) (M+Na) + =825/827/829 (Br 2 )

EXAMPLE 27

1-[4-amino-N-[(4-amino-1-piperidinyl)carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine (No. 564)

653 mg (10.4 mMol) 95% sodium cyanoborohydride (Aldrich 15.615-9) was stirred into the mixture of 930 mg (1.48 mMol) 1-[4-amino-3,5-dibromo-N-[(4-oxo-1-piperidinyl)carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine, 1143 mg (14.8 mMol) ammonium acetate (Merck No. 1115) and 30 ml anhydrous methanol at room temperature, and was stirred overnight. The deposit was adjusted to pH≦2 with conc. hydrochloric acid and was evaporated in a vacuum. The residue is taken up in water and made alkaline with 40% soda lye. Exhaustive extraction with dichloromethane followed, then the combined extracts were dried over sodium sulphate and evaporated in a vacuum. The residue was purified over 100 g silica gel (Amicon, 35-70 μm) by column chromatography using dichloromethane/methanol/conc. ammonia(60/40/5 v/v/v) for elution. From the suitable fractions, 250 mg (270% of theory) of the sought substance was isolated as a colourless, amorphous product of R f 0.15 (dichloromethane/methanol/conc. ammonia 50/50/0.5 v/v/v).

IR(KBr): 1618 wide cm −1 (C═O)

ESI-MS: (M+H) + =627/629/631 (Br 2 ) (M+Na) + =649/651/653 (Br 2 ) (M+2H) ++ =314/315/316 (Br 2 )

EXAMPLE 28

(R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorphenyl)methyl]-1,4-dioxobutyl]-4-(hydroxycarbonylmethyl)-piperidine (No. 596)

Produced analogously to Example A55 from (R,S)-1-[4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(ethoxycarbonylmethyl)-piperidine by saponification with soda lye in a yield of 866 of theory. Colourless, amorphous substance of R f 0.76 (ethyl ethanoate/methanol/glacial acetic acid 70/30/1 v/v/v).

IR(KBr): 1716, 1635 cm −1 (C═O)

ESI-MS: (M−H) − =613/615/617 (Cl 2 ) (M+H) + =615/617/619 (Cl 2 ) (M+Na) + =637/639/641 (C12)

EXAMPLE 29

1-[N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-carbonyl]-3-(1H-tetrazol-5-yl)-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine (No. 632)

8.5 g (35 mMol) tributyl tin(IV)-azide (Synthesis 1976, 330) was added to a solution of 1.6 g (2.68 mMol) 1-[3-cyano-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine in 400 ml toluene and the mixture was refluxed for 4 days. The residue remaining after dispellation of the solvent was stirred with ethyl ethanoate, the obtained precipitate was suction filtered and purified over silica gel by column chromatography using FM1 as an eluent. After the usual further processing, yield is 400 mg (24% of theory) of colourless crystals of R f 0.2 (FM1)

IR(KBr): 1653 cm −1 (C═O)

ESI-MS: (M+H) + =641 (M+Na) + =663

The following Examples describe the preparation of pharmaceutically useful forms which contain as active substance any desired compound of general formula I:

EXAMPLE I

Calpsules for Powder Inhalation Containing 1 mg of Active Substance

Composition:

1 capsule for powder inhalation contains:

Active substance       1.0 mg
Lactose                20.0 mg
Hard gelatine capsules 50.0 mg
                       71.0 mg

Method of Preparation

The active substance is ground to the particle size required for inhalants. The ground active substance is homogeneously mixed with the lactose. The mixture is packed into hard gelatine capsules.

EXAMPLE II

Inhalable Solution for Respimat® Containing 1 mg of Active Substance

Composition:

1 stroke contains:

	Active substance	1.0	mg
	Benzalkonium chloride	0.002	mg
	Disodium edetate	0.0075	mg
	Purified water ad	15.0	μl

Method of Preparation

The active substance and benzalkonium chloride are dissolved in water and transferred into Respimat® cartridges.

EXAMPLE III

Inhalable Solution for Nebulisers Containing 1 mg of Active Substance

Composition:

1 vial contains:

	Active substance	0.1	g
	Sodium chloride	0.18	g
	Benzalkonium chloride	0.002	g
	Purified water ad	20.0	ml

Method of Preparation

Active substance, sodium chloride and benzalkonium chloride are dissolved in water.

EXAMPLE IV

Propellant Gas Metering Aerosol Containing 1 mg of Active Substance

Composition:

1 stroke contains:

	Active substance	1.0	mg
	Lecithin	0.1	%
	Propellant gas ad	50.0	μl

Method of Preparation

The micronised active substance is homogeneously suspended in a mixture of lecithin and propellant gas. The suspension is transferred into a pressurised container with metering valve.

EXAMPLE V

Nasal Spray Containing 1 mg of Active Substance

Composition:

	Active substance	1.0	mg
	Sodium chloride	0.9	mg
	Benzalkonium chloride	0.025	mg
	Disodium edetate	0.05	mg
	Purified water ad	0.1	ml

Method of Preparation

The active substance and adjuvants are dissolved in water and transferred into a suitable container.

EXAMPLE VI

Injectable Solution Containing 5 mg of Active Substance Per 5 mg

Composition:

	Active substance	5	mg
	Glucose	250	mg
	Human-serum-albumin	10	mg
	Glycofurol	250	mg
	Water for injections ad	5	ml

Preparation

Glycofurol and glucose are dissolved in water for injections (WfI); human-serum-album in is added; active substance is dissolved with heating; solution is made up to required volume with WfI; transferred into ampoules under nitrogen gas.

EXAMPLE VII

Injectable Solution Containing 100 mg of Active Substance Per 20 mg

Composition:

	Active substance	100	mg
	Monopotassium dihydrogen phosphate = KH 2 PO 4	12	mg
	Disodium hydrogen phosphate = Na 2 HPO 4 .2H 2 O	2	mg
	Sodium chloride	180	mg
	Human-serum-albumin	50	mg
	Polysorbate 80	20	mg
	Water for injections ad	20	ml

Preparation

Polysorbate 80, sodium chloride, monopotassium dihydrogen phosphate and disodium hydrogen phosphate are dissolved in water for injections (WfI); human-serum-albumin is added; active substance is dissolved with heating; solution is made up to required volume with WfI; transferred into ampoules.

EXAMPLE VIII

Lysophilisate Containing 10 mg of Active Substance

Composition:

	Active substance	10	mg
	Mannitol	300	mg
	Human-serum-albumin	20	mg

Preparation

Mannitol is dissolved in water for injections (WfI); human-serum-albumin is added; active substance is dissolved with heating; solution is made up to required volume with WfI; transferred into vials and freeze-dried.

Solvent for lyophilisate:

	Polysorbate 80 = Tween 80	20	mg
	Mannitol	200	mg
	Water for injections ad	10	ml

Preparation

Polysorbate 80 and mannitol are dissolved in water for injections (WfI) and transferred into ampoules.

EXAMPLE IX

Tablets Containing 20 mg of Active Substance

Composition:

	Active substance	20	mg
	Lactose	120	mg
	Corn starch	40	mg
	Magnesium stearate	2	mg
	Povidon K 25	18	mg

Preparation

Active substance, lactose and corn starch are homogeneously mixed; granulated with an aqueous solution of Povidon; mixed with magnesium stearate; pressed in a tablet press; weight of tablet 200 mg.

EXAMPLE X

Capsules Containing 20 mg of Active Substance

Composition:

	Active substance	20	mg
	Corn starch	80	mg
	Highly dispersed silicic acid	5	mg
	Magnesium stearate	2.5	mg

Preparation

Active substance, corn starch and silicic acid are homogeneously mixed; mixed with magnesium stearate; then the mixture is packed into size 3 hard gelatine capsules using a capsule filling machine.

EXAMPLE XI

Suppositories Containing 50 mg of Active Substance

Composition:

	Active substance	50	mg
	Hard fat (adeps solidus) q.s. ad	1700	mg

Preparation

Hard fat is melted at about 38° C.; ground active substance is homogeneously dispersed in the molten hard fat; then after cooling to about 35° C. the melt is poured into chilled moulds.

EXAMPLE XII

Aqueous Solution for Nasal Application Containing 10 mg Active Substance

Composition:

	Active substance	10.0	mg
	Hydrochloric acid in quantity required
	for formation of a neutral salt
	Methylparahydroxybenzoate (PHB)	0.01	mg
	Propylparahydroxybenzoate (PHB)	0.005	mg
	Purified water ad	1.0	ml

Preparation

The active substance is dissolved in purified water; Hydrochloric acid is added until the solution is clear; PHB methyl and propyl esters are added; the solution is made up to required volume with purified water; the solution is sterile-filtered and is transferred into an appropriate container.

EXAMPLE XIII

Aqueous Solution for Nasal Application Containing 5 mg Active Substance

Composition:

	Active substance	5	mg
	1,2-propandiol	300	mg
	Hydroxyethylcellulose	5	mg
	Sorbic acid	1	mg
	Purified water ad	1	ml

Preparation

The active substance is dissolved in 1,2-propandiol; a hydroxy-ethyl-cellulose solution is prepared in purified water containing sorbic acid and is added to the active substance solution; the solution is sterile-filtered and is transferred into an appropriate container.

EXAMPLE XIV

Aqueous Solution for Intravenous Application Containing 5 mg Active Substance

Composition:

	Active substance	5	mg
	1,2-propandiol	300	mg
	Mannitol	50	mg
	Water for injections (WfI) ad	1	ml

Preparation

The active substance is dissolved in 1,2-propandiol; the solution is approximately made up to the required volume with WfI; the mannitol is added and the solution is made up to required volume with WfI; the solution is sterile-filtered, transferred into individual containers and autoclaved.

EXAMPLE XV

Liposomal Formulation for Intravenous Injection Containing 7.5 mg Active Substance

Composition:

	Active substance	7.5	mg
	Egg-lecithin, e.g. lipoid E 80	100.0	mg
	Cholesterol	50.0	mg
	Glycerine	50.0	mg
	Water for injections ad	1.0	ml

Preparation

The active substance is dissolved in a mixture of lecithin and cholesterol; the solution is added to a mixture of glycerine and WfI and is homogenised by means of high-pressure homogenisation or microfluidiser technology; the liposomal formulation obtained in this manner is transferred into an appropriate container under aseptic conditions.

EXAMPLE XVI

Suspension for Nasal Application Containing 20 mg Active Substance

Composition:

	Active substance	20.0	mg
	Carboxymethylcellulose (CMC)	20.0	mg
	Sodium monohydrogen phosphate/sodium-		q.s.
	dihydrogen phosphate buffer pH 6.8
	Sodium chloride	8.0	mg
	Methylparahydroxybenzoate	0.01	mg
	Propylparahydroxybenzoate	0.003	mg
	Purified water ad	1.0	ml

Preparation

The active substance is suspended in an aqueous CMC solution; the other components are added to the suspension one after another and the suspension is made up to required volume with purified water.

EXAMPLE XVII

Aqueous Solution for Subcutaneous Application Containing 10 mg Active Substance

Composition:

	Active substance	10.0	mg
	Sodium monohydrogen phosphate/sodium	7.0
	dihydrogen phosphate buffer q.s. ad pH
	Sodium chloride	4.0	mg
	Water for injections ad	0.5	ml

Preparation

The active substance is dissolved in the phosphate buffer solution, after addition of the sodium chloride the solution is made up to required volume with water. The solution is sterile-filtered and is autoclaved after being transferred into an appropriate container.

EXAMPLE XVIII

Aqueous Solution for Subcutaneas Application Containing 5 mg Active Substance

Composition:

	Active substance	5.0	mg
	Polysorbate 80	0.5	mg
	Water for injections ad	0.5	ml

Preparation

The active substance is suspended in the polysorbate 80 solution and is reduced to a particle size of approx. 1 μm by means of a suitable dispersion technique (e.g. wet milling, high-pressure homogenisation, micro-fluidisation, etc.). The suspension is transferred into an appropriate container under aseptic conditions.

Claims

1. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine or a physiologically acceptable salt or a tautomer thereof.

2. 1-[4-Amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine or a physiologically acceptable salt or a tautomer thereof.

3. A method for the treatment of headaches, or morphine tolerance, which method comprises the administration of a compound in accordance with claim 1 or 2.